lamotrigine has been researched along with Aura in 1023 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Participants with focal epilepsy were randomised to receive lamotrigine, levetiracetam or zonisamide." | 9.41 | Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. ( Appleton, R; Baker, G; Balabanova, S; Brown, R; Burnside, G; Hindley, D; Howell, S; Hughes, DA; Leach, JP; Maguire, M; Marson, AG; Mohanraj, R; Plumpton, CO; Sills, G; Smith, D; Smith, PE; Taylor, C; Tudur-Smith, C; Williamson, PR, 2021) |
| "Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)." | 9.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
| "This study provides evidence that the disparate lamotrigine products studied are bioequivalent when tested in people with epilepsy taking concomitant antiepileptic drugs." | 9.24 | Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. ( Berg, M; Diaz, FJ; Dworetzky, BA; Elder, EJ; Gidal, BE; Jiang, W; Jiang, X; Krebill, R; Pollard, JR; Privitera, MD; Switzer, RD; Szaflarski, JP; Welty, TE, 2017) |
| "A literature search was performed in the PubMed, Embase, and OVID-Medline databases to identify articles related to epilepsy and lamotrigine that were published from the establishment of the database to April 2021." | 9.22 | The efficacy of lamotrigine after failure of the first administration of valproate in treating epilepsy: a systematic review and meta-analysis. ( He, J; Wu, X; Zhou, D, 2022) |
| "Lamotrigine is the most widely used anti-epileptic drug in pregnancy because of its low teratogenicity." | 9.22 | Dosage Optimization of Lamotrigine in Pregnancy: A Pharmacometric Approach Using Modeling and Simulation. ( G, SS; Kp, A; Pa, B; Thomas, G, 2022) |
| "Lamotrigine (LTG) is used to treat epilepsy." | 9.22 | Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy. ( Hirai, K; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Umemura, A; Yamamoto, Y, 2016) |
| " In this trial, we assessed US Food and Drug Administration (FDA) bioequivalence standards by studying the effects of switching between two disparate generic immediate-release lamotrigine products in patients with epilepsy." | 9.22 | Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. ( Berg, M; Diaz, FJ; Dworetzky, BA; Elder, EJ; Gidal, BE; Jiang, W; Jiang, X; Krebill, R; Pollard, JR; Privitera, MD; Szaflarski, JP; Welty, TE, 2016) |
| "A classic 2-period crossover bioavailability study was conducted to evaluate the relative and absolute bioavailability of immediate-release (IR) and extended-release (XR) lamotrigine formulations under steady-state conditions in elderly patients with epilepsy." | 9.20 | Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology. ( Birnbaum, AK; Brundage, RC; Leppik, IE; Polepally, AR; Ramsay, RE; Rarick, JO; Remmel, RP, 2015) |
| "To determine the tolerability and efficacy of lamotrigine extended-release (LTG XR) as adjunctive therapy with optional conversion to monotherapy in patients ages≥65 years with epilepsy." | 9.19 | Lamotrigine extended-release as adjunctive therapy with optional conversion to monotherapy in older adults with epilepsy. ( Hammer, AE; Huffman, R; Leroy, R; Messenheimer, JA; Van Cott, A; VanLandingham, K; Vuong, A; Wechsler, RT, 2014) |
| "The aim of the study was to investigate immunoglobulin levels in patients with epilepsy using the antiepileptic drugs (AED) levetiracetam (LEV), carbamazepine (CBZ), or lamotrigine (LTG)." | 9.17 | Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine. ( Frøland, SS; Luef, G; Mochol, M; Mushtaq, U; Rauchenzauner, M; Svalheim, S; Taubøll, E, 2013) |
| "Of the newer antiepileptic drugs, lamotrigine (LTG) and levetiracetam (LEV) are popular first choice drugs for epilepsy." | 9.16 | The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study. ( Arnold, S; Bauer, S; Beige, A; Berrouschot, J; Burchardi, N; Eisensehr, I; Evers, S; Haag, A; Hallmeyer-Elgner, S; Hamer, HM; Klein, KM; Kovac, S; Lerche, H; Niedhammer, M; Oertel, WH; Reif, PS; Rosenow, F; Roth, E; Schade-Brittinger, C; Schröder, M; Springub, J; Strzelczyk, A; Weber, Y; Winkler, G, 2012) |
| "This open label study suggests that the combination of valproate, lamotrigine, and a benzodiazepine can markedly reduce the frequency of epileptic drop attacks in patients with generalized or multifocal epilepsies." | 9.15 | Long-term control of epileptic drop attacks with the combination of valproate, lamotrigine, and a benzodiazepine: a 'proof of concept,' open label study. ( Bastos, FA; Machado, VH; Palmini, A; Rotert, R, 2011) |
| "To prospectively analyse the pharmacokinetics of lamotrigine (LTG) during pregnancy and lactation in a consecutive series of epileptic pregnant women." | 9.14 | Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. ( Bauer, S; Dudenhausen, JW; Fotopoulou, C; Henrich, W; Kretz, R; Schefold, JC; Schmitz, B, 2009) |
| " We evaluated the reproductive endocrine and insulin-related metabolic parameters in men and women with untreated epilepsy randomized to valproate (n=44) or lamotrigine (n=37) monotherapy for 12 months." | 9.14 | Effects of valproate or lamotrigine monotherapy on the reproductive endocrine and insulin-related metabolic profile in Chinese adults with epilepsy: a prospective randomized study. ( Chan, IH; Chan, MH; Hui, AC; Hui, KF; Kwan, P; Lam, CW; Leung, H; Ng, PW; Yip, FP, 2009) |
| "During an international double-blind trial evaluating the efficacy and tolerability of lamotrigine and carbamazepine in patients aged >or=65 with newly diagnosed epilepsy, the comparative effects of the drugs on health-related quality of life were investigated based on screening and 12-, 28-, and 40-week data, using the modified Side Effect and Life Satisfaction (SEALS) Inventory and the Liverpool Adverse Event Profile." | 9.14 | Antiepileptic drugs and quality of life in the elderly: results from a randomized double-blind trial of carbamazepine and lamotrigine in patients with onset of epilepsy in old age. ( Abdelnoor, M; Gjerstad, L; Isojärvi, J; Perucca, E; Saetre, E; Taubøll, E, 2010) |
| "To evaluate development of components of polycystic ovary syndrome (PCOS) and PCOS in women with epilepsy initiating valproate or lamotrigine therapy." | 9.13 | Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. ( Adams, JM; Bhatt, M; Hayes, FJ; Isojärvi, J; Morrell, MJ; Ozkara, C; Sluss, PM; Warnock, CR, 2008) |
| "These analyses, conducted on a data set drawn from a previously reported, open-label, multicentre, prospective study, examined the effect of lamotrigine on mood in adults aged>or=50 years with epilepsy and co-morbid depressive symptoms." | 9.13 | Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study. ( Fakhoury, TA; Hammer, AE; Miller, JM; Vuong, A, 2008) |
| "To compare the pharmacokinetics (PK) of lamotrigine (LTG) when converting from twice-daily immediate-release (LTG-IR) to once-daily extended-release (LTG-XR) in subjects with epilepsy." | 9.13 | Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). ( Ali, I; Hammer, AE; Job, S; Lemme, F; Messenheimer, JA; Oliver-Willwong, R; Tompson, DJ; Vuong, A; Zhu, L, 2008) |
| " Patients with an epilepsy diagnosis (International Classification of Diseases-9 345) and treated with lamotrigine for >60 of the 90 days before the entry date of generic lamotrigine in Quebec (February 1, 2003) were selected." | 9.13 | Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. ( Duh, MS; Lefebvre, P; LeLorier, J; Manjunath, R; Paradis, PE; Sheehy, O; Weiner, J, 2008) |
| " This paper aims to undertake a comprehensive review regarding the possible risks of four classical (phenytoin, carbamazepine, phenobarbital, and valproate) and two newer (lamotrigine and levetiracetam) AEDs during pregnancy." | 9.12 | Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications. ( Demir, O; Kaplan, YC, 2021) |
| "This study was performed to evaluate carnitine deficiency in a large series of epilepsy children and adolescents treated with old and new antiepileptic drugs with or without ketogenic diet." | 9.12 | Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. ( Auricchio, G; Coppola, G; Epifanio, G; Federico, RR; Pascotto, A; Resicato, G, 2006) |
| "To assess the course of sexual function in epilepsy patients treated with lamotrigine." | 9.12 | Effect of lamotrigine on sexual function in patients with epilepsy. ( Alamo, C; García-García, P; Gil-Nagel, A; López-Muñoz, F; Moncada, I; Serratosa, JM, 2006) |
| "To compare the cognitive effects of lamotrigine vs topiramate as adjunctive therapy in adults with epilepsy." | 9.12 | Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. ( Biton, V; Blum, D; Chung, S; Fakhoury, T; Hammer, A; Isojärvi, J; Meador, K; Mills, K; Shneker, B, 2006) |
| "This is the first report comparing intrasubject lamotrigine (LTG) plasma concentrations between hormonal contraceptive (HC) intake and week-off phases in epilepsy patients receiving combined LTG and HC treatment." | 9.12 | Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. ( Albani, F; Ambrosetto, G; Avoni, P; Baruzzi, A; Bisulli, F; Contin, M; Riva, R; Tinuper, P, 2006) |
| "In eight women treated with lamotrigine monotherapy, the lamotrigine dose/plasma concentration (D/C) ratio increased by 295% from baseline outside pregnancy to midgestation, whereas in six women treated with lamotrigine in combination with valproate, the increase was only 60%." | 9.12 | Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. ( Luef, G; Ohman, I; Pittschieler, S; Sabers, A; Tomson, T, 2006) |
| "In this investigation, the effects of lamotrigine versus placebo on depressive symptoms in patients with epilepsy were prospectively assessed." | 9.12 | Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. ( Ettinger, AB; Hammer, AE; Kustra, RP, 2007) |
| "This open-label study evaluated the antidepressant qualities of lamotrigine (LTG) in people with epilepsy." | 9.12 | Lamotrigine in patients with epilepsy and comorbid depressive symptoms. ( Barry, JJ; Fakhoury, TA; Hammer, AE; Mitchell Miller, J; Vuong, A, 2007) |
| "We have performed a randomised, prospective study to compare the efficacy and tolerability of sodium valproate (VPA) and lamotrigine (LTG) monotherapy, and their effects on circulating androgenic hormones, in newly diagnosed epilepsy." | 9.12 | Sodium valproate versus lamotrigine: a randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy. ( Brodie, MJ; Butler, E; Hitiris, N; Leach, JP; Leach, VM; Parker, P; Sills, GJ; Stephen, LJ; Wilson, EA, 2007) |
| "To assess the comparative effectiveness, efficacy, and tolerability of lamotrigine (LTG) and sustained-release carbamazepine (CBZ) in the treatment of newly diagnosed epilepsy in the elderly." | 9.12 | An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. ( Gjerstad, L; Isojärvi, J; Perucca, E; Saetre, E, 2007) |
| "To determine whether levetiracetam (LEV) affects plasma concentrations of carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy." | 9.12 | Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. ( De Smedt, H; Otoul, C; Stockis, A, 2007) |
| "This randomized, open-label study was designed to compare the efficacy and tolerability of lamotrigine monotherapy with those of valproate and carbamazepine monotherapy in patients with epilepsy whose seizures were uncontrolled on their prestudy antiepileptic drug monotherapy." | 9.11 | Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy. ( Fakhoury, TA; Hammer, AE; Messenheimer, JA; Vuong, A, 2004) |
| "A dosing algorithm was used to guide the conversion of 77 patients with epilepsy (16 years of age) from valproate monotherapy through lamotrigine adjunctive therapy at 200mg daily to lamotrigine monotherapy at 500 mg daily in an open-label study comprising a lamotrigine escalation phase (8 weeks), a valproate withdrawal phase (6 weeks), and a lamotrigine monotherapy phase (4 weeks)." | 9.11 | A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy. ( Biton, V; Blum, D; Hammer, AE; Messenheimer, JA; Natarajan, S; Sale, ME; Vuong, A, 2005) |
| "The present study was designed to assess the effect of the addition of zonisamide (ZNS) on lamotrigine (LTG) disposition and the safety of the combination under steady-state conditions in patients with epilepsy." | 9.11 | Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ( Brodie, MJ; Levy, RH; Pan, WJ; Ragueneau-Majlessi, I; Shah, J; Smith, DF, 2005) |
| "To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy." | 9.11 | New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. ( Boardman, KD; Carter, GS; Collins, JF; Felicetta, J; Frederick, T; Marks, W; Pryor, F; Ramsay, RE; Rowan, AJ; Spitz, M; Tomyanovich, ML; Towne, A; Uthman, BM, 2005) |
| "This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy." | 9.10 | Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002) |
| "To investigate the tolerability and pharmacokinetics of oral loading with lamotrigine (LTG) among epilepsy patients after temporary drug discontinuation in an epilepsy monitoring unit." | 9.10 | Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. ( Del Mar Carreño, M; Hovinga, CA; Lardizabal, DV; Morris, HH, 2003) |
| "This study evaluated the effects of lamotrigine as adjunctive therapy for refractory epilepsy in patients with mental retardation." | 9.10 | Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation. ( Barrett, PS; FineSmith, R; Hammer, AE; McKee, JR; Sunder, TR; Varner, JA; Vuong, A, 2003) |
| "The authors assessed the effect of concomitant antiepileptic therapy on steady-state plasma concentrations of the new antiepileptic drug (AED) topiramate and the potential relation between topiramate plasma levels and side effects in a cohort of 116 patients with epilepsy." | 9.10 | Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. ( Albani, F; Avoni, P; Baruzzi, A; Contin, M; Riva, R, 2002) |
| "Accumulating data suggest that the antiepilepsy drug lamotrigine, which has been available for adult use for more than a decade, also confers broad-spectrum, well-tolerated control of epilepsy in children." | 9.10 | Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy. ( Duchowny, M; Gilman, J; Messenheimer, J; Risner, M; Womble, G, 2002) |
| "In a multicentre, double-blind trial 150 elderly patients (mean age 77 years) with newly diagnosed epilepsy were randomised in a 2:1 ratio to treatment with lamotrigine (LTG) or carbamazepine (CBZ)." | 9.09 | Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. ( Brodie, MJ; Giorgi, L; Overstall, PW, 1999) |
| "5-18 yrs with intractable epilepsy and comedicated with carbamazepine or valproate." | 9.09 | Plasma and urinary serotonin and 5-HIAA in children treated with lamotrigine for intractable epilepsy. ( Jović, NJ; Majkić-Singh, N; Milovanović, DD; Mirković, D, 1999) |
| "This prospective observational study explored the efficacy and tolerability of topiramate (TPM) in patients with refractory epilepsy attending a single outpatient clinic." | 9.09 | Topiramate in refractory epilepsy: a prospective observational study. ( Brodie, MJ; Sills, GJ; Stephen, LJ, 2000) |
| "to describe the population pharmacokinetics of lamotrigine (LTG) in developmentally disabled (DD) patients with epilepsy and (2) to determine if there is an effect of valproate (VPA) concentration on the extent of the pharmacokinetic interaction between VPA and LTG." | 9.09 | Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ( Anderson, GD; Gidal, BE; Lanning, A; Rutecki, PR; Shaw, R, 2000) |
| " The primary aim of the study was to evaluate lamotrigine add-on therapy and consecutive monotherapy in patients with epilepsy whose seizures were not controlled by carbamazepine or valproate." | 9.09 | Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy. ( Jozwiak, S; Terczynski, A, 2000) |
| "Lamotrigine (LTG) is one of the newer antiepileptic drugs which has been shown to have a spectrum of drug interactions (including with other epilepsy drugs) that can have a pronounced effect on LTG kinetics." | 9.09 | Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? ( Black, AB; Lam, E; Morris, RG; Westley, IS, 2000) |
| "To compare the incidence and magnitude of change in body weight associated with lamotrigine or divalproex sodium monotherapy in patients with epilepsy." | 9.09 | Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. ( Barrett, PS; Biton, V; Hammer, AE; Mirza, W; Montouris, G; Vuong, A, 2001) |
| "The aim of this study was to evaluate the efficacy and safety of gabapentin in patients with learning disabilities and resistant epilepsy, comparing the effects of gabapentin with lamotrigine on efficacy, behaviour and mood." | 9.09 | A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. ( Brown, S; Crawford, P; Kerr, M, 2001) |
| "The study was designed to evaluate optimal use of add-on lamotrigine in the treatment of children and adults with refractory epilepsy of any type." | 9.09 | [Optimal use of lamotrigine in clinical practice: results of an open multicenter trial in refractory epilepsy]. ( Arzimanoglou, A; Baldy-Moulinier, M; Bidaut-Mazel, C; Kulak, I, 2001) |
| "Lamotrigine (LTG) as both effective against a wide range of seizure types and epileptic syndromes and well tolerated drug is being used in mono--as well as in polytherapy of pharmacoresistant epilepsy." | 9.09 | Long-term monotherapy with lamotrigine in newly diagnosed epilepsy in adults. ( Chmielewska, B; Kamiński, ML; Kawka, Z, 2001) |
| " Use of the drug as monotherapy was investigated in a double-blind, randomised, parallel-group comparison with carbamazepine in newly diagnosed epilepsy." | 9.08 | Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. ( Brodie, MJ; Richens, A; Yuen, AW, 1995) |
| "To examine the population pharmacokinetics of lamotrigine in patients newly diagnosed with epilepsy and receiving oral lamotrigine monotherapy for up to 48 weeks." | 9.08 | Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. ( Hussein, Z; Posner, J, 1997) |
| "We report the results of an open trial with lamotrigine (LTG) as add-on drug in children and adolescents with refractory epilepsy and mental delay." | 9.08 | Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial. ( Coppola, G; Pascotto, A, 1997) |
| "Lamotrigine was an effective and well-tolerated treatment for seizures associated with the Lennox-Gastaut syndrome." | 9.08 | Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. ( Arvidsson, JF; Barrera, MN; Manasco, P; Motte, J; Mullens, EL; Trevathan, E, 1997) |
| "This open pilot study was performed to evaluate the effect of Lamotrigine (LTG) in girls with Rett syndrome (RS) regarding seizure frequency, effect on gross motor dyspraxia and safety." | 9.08 | Lamotrigine in Rett syndrome: treatment experience from a pilot study. ( Hagberg, B; Stenbom, Y; Tonnby, B, 1998) |
| "We report open-label clinical observations of additional lamotrigine (LTG) in 16 adult patients with refractory epilepsy, aimed to assess the long-term efficacy and safety of LTG in clinical use." | 9.07 | Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy. ( Cocito, L; Loeb, C; Maffini, M, 1994) |
| "Lamotrigine (LTG) is a new antiepileptic drug which is effective in refractory epilepsy and which has been shown to have weak antifolate properties in vitro." | 9.07 | An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. ( Patsalos, PN; Sander, JW, 1992) |
| "Lamotrigine, a novel anticonvulsant, has been evaluated in patients with epilepsy using the method of interictal EEG spike counting." | 9.06 | The effect of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy. ( Jawad, S; Oxley, J; Richens, A; Yuen, WC, 1986) |
| "To conduct a literature review of the impact on cognition and mood status of lacosamide (LCM) in people with epilepsy." | 9.05 | The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy. ( Chang, YP; Huang, LC; Li, KY; Yang, YH, 2020) |
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 8.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| "To investigate the efficacy and safety of lamotrigine monotherapy in children with epilepsy via a systematic review." | 8.93 | [Lamotrigine monotherapy in children with epilepsy: a systematic review]. ( Huang, L; Liu, YT; Zeng, LN; Zhang, LL, 2016) |
| "Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are fatal adverse cutaneous drug reactions which may be induced by phenytoin (PHT) or lamotrigine (LTG)." | 8.91 | HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies. ( Huo, J; Li, X; Mei, S; Wang, J; Yu, K; Zhao, Z; Zhu, Y, 2015) |
| "The paper presents the review of literature on the age aspect of using lamotrigine in pubertal period, in women of reproductive age, during pregnancy and lactation and in climacteric period." | 8.87 | [Lamotrigine in treatment of women with epilepsy]. ( Agranovich, OV; Dranko, DV; Vlasov, PN, 2011) |
| "To provide an overview of the available literature concerning the prevention of congenital malformations following the use of lamotrigine (LMT) during pregnancy." | 8.85 | [Teratogenic effects of lamotrigine in women with bipolar disorder]. ( Berwaerts, K; De Fruyt, J; Sienaert, P, 2009) |
| " Controlled trials in elderly patients with epilepsy demonstrate efficacy and tolerability comparable to gabapentin." | 8.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| "Lamotrigine (LTG) is a generally well-tolerated antiepileptic drug (AED) with broad-spectrum efficacy in several forms of partial and generalized epilepsy and is also licensed for use in bipolar disorder in several countries." | 8.84 | Development of psychosis in patients with epilepsy treated with lamotrigine: report of six cases and review of the literature. ( Boehme, V; Brandt, C; Fueratsch, N; Kramme, C; Pieridou, M; Pohlmann-Eden, B; Villagran, A; Woermann, F, 2007) |
| "This paper briefly reviews and comments on the development of lamotrigine as a treatment for bipolar disorder." | 8.84 | Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence. ( Ascher, JA; Bowden, CL; Calabrese, JR; DeVeaugh-Geiss, J; Evoniuk, G; Weisler, RH, 2008) |
| "Lamotrigine is an anticonvulsant drug with good efficacy and safety in the treatment of epilepsy." | 8.82 | Lamotrigine in mood disorders. ( Green, B, 2003) |
| "To correlate lamotrigine (LTG) serum concentrations (levels) with tolerability in patients with epilepsy." | 8.82 | Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. ( Adams, DJ; Bazil, CW; Buchsbaum, R; Du, Y; Hager, M; Hirsch, LJ; Morrell, MJ; Resor, SR; Spencer, HT; Straka, T; Weintraub, D, 2004) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 8.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "Lamotrigine is an antiepileptic drug which is believed to suppress seizures by inhibiting the release of excitatory neurotransmitters." | 8.78 | Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. ( Chrisp, P; Goa, KL; Ross, SR, 1993) |
| "S Food and Drug Administration warnings that lamotrigine, a common sodium channel modulating anti-seizure medication (NaM-ASM), could increase the risk of sudden death in patients with structural or ischaemic cardiac disease, however, its implications for Sudden Unexpected Death in Epilepsy (SUDEP) are unclear." | 8.31 | Risk of sudden unexpected death in epilepsy (SUDEP) with lamotrigine and other sodium channel-modulating antiseizure medications. ( Auvrez, C; Barnard, S; Berkovic, SF; Chen, Z; Cook, MJ; D'Souza, W; Devinsky, O; Friedman, D; Kwan, P; Laze, J; Nightscales, R; O'Brien, TJ; Perucca, P; Sivathamboo, S; Tao, G, 2023) |
| " In the present work, BCRP's role as a mechanism that might contribute to drug-resistant epilepsy (DRE) in a mouse model of acute seizures was studied with further assessment of the effect of its inhibition by ko143 and metformin (MET) on lamotrigine (LTG) bioavailability and efficacy." | 8.31 | Implications of BCRP modulation on PTZ-induced seizures in mice: Role of ko143 and metformin as adjuvants to lamotrigine. ( El-Sayed, NS; Fathelbab, MH; Harby, SA; Khalil, NA; Saleh, SR; Thabet, EH, 2023) |
| "Dose-adjusted lamotrigine troughs in epilepsy patients with variant UGT2B7 -161C > T or UGT1A4*3 c." | 8.31 | Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy. ( Božina, N; Domjanović, IK; Gadže, ŽP; Ganoci, L; Lovrić, M; Romić, ZČ; Šimičević, L; Sporiš, IŠ; Trkulja, V, 2023) |
| "Our results do not support a significant difference in the reporting risk for cardiac arrest, syncope, tachyarrhythmia, and bradyarrhythmia with lamotrigine in the epileptic indication." | 8.31 | Investigation of cardiac arrhythmia events in patients treated with lamotrigine: FDA adverse event reporing system analysis. ( Aboukaoud, M; Maor, E; Wilf-Yarkoni, A, 2023) |
| "Maintaining seizure control with lamotrigine is complicated by altered pharmacokinetics and existence of subpopulations in whom clearance increases or remains constant during pregnancy." | 8.31 | Empiric dosing strategies to predict lamotrigine concentrations during pregnancy. ( Barry, JM; Birnbaum, AK; French, JA; Harden, CL; Karanam, A; Pennell, PB, 2023) |
| "In a nation-wide population-based longitudinal register linkage study for the first time 1) to investigate long-term response to lithium in patients with bipolar disorder with and without comorbid epilepsy, and 2) within patients with bipolar disorder and comorbid epilepsy to compare differences in responses between lithium, valproate and lamotrigine." | 8.12 | Response to lithium and anticonvulsants among patients with bipolar disorder with and without comorbid epilepsy - A nation-wide population-based longitudinal study. ( Budtz-Jørgensen, E; Gerds, T; Kessing, LV; Ziersen, SC, 2022) |
| "AbstractThe aim of this study was to explore the effect of lamotrigine (LTG) on blood ammonia level in patients with epilepsy and identify risk factors affecting blood ammonia level." | 8.12 | Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine. ( Chen, J; Chen, X; Chen, Y; Miao, J; Wang, R; Zeng, J; Zhuang, X, 2022) |
| "To compare the hazard for all-cause mortality and mortality due to heart failure (HF) between valproate (VPA) and levetiracetam (LEV)/lamotrigine (LTG) users in patients aged ≥ 65 with comorbidities of epilepsy and HF." | 8.12 | The Relationship Between Valproate and Lamotrigine/Levetiracetam Use and Prognosis in Patients With Epilepsy and Heart Failure: A Danish Register-Based Study. ( Gardella, E; Kragholm, K; Liang, D; Polcwiartek, C; Sessa, M, 2022) |
| "This study has developed and validated a novel UPLC method to quantify lacosamide (LCM), oxcarbazepine (OXC), and lamotrigine (LTG) in children with epilepsy in Xinjiang, China." | 8.02 | Development and validation of an innovative UPLC method to quantify lacosamide, oxcarbazepine, and lamotrigine in the serum of children with epilepsy in China. ( Feng, J; Li, HJ; Ma, L; Sun, L; Sun, Y; Wang, TT; Yu, J; Yu, LH; Zhao, T, 2021) |
| "During pregnancy, various physiological changes occur that can alter the pharmacokinetics of antiepileptic drugs, such as lamotrigine (LTG)." | 8.02 | Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy. ( Cao, YF; Guo, Y; Sun, XY; Tao, YY; Wang, ML; Wang, ZY; Zhao, L, 2021) |
| "Lamotrigine and lacosamide show similar effectiveness in diffuse glioma patients with epilepsy." | 8.02 | The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide. ( Dirven, L; Fiocco, M; Koekkoek, JAF; Kouwenhoven, MCM; Taphoorn, MJB; van den Bent, MJ; van der Meer, PB; van Opijnen, MP, 2021) |
| "This prospective cohort study of therapeutic drug monitoring included 582 Chinese epilepsy patients receiving lamotrigine monotherapy." | 8.02 | Redefining the age-specific therapeutic ranges of lamotrigine for patients with epilepsy: A step towards optimizing treatment and increasing cost-effectiveness. ( Ma, YY; Wang, HX; Wang, ML; Zhao, LM; Zhao, MM, 2021) |
| "We sought to explore the effects of sodium valproate combined with lamotrigine on quality of life and serum inflammatory factors in patients with poststroke secondary epilepsy." | 7.96 | Effects of Sodium Valproate Combined with Lamotrigine on Quality of Life and Serum Inflammatory Factors in Patients with Poststroke Secondary Epilepsy. ( Guo, D; Hao, F; Li, X; Liu, X; Sun, J; Tang, W; Tao, S, 2020) |
| "Determine the genetic cause of the intellectual disability, epilepsy and Brugada syndrome of the patient and try to establish a possible correlation between the genetic background and the Brugada syndrome pattern under lamotrigine treatment." | 7.96 | Lamotrigine induced Brugada-pattern in a patient with genetic epilepsy associated with a novel variant in SCN9A. ( Alcalde, M; Banfi, P; Brugada, R; Campuzano, O; Coll, M; Mauri, M; Oliva, A; Princiotta, L; Striano, P; Versino, M, 2020) |
| "Dose individualization is essential in epilepsy treatment, especially in antiepileptic drugs that present high interindividual variability such as lamotrigine." | 7.96 | Dosing Recommendations Based on Population Pharmacokinetics of Lamotrigine in Mexican Adult Patients With Epilepsy. ( Chávez-Castillo, CE; Medellín-Garibay, SE; Milán-Segovia, RDC; Rodríguez-Leyva, I; Romano-Moreno, S, 2020) |
| "The aim of this study was to evaluate the effects of valproate (VPA), lamotrigine (LTG), and levetiracetam (LEV) on bone turnover and bone mineral density (BMD) in newly diagnosed adult patients with epilepsy." | 7.96 | Effects of valproate, lamotrigine, and levetiracetam monotherapy on bone health in newly diagnosed adult patients with epilepsy. ( Guo, Y; Huang, Y; Lin, Z; Yu, L, 2020) |
| "56 G > A rs17183814 on the response to lamotrigine monotherapy in patients with focal epilepsy in Herzegovina area, Bosnia and Herzegovina." | 7.91 | Lack of association of SCN2A rs17183814 polymorphism with the efficacy of lamotrigine monotherapy in patients with focal epilepsy from Herzegovina area, Bosnia and Herzegovina. ( Basic, S; Bozina, N; Markovic, I; Pejanovic-Skobic, N, 2019) |
| "The aims of this study were to identify the influencing factors such as gender, age, dose and combinations of other antiepileptic drugs (AEDs), especially in triple combinations on the pharmacokinetic of Lamotrigine (LTG) in epilepsy patients of Northwest Chinese Han population." | 7.91 | The influence of concomitant antiepileptic drugs on lamotrigine serum concentrations in Northwest Chinese Han population with epilepsy. ( Han, X; Huang, J; Lv, J; Ma, L; Nie, X; Peng, L; Wang, J; Xia, L; Zan, X, 2019) |
| "To evaluate the pharmacokinetic changes in lamotrigine (LTG) from prepregnancy to postpartum and to assess the impact of therapeutic drug monitoring (TDM) on seizure management during pregnancy in a Chinese population." | 7.91 | Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy. ( Ding, Y; Guo, Y; Tan, X; Zhang, S, 2019) |
| "This study investigated the effect of delayed or missed doses on the pharmacokinetics (PK) of lamotrigine (LTG) in children with epilepsy and established remedial dosing recommendations for nonadherent patients." | 7.91 | Remedial dosing recommendations for delayed or missed doses of lamotrigine in pediatric patients with epilepsy using Monte Carlo simulations. ( Ding, JJ; Jiao, Z; Wang, CY; Yu, EQ; Zhang, XH, 2019) |
| "To assess the relative risk of oral clefts associated with maternal use of high and low doses of topiramate during the first trimester for epilepsy and nonepilepsy indications." | 7.88 | Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. ( Bateman, BT; Cohen, JM; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Patorno, E; Pennell, PB, 2018) |
| "To evaluate the impact of maternal UGT1A4 and UGT2B7 genetic polymorphisms and sex of foetus on gestation-induced changes in lamotrigine (LTG) clearance during pregnancy and post-partum (PP)." | 7.88 | UGT polymorphisms and lamotrigine clearance during pregnancy. ( Ekström, L; Hansen, TF; Öhman, I; Petrenaite, V; Sabers, A; Sæbye, D; Tomson, T, 2018) |
| "Adults with epilepsy on lamotrigine monotherapy (n = 131) or lamotrigine + valproate treatment (n = 74) were genotyped and steady-state lamotrigine and valproate morning troughs were determined as a part of routine therapeutic drug monitoring." | 7.88 | Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. ( Božina, N; Čajić, I; Ganoci, L; Klarica Domjanović, I; Lovrić, M; Petelin-Gadže, Ž; Trkulja, V, 2018) |
| "Valproic acid (VPA) is widely used in the treatment of children with epilepsy." | 7.83 | Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine. ( Dong, Y; Guo, Y; Liang, M; Meng, H; Qiu, F; Wang, Q; Yun, W; Zhao, L, 2016) |
| "It may be appropriate to reach a daily lamotrigine dose above 250 mg in adult patients suffering from epilepsy for more than 5 years using lamotrigine as monotherapy." | 7.83 | Lamotrigine as monotherapy in clinical practice: efficacy of various dosages in epilepsy. ( Eilam, A; Gilad, R; Warshavsky, A, 2016) |
| "Although it has been reported that some antiepileptic drugs have inducing or inhibiting effects on lamotrigine (LTG) clearance, whether they have the same effects in Asian epilepsy patients as in those in other countries has not been clarified, especially in children." | 7.83 | The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy. ( Abe, S; Azuma, Y; Ishihara, N; Ito, Y; Itomi, K; Kidokoro, H; Kojima, S; Kurahashi, H; Kurahashi, N; Maruyama, K; Natsume, J; Negoro, T; Okumura, A; Suzuki, M; Takeuchi, T; Tsuji, T; Watanabe, K; Yamada, K; Yamamoto, H, 2016) |
| "The pharmacokinetics of Lamotrigine (LTG) varies widely among patients with epilepsy." | 7.83 | Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. ( Ding, MP; Jin, B; Liu, ZR; Lu, RY; Shen, CH; Tang, YL; Wang, S; Zhang, YX, 2016) |
| "Lamotrigine (LTG) is a widely used antiepileptic-drug (AED) for the treatment of epilepsy." | 7.81 | Effect of comedication on lamotrigine clearance in Korean epilepsy patients. ( Hong, SB; Joo, EY; Kim, HJ; Kim, TE; Lee, SY; Seo, DW, 2015) |
| "To assess the effect and tolerability of zonisamide (ZNS) as adjunctive treatment for difficult-to-treat epilepsy in adult Scandinavian patients." | 7.81 | Retention rate of zonisamide in intractable epilepsy. ( Andersen, H; Lindstrøm, P; Nakken, KO, 2015) |
| " After a lamotrigine-induced Stevens-Johnson syndrome (SJS) occurred, she presented with total collapse of the right lung on admission, which was subsequently complicated by a pneumothorax during conservative treatment, but with the re-expansion of the right upper lobe after intervention." | 7.81 | Bronchiolitis obliterans complicating a pneumothorax after Stevens-Johnson syndrome induced by lamotrigine. ( Cheng, QS; Li, XF; Lu, Q; Ni, YF; Wang, WP; Wei, YN, 2015) |
| "This study evaluated the influence of concomitant antiepileptic drugs (AEDs) on the plasma concentration of lamotrigine (LTG) in pediatric patients with epilepsy." | 7.81 | Influence of uridine diphosphate glucuronosyltransferase inducers and inhibitors on the plasma lamotrigine concentration in pediatric patients with refractory epilepsy. ( Ikeda, H; Imai, K; Inoue, Y; Kagawa, Y; Nakai, M; Takahashi, M; Takahashi, Y; Yamamoto, Y, 2015) |
| "Lamotrigine (LTG) is widely used in the treatment of children with epilepsy." | 7.81 | Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy. ( Dong, Y; Guo, Y; Liang, M; Qiu, F; Wang, Q; Yun, W; Zhao, L, 2015) |
| "This randomized, double-blind, multiple-dose, steady-state, fully replicated bioequivalence study compared generic lamotrigine to brand-name Lamictal in "generic-brittle" patients with epilepsy (n = 34) who were already taking lamotrigine." | 7.81 | Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard. ( Jiang, W; Jones, JW; Kane, MA; Krumholz, A; Lionberger, R; Polli, JE; Temple, R; Ting, TY; Wong, J, 2015) |
| "Lamotrigine (LTG) is commonly used to control seizure in epilepsy patients and with referenced therapeutic windows in clinical practice." | 7.81 | Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients. ( Chen, Z; Huang, M; Li, H; Li, J; Wang, X; Xie, W; Zhang, J; Zhou, L; Zhou, Y, 2015) |
| "The aims of this study were to characterize a lamotrigine-resistant kindled model of epilepsy in mice, to study the anticonvulsant effect of carbamazepine (CBZ) and valproic acid (VPA), and to probe into the mechanism for resistance." | 7.80 | Characterization of a lamotrigine-resistant kindled model of epilepsy in mice: evaluation of drug resistance mechanisms. ( Mehndiratta, M; Pillai, KK; Singh, E, 2014) |
| "The combination of lamotrigine and valproate/divalproex sodium has been shown to be effective in the treatment of refractory epilepsy." | 7.79 | Valproate and lamotrigine in pediatric patients with refractory epilepsy: after the first year. ( Thome-Souza, S; Valente, KD, 2013) |
| "Lamotrigine (LTG) has a good efficacy and tolerability as initial monotherapy for patients with newly diagnosed epilepsy (NDE)." | 7.79 | Depression in patients with newly diagnosed epilepsy predicts lamotrigine-induced rash: a short-term observational study. ( Park, SP, 2013) |
| "To estimate the incidence of sudden unexpected death in epilepsy (SUDEP) in Rogaland County, Norway, in the period August 1 1995-July 31 2005, and to investigate whether use of lamotrigine (LTG) was associated with increased risk in female patients or other subgroups." | 7.78 | Increased risk of sudden unexpected death in epilepsy in females using lamotrigine: a nested, case-control study. ( Aurlien, D; Gjerstad, L; Larsen, JP; Taubøll, E, 2012) |
| "The purpose of this case series is to characterize a recently identified association of the antiepileptic drug (AED) lamotrigine with aseptic meningitis based on cases reported to the Food and Drug Administration (FDA)'s Adverse Event Reporting System (AERS) database." | 7.78 | Lamotrigine and aseptic meningitis. ( Avigan, M; Kortepeter, C; Simms, KM, 2012) |
| "We recruited 222 patients with epilepsy who were prescribed lamotrigine in monotherapy or polytherapy." | 7.78 | Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. ( Božina, N; Božina, T; Granić, P; Hajnšek, S; Kuzman, MR; Lalić, Z; Lovrić, M; Sporiš, D, 2012) |
| "To establish a population pharmacokinetics (PPK) model for lamotrigine (LTG) in Chinese children with epilepsy in order to formulate an individualized dosage guideline." | 7.78 | Population pharmacokinetics of lamotrigine in Chinese children with epilepsy. ( Bao, WQ; He, DK; Li, L; Liu, HT; Lu, W; Qin, J; Song, XQ; Wang, L; Zhang, JM; Zhang, S, 2012) |
| "To study the effectiveness and safety of lamotrigine monotherapy for treatment of epilepsy, systemic evaluation was carried out on published comparative trials between lamotrigine and carbamazepine." | 7.78 | Effectiveness and safety assessment of lamotrigine monotherapy for treatment of epilepsy. ( Gao, F; He, H; Jiang, W; Li, XW; Liu, YF; Ma, L; Meng, XD; Wei, D, 2012) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 7.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| "Lamotrigine is a newer antiepileptic drug useful as oral adjunctive therapy in refractory epilepsy." | 7.77 | Add-on lamotrigine in pediatric epilepsy in India. ( Jain, R; Juneja, M; Mishra, D, 2011) |
| "To investigate the physiological mechanisms behind the pronounced decline of lamotrigine (LTG) serum concentrations during pregnancy." | 7.77 | Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol. ( Bråthen, G; Brodtkorb, E; Helde, G; Reimers, A, 2011) |
| "Lamotrigine (LTG) which has a widespread use in epilepsy treatment as an antiepileptic agent is metabolized by UDP-glucuronosyl transferase (UGT) enzymes." | 7.77 | The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. ( Aker, RG; Goren, MZ; Gulcebi, MI; Onat, FY; Ozkara, C; Ozkaynakcı, A, 2011) |
| "To evaluate steroid alterations in women with epilepsy (WWE) on lamotrigine monotherapy." | 7.77 | The steroid metabolome in lamotrigine-treated women with epilepsy. ( Dušková, M; Hill, M; Kancheva, L; Kancheva, R; Kubátová, J; Marusič, P; Pařízek, A; Stárka, L; Velíková, M; Vrbíková, J; Zárubová, J, 2011) |
| "We investigated the effect of lamotrigine (LTG) add-on therapy in 50 patients with childhood-onset refractory epilepsy (25 males and 25 females): 15 with localization-related epilepsy, 33 with generalized epilepsy, and 2 with undetermined epilepsy." | 7.77 | [Lamotrigine add-on therapy for childhood-onset refractory epilepsy: comparison of the efficacy between 3 months and 6 months after initiation]. ( Endoh, F; Kobayashi, K; Ohtsuka, Y; Watanabe, K; Yoshinaga, H, 2011) |
| "We present an implementation of a method we previously reported allowing the newer antiepileptic drugs (AEDs) rufinamide (RFN) and zonisamide (ZNS) to be simultaneously determined with lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine (MHD) and felbamate (FBM) in plasma of patients with epilepsy using high performance liquid chromatography (HPLC) with UV detection." | 7.76 | Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. ( Albani, F; Baruzzi, A; Candela, C; Contin, M; Mohamed, S; Riva, R, 2010) |
| "The aim of the study was to investigate risk factors for cardiovascular disease in patients with epilepsy using the new antiepileptic drug levetiracetam (LEV), compared with patients taking carbamazepine (CBZ) or lamotrigine (LTG)." | 7.76 | Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. ( Gjerstad, L; Luef, G; Mørkrid, L; Rauchenzauner, M; Svalheim, S; Taubøll, E, 2010) |
| " Patients with clinically stable partial or generalized epilepsy, already receiving lamotrigine or valproic acid on monotherapy, were assessed in two visits: baseline and at 6 months." | 7.76 | Quality of life and treatment satisfaction in Spanish epilepsy patients on monotherapy with lamotrigine or valproic acid. ( Barriga, J; Cobaleda, S; Codina, M; Lahuerta, J; Morales, MD; Viteri, C, 2010) |
| "To assess possible alterations in the pharmacokinetics of lamotrigine (LTG) in menopause, we reviewed the database of the drug monitoring service at the Karolinska University Hospital." | 7.76 | Are lamotrigine kinetics altered in menopause? Observations from a drug monitoring database. ( Lukic, S; Ohman, I; Tomson, T, 2010) |
| "Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter." | 7.76 | Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| "To report on a patient with epilepsy who developed leukopenia and thrombocytopenia during phenobarbital/lamotrigine treatment." | 7.76 | Phenobarbital/Lamotrigine coadministration-induced blood dyscrasia in a patient with epilepsy. ( Calabrò, G; De Sarro, G; Gallelli, L; Siniscalchi, A; Tolotta, GA, 2010) |
| "Lamotrigine (LTG) has shown to confer broad-spectrum, well-tolerated control of epilepsy." | 7.75 | Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy. ( Hardison, HH; Khurana, DS; Kothare, SV; Legido, A; Marks, HG; Melvin, JJ; Piñol-Ripoll, G; Valencia, I, 2009) |
| "We evaluated the serum leptin and insulin as predictors of weight gain in children receiving long-term treatment with valproate (VPA), carbamazepine (CBZ), lamotrigine (LTG)." | 7.75 | States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. ( Fida, NM; Hamed, EA; Hamed, SA, 2009) |
| "Variations in the plasma concentration of levetiracetam during pregnancy and postpartum were prospectively monitored in five women to investigate their potential implications in epilepsy management and child outcome." | 7.75 | Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. ( Cid, AO; Juste, AO; López-Fraile, IP; Modrego, PJ, 2009) |
| "Lamotrigine is frequently used to manage epilepsy during pregnancy." | 7.75 | Lamotrigine and twin pregnancy, incidental event or possible correlation? ( Azimi, AR; Karvigh, SA; Motamedi, M; Navardi, S; Sahraian, MA, 2009) |
| "Using a retrospective chart review, we identified six patients with epilepsy who reported transient emergent psychological symptoms during stable, chronic lamotrigine monotherapy." | 7.75 | End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. ( Frey, LC; Shrestha, A; Spitz, MC; Strom, LA, 2009) |
| "To report a case of severe apnea in an infant exposed to lamotrigine through breast-feeding." | 7.75 | Severe apnea in an infant exposed to lamotrigine in breast milk. ( Aronsen, L; Nordmo, E; Småbrekke, L; Vorren, S; Wasland, K, 2009) |
| "The purpose of this study was to derive a population pharmacokinetics (PPK) model of lamotrigine clearance as well as to identify and describe factors that influence it in Serbian patients with epilepsy." | 7.75 | Population pharmacokinetics of lamotrigine in patients with epilepsy. ( Jankovic, SM; Milovanovic, JR, 2009) |
| "We prospectively surveyed 23 pregnant women with epilepsy on lamotrigine monotherapy and reported outcome of their pregnancies, including one fetal intrauterine death, one spontaneous abortion and two preterm deliveries." | 7.75 | Prospective surveillance of Croatian pregnant women on lamotrigine monotherapy--aspects of pre-pregnancy counseling and drug monitoring. ( Bakulić, TI; Bosnjak-Pasić, M; Cvitanović-Sojat, L; Demarin, V; Fucić, A; Gjergja-Juraski, R; Mikula, I; Miskov, S, 2009) |
| "This study develops a population pharmacokinetic model for lamotrigine (LTG) in Spanish and German patients diagnosed with epilepsy." | 7.74 | Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ( Buelga, DS; Domínguez-Gil, A; Elger, CE; García, MJ; Otero, MJ; Rivas, N; Santos-Borbujo, J, 2008) |
| "We retrospectively reviewed medical records from 20 patients treated with lamotrigine (LTG) who underwent epilepsy surgery between January 1997 and February 2004." | 7.74 | Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery. ( Aktas, O; Fritz, G; Lehmann, TN; Meencke, HJ; Paul, F; Veauthier, C; Zipp, F, 2007) |
| "The aim of this study was to characterize outcomes in patients with epilepsy who experienced adverse reactions on switching from branded to generic lamotrigine and who were subsequently switched back to the branded formulation." | 7.74 | Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. ( Makus, KG; McCormick, J, 2007) |
| "To characterize the magnitude and course of alterations in total and free lamotrigine (LTG) clearance (Cl) during pregnancy and the postpartum period, to assess the impact of therapeutic drug monitoring (TDM) on seizure frequency, to determine the ratio to individual target LTG concentration that is associated with increased seizure risk, and to evaluate maternal postpartum toxicity." | 7.74 | Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. ( Holley, DK; Koganti, A; Newman, M; Newport, DJ; Peng, L; Pennell, PB; Ritchie, JC; Stowe, ZN, 2008) |
| "To further characterize pregnancy-induced alterations in the pharmacokinetics of lamotrigine (LTG)." | 7.74 | Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. ( Beck, O; Ohman, I; Tomson, T; Vitols, S, 2008) |
| "To establish a population pharmacokinetics (PPK) model of lamotrigine, an antiepileptic drug, in Chinese children with epilepsy to formulate an individualized dosage guideline." | 7.74 | [Population pharmacokinetics of lamotrigine in Chinese children with epilepsy]. ( Lu, W; Wang, L; Zhang, S, 2008) |
| "The infant exposed in the first trimester of pregnancy to the anticonvulsant drug lamotrigine has an increased risk to have an isolated cleft palate or cleft lip deformity." | 7.74 | Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. ( Baldwin, EJ; Glassman, L; Habecker, E; Holmes, LB; Smith, CR; Wong, SL; Wyszynski, DF, 2008) |
| "To evaluate whether the administration of lamotrigine (LTG) or valproate (VPA) changes concentrations of plasma total homocysteine (tHcy), plasma and red-cell folate and plasma Vitamin B-12, we measured these indices in a total of 20 patients with epilepsy before and after a 32-week period of monotherapy of LTG or VPA." | 7.73 | Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy. ( Gidal, BE; Hammer, A; Tamura, T; Vuong, A, 2005) |
| "The aim of the study was to obtain pharmacokinetic data for carbamazepine (CBZ) and its fractions not bound with proteins in bitherapy with lamotrigine (LTG), topiramate (TPM), vigabatrin (VGB) or valproic acid (VPA) in children and adolescents treated for epilepsy." | 7.73 | Pharmacokinetic interactions of carbamazepine with some antiepileptic drugs during epilepsy treatment in children and adolescents. ( Steinborn, B, 2005) |
| "A very simple and fast method has been developed and validated for simultaneous determination of the new generation antiepileptic drugs (AEDs) lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine and felbamate in plasma of patients with epilepsy using high-performance liquid chromatography (HPLC) with spectrophotometric detection." | 7.73 | Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. ( Albani, F; Balboni, M; Baruzzi, A; Callegati, E; Candela, C; Contin, M; Riva, R, 2005) |
| "Authors presented the data on the efficacy and tolerability of the new anticonvulsant drug topiramate (topamax) in the treatment of 110 children aged from 6 months to 16 years with pharmacoresistant types of epilepsy including 42 patients with tuberous sclerosis." | 7.73 | [The efficacy of topiramate (topamax) in the treatment of resistant epilepsy in children]. ( Belousova, ED; Dorofeeva, MIu; Ermakov, AIu, 2005) |
| "Anticonvulsant hypersensitivity syndrome (AHS) developing to lamotrigine, a non-aromatic anticonvulsant, has rarely been reported." | 7.73 | Anticonvulsant hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. ( Gogtay, NJ; Kanchan, S; Karande, S; Kshirsagar, NA, 2006) |
| "To determine whether the efficacy and tolerability of adjunctive lamotrigine differ as a function of whether persons with mental retardation and refractory epilepsy resided in institutions or the community." | 7.73 | Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation. ( Hammer, AE; McKee, JR; Sunder, TR; Vuongc, A, 2006) |
| "A four-year-old male with symptomatic generalized epilepsy presented with ataxia, eye rolling, and episodes of back arching which were of non-epileptic origin following the introduction of clobazam at 0." | 7.73 | Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. ( Aylett, SE; Berry, D; Cross, H, 2006) |
| " The mother had been treated with valproic acid (1800mg per day) and lamotrigine (100mg per day) throughout pregnancy." | 7.72 | Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. ( Cogulu, O; Gunduz, C; Kultursay, N; Ozkinay, F; Yilmaz, D, 2003) |
| " In the present study, lamotrigine (LTG), one of the newer antiepileptic drugs, was evaluated for its effect on epilepsy, mood and memory in mice." | 7.72 | Effects of folic acid and lamotrigine therapy in some rodent models of epilepsy and behaviour. ( Ali, A; Pal, SN; Pillai, KK, 2003) |
| "This open-label, cross-sectional study compared (1) endocrine and lipid measures during the early follicular phase of the menstrual cycle; (2) prevalence of menstrual disorders (from patient diaries recorded over three cycles); and (3) body weight of women with epilepsy on lamotrigine monotherapy (n=119) with those on valproate monotherapy (n=103) for <5 years." | 7.72 | Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. ( Ayala, R; Dam, M; Gomez, G; Isojärvi, J; Messenheimer, J; Morrell, MJ; O'Neill, F; Taylor, AE; Tennis, P, 2003) |
| "This study was performed to clarify alterations in lamotrigine (LTG) clearance during pregnancy and childbirth." | 7.72 | The impact of pregnancy and childbirth on the metabolism of lamotrigine. ( Helmers, SL; Henry, TR; Montgomery, JQ; Newport, DJ; Pennell, PB; Stowe, ZN, 2004) |
| "To evaluate changes in lamotrigine (LTG) clearance before, during, and after pregnancy." | 7.71 | Lamotrigine clearance during pregnancy. ( Blesi, K; Leppik, IE; Remmel, R; Sathanandan, ST; Tran, TA, 2002) |
| "In 1992, the International Lamotrigine Pregnancy Registry was initiated to enroll prospectively and to monitor pregnancies exposed to lamotrigine (LTG) for the occurrence of major birth defects." | 7.71 | Preliminary results on pregnancy outcomes in women using lamotrigine. ( Eldridge, RR; Tennis, P, 2002) |
| "To determine whether long-term treatment with valproate (VPA) and/or lamotrigine (LTG) in children with epilepsy is associated with altered growth and/or bone metabolism." | 7.71 | Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. ( Atkinson, SA; Guo, CY; Ronen, GM, 2001) |
| "To determine the tolerability of lamotrigine in elderly patients with epilepsy." | 7.71 | The tolerability of lamotrigine in elderly patients with epilepsy. ( Giorgi, L; Gomez, G; Hammer, AE; O'Neill, F; Risner, M, 2001) |
| "An observational study of all children with intractable epilepsy at the Paediatric Institute prescribed Lamotrigine as an add-on therapy between January 1994 and November 1998 was conducted." | 7.71 | Lamotrigine as an add-on therapy in intractable paediatric epilepsy--the Kuala Lumpur Hospital experience. ( Hussain, IH; Sofiah, A; Vigneswari, G, 2001) |
| "Lamotrigine (LTG) is a valuable addition to the medical management of epilepsy with wide spectrum of efficacy and good outcomes for quality of life." | 7.70 | Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. ( Beran, RG; Gibson, RJ, 1998) |
| "To evaluate the effect of lamotrigine (LTG) on several humoral and cellular immune functions in children with epilepsy and the change in immunological status in patients with LTG-induced rash." | 7.70 | Lamotrigine hypersensitivity in childhood epilepsy. ( Iannetti, P; Pacifici, R; Raucci, U; Zuccaro, P, 1998) |
| "To describe significant positive or negative psychotropic effects of lamotrigine (LTG) observed in epilepsy patients with mental retardation (MR)." | 7.70 | Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. ( Devinsky, O; Dhoon, A; Ettinger, AB; Kanner, A; Saracco, J; Weisbrot, DM, 1998) |
| "To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation." | 7.70 | The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. ( Chadwick, DW; Fenwick, PB; Mawer, GE; Sander, JW; Wong, IC, 1999) |
| "The authors examined the interindividual correlation between saliva and serum concentrations of lamotrigine (LTG) and the relationship between LTG concentration in saliva and the free LTG concentration in serum in 40 patients with epilepsy, aged 16 to 73 years, receiving stable doses of LTG and comedication." | 7.70 | Saliva and serum concentration of lamotrigine in patients with epilepsy. ( Klitgaard, NA; Kristensen, O; Tsiropoulos, I, 2000) |
| "We sought to determine the long-term retention rates of lamotrigine (LTG), gabapentin (GBP), and topiramate (TPM) therapy for patients at a tertiary referral clinic for chronic, refractory epilepsy." | 7.70 | Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. ( Lhatoo, SD; Polizzi, G; Sander, JW; Wong, IC, 2000) |
| "This open study reports the use of lamotrigine in 93 adults and children with drug resistant epilepsy." | 7.69 | Lamotrigine: clinical experience in 93 patients with epilepsy. ( Buchanan, N, 1995) |
| "Fifty children and adolescents with intractable epilepsy were treated with lamotrigine." | 7.69 | Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. ( Bauzienè, R; Uvebrant, P, 1994) |
| "We prospectively monitored our experience of lamotrigine as add-on therapy in 45 patients with refractory epilepsy." | 7.69 | Impact of lamotrigine on patients with refractory epilepsy: the Leicester experience. ( Martin, PJ; Millac, PA, 1994) |
| "Fifty-two children with intractable epilepsy received lamotrigine as add-on therapy on a compassionate basis." | 7.69 | [Treatment of childhood epilepsy with lamotrigine. An evaluation of efficacy in different types of epilepsy]. ( Sommer, B; Uldall, PV, 1996) |
| "This study was initiated to evaluate the long-term safety, tolerability and effect on seizure control of lamotrigine (Lamictal) in paediatric patients with epilepsy." | 7.69 | Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy. ( Alving, J; Besag, FM; Dulac, O; Mullens, EL, 1997) |
| "A retrospective survey was carried out of add-on treatment with lamotrigine (LTG) and vigabatrin (GVG) in 109 children with severe epilepsy, treated between 1987 and 1994, identified from a total population of 300 patients seen annually, in a tertiary referral outpatient clinic in Cardiff, Wales." | 7.69 | A survey of lamotrigine and vigabatrin treatment in children with severe epilepsy. ( Gordon, GS; Schapel, GJ; Wallace, SJ, 1997) |
| "To examine the safety of lamotrigine (LTG) used in general practice to treat epilepsy." | 7.69 | Safety of long-term lamotrigine in epilepsy. ( Freemantle, SN; Mackay, FJ; Mann, RD; Pearce, GL; Wilton, LV, 1997) |
| "Sound-induced seizures in genetically epilepsy-prone rats were used to compare the anticonvulsant effect of phenytoin and diazepam with compounds which decrease glutamatergic neurotransmission including excitatory amino acid antagonists acting at N-methyl-D-aspartate (NMDA) receptors: D(-)CPPene, CGP 37849 and MK 801 or at the glycine/NMDA site: ACPC (1-aminocyclopropane-dicarboxylic acid) (partial agonist) or non-NMDA receptors: NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]-quinoxaline." | 7.68 | Excitatory amino acid antagonists, lamotrigine and BW 1003C87 as anticonvulsants in the genetically epilepsy-prone rat. ( al-Zubaidy, ZA; Chapman, AG; Meldrum, BS; Smith, SE, 1993) |
| "We report the effects of the addition of lamotrigine, a novel antiepileptic drug, to the therapy of 125 patients with severe refractory epilepsy." | 7.68 | The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. ( Hart, YM; Patsalos, PN; Sander, JW; Shorvon, SD; Trevisol-Bittencourt, PC, 1990) |
| "Lamotrigine is an antiepileptic drug that can be used to control many types of seizures as a single-agent or an add-on therapy in patients over 2 years of age." | 6.82 | Lamotrigine induced priapism in children: case analysis and literature review. ( Cao, SS; Cao, XY; Ge, J; Guan, Y; Mu, F; Qiao, Y; Tang, M; Wang, JW, 2022) |
| "Lamotrigine (LTG) is an antiepileptic drug (AED) that was approved in Japan in 2008." | 6.77 | Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients. ( Inoue, Y; Kagawa, Y; Matsuda, K; Takahashi, Y; Yamamoto, Y, 2012) |
| " The similarity of CL/F values also was reflected by the similar exposure (AUCss), Cmax, and Cmin values of TPM in the absence, and presence of LTG." | 6.71 | Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. ( Berry, DJ; Bialer, M; Brodie, MJ; Chadwick, D; Doose, DR; Oxbury, J; Schwabe, S; Wilson, EA, 2003) |
| " Patients were converted during an lamotrigine via a protocol-specified dosing algorithm or to conventional therapy via standard dosing guidelines." | 6.71 | Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. ( Hammer, AE; Kaminow, L; Schimschock, JR; Vuong, A, 2003) |
| " An important side effect associated with the long-term use of some antiepileptic drugs is change in body weight, followed by an increased risk for subsequent maturational problems in pediatric epilepsy patients." | 6.70 | Normal growth during lamotrigine monotherapy in pediatric epilepsy patients -- a prospective evaluation of 103 children and adolescents. ( Ueberall, MA, 2001) |
| "Lamotrigine is an effective add-on therapy against a range of epileptic seizure types." | 6.69 | Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. ( Abbott, R; Dellaportas, CI; Findley, LJ; Gibberd, FB; Gross, M; Park, DM; Perkin, GD; Steiner, TJ, 1999) |
| "Lamotrigine was effective in all seizure types examined, particularly for typical and atypical absence seizures." | 6.68 | Lamotrigine for the treatment of epilepsy in childhood. ( Alving, J; Besag, FM; Dulac, O; Hosking, G; Spencer, SC; Wallace, SJ, 1995) |
| " The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43." | 6.68 | Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ( Boreus, L; Eriksson, AS; Hoppu, K; Nergårdh, A, 1996) |
| " Headache, drowsiness, faintness, and diplopia, the common adverse events (AEs), were mild to moderate in intensity and occurred in 50-75% of patients in both groups (except for diplopia, occurring only with LTG)." | 6.68 | Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study. ( Gay, P; Lai, AA; Madsen, J; Matsuo, F; Risner, ME; Rollins, DE; Tolman, KG, 1996) |
| " Both dosage regimens of lamotrigine were well tolerated." | 6.68 | A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. ( Dam, M; Reunanen, M; Yuen, AW, 1996) |
| " Subjects were allocated to 1 of 2 dosing schedules according to their concomitant AEDs." | 6.67 | A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. ( Hamilton, MJ; Oxley, JR; Patsalos, PN; Sander, JW; Yuen, WC, 1990) |
| " Dosage was adjusted on the basis of estimated half-life." | 6.66 | Seven day administration of lamotrigine in epilepsy: placebo-controlled add-on trial. ( Beintema, DJ; Binnie, CD; Debets, RM; Meijer, JW; Meinardi, H; Peck, AW; Van Emde Boas, W; Westendorp, AM; Yuen, WC, 1987) |
| "Lamotrigine (LTG) is a second generation anti-epileptic drug (AED) with broad spectrum of activity, a favourable side-effect profile, simpler dosing than earlier drugs and efficacious in diverse epilepsy syndromes." | 6.53 | A pharmacological overview of lamotrigine for the treatment of epilepsy. ( Arjunan, K; Eswaramoorthy, M; Jakki, SL; Nanjan, MJ; Senthil, V; Shanmuganathan, S; Yasam, VR, 2016) |
| "Lamotrigine has been demonstrated to be effective as both an antiepileptic drug and a mood stabiliser." | 6.49 | Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons? ( Dodd, S; Horgan, D; Vajda, FJ, 2013) |
| "Lamotrigine is a sodium-channel-modulating, antiepileptic drug (AED), which was approved in the USA in 1994 for use in partial-onset seizures." | 6.48 | Lamotrigine use in pregnancy. ( Aggarwal, P; Moore, JL, 2012) |
| "Epilepsy is a neurological disorder primarily characterized by recurrent, unprovoked seizures resulting from excessive or synchronous neuronal activity in the brain." | 6.46 | Extended-release lamotrigine in the treatment of patients with epilepsy. ( Sajatovic, M; Syed, TU, 2010) |
| " The bioavailability of LTG-XR is similar to that of LTG-IR, except in patients taking enzyme-inducing AEDs in whom the bioavailability of LTG-XR is 21% lower." | 6.45 | Once-daily lamotrigine extended release for epilepsy management. ( Rheims, S; Ryvlin, P, 2009) |
| "Lamotrigine is a relatively new AED which is licensed in many countries for use as an initial monotherapy." | 6.43 | Lamotrigine versus carbamazepine monotherapy for epilepsy. ( Gamble, CL; Marson, AG; Williamson, PR, 2006) |
| "Lamotrigine has good absorption, minimal plasma protein binding and linear pharmacokinetics." | 6.43 | Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. ( Biton, V, 2006) |
| "Lamotrigine is a broad-spectrum antiepileptic drug, initially approved in 1994 for the adjunctive treatment of partial seizures in adults and for the generalized seizures of Lennox-Gastaut syndrome in pediatric (>2 years old) and adult populations." | 6.43 | Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders. ( Arif, H; Hirsch, LJ; Malik, S, 2006) |
| "Lamotrigine is an anti-epileptic agent with broad efficacy." | 6.42 | Review of lamotrigine and its clinical applications in epilepsy. ( Choi, H; Morrell, MJ, 2003) |
| "Plasma concentrations of lamotrigine, an antiepileptic drug obtained in three adult controlled clinical trials conducted in the United States were pooled and analyzed using NONMEM, a population pharmacokinetic computer program, to facilitate development of dosing guidelines." | 6.40 | Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. ( Chen, C; Cox, E; Fiedler-Kelly, J; Grasela, TH; Risner, ME; Womble, GP, 1999) |
| "Vigabatrin is a specific and irreversible inhibitor of the enzyme gamma-amino-butyric-acid (GABA) transferase." | 6.39 | [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. ( Krämer, G; Vogt, H, 1995) |
| "Felbamate was licensed in 1993 for use as adjunctive therapy or monotherapy in adults with partial or tonic-clonic seizures and as adjunctive therapy for children with the Lennox-Gastaut syndrome." | 6.39 | Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin. ( Laxer, KD, 1994) |
| "Lamotrigine is an antiepileptic agent which blocks voltage-dependent sodium channels, thereby preventing excitatory neurotransmitter release." | 6.39 | Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. ( Fitton, A; Goa, KL, 1995) |
| "Lamotrigine." | 5.91 | Formulation and characterization of lamotrigine nasal insert targeted brain for enhanced epilepsy treatment. ( Abdel-Hakeem, M; Abdelkader, G; Abdelmonem, R; El-Enin, HAA, 2023) |
| "Lamotrigine toxicity can cause coma, seizures, and intraventricular conduction disturbances, and treatment options include good supportive care." | 5.72 | Effectiveness of multiple-dose activated charcoal in lamotrigine poisoning: a case series. ( Haga, Y; Hanazawa, T; Hatanaka, K; Kamijo, Y; Kitamoto, T; Ochiai, H; Yoshizawa, T, 2022) |
| "The study intended to analyze the effects of a group nursing intervention on quality of life (QoL) of patients with epilepsy (EP) after treatment with sodium valproate combined with lamotrigine." | 5.69 | Value of Group Intervention on Prognosis of Quality of Life in Epileptic Patients Treated With Sodium Valproate and Lamotrigine. ( Fan, X; Li, X; Li, Y; Wang, D; Wang, M; Xie, Z; Yin, J; Yu, J; Yu, M, 2023) |
| "Carbamazepine was ineffective, and seizures were exacerbated with levetiracetam (LEV)." | 5.56 | Improvement of epilepsy with lacosamide in a patient with ring chromosome 20 syndrome. ( Goji, A; Kagami, S; Mori, T; Tayama, T; Toda, Y, 2020) |
| "Tremor was visually assessed by clinical tremor rating scales." | 5.51 | Lamotrigine Induces Tremor among Epilepsy Patients Probably via Cerebellar Pathways. ( Farkas, Z; Juhos, V; Kamondi, A; Kelemen, A; Kovács, A; Szűcs, A, 2019) |
| "The objectives of this study were to investigate the effect of age on pharmacokinetic parameters of lamotrigine (LTG) and estimate parameter variability." | 5.48 | Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age. ( Birnbaum, AK; Brundage, RC; Kistner, BM; Leppik, IE; Pennell, PB; Polepally, AR; Ramsay, RE; Remmel, RP; White, JR, 2018) |
| " Therefore, this study aimed to establish a population pharmacokinetic (PPK) model of LTG in Chinese children with epilepsy and to comprehensively evaluate the effects of genetic variations in drug-metabolizing enzymes, transporters, and a transcriptional regulator on LTG pharmacokinetics." | 5.48 | A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy. ( Chen, Y; Lu, T; Wang, H; Wang, Z; Xu, S; Zhao, L; Zhao, M, 2018) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 5.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| "Lamotrigine (LTG) is a broad-spectrum antiepileptic drug that is widely used in clinic." | 5.46 | Effect of lamotrigine on epilepsy-induced cognitive impairment and hippocampal neuronal apoptosis in pentylenetetrazole-kindled animal model. ( Dong, RF; Tian, S; Wang, WP; Zhang, B; Zhang, C; Zhang, JW, 2017) |
| " The correlation with dose may be a spurious finding related to the fact that physicians, in adjusting dosage according to clinical response, are more likely to use larger doses in patients with high clearance values." | 5.43 | An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. ( Alexandre, V; Baldoni, AO; de Santi Ferreira, FI; Freitas-Lima, P; Martinez, EZ; Pereira, LR; Perucca, E; Queiroz, RH; Sakamoto, AC, 2016) |
| "Participants with focal epilepsy were randomised to receive lamotrigine, levetiracetam or zonisamide." | 5.41 | Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. ( Appleton, R; Baker, G; Balabanova, S; Brown, R; Burnside, G; Hindley, D; Howell, S; Hughes, DA; Leach, JP; Maguire, M; Marson, AG; Mohanraj, R; Plumpton, CO; Sills, G; Smith, D; Smith, PE; Taylor, C; Tudur-Smith, C; Williamson, PR, 2021) |
| "The anti-epileptic drug lamotrigine (LTG) has been widely used to treat various neurological disorders, including epilepsy and bipolar disorder." | 5.41 | Understanding Lamotrigine's Role in the CNS and Possible Future Evolution. ( Costa, B; Vale, N, 2023) |
| "Gabapentin as monotherapy probably controlled seizures no better and no worse than comparator AEDs (lamotrigine, carbamazepine, oxcarbazepine, and topiramate)." | 5.41 | Gabapentin monotherapy for epilepsy: A review. ( Abakumova, T; Hoyle, CHV; Ziganshina, LE, 2023) |
| "Epilepsy was induced in seven C57Bl/6 mice by injections of KA (20 mg/kg) on days 1 and 5, which produced severe acute seizures and spontaneous seizures 10 days later." | 5.40 | Cardiac phenomena during kainic-acid induced epilepsy and lamotrigine antiepileptic therapy. ( Dibué, M; Hänggi, D; Hescheler, J; Kamp, MA; Neumaier, F; Schneider, T; Steiger, HJ, 2014) |
| "People with epilepsy have a high incidence of mood disorders that may affect their quality of life." | 5.39 | [Mood States in outpatients with lesional epilepsy at the neurosurgical clinic and improvement in mood States after lamotrigine addiction]. ( Kajita, Y; Nagai, T; Wakabayashi, T; Yoshida, K, 2013) |
| "He had been on a lamotrigine treatment due to epilepsy, and after cessation of lamotrigine, his cardiac enzyme levels returned to normal." | 5.38 | Lamotrigine related myocarditis: case report. ( Bayhan, T; Karagöz, T; Sahin, M; Yıldırım, I, 2012) |
| "Lamotrigine was more effective at lower doses and in older children." | 5.38 | Lamotrigine serum concentration in children with epilepsy. ( Bar-Haim, A; Berkovitch, M; Braunstein, R; Gandelman-Marton, R; Heyman, E; Lahat, E; Lavie, R, 2012) |
| "Lamotrigine has the advantage to have an antidepressive effect and to be well tolerated in the majority of the cases." | 5.37 | Lamotrigine-trigged obstructive hypertrophic cardiomyopathy, epilepsy and metabolic myopathy. ( Finsterer, J; Höftberger, R; Stöllberger, C, 2011) |
| " Newly diagnosed 52 pediatric epileptic patients were assessed standard speech test through a Computerized Speech Lab applied before the beginning of therapy with lamotrigine and 2months after dosage had been stabilized." | 5.37 | Acoustic effects of lamotrigine in pediatric patients with epilepsy. ( Choi, YM; Eun, SH; Kim, SJ; Seol, IJ; Yun, M, 2011) |
| " All 9 patients became hyperactive and agitated over a broad range of lamotrigine dosing (0." | 5.36 | Reversible lamotrigine-induced neurobehavioral disturbances in children with epilepsy. ( Cardenas, JF; Ng, YT; Rho, JM, 2010) |
| "Lamotrigine has been widely used, mainly due to their greater tolerability and lower rate of drug interactions with other antiepileptic drugs however the newest antiepileptic drugs have high cost to patient." | 5.36 | [Interchangeability among therapeutics equivalents of lamotrigine in the treatment of refractory epilepsy patients: risks and benefits]. ( Alexandre, V; Feletti, F; Girolineto, BM; Pereira, LR; Queiroz, RH; Sakamoto, AC, 2010) |
| " The manufacturer recommends half the dosage of lamotrigine monotherapy when the patient also uses valproate." | 5.35 | Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. ( Aldenkamp, AP; Bootsma, HP; Hulsman, J; Lambrechts, D; Leenen, L; Majoie, M; Savelkoul, M; Schellekens, A; Vos, AM, 2008) |
| "Lamotrigine (LTG) has recently been shown to inhibit the cardiac rapid delayed rectifier potassium ion current (Ikr)." | 5.34 | Lamotrigine in idiopathic epilepsy - increased risk of cardiac death? ( Aurlien, D; Gjerstad, L; Taubøll, E, 2007) |
| "Lamotrigine was escalated according to a target dose of 200 mg/day over 8-weeks." | 5.34 | Conversion to lamotrigine monotherapy from valproate monotherapy in older adolescent patients with epilepsy. ( Baumann, RJ; Fakhoury, TA; Hammer, AE; Kustra, RP; Messenheimer, JA; Vuong, A, 2007) |
| "Lamotrigine is an antiepileptic agent used in a wide range of seizure disorders among the elderly." | 5.33 | [Drug hypersensitivity syndrome with lamotrigine two cases in elderly]. ( Bourdel-Marchasson, I; Jeandel, PY; Rainfray, M; Traissac, T, 2005) |
| "Vascular epilepsy was the most frequent diagnosis (56% of patients), and concomitant medication was required by 75% of patients." | 5.33 | Lamotrigine and epilepsy in the elderly: observational study of low-dose monotherapy. ( Mauri Llerda, JA; Mercadé, JM; Padró, LL; Salas Puig, J; Tejero, C, 2005) |
| "Lamotrigine (LTG) was reported to have a positive profile especially regarding cognition." | 5.33 | Long-term profile of lamotrigine in 119 children with epilepsy. ( Brodbeck, V; Fietzek, U; Heinen, F; Jansen, V; Muehe, C; Weber, G, 2006) |
| "Epilepsy is a major comorbid condition in adolescents with mental retardation and is often characterized by multiple seizure types that are refractory to treatment." | 5.33 | Adjunctive lamotrigine for refractory epilepsy in adolescents with mental retardation. ( Hammer, AE; McKee, JR; Sunder, TR; Vuong, A, 2006) |
| "Lamotrigine (LTG) was added to other antiepileptic drugs (AEDs) in a study of adjunctive therapy." | 5.32 | Improved mood states with lamotrigine in patients with epilepsy. ( Cramer, JA; Hammer, AE; Kustra, RP, 2004) |
| " The severity of the cognitive side effects of TPM may be related to dosing to a certain extent, but this relationship may be disclosed only with larger sample sizes." | 5.32 | Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. ( Elger, CE; Helmstaedter, C; Kockelmann, E, 2004) |
| "Mean lamotrigine dose was 272 +/- 133 mg per day." | 5.31 | Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation. ( Gidal, BE; Lott, RS; Marty, KJ; Rutecki, P; Shaw, R; Speth, J; Walker, JK, 2000) |
| "Patients with generalized epilepsy (p = 0." | 5.31 | A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. ( Lhatoo, SD; Mawer, GE; Sander, JW; Wong, IC, 2001) |
| "No subjects reported insomnia with treatment." | 5.31 | The effects of lamotrigine on sleep in patients with epilepsy. ( Dinner, D; Foldvary, N; Lee, J; Morris, HH; Perry, M, 2001) |
| " Side effects were mild, but frequent; only four patients discontinued LTG because of adverse effects." | 5.31 | [Lamotrigine in the adult-onset epilepsy: efficacy and long-term safety]. ( Alegre, M; Iriarte, J; Lázaro, D; Schlumberger, E; Urrestarazu, E; Viteri, C, 2002) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 5.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| " Then, LTG was increased in steps to maximal dosage (200 mg or 400 mg per day) within seven weeks and maintained for three months while pre-existing antiepileptic drugs remained unchanged." | 5.30 | Lamotrigine as add-on therapy in adult patients with refractory epilepsy. ( Kwan, SY; Lin, YY; Su, MS; Yen, DJ; Yiu, CH, 1997) |
| "Lamotrigine is a phenyltriazine anticonvulsant recently approved for clinical use." | 5.30 | High-performance liquid chromatography quantitation of plasma lamotrigine concentrations: application measuring trough concentrations in patients with epilepsy. ( Morris, RG; Sallustio, BC, 1997) |
| "Seventy-one patients had partial epilepsy and 21 had primary generalized epilepsy." | 5.29 | [Lamotrigine treatment of 92 patients with intractable epilepsy]. ( Dam, M; Gram, L; Karlsborg, M, 1996) |
| "To investigate the development of reproductive endocrine changes in Indian women with epilepsy initiating on either Valproate (VPA) or Lamotrigine (LTG) monotherapy." | 5.27 | Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either Valproate or Lamotrigine monotherapy: A prospective study. ( Sadhotra, A; Sidhu, HS; Srinivasa, R, 2018) |
| "Pregnant women with epilepsy on one or more of the following AEDs: lamotrigine, carbamazepine, phenytoin or levetiracetam." | 5.27 | AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies. ( Bagary, M; Coleman, J; D'Amico, M; Denny, E; Dodds, J; Eldridge, S; Greenhill, L; Hard, K; Kelso, A; Khan, KS; Marlin, N; McCorry, D; Middleton, L; Moss, N; Newton, S; Pirie, A; Pullen, A; Rikunenko, R; Roberts, T; Rogozińska, E; Thangaratinam, S; Weckesser, A, 2018) |
| "Standard lipid fractions, lipoprotein(a), and C-reactive protein (CRP) were examined in a subset of those participating in the STEP-ONE trial, in which elderly patients with new epilepsy were randomized to treatment with carbamazepine, lamotrigine, or levetiracetam." | 5.27 | Impact of carbamazepine, lamotrigine, and levetiracetam on vascular risk markers and lipid-lowering agents in the elderly. ( Chervoneva, I; Kraemer, G; Mintzer, S; Trinka, E; Werhahn, KJ, 2018) |
| " All patients received a single dose of lamotrigine in the second week to determine single-dose pharmacokinetic parameters." | 5.27 | Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ( Hamilton, MJ; Jawad, S; Oxley, JR; Peck, AW; Richens, A; Yuen, WC, 1987) |
| " Valproic acid appears to be use cautionally in obese females with epilepsy." | 5.24 | Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study. ( Sadhotra, A; Sidhu, HS; Srinivas, R, 2017) |
| "This study provides evidence that the disparate lamotrigine products studied are bioequivalent when tested in people with epilepsy taking concomitant antiepileptic drugs." | 5.24 | Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial. ( Berg, M; Diaz, FJ; Dworetzky, BA; Elder, EJ; Gidal, BE; Jiang, W; Jiang, X; Krebill, R; Pollard, JR; Privitera, MD; Switzer, RD; Szaflarski, JP; Welty, TE, 2017) |
| "A literature search was performed in the PubMed, Embase, and OVID-Medline databases to identify articles related to epilepsy and lamotrigine that were published from the establishment of the database to April 2021." | 5.22 | The efficacy of lamotrigine after failure of the first administration of valproate in treating epilepsy: a systematic review and meta-analysis. ( He, J; Wu, X; Zhou, D, 2022) |
| "There is insufficient evidence to support or refute that lamotrigine is associated with sudden death or ECG changes in people with or without epilepsy as compared to antiseizure medication or placebo, due to the high risk of bias in most studies and low precision and inconsistency in the reported results." | 5.22 | Sudden Death and Cardiac Arrythmia With Lamotrigine: A Rapid Systematic Review. ( Bunschoten, JW; Devinsky, O; French, JA; Husein, N; Keezer, MR; Sander, JW; Thijs, RD, 2022) |
| "12) when compared to those following lamotrigine (LTG) exposure during pregnancy (3 studies [n = 591])." | 5.22 | Adverse fetal and neonatal outcomes following in-utero exposure to oxcarbazepine: A systematic review and meta-analysis. ( Ahmad, S; Athar, F; Cheema, HA; Ehsan, M; Farooq, M; Lo, KB; Naveed, A; Umer, M, 2022) |
| "Lamotrigine is the most widely used anti-epileptic drug in pregnancy because of its low teratogenicity." | 5.22 | Dosage Optimization of Lamotrigine in Pregnancy: A Pharmacometric Approach Using Modeling and Simulation. ( G, SS; Kp, A; Pa, B; Thomas, G, 2022) |
| "Lamotrigine owing to its excellent inhibitory property of neurotransmitter release especially glutamate is used in the treatment of epilepsy as a second-line antiepileptic drug." | 5.22 | Lamotrigine-A Review of Analytical Methods Developed for Pharmaceutical Formulations and Biological Matrices. ( Kumar, L; S, S; Verma, R, 2022) |
| "Lamotrigine (LTG) is used to treat epilepsy." | 5.22 | Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy. ( Hirai, K; Imai, K; Inoue, K; Inoue, Y; Itoh, K; Suzuki, E; Takahashi, T; Takahashi, Y; Tsuji, D; Umemura, A; Yamamoto, Y, 2016) |
| " In this trial, we assessed US Food and Drug Administration (FDA) bioequivalence standards by studying the effects of switching between two disparate generic immediate-release lamotrigine products in patients with epilepsy." | 5.22 | Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. ( Berg, M; Diaz, FJ; Dworetzky, BA; Elder, EJ; Gidal, BE; Jiang, W; Jiang, X; Krebill, R; Pollard, JR; Privitera, MD; Szaflarski, JP; Welty, TE, 2016) |
| "We included 100 patients with epilepsy on stable dosing with lamotrigine as mono or adjunctive therapy." | 5.22 | Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters. ( Dolžan, V; Grabnar, I; Kastelic, M; Lorber, B; Milosheska, D; Vovk, T, 2016) |
| "A classic 2-period crossover bioavailability study was conducted to evaluate the relative and absolute bioavailability of immediate-release (IR) and extended-release (XR) lamotrigine formulations under steady-state conditions in elderly patients with epilepsy." | 5.20 | Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology. ( Birnbaum, AK; Brundage, RC; Leppik, IE; Polepally, AR; Ramsay, RE; Rarick, JO; Remmel, RP, 2015) |
| "To determine the tolerability and efficacy of lamotrigine extended-release (LTG XR) as adjunctive therapy with optional conversion to monotherapy in patients ages≥65 years with epilepsy." | 5.19 | Lamotrigine extended-release as adjunctive therapy with optional conversion to monotherapy in older adults with epilepsy. ( Hammer, AE; Huffman, R; Leroy, R; Messenheimer, JA; Van Cott, A; VanLandingham, K; Vuong, A; Wechsler, RT, 2014) |
| "The aim of the study was to investigate immunoglobulin levels in patients with epilepsy using the antiepileptic drugs (AED) levetiracetam (LEV), carbamazepine (CBZ), or lamotrigine (LTG)." | 5.17 | Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine. ( Frøland, SS; Luef, G; Mochol, M; Mushtaq, U; Rauchenzauner, M; Svalheim, S; Taubøll, E, 2013) |
| "In this prospective, observational, assessor-masked, multicentre study, we enrolled pregnant women with epilepsy on antiepileptic drug monotherapy (carbamazepine, lamotrigine, phenytoin, or valproate) between October, 1999, and February, 2004, at 25 epilepsy centres in the UK and the USA." | 5.17 | Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. ( Baker, GA; Bromley, RL; Browning, N; Clayton-Smith, J; Cohen, MJ; Kalayjian, LA; Kanner, A; Liporace, JD; Loring, DW; Meador, KJ; Pennell, PB; Privitera, M, 2013) |
| "The extent of lamotrigine interactions was investigated dependent on age, gender, weight and dose of concomitant carbamazepine and/or valproic acid in 65 patients with epilepsy." | 5.16 | Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics. ( Brzaković, BB; Martinović, ZJ; Miljković, BR; Pokrajac, MV; Prostran, MŠ; Vezmar Kovačević, SD; Vučićević, KM, 2012) |
| "Of the newer antiepileptic drugs, lamotrigine (LTG) and levetiracetam (LEV) are popular first choice drugs for epilepsy." | 5.16 | The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study. ( Arnold, S; Bauer, S; Beige, A; Berrouschot, J; Burchardi, N; Eisensehr, I; Evers, S; Haag, A; Hallmeyer-Elgner, S; Hamer, HM; Klein, KM; Kovac, S; Lerche, H; Niedhammer, M; Oertel, WH; Reif, PS; Rosenow, F; Roth, E; Schade-Brittinger, C; Schröder, M; Springub, J; Strzelczyk, A; Weber, Y; Winkler, G, 2012) |
| "To explore the efficacy and safety of the combined therapy of valproic acid (VPA) and lamotrigine (LTG) for various types of epilepsy." | 5.16 | [Efficacy and safety of the combined therapy of valproic acid and lamotrigine for epileptics]. ( Hu, Q; Kang, HC; Li, X; Liu, XY; Liu, ZG; Wang, M; Xu, F; Zeng, Z; Zhu, SQ, 2012) |
| "This open label study suggests that the combination of valproate, lamotrigine, and a benzodiazepine can markedly reduce the frequency of epileptic drop attacks in patients with generalized or multifocal epilepsies." | 5.15 | Long-term control of epileptic drop attacks with the combination of valproate, lamotrigine, and a benzodiazepine: a 'proof of concept,' open label study. ( Bastos, FA; Machado, VH; Palmini, A; Rotert, R, 2011) |
| "All patients treated with lamotrigine, levetiracetam or topiramate in the Epilepsy Centre were identified." | 5.14 | The impact of side effects on long-term retention in three new antiepileptic drugs. ( Aldenkamp, AP; Bootsma, HP; de Krom, M; Hekster, YA; Hulsman, J; Lambrechts, D; Majoie, M; Ricker, L; Schellekens, A, 2009) |
| "To prospectively analyse the pharmacokinetics of lamotrigine (LTG) during pregnancy and lactation in a consecutive series of epileptic pregnant women." | 5.14 | Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. ( Bauer, S; Dudenhausen, JW; Fotopoulou, C; Henrich, W; Kretz, R; Schefold, JC; Schmitz, B, 2009) |
| "To investigate the comparative effects of carbamazepine (CBZ) and lamotrigine (LTG) on electrocardiography (ECG) parameters in elderly patients with newly diagnosed epilepsy." | 5.14 | Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. ( Abdelnoor, M; Amlie, JP; Anfinsen, OG; Gjerstad, L; Isojärvi, J; Perucca, E; Saetre, E; Taubøll, E; Tossebro, M, 2009) |
| " We evaluated the reproductive endocrine and insulin-related metabolic parameters in men and women with untreated epilepsy randomized to valproate (n=44) or lamotrigine (n=37) monotherapy for 12 months." | 5.14 | Effects of valproate or lamotrigine monotherapy on the reproductive endocrine and insulin-related metabolic profile in Chinese adults with epilepsy: a prospective randomized study. ( Chan, IH; Chan, MH; Hui, AC; Hui, KF; Kwan, P; Lam, CW; Leung, H; Ng, PW; Yip, FP, 2009) |
| " The present study investigated reproductive and sexual function in patients with epilepsy (aged 18-45) treated with levetiracetam (LEV: 30 men/26 women), carbamazepine (CBZ: 63 men/30 women), or lamotrigine (LTG: 37 men/40 women) monotherapy and in healthy controls (36 men/44 women)." | 5.14 | Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. ( Bertelsen, M; Gjerstad, L; Lossius, A; Luef, G; Mørkrid, L; Rauchenzauner, M; Sandvand, F; Svalheim, S; Taubøll, E, 2009) |
| "During an international double-blind trial evaluating the efficacy and tolerability of lamotrigine and carbamazepine in patients aged >or=65 with newly diagnosed epilepsy, the comparative effects of the drugs on health-related quality of life were investigated based on screening and 12-, 28-, and 40-week data, using the modified Side Effect and Life Satisfaction (SEALS) Inventory and the Liverpool Adverse Event Profile." | 5.14 | Antiepileptic drugs and quality of life in the elderly: results from a randomized double-blind trial of carbamazepine and lamotrigine in patients with onset of epilepsy in old age. ( Abdelnoor, M; Gjerstad, L; Isojärvi, J; Perucca, E; Saetre, E; Taubøll, E, 2010) |
| "To evaluate development of components of polycystic ovary syndrome (PCOS) and PCOS in women with epilepsy initiating valproate or lamotrigine therapy." | 5.13 | Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. ( Adams, JM; Bhatt, M; Hayes, FJ; Isojärvi, J; Morrell, MJ; Ozkara, C; Sluss, PM; Warnock, CR, 2008) |
| "These analyses, conducted on a data set drawn from a previously reported, open-label, multicentre, prospective study, examined the effect of lamotrigine on mood in adults aged>or=50 years with epilepsy and co-morbid depressive symptoms." | 5.13 | Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study. ( Fakhoury, TA; Hammer, AE; Miller, JM; Vuong, A, 2008) |
| "To compare the pharmacokinetics (PK) of lamotrigine (LTG) when converting from twice-daily immediate-release (LTG-IR) to once-daily extended-release (LTG-XR) in subjects with epilepsy." | 5.13 | Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study). ( Ali, I; Hammer, AE; Job, S; Lemme, F; Messenheimer, JA; Oliver-Willwong, R; Tompson, DJ; Vuong, A; Zhu, L, 2008) |
| "A subsample of 67 adult patients with partial seizures participating in a randomized, double-blind study comparing the cognitive effects of adjunctive lamotrigine (LTG) and adjunctive topiramate (TPM) was administered Performance On-Line (POL) in addition to a battery of neuropsychological tests at baseline, week 8 and week 16 of treatment." | 5.13 | Relative influences of adjunctive topiramate and adjunctive lamotrigine on scanning and the effective field of view. ( Blum, DE; Caldwell, PT; Drazkowski, JF; Hammer, AE; Kustra, RP; Mills, KC, 2008) |
| "To evaluate therapeutic drug monitoring (TDM) of lamotrigine (LTG) with establishment of individual therapeutic thresholds (TT) in outpatients of a tertiary epilepsy centre on monotherapy." | 5.13 | Lamotrigine therapeutic thresholds. ( Dahl, M; Nielsen, KA; Søndergaard Khinchi, M; Wolf, P, 2008) |
| " Patients with an epilepsy diagnosis (International Classification of Diseases-9 345) and treated with lamotrigine for >60 of the 90 days before the entry date of generic lamotrigine in Quebec (February 1, 2003) were selected." | 5.13 | Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. ( Duh, MS; Lefebvre, P; LeLorier, J; Manjunath, R; Paradis, PE; Sheehy, O; Weiner, J, 2008) |
| " This paper aims to undertake a comprehensive review regarding the possible risks of four classical (phenytoin, carbamazepine, phenobarbital, and valproate) and two newer (lamotrigine and levetiracetam) AEDs during pregnancy." | 5.12 | Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications. ( Demir, O; Kaplan, YC, 2021) |
| "This review does not provide sufficient evidence to support levetiracetam, phenobarbital or lamotrigine for the treatment of epilepsy in people with Alzheimer's disease." | 5.12 | Treatment of epilepsy for people with Alzheimer's disease. ( Liu, J; Wang, LN, 2021) |
| "This study was performed to evaluate carnitine deficiency in a large series of epilepsy children and adolescents treated with old and new antiepileptic drugs with or without ketogenic diet." | 5.12 | Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet. ( Auricchio, G; Coppola, G; Epifanio, G; Federico, RR; Pascotto, A; Resicato, G, 2006) |
| "To assess the course of sexual function in epilepsy patients treated with lamotrigine." | 5.12 | Effect of lamotrigine on sexual function in patients with epilepsy. ( Alamo, C; García-García, P; Gil-Nagel, A; López-Muñoz, F; Moncada, I; Serratosa, JM, 2006) |
| "Quantitative EEG (QEEG) effects of therapeutic doses of carbamazepine (CBZ), oxcarbazepine (OXC), valproate (VA) and lamotrigine (LA) monotherapy were investigated in patients with beginning epilepsy." | 5.12 | Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings. ( Altmann, A; Bessenyei, M; Clemens, B; Hollódy, K; Jerney, J; Kollár, K; Ménes, A; Piros, P; Rosdy, B; Rózsavölgyi, M; Steinecker, K, 2006) |
| "To compare the cognitive effects of lamotrigine vs topiramate as adjunctive therapy in adults with epilepsy." | 5.12 | Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. ( Biton, V; Blum, D; Chung, S; Fakhoury, T; Hammer, A; Isojärvi, J; Meador, K; Mills, K; Shneker, B, 2006) |
| "This is the first report comparing intrasubject lamotrigine (LTG) plasma concentrations between hormonal contraceptive (HC) intake and week-off phases in epilepsy patients receiving combined LTG and HC treatment." | 5.12 | Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. ( Albani, F; Ambrosetto, G; Avoni, P; Baruzzi, A; Bisulli, F; Contin, M; Riva, R; Tinuper, P, 2006) |
| "In eight women treated with lamotrigine monotherapy, the lamotrigine dose/plasma concentration (D/C) ratio increased by 295% from baseline outside pregnancy to midgestation, whereas in six women treated with lamotrigine in combination with valproate, the increase was only 60%." | 5.12 | Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. ( Luef, G; Ohman, I; Pittschieler, S; Sabers, A; Tomson, T, 2006) |
| "In this investigation, the effects of lamotrigine versus placebo on depressive symptoms in patients with epilepsy were prospectively assessed." | 5.12 | Effect of lamotrigine on depressive symptoms in adult patients with epilepsy. ( Ettinger, AB; Hammer, AE; Kustra, RP, 2007) |
| "This open-label study evaluated the antidepressant qualities of lamotrigine (LTG) in people with epilepsy." | 5.12 | Lamotrigine in patients with epilepsy and comorbid depressive symptoms. ( Barry, JJ; Fakhoury, TA; Hammer, AE; Mitchell Miller, J; Vuong, A, 2007) |
| "This study evaluates the effect of oral contraceptives on lamotrigine (LTG) plasma concentrations and urine excretion of LTG metabolites in a double-blind, placebo-controlled, crossover study in patients with epilepsy." | 5.12 | Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. ( Atterman, J; Christensen, J; Ohman, I; Petrenaite, V; Sabers, A; Sidenius, P; Tomson, T, 2007) |
| "We have performed a randomised, prospective study to compare the efficacy and tolerability of sodium valproate (VPA) and lamotrigine (LTG) monotherapy, and their effects on circulating androgenic hormones, in newly diagnosed epilepsy." | 5.12 | Sodium valproate versus lamotrigine: a randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy. ( Brodie, MJ; Butler, E; Hitiris, N; Leach, JP; Leach, VM; Parker, P; Sills, GJ; Stephen, LJ; Wilson, EA, 2007) |
| "To assess the comparative effectiveness, efficacy, and tolerability of lamotrigine (LTG) and sustained-release carbamazepine (CBZ) in the treatment of newly diagnosed epilepsy in the elderly." | 5.12 | An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. ( Gjerstad, L; Isojärvi, J; Perucca, E; Saetre, E, 2007) |
| "To determine whether levetiracetam (LEV) affects plasma concentrations of carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy." | 5.12 | Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. ( De Smedt, H; Otoul, C; Stockis, A, 2007) |
| "To compare clinicians' choice of one of the standard epilepsy drug treatments (carbamazepine or valproate) versus appropriate comparator new drugs." | 5.12 | A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. ( Appleton, R; Baker, GA; Chadwick, DW; Doughty, J; Eaton, B; Gamble, C; Jacoby, A; Marson, AG; Shackley, P; Smith, DF; Tudur-Smith, C; Vanoli, A; Williamson, PR, 2007) |
| "This randomized, open-label study was designed to compare the efficacy and tolerability of lamotrigine monotherapy with those of valproate and carbamazepine monotherapy in patients with epilepsy whose seizures were uncontrolled on their prestudy antiepileptic drug monotherapy." | 5.11 | Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy. ( Fakhoury, TA; Hammer, AE; Messenheimer, JA; Vuong, A, 2004) |
| "In a double-blinded, placebo-controlled, crossover study, 61 children with well-controlled or mild epilepsy were randomly assigned to add-on therapy with either lamotrigine followed by placebo or placebo followed by lamotrigine." | 5.11 | Treatment of interictal epileptiform discharges can improve behavior in children with behavioral problems and epilepsy. ( Binnie, CD; Pressler, RM; Robinson, RO; Wilson, GA, 2005) |
| "A dosing algorithm was used to guide the conversion of 77 patients with epilepsy (16 years of age) from valproate monotherapy through lamotrigine adjunctive therapy at 200mg daily to lamotrigine monotherapy at 500 mg daily in an open-label study comprising a lamotrigine escalation phase (8 weeks), a valproate withdrawal phase (6 weeks), and a lamotrigine monotherapy phase (4 weeks)." | 5.11 | A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy. ( Biton, V; Blum, D; Hammer, AE; Messenheimer, JA; Natarajan, S; Sale, ME; Vuong, A, 2005) |
| "The present study was designed to assess the effect of the addition of zonisamide (ZNS) on lamotrigine (LTG) disposition and the safety of the combination under steady-state conditions in patients with epilepsy." | 5.11 | Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. ( Brodie, MJ; Levy, RH; Pan, WJ; Ragueneau-Majlessi, I; Shah, J; Smith, DF, 2005) |
| "To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy." | 5.11 | New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. ( Boardman, KD; Carter, GS; Collins, JF; Felicetta, J; Frederick, T; Marks, W; Pryor, F; Ramsay, RE; Rowan, AJ; Spitz, M; Tomyanovich, ML; Towne, A; Uthman, BM, 2005) |
| "Evaluation of the effectiveness of lamotrigine in a population-based cohort of epilepsy patients." | 5.11 | Effectiveness of lamotrigine in clinical practice: results of a retrospective population-based study. ( Deckers, CL; Egberts, AC; Hekster, YA; Keyser, A; Knoester, PD; Renier, WO, 2005) |
| "We reviewed 570 medical charts of outpatients 12 years and older seen at the Columbia Comprehensive Epilepsy Center who received lamotrigine as monotherapy or adjunctive therapy." | 5.11 | Effect of antiepileptic drug comedication on lamotrigine clearance. ( Buchsbaum, R; Hirsch, LJ; Resor, SR; Weintraub, D, 2005) |
| "Subjects were 85 men with localization-related epilepsy (25 on carbamazepine [CBZ], 25 on phenytoin [PHT], 25 on lamotrigine [LTG], and 10 untreated for at least 6 months [no AED]) and 25 controls." | 5.11 | Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. ( Bromfield, EB; Drislane, FW; Dworetzky, BA; Farina, EL; Frye, CA; Herzog, AG; Pennell, PB; Schomer, DL, 2005) |
| "This randomised, double-blind study compared the newer antiepileptic drugs (AEDs) gabapentin (GBP) and lamotrigine (LTG) as monotherapy in newly diagnosed epilepsy." | 5.10 | Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. ( Anhut, H; Brodie, MJ; Chadwick, DW; Garofalo, EA; Maton, S; Messmer, SL; Murray, G; Otte, A; Sauermann, W, 2002) |
| "To investigate the tolerability and pharmacokinetics of oral loading with lamotrigine (LTG) among epilepsy patients after temporary drug discontinuation in an epilepsy monitoring unit." | 5.10 | Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. ( Del Mar Carreño, M; Hovinga, CA; Lardizabal, DV; Morris, HH, 2003) |
| "This study evaluated the effects of lamotrigine as adjunctive therapy for refractory epilepsy in patients with mental retardation." | 5.10 | Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation. ( Barrett, PS; FineSmith, R; Hammer, AE; McKee, JR; Sunder, TR; Varner, JA; Vuong, A, 2003) |
| "To compare the relationship between serum and salivary concentrations of lamotrigine in pediatric and adult epilepsy populations." | 5.10 | Correlation of lamotrigine concentrations between serum and saliva. ( Baumann, RJ; deGrauw, TJ; Fakhoury, TA; Grim, SA; Miles, MV; Ryan, M; Strawsburg, RH; Tang, PH, 2003) |
| "The authors assessed the effect of concomitant antiepileptic therapy on steady-state plasma concentrations of the new antiepileptic drug (AED) topiramate and the potential relation between topiramate plasma levels and side effects in a cohort of 116 patients with epilepsy." | 5.10 | Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. ( Albani, F; Avoni, P; Baruzzi, A; Contin, M; Riva, R, 2002) |
| "Accumulating data suggest that the antiepilepsy drug lamotrigine, which has been available for adult use for more than a decade, also confers broad-spectrum, well-tolerated control of epilepsy in children." | 5.10 | Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy. ( Duchowny, M; Gilman, J; Messenheimer, J; Risner, M; Womble, G, 2002) |
| "We evaluated the pharmacokinetics of lamotrigine in 12 children with epilepsy who were receiving no other antiepileptic drugs." | 5.09 | Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. ( Casale, EJ; Chen, C; Culverhouse, EH; Duncan, B; Gilman, J, 1999) |
| "In a multicentre, double-blind trial 150 elderly patients (mean age 77 years) with newly diagnosed epilepsy were randomised in a 2:1 ratio to treatment with lamotrigine (LTG) or carbamazepine (CBZ)." | 5.09 | Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. ( Brodie, MJ; Giorgi, L; Overstall, PW, 1999) |
| "Our objective was to determine, in three separate studies, the effects of controlled-release carbamazepine (CBZ-CR), lamotrigine (LTG), and gabapentin (GBP) on nocturnal sleep in epilepsy." | 5.09 | Effect of anticonvulsants on nocturnal sleep in epilepsy. ( Diomedi, M; Gigli, GL; Marciani, MG; Placidi, F; Romigi, A; Scalise, A, 2000) |
| "5-18 yrs with intractable epilepsy and comedicated with carbamazepine or valproate." | 5.09 | Plasma and urinary serotonin and 5-HIAA in children treated with lamotrigine for intractable epilepsy. ( Jović, NJ; Majkić-Singh, N; Milovanović, DD; Mirković, D, 1999) |
| "Good efficiency (at least 50% reduction of crises) has been demonstrated for lamotrigine in children with generalized epilepsy (62." | 5.09 | [Lamotrigine therapy in children. Retrospective study of 32 children]. ( Chabrol, B; Léthel, V; Livet, MO; Mancini, J, 2000) |
| "This prospective observational study explored the efficacy and tolerability of topiramate (TPM) in patients with refractory epilepsy attending a single outpatient clinic." | 5.09 | Topiramate in refractory epilepsy: a prospective observational study. ( Brodie, MJ; Sills, GJ; Stephen, LJ, 2000) |
| "to describe the population pharmacokinetics of lamotrigine (LTG) in developmentally disabled (DD) patients with epilepsy and (2) to determine if there is an effect of valproate (VPA) concentration on the extent of the pharmacokinetic interaction between VPA and LTG." | 5.09 | Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. ( Anderson, GD; Gidal, BE; Lanning, A; Rutecki, PR; Shaw, R, 2000) |
| " The primary aim of the study was to evaluate lamotrigine add-on therapy and consecutive monotherapy in patients with epilepsy whose seizures were not controlled by carbamazepine or valproate." | 5.09 | Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy. ( Jozwiak, S; Terczynski, A, 2000) |
| "Lamotrigine (LTG) is one of the newer antiepileptic drugs which has been shown to have a spectrum of drug interactions (including with other epilepsy drugs) that can have a pronounced effect on LTG kinetics." | 5.09 | Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? ( Black, AB; Lam, E; Morris, RG; Westley, IS, 2000) |
| "To compare the incidence and magnitude of change in body weight associated with lamotrigine or divalproex sodium monotherapy in patients with epilepsy." | 5.09 | Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. ( Barrett, PS; Biton, V; Hammer, AE; Mirza, W; Montouris, G; Vuong, A, 2001) |
| "The aim of this study was to evaluate the efficacy and safety of gabapentin in patients with learning disabilities and resistant epilepsy, comparing the effects of gabapentin with lamotrigine on efficacy, behaviour and mood." | 5.09 | A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. ( Brown, S; Crawford, P; Kerr, M, 2001) |
| "The study was designed to evaluate optimal use of add-on lamotrigine in the treatment of children and adults with refractory epilepsy of any type." | 5.09 | [Optimal use of lamotrigine in clinical practice: results of an open multicenter trial in refractory epilepsy]. ( Arzimanoglou, A; Baldy-Moulinier, M; Bidaut-Mazel, C; Kulak, I, 2001) |
| "Lamotrigine (LTG) as both effective against a wide range of seizure types and epileptic syndromes and well tolerated drug is being used in mono--as well as in polytherapy of pharmacoresistant epilepsy." | 5.09 | Long-term monotherapy with lamotrigine in newly diagnosed epilepsy in adults. ( Chmielewska, B; Kamiński, ML; Kawka, Z, 2001) |
| " Use of the drug as monotherapy was investigated in a double-blind, randomised, parallel-group comparison with carbamazepine in newly diagnosed epilepsy." | 5.08 | Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. ( Brodie, MJ; Richens, A; Yuen, AW, 1995) |
| "Three hundred and forty seven patients with epilepsy from 54 centres across Europe not fully controlled with sodium valproate (VPA, n = 117), carbamazepine (CBZ, n = 129), phenytoin (PHT, n = 92) or phenobarbital (PB, n = 9) monotherapy were recruited into a lamotrigine (LTG) substitution study." | 5.08 | Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. ( Brodie, MJ; Yuen, AW, 1997) |
| "To examine the population pharmacokinetics of lamotrigine in patients newly diagnosed with epilepsy and receiving oral lamotrigine monotherapy for up to 48 weeks." | 5.08 | Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. ( Hussein, Z; Posner, J, 1997) |
| "We report the results of an open trial with lamotrigine (LTG) as add-on drug in children and adolescents with refractory epilepsy and mental delay." | 5.08 | Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial. ( Coppola, G; Pascotto, A, 1997) |
| "Lamotrigine was an effective and well-tolerated treatment for seizures associated with the Lennox-Gastaut syndrome." | 5.08 | Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. ( Arvidsson, JF; Barrera, MN; Manasco, P; Motte, J; Mullens, EL; Trevathan, E, 1997) |
| "This open pilot study was performed to evaluate the effect of Lamotrigine (LTG) in girls with Rett syndrome (RS) regarding seizure frequency, effect on gross motor dyspraxia and safety." | 5.08 | Lamotrigine in Rett syndrome: treatment experience from a pilot study. ( Hagberg, B; Stenbom, Y; Tonnby, B, 1998) |
| "We report open-label clinical observations of additional lamotrigine (LTG) in 16 adult patients with refractory epilepsy, aimed to assess the long-term efficacy and safety of LTG in clinical use." | 5.07 | Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy. ( Cocito, L; Loeb, C; Maffini, M, 1994) |
| " Psychological assessment and seizure frequency were monitored in patients whose epilepsy was treated with lamotrigine (LTG) or placebo." | 5.07 | Seizure severity and the quality of life. ( Baker, G; Chadwick, D; Davis, G; Dewey, M; Smith, D, 1993) |
| "Lamotrigine (LTG) is a new antiepileptic drug which is effective in refractory epilepsy and which has been shown to have weak antifolate properties in vitro." | 5.07 | An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. ( Patsalos, PN; Sander, JW, 1992) |
| "Lamotrigine, a novel anticonvulsant, has been evaluated in patients with epilepsy using the method of interictal EEG spike counting." | 5.06 | The effect of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy. ( Jawad, S; Oxley, J; Richens, A; Yuen, WC, 1986) |
| "To conduct a literature review of the impact on cognition and mood status of lacosamide (LCM) in people with epilepsy." | 5.05 | The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy. ( Chang, YP; Huang, LC; Li, KY; Yang, YH, 2020) |
| "We conducted this meta-analysis to evaluate effects of second-generation anti-epileptic drugs (AEDs; levetiracetam, lamotrigine) compared to first-generation AEDs (valproic acid, carbamazepine) on bone metabolism in epilepsy patients." | 5.01 | Effects of Second-Generation Antiepileptic Drugs Compared to First-Generation Antiepileptic Drugs on Bone Metabolism in Patients with Epilepsy: A Meta-Analysis. ( Chen, Y; Fu, J; Li, J; Peng, L; Tao, T, 2019) |
| " The point estimates of carbamazepine and lamotrigine efficacy showed their superiority with respect to all comparator antiepileptic drugs for the treatment of newly diagnosed focal epilepsy." | 4.98 | Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis. ( Crescioli, G; De Masi, S; Guerrini, R; Ilvento, L; Lucenteforte, E; McGreevy, KS; Mugelli, A; Pugi, A; Rosati, A; Virgili, G, 2018) |
| "Lamotrigine is used in pregnancy to control epilepsy and mood disorders." | 4.95 | Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis. ( Adams-Webber, T; Barzilay, E; Leibson, T; Nulman, I; Pariente, G; Shulman, T, 2017) |
| " Oxcarbazepine and lamotrigine were associated with increased occurrence of autism." | 4.95 | Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. ( Cogo, E; D'Souza, J; Finkelstein, Y; Hemmelgarn, BR; Hutton, B; Kealey, R; MacDonald, H; Reynen, E; Rios, P; Soobiah, C; Straus, SE; Thavorn, K; Tricco, AC; Veroniki, AA; Yazdi, F, 2017) |
| "To investigate the efficacy and safety of lamotrigine monotherapy in children with epilepsy via a systematic review." | 4.93 | [Lamotrigine monotherapy in children with epilepsy: a systematic review]. ( Huang, L; Liu, YT; Zeng, LN; Zhang, LL, 2016) |
| "Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are fatal adverse cutaneous drug reactions which may be induced by phenytoin (PHT) or lamotrigine (LTG)." | 4.91 | HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies. ( Huo, J; Li, X; Mei, S; Wang, J; Yu, K; Zhao, Z; Zhu, Y, 2015) |
| "We searched MEDLINE (1966-2012), EMBASE (1980-2012) and Cochrane, for relevant citations on the effectiveness of different monitoring strategies on seizure deterioration in pregnant women with epilepsy on lamotrigine." | 4.90 | Effects of monitoring strategies on seizures in pregnant women on lamotrigine: a meta-analysis. ( Al Wattar, BH; Bagary, M; Doug, M; Greenhill, L; Houston, V; Khan, KS; McCorry, D; Pirie, AM; Pirie, DA; Siddiqua, A; Thangaratinam, S, 2014) |
| "The paper presents the review of literature on the age aspect of using lamotrigine in pubertal period, in women of reproductive age, during pregnancy and lactation and in climacteric period." | 4.87 | [Lamotrigine in treatment of women with epilepsy]. ( Agranovich, OV; Dranko, DV; Vlasov, PN, 2011) |
| " It is unclear whether or not monotherapy with the new AEDs offers higher efficacy and/or lower side effects compared to classic AEDs (phenobarbital, phenytoin, carbamazepine, or valproate) thereby significantly improving the quality of life in children with epilepsy." | 4.85 | [Role of monotherapy with new antiepileptic drugs in the treatment of childhood epilepsy]. ( Legido, A; Valencia, I, 2009) |
| "Studies have confirmed that the elimination of lamotrigine and the active metabolite of oxcarbazepine is enhanced during pregnancy." | 4.85 | Managing antiepileptic drugs during pregnancy and lactation. ( Sabers, A; Tomson, T, 2009) |
| "To provide an overview of the available literature concerning the prevention of congenital malformations following the use of lamotrigine (LMT) during pregnancy." | 4.85 | [Teratogenic effects of lamotrigine in women with bipolar disorder]. ( Berwaerts, K; De Fruyt, J; Sienaert, P, 2009) |
| " The USA guideline for epilepsy treatment recommends that patients with newly diagnosed epilepsy can be treated with gabapentin, lamotrigine, topiramate, and oxcarbazepine." | 4.84 | [Newer antiepileptic drugs]. ( Matsuura, M, 2007) |
| " Controlled trials in elderly patients with epilepsy demonstrate efficacy and tolerability comparable to gabapentin." | 4.84 | Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia. ( Nanry, K; Ramsay, E; Sajatovic, M; Thompson, T, 2007) |
| "Lamotrigine (LTG) is a generally well-tolerated antiepileptic drug (AED) with broad-spectrum efficacy in several forms of partial and generalized epilepsy and is also licensed for use in bipolar disorder in several countries." | 4.84 | Development of psychosis in patients with epilepsy treated with lamotrigine: report of six cases and review of the literature. ( Boehme, V; Brandt, C; Fueratsch, N; Kramme, C; Pieridou, M; Pohlmann-Eden, B; Villagran, A; Woermann, F, 2007) |
| " As the result of the detailed analysis of the literature the author recommends lamotrigine, carbamazepine and oxcarbazepine as first choice antiepileptic drug for epileptic patients suffering from depressive disorder, too." | 4.84 | [Effects of antiepileptic drugs on mood of people with epilepsy]. ( Rajna, P, 2007) |
| "This paper briefly reviews and comments on the development of lamotrigine as a treatment for bipolar disorder." | 4.84 | Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence. ( Ascher, JA; Bowden, CL; Calabrese, JR; DeVeaugh-Geiss, J; Evoniuk, G; Weisler, RH, 2008) |
| "Lamotrigine is an anticonvulsant drug with good efficacy and safety in the treatment of epilepsy." | 4.82 | Lamotrigine in mood disorders. ( Green, B, 2003) |
| "Lamotrigine and oxcarbazepine demonstrated efficacy in randomized active-control trials in patients with newly diagnosed epilepsy and in substitution trials in patients refractory to conventional AEDs." | 4.82 | Monotherapy in epilepsy: role of the newer antiepileptic drugs. ( Vazquez, B, 2004) |
| "To correlate lamotrigine (LTG) serum concentrations (levels) with tolerability in patients with epilepsy." | 4.82 | Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. ( Adams, DJ; Bazil, CW; Buchsbaum, R; Du, Y; Hager, M; Hirsch, LJ; Morrell, MJ; Resor, SR; Spencer, HT; Straka, T; Weintraub, D, 2004) |
| "The introduction of these new antiepileptic drugs, from felbamate to levetiracetam, raised hope of control of epilepsy with fewer adverse effects and improved quality of life." | 4.81 | New antiepileptic drug therapies. ( Bergin, AM; Connolly, M, 2002) |
| "Accumulating data suggest that lamotrigine, which has been available for adult use in epilepsy for more than a decade in clinical practice, also confers effective, well-tolerated control of a range of childhood epilepsies." | 4.81 | Efficacy and safety of lamotrigine in pediatric patients. ( Messenheimer, J, 2002) |
| "To provide a qualitative, systematic update and review of the pharmacology, pharmacokinetics, efficacy in mood disorders, adverse effects, and costs of lamotrigine." | 4.81 | Lamotrigine update and its use in mood disorders. ( Hurley, SC, 2002) |
| "We systematically reviewed and analyzed published and unpublished cases of Stevens-Johnson syndrome (SJS), or toxic epidermal necrolysis (TEN) associated with lamotrigine (LTG) therapy to identify characteristics of these reactions." | 4.80 | Lamotrigine-induced severe cutaneous adverse reactions. ( Schlienger, RG; Shapiro, LE; Shear, NH, 1998) |
| " More specifically, vigabatrin, which is a very useful and well tolerated new antiepileptic drug for refractory partial epilepsy, should be started at a low dosage of 0." | 4.79 | The new anticonvulsant drugs. Implications for avoidance of adverse effects. ( Krämer, G; Schmidt, D, 1994) |
| "Data from five almost identical protocols have been pooled to give the results of treatment with lamotrigine in 285 children with refractory epilepsy." | 4.79 | Lamotrigine--a clinical overview. ( Wallace, SJ, 1994) |
| "Lamotrigine (LTG) is a novel antiepileptic drug (AED) with a spectrum of activity in animal models of epilepsy similar to that of phenytoin and carbamazepine." | 4.79 | Lamotrigine. ( Messenheimer, JA, 1995) |
| "To evaluate the efficacy and tolerability of the newly developed antiepileptic drugs gabapentin, lamotrigine, tiagabine, topiramate, vigabatrin, and zonisamide in patients with refractory partial epilepsy." | 4.79 | New antiepileptic drugs: a systematic review of their efficacy and tolerability. ( Chadwick, DW; Kadir, ZA; Marson, AG, 1996) |
| "Gabapentin, lamotrigine, tiagabine, topiramate, vigabatrin, and zonisamide are all administered as add-on therapy for treatment of patients with refractory epilepsy." | 4.79 | Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. ( Chadwick, DW; Kadir, Z; Marson, T, 1996) |
| "Since 1994, three new antiepileptic drugs, felbamate, lamotrigene, and gabapentin, have been released for the treatment of epilepsy." | 4.79 | A review of the newer antiepileptic drugs and the ketogenic diet. ( Barron, TF; Hunt, SL, 1997) |
| "The pharmacokinetics of lamotrigine have been studied in single and multiple dose studies in animals, normal volunteers, and patients with epilepsy." | 4.79 | Lamotrigine: pharmacokinetics. ( Garnett, WR, 1997) |
| "Gabapentin (GBP), lamotrigine (LTG), tiagabine (TGB), topiramate (TPM), vigabatrin (VGB), and zonisamide (ZNS) are all in use as "add-on" treatment for patients with refractory epilepsy." | 4.79 | The new antiepileptic drugs: a systematic review of their efficacy and tolerability. ( Chadwick, DW; Hutton, JL; Kadir, ZA; Marson, AG, 1997) |
| "Lamotrigine is an antiepileptic drug which is believed to suppress seizures by inhibiting the release of excitatory neurotransmitters." | 4.78 | Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. ( Chrisp, P; Goa, KL; Ross, SR, 1993) |
| " Felbamate (FBM) is effective in the treatment of partial seizures and Lennox-Gastaut epilepsy." | 4.78 | Advances in the pharmacotherapy of epilepsy. ( Ramsay, RE, 1993) |
| "S Food and Drug Administration warnings that lamotrigine, a common sodium channel modulating anti-seizure medication (NaM-ASM), could increase the risk of sudden death in patients with structural or ischaemic cardiac disease, however, its implications for Sudden Unexpected Death in Epilepsy (SUDEP) are unclear." | 4.31 | Risk of sudden unexpected death in epilepsy (SUDEP) with lamotrigine and other sodium channel-modulating antiseizure medications. ( Auvrez, C; Barnard, S; Berkovic, SF; Chen, Z; Cook, MJ; D'Souza, W; Devinsky, O; Friedman, D; Kwan, P; Laze, J; Nightscales, R; O'Brien, TJ; Perucca, P; Sivathamboo, S; Tao, G, 2023) |
| "We identified a significant decrease in the serum concentrations of clobazam, desmethylclobazam, and lamotrigine following a 12-week ketogenic diet intervention in children with drug resistant epilepsy." | 4.31 | Decreased serum concentrations of antiseizure medications in children with drug resistant epilepsy following treatment with ketogenic diet. ( Gervin, K; Iversen, PO; Kverneland, M; Landmark, CJ; Pedersen, S; Rudi, K; Selmer, KK, 2023) |
| " In the present work, BCRP's role as a mechanism that might contribute to drug-resistant epilepsy (DRE) in a mouse model of acute seizures was studied with further assessment of the effect of its inhibition by ko143 and metformin (MET) on lamotrigine (LTG) bioavailability and efficacy." | 4.31 | Implications of BCRP modulation on PTZ-induced seizures in mice: Role of ko143 and metformin as adjuvants to lamotrigine. ( El-Sayed, NS; Fathelbab, MH; Harby, SA; Khalil, NA; Saleh, SR; Thabet, EH, 2023) |
| "Findings from this explorative study strengthen the evidence for the warning against the use of valproate in pregnancy and raise concern of risks of specific psychiatric disorders associated with topiramate and levetiracetam." | 4.31 | Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. ( Alvestad, S; Bjørk, MH; Christensen, J; Cohen, JM; Dreier, JW; Furu, K; Gissler, M; Igland, J; Leinonen, MK; Sun, Y; Tomson, T; Zoega, H, 2023) |
| "Dose-adjusted lamotrigine troughs in epilepsy patients with variant UGT2B7 -161C > T or UGT1A4*3 c." | 4.31 | Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy. ( Božina, N; Domjanović, IK; Gadže, ŽP; Ganoci, L; Lovrić, M; Romić, ZČ; Šimičević, L; Sporiš, IŠ; Trkulja, V, 2023) |
| "Our results do not support a significant difference in the reporting risk for cardiac arrest, syncope, tachyarrhythmia, and bradyarrhythmia with lamotrigine in the epileptic indication." | 4.31 | Investigation of cardiac arrhythmia events in patients treated with lamotrigine: FDA adverse event reporing system analysis. ( Aboukaoud, M; Maor, E; Wilf-Yarkoni, A, 2023) |
| "Despite widespread monotherapy use of lamotrigine or levetiracetam during pregnancy, prospectively collected, blinded child development data are still limited." | 4.31 | Neurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study. ( Bromley, RL; Bullen, P; Campbell, E; Clayton-Smith, J; Craig, J; García-Fiñana, M; Hughes, DM; Ingham, A; Irwin, B; Jackson, C; Kelly, T; Morrow, J; Rushton, S; Winterbottom, J; Wood, A; Yates, LM, 2023) |
| "Maintaining seizure control with lamotrigine is complicated by altered pharmacokinetics and existence of subpopulations in whom clearance increases or remains constant during pregnancy." | 4.31 | Empiric dosing strategies to predict lamotrigine concentrations during pregnancy. ( Barry, JM; Birnbaum, AK; French, JA; Harden, CL; Karanam, A; Pennell, PB, 2023) |
| "Use of valproate and carbamazepine decreased progressively, use of lamotrigine remained relatively static, and the use of levetiracetam increased progressively, whereas the use of topiramate first increased and then fell again, associated with a temporary increase in malformation-associated pregnancy rate." | 4.31 | Changes over 24 years in a pregnancy register - Teratogenicity and epileptic seizure control. ( Eadie, M; Graham, J; Hitchcock, A; Lander, C; O'Brien, T; Perucca, P; Vajda, F, 2023) |
| " In our case series, lamotrigine proved to be less effective and less controllable than other drugs during pregnancy." | 4.12 | [Women with epilepsy before and during pregnancy: a case series of outpatient counseling in a tertiary epilepsy center]. ( Bien, CG; Hagemann, A; Knaak, N; Müffelmann, B, 2022) |
| "In a nation-wide population-based longitudinal register linkage study for the first time 1) to investigate long-term response to lithium in patients with bipolar disorder with and without comorbid epilepsy, and 2) within patients with bipolar disorder and comorbid epilepsy to compare differences in responses between lithium, valproate and lamotrigine." | 4.12 | Response to lithium and anticonvulsants among patients with bipolar disorder with and without comorbid epilepsy - A nation-wide population-based longitudinal study. ( Budtz-Jørgensen, E; Gerds, T; Kessing, LV; Ziersen, SC, 2022) |
| "AbstractThe aim of this study was to explore the effect of lamotrigine (LTG) on blood ammonia level in patients with epilepsy and identify risk factors affecting blood ammonia level." | 4.12 | Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine. ( Chen, J; Chen, X; Chen, Y; Miao, J; Wang, R; Zeng, J; Zhuang, X, 2022) |
| "1%) received an anti-epileptic medication during pregnancy of which more than half received lamotrigine or levetiracetam." | 4.12 | Use of antiepileptic drugs by trimester. ( Benson, RJ; D'Alton, ME; Friedman, AM; Huang, Y; Logue, TC; Pack, AM; Wright, JD, 2022) |
| "In this report, successful management of lamotrigine-influenced GE in a 24-year-old patient with epilepsy by gingivectomy followed by stringent oral hygiene protocol is presented." | 4.12 | Lamotrigine-Induced Gingival Enlargement: An Older Problem Due to a Newer Drug - A Rare Case Report. ( Rajendran, P, 2022) |
| " Our results suggest an association between disabling seizure occurrence during pregnancy and lamotrigine usage in polytherapy that warrants further evaluation." | 4.12 | Epilepsy and Pregnancy: An Audit of Specialized Care. ( Li, J; Nguyen, DK; Toffa, DH, 2022) |
| "To compare the hazard for all-cause mortality and mortality due to heart failure (HF) between valproate (VPA) and levetiracetam (LEV)/lamotrigine (LTG) users in patients aged ≥ 65 with comorbidities of epilepsy and HF." | 4.12 | The Relationship Between Valproate and Lamotrigine/Levetiracetam Use and Prognosis in Patients With Epilepsy and Heart Failure: A Danish Register-Based Study. ( Gardella, E; Kragholm, K; Liang, D; Polcwiartek, C; Sessa, M, 2022) |
| "The Food and Drug Administration (FDA) is advising health care practitioners that lamotrigine (Lamictal), used in managing seizures and bipolar disorder, may increase the risk of serious and potentially lethal arrythmias." | 4.02 | Lamotrigine may Increase Risk of Arrythmias. ( Aschenbrenner, DS, 2021) |
| "This study has developed and validated a novel UPLC method to quantify lacosamide (LCM), oxcarbazepine (OXC), and lamotrigine (LTG) in children with epilepsy in Xinjiang, China." | 4.02 | Development and validation of an innovative UPLC method to quantify lacosamide, oxcarbazepine, and lamotrigine in the serum of children with epilepsy in China. ( Feng, J; Li, HJ; Ma, L; Sun, L; Sun, Y; Wang, TT; Yu, J; Yu, LH; Zhao, T, 2021) |
| " Exanthema as especially clinically relevant adverse drug event was rightly chosen for carbamazepine by 18 (8%) and for lamotrigine by 12 (5%) participants." | 4.02 | Knowledge of epilepsy among German pharmacists. ( Bertsche, A; Bertsche, T; Herziger, B; Jeschke, S; Müller, RM; Neininger, MP, 2021) |
| "During pregnancy, various physiological changes occur that can alter the pharmacokinetics of antiepileptic drugs, such as lamotrigine (LTG)." | 4.02 | Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy. ( Cao, YF; Guo, Y; Sun, XY; Tao, YY; Wang, ML; Wang, ZY; Zhao, L, 2021) |
| "Lamotrigine displayed the lowest risk of discontinuation when prescribed as initial monotherapy for epilepsy in MS." | 4.02 | Retention of antiseizure medications for epilepsy in multiple sclerosis: A retrospective observational study. ( Burman, J; Håkansson, S; Mahamud, Z; Zelano, J, 2021) |
| "We prospectively enrolled 33 adult patients (age 18-85) who were diagnosed with epilepsy and started lamotrigine administration for the first time at a single tertiary hospital." | 4.02 | A new rapid titration protocol for lamotrigine that reduces the risk of skin rash. ( Chang, H; Chu, K; Jang, Y; Jun, JS; Jung, KH; Jung, KY; Kang, HR; Kim, N; Kim, TJ; Lee, SK; Lee, ST; Moon, J; Park, KI; Shin, YW, 2021) |
| "Lamotrigine and lacosamide show similar effectiveness in diffuse glioma patients with epilepsy." | 4.02 | The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide. ( Dirven, L; Fiocco, M; Koekkoek, JAF; Kouwenhoven, MCM; Taphoorn, MJB; van den Bent, MJ; van der Meer, PB; van Opijnen, MP, 2021) |
| "This prospective cohort study of therapeutic drug monitoring included 582 Chinese epilepsy patients receiving lamotrigine monotherapy." | 4.02 | Redefining the age-specific therapeutic ranges of lamotrigine for patients with epilepsy: A step towards optimizing treatment and increasing cost-effectiveness. ( Ma, YY; Wang, HX; Wang, ML; Zhao, LM; Zhao, MM, 2021) |
| "We sought to explore the effects of sodium valproate combined with lamotrigine on quality of life and serum inflammatory factors in patients with poststroke secondary epilepsy." | 3.96 | Effects of Sodium Valproate Combined with Lamotrigine on Quality of Life and Serum Inflammatory Factors in Patients with Poststroke Secondary Epilepsy. ( Guo, D; Hao, F; Li, X; Liu, X; Sun, J; Tang, W; Tao, S, 2020) |
| "Determine the genetic cause of the intellectual disability, epilepsy and Brugada syndrome of the patient and try to establish a possible correlation between the genetic background and the Brugada syndrome pattern under lamotrigine treatment." | 3.96 | Lamotrigine induced Brugada-pattern in a patient with genetic epilepsy associated with a novel variant in SCN9A. ( Alcalde, M; Banfi, P; Brugada, R; Campuzano, O; Coll, M; Mauri, M; Oliva, A; Princiotta, L; Striano, P; Versino, M, 2020) |
| "Dose individualization is essential in epilepsy treatment, especially in antiepileptic drugs that present high interindividual variability such as lamotrigine." | 3.96 | Dosing Recommendations Based on Population Pharmacokinetics of Lamotrigine in Mexican Adult Patients With Epilepsy. ( Chávez-Castillo, CE; Medellín-Garibay, SE; Milán-Segovia, RDC; Rodríguez-Leyva, I; Romano-Moreno, S, 2020) |
| "The objective of the study was to describe the effect of the vaginal ring and transdermal patch on lamotrigine serum levels in women with epilepsy." | 3.96 | Contraceptive vaginal ring reduces lamotrigine levels. ( Bachman, E; Gerard, EE; King, A; Lee, J; Macken, MP, 2020) |
| "The aim of this study was to evaluate the effects of valproate (VPA), lamotrigine (LTG), and levetiracetam (LEV) on bone turnover and bone mineral density (BMD) in newly diagnosed adult patients with epilepsy." | 3.96 | Effects of valproate, lamotrigine, and levetiracetam monotherapy on bone health in newly diagnosed adult patients with epilepsy. ( Guo, Y; Huang, Y; Lin, Z; Yu, L, 2020) |
| "The aim of the study was to assess whether, male patients with epilepsy, switching from valproic acid (VPA) to levetiracetam (LEV) or lamotrigine (LMG) critically improves sperm counts and parameters, increasing chance of patients' female partners to spontaneously conceive." | 3.96 | An open study of valproate in subfertile men with epilepsy. ( Georgiou, I; Kostoulas, C; Markoula, S; Siarava, E; Zikopoulos, A, 2020) |
| "56 G > A rs17183814 on the response to lamotrigine monotherapy in patients with focal epilepsy in Herzegovina area, Bosnia and Herzegovina." | 3.91 | Lack of association of SCN2A rs17183814 polymorphism with the efficacy of lamotrigine monotherapy in patients with focal epilepsy from Herzegovina area, Bosnia and Herzegovina. ( Basic, S; Bozina, N; Markovic, I; Pejanovic-Skobic, N, 2019) |
| "Lamotrigine and levetiracetam have higher retention rates than carbamazepine in poststroke epilepsy." | 3.91 | Retention rate of first antiepileptic drug in poststroke epilepsy: A nationwide study. ( Åsberg, S; Kumlien, E; Larsson, D; Zelano, J, 2019) |
| "The aims of this study were to identify the influencing factors such as gender, age, dose and combinations of other antiepileptic drugs (AEDs), especially in triple combinations on the pharmacokinetic of Lamotrigine (LTG) in epilepsy patients of Northwest Chinese Han population." | 3.91 | The influence of concomitant antiepileptic drugs on lamotrigine serum concentrations in Northwest Chinese Han population with epilepsy. ( Han, X; Huang, J; Lv, J; Ma, L; Nie, X; Peng, L; Wang, J; Xia, L; Zan, X, 2019) |
| "Lamotrigine has become the most frequently prescribed drug in the treatment of pregnant women with epilepsy." | 3.91 | A Short Communication: Lamotrigine Levels in Milk, Mothers, and Breastfed Infants During the First Postnatal Month. ( Brozmanova, H; Grundmann, M; Kacirova, I, 2019) |
| "To evaluate the pharmacokinetic changes in lamotrigine (LTG) from prepregnancy to postpartum and to assess the impact of therapeutic drug monitoring (TDM) on seizure management during pregnancy in a Chinese population." | 3.91 | Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy. ( Ding, Y; Guo, Y; Tan, X; Zhang, S, 2019) |
| "This study investigated the effect of delayed or missed doses on the pharmacokinetics (PK) of lamotrigine (LTG) in children with epilepsy and established remedial dosing recommendations for nonadherent patients." | 3.91 | Remedial dosing recommendations for delayed or missed doses of lamotrigine in pediatric patients with epilepsy using Monte Carlo simulations. ( Ding, JJ; Jiao, Z; Wang, CY; Yu, EQ; Zhang, XH, 2019) |
| "The study included the children of 83 epileptic women treated with lamotrigine during pregnancy, at a tertiary medical centre between 2004-2014." | 3.88 | Short- and long-term complications of in utero exposure to lamotrigine. ( Berger, I; Cohen-Israel, M; Klinger, G; Linder, N; Martonovich, EY; Stahl, B, 2018) |
| "To assess the relative risk of oral clefts associated with maternal use of high and low doses of topiramate during the first trimester for epilepsy and nonepilepsy indications." | 3.88 | Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. ( Bateman, BT; Cohen, JM; Desai, RJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Patorno, E; Pennell, PB, 2018) |
| "To evaluate the impact of maternal UGT1A4 and UGT2B7 genetic polymorphisms and sex of foetus on gestation-induced changes in lamotrigine (LTG) clearance during pregnancy and post-partum (PP)." | 3.88 | UGT polymorphisms and lamotrigine clearance during pregnancy. ( Ekström, L; Hansen, TF; Öhman, I; Petrenaite, V; Sabers, A; Sæbye, D; Tomson, T, 2018) |
| "A total of 304 patients with epilepsy, aged 18-70 years, were divided into a lamotrigine monotherapy group and groups receiving lamotrigine with AEDs that act as enzyme inducers, enzyme inhibitors, or both." | 3.88 | Effect of antiepileptic drug comedication on lamotrigine concentrations. ( Božina, N; Čajić, I; Klarica Domjanović, I; Lovrić, M; Petelin Gadže, Ž, 2018) |
| "Adults with epilepsy on lamotrigine monotherapy (n = 131) or lamotrigine + valproate treatment (n = 74) were genotyped and steady-state lamotrigine and valproate morning troughs were determined as a part of routine therapeutic drug monitoring." | 3.88 | Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. ( Božina, N; Čajić, I; Ganoci, L; Klarica Domjanović, I; Lovrić, M; Petelin-Gadže, Ž; Trkulja, V, 2018) |
| " The past medical history of the patient was significant for post-stroke epilepsy for which she was on oxcarbazepine." | 3.88 | Lesson of the month 1: To stop a fit, but swinging low. ( Agrawal, A; Ogbebor, O; Yegneswaran, B, 2018) |
| "The purpose of this study was to determine the effect of lamotrigine (LTG) and levetiracetam (LEV) as mono- and polytherapy on biochemical markers of bone turnover and bone mineral density in Egyptian adult patients with epilepsy." | 3.88 | Levetiracetam and lamotrigine effects as mono- and polytherapy on bone mineral density in epileptic patients. ( Akef, GH; Allah, HMS; El-Haggar, SM; Mostafa, TM, 2018) |
| "To determine how early lamotrigine clearance (LTG-CL/F) increases during early pregnancy in women with epilepsy and to quantify the relationship of LTG-CL/F to estradiol concentrations and gestational week." | 3.88 | Lamotrigine clearance increases by 5 weeks gestational age: Relationship to estradiol concentrations and gestational age. ( Allien, S; Barnard, S; Birnbaum, AK; Callisto, SP; French, JA; Harden, CL; Karanam, A; Lau, C; Pennell, PB, 2018) |
| "A limited number of anti-epileptic drugs accounted for the treatment of a majority of new patients with epilepsy (carbamazepine, lamotrigine and valproate accounted for more than 70%)." | 3.85 | Patterns of antiepileptic drug prescription in Sweden: A register-based approach. ( Berggren, F; Berling, P; Bolin, K; Gauffin, H; Landtblom, AM; Morberg, S, 2017) |
| "Valproic acid (VPA) is widely used in the treatment of children with epilepsy." | 3.83 | Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine. ( Dong, Y; Guo, Y; Liang, M; Meng, H; Qiu, F; Wang, Q; Yun, W; Zhao, L, 2016) |
| "It may be appropriate to reach a daily lamotrigine dose above 250 mg in adult patients suffering from epilepsy for more than 5 years using lamotrigine as monotherapy." | 3.83 | Lamotrigine as monotherapy in clinical practice: efficacy of various dosages in epilepsy. ( Eilam, A; Gilad, R; Warshavsky, A, 2016) |
| " We aimed to assess intrasubject variation in plasma concentrations of lamotrigine (LTG), levetiracetam (LEV) and topiramate (TPM) after generic substitution compared with a stable brand-name drug regimen in a population of patients with epilepsy." | 3.83 | Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens. ( Alberghini, L; Benini, G; Candela, C; Contin, M; Riva, R, 2016) |
| "Although it has been reported that some antiepileptic drugs have inducing or inhibiting effects on lamotrigine (LTG) clearance, whether they have the same effects in Asian epilepsy patients as in those in other countries has not been clarified, especially in children." | 3.83 | The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy. ( Abe, S; Azuma, Y; Ishihara, N; Ito, Y; Itomi, K; Kidokoro, H; Kojima, S; Kurahashi, H; Kurahashi, N; Maruyama, K; Natsume, J; Negoro, T; Okumura, A; Suzuki, M; Takeuchi, T; Tsuji, T; Watanabe, K; Yamada, K; Yamamoto, H, 2016) |
| "The alterations observed in body composition with valproic acid in contrast to other AEDs like levetiracetam, carbamazepine and phenytoin could affect treatment response in epilepsy especially in subjects with already altered body composition status like obese and thin frail patients, which needs to be established by prospective studies (CTRI/2013/05/003701)." | 3.83 | Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs. ( Gupta, YK; Kakkar, AK; Sarangi, SC; Tripathi, M, 2016) |
| "We compared persistence of antiepileptic drugs (AEDs) including carbamazepine, oxcarbazepine, gabapentin, lamotrigine, topiramate, valproic acid, and phenytoin in an Asian population with epilepsy." | 3.83 | Comparative persistence of antiepileptic drugs in patients with epilepsy: A STROBE-compliant retrospective cohort study. ( Hsieh, CY; Huang, CW; Lai, EC; Lin, SJ; Setoguchi, S; Su, CC; Yang, YK, 2016) |
| "The pharmacokinetics of Lamotrigine (LTG) varies widely among patients with epilepsy." | 3.83 | Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy. ( Ding, MP; Jin, B; Liu, ZR; Lu, RY; Shen, CH; Tang, YL; Wang, S; Zhang, YX, 2016) |
| "Lamotrigine (LTG) is a widely used antiepileptic-drug (AED) for the treatment of epilepsy." | 3.81 | Effect of comedication on lamotrigine clearance in Korean epilepsy patients. ( Hong, SB; Joo, EY; Kim, HJ; Kim, TE; Lee, SY; Seo, DW, 2015) |
| "To assess the effect and tolerability of zonisamide (ZNS) as adjunctive treatment for difficult-to-treat epilepsy in adult Scandinavian patients." | 3.81 | Retention rate of zonisamide in intractable epilepsy. ( Andersen, H; Lindstrøm, P; Nakken, KO, 2015) |
| " After a lamotrigine-induced Stevens-Johnson syndrome (SJS) occurred, she presented with total collapse of the right lung on admission, which was subsequently complicated by a pneumothorax during conservative treatment, but with the re-expansion of the right upper lobe after intervention." | 3.81 | Bronchiolitis obliterans complicating a pneumothorax after Stevens-Johnson syndrome induced by lamotrigine. ( Cheng, QS; Li, XF; Lu, Q; Ni, YF; Wang, WP; Wei, YN, 2015) |
| " VPA and CBZ proved to be equally effective in Rett patients who presented seizures within the typical age range (4-5 years), while Lamotrigine (LTG) was effective for patients in whom epilepsy started later." | 3.81 | Antiepileptic drugs in Rett Syndrome. ( Baglietto, MG; Calevo, MG; Canevini, M; Giacomini, T; Giordano, L; Hayek, Y; Pintaudi, M; Renieri, A; Russo, S; Traverso, M; Veneselli, E; Vignoli, A, 2015) |
| "This study evaluated the influence of concomitant antiepileptic drugs (AEDs) on the plasma concentration of lamotrigine (LTG) in pediatric patients with epilepsy." | 3.81 | Influence of uridine diphosphate glucuronosyltransferase inducers and inhibitors on the plasma lamotrigine concentration in pediatric patients with refractory epilepsy. ( Ikeda, H; Imai, K; Inoue, Y; Kagawa, Y; Nakai, M; Takahashi, M; Takahashi, Y; Yamamoto, Y, 2015) |
| "In this cross-sectional study, 60 patients with epilepsy who were receiving valproate (VPA) (n = 30) or lamotrigine (LTG) (n = 30) monotherapy were enrolled." | 3.81 | Effects of antiepileptic drug monotherapy on one-carbon metabolism and DNA methylation in patients with epilepsy. ( Chen, Y; Chen, Z; Fang, Z; Huang, M; Li, H; Ni, G; Qin, J; Zhou, J; Zhou, L; Zhou, Y, 2015) |
| "Lamotrigine (LTG) is widely used in the treatment of children with epilepsy." | 3.81 | Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy. ( Dong, Y; Guo, Y; Liang, M; Qiu, F; Wang, Q; Yun, W; Zhao, L, 2015) |
| " We evaluated influence of DHA on anticonvulsant activity of AEDs phenytoin, valproate, and lamotrigine in maximal electroshock (MES), pentylenetetrazole (PTZ), and kindling models of epilepsy." | 3.81 | Synergistic effect of docosahexaenoic acid on anticonvulsant activity of valproic acid and lamotrigine in animal seizure models. ( Babapour, V; Gavzan, H; Sardari, S; Sayyah, M, 2015) |
| "This randomized, double-blind, multiple-dose, steady-state, fully replicated bioequivalence study compared generic lamotrigine to brand-name Lamictal in "generic-brittle" patients with epilepsy (n = 34) who were already taking lamotrigine." | 3.81 | Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard. ( Jiang, W; Jones, JW; Kane, MA; Krumholz, A; Lionberger, R; Polli, JE; Temple, R; Ting, TY; Wong, J, 2015) |
| "Lamotrigine (LTG) is commonly used to control seizure in epilepsy patients and with referenced therapeutic windows in clinical practice." | 3.81 | Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients. ( Chen, Z; Huang, M; Li, H; Li, J; Wang, X; Xie, W; Zhang, J; Zhou, L; Zhou, Y, 2015) |
| " Therefore, this multicenter cross-sectional study aimed to evaluate the prevalence of reproductive endocrine dysfunctions in pubertal females with epilepsy receiving VPA, lamotrigine (LTG), or levetiracetam (LEV) monotherapy." | 3.80 | Reproductive endocrine health in pubertal females with epilepsy on antiepileptic drugs: time to screen? ( Agostinelli, S; Baumann, M; Haberlandt, E; Luef, G; Pizzolorusso, A; Prieschl, M; Rauchenzauner, M; Roscia, S; Rostasy, K; Verrotti, A; Wildt, L, 2014) |
| " Here we provide updated results from the UK Epilepsy and Pregnancy Register of the risk of MCMs after monotherapy exposure to valproate, carbamazepine and lamotrigine." | 3.80 | Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. ( Campbell, E; Craig, J; Delanty, N; Hunt, SJ; Irwin, B; Kennedy, F; Liggan, B; Morrison, PJ; Morrow, J; Parsons, L; Russell, A; Smithson, WH, 2014) |
| " We developed a stable-labeled IV formulation of lamotrigine (LTG) for studying pharmacokinetics in epilepsy patients." | 3.80 | Safety of an intravenous formulation of lamotrigine. ( Birnbaum, AK; Conway, JM; Leppik, IE; Pennell, PB; Rarick, JO; Remmel, RP; White, JR, 2014) |
| "Women with epilepsy using LTG in combination with valproate (VPA; n=7), carbamazepine (CBZ; n=3) or oxcarbazepine (OXC; n=1) were evaluated during two periods of 28 days cyclic OC use, monitoring antiepileptic drug (AED) levels every other day with the dried blood spot sampling method." | 3.80 | Effect of oral contraceptives on lamotrigine levels depends on comedication. ( Lambrechts, DA; Lindhout, D; Sander, JW; Wegner, I; Wilhelm, AJ, 2014) |
| "The aims of this study were to characterize a lamotrigine-resistant kindled model of epilepsy in mice, to study the anticonvulsant effect of carbamazepine (CBZ) and valproic acid (VPA), and to probe into the mechanism for resistance." | 3.80 | Characterization of a lamotrigine-resistant kindled model of epilepsy in mice: evaluation of drug resistance mechanisms. ( Mehndiratta, M; Pillai, KK; Singh, E, 2014) |
| "Evidence from this and other studies suggests that lamotrigine and levetiracetam have low risk for teratogenesis, but that topiramate exposure early in pregnancy may be associated with dose-related anatomical teratogenesis, as valproate is already known to be." | 3.80 | The teratogenicity of the newer antiepileptic drugs - an update. ( Eadie, MJ; Graham, J; Lander, CM; O'Brien, TJ; Vajda, FJ, 2014) |
| "The aim of our research was to evaluate some biochemical changes in blood during lamotrigine (LTG) monotherapy of adult patients with epilepsy, and to check possible associations between typical selenium status parameters and the frequency of seizures." | 3.79 | Antioxidant agents and physiological responses in adult epileptic patients treated with lamotrigine. ( Atroshi, F; Bartoń, H; Kaipainen, P; Kaski, M; Kryczyk, J; Nicol, F; Ounjaijean, S; Płonka-Półtorak, E; Westermarck, T; Zagrodzki, P, 2013) |
| "The combination of lamotrigine and valproate/divalproex sodium has been shown to be effective in the treatment of refractory epilepsy." | 3.79 | Valproate and lamotrigine in pediatric patients with refractory epilepsy: after the first year. ( Thome-Souza, S; Valente, KD, 2013) |
| "Lamotrigine (LTG) has a good efficacy and tolerability as initial monotherapy for patients with newly diagnosed epilepsy (NDE)." | 3.79 | Depression in patients with newly diagnosed epilepsy predicts lamotrigine-induced rash: a short-term observational study. ( Park, SP, 2013) |
| " We present a 12-year-old girl with epilepsy who developed TEN after about 14 days of lamotrigine treatment." | 3.79 | A lamotrigine induced toxic epidermal necrolysis in a child. ( Altun, F; Bilgili, SG; Bulut, G; Burakgazi, AZ; Calka, O; Karadag, AS, 2013) |
| "In this retrospective controlled study, the impact of adjunctive lacosamide (LCM) on cognition in patients with epilepsy was evaluated and compared with that of topiramate (TPM) and lamotrigine (LTG) in a naturalistic outpatient setting." | 3.79 | The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. ( Helmstaedter, C; Witt, JA, 2013) |
| "To estimate the incidence of sudden unexpected death in epilepsy (SUDEP) in Rogaland County, Norway, in the period August 1 1995-July 31 2005, and to investigate whether use of lamotrigine (LTG) was associated with increased risk in female patients or other subgroups." | 3.78 | Increased risk of sudden unexpected death in epilepsy in females using lamotrigine: a nested, case-control study. ( Aurlien, D; Gjerstad, L; Larsen, JP; Taubøll, E, 2012) |
| "The purpose of this case series is to characterize a recently identified association of the antiepileptic drug (AED) lamotrigine with aseptic meningitis based on cases reported to the Food and Drug Administration (FDA)'s Adverse Event Reporting System (AERS) database." | 3.78 | Lamotrigine and aseptic meningitis. ( Avigan, M; Kortepeter, C; Simms, KM, 2012) |
| "Based on epidemiological data it is advised to whenever possible avoid valproic acid during pregnancy." | 3.78 | Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes. ( Boersma, C; de Jong-van den Berg, LT; Jentink, J; Postma, MJ, 2012) |
| " Lamotrigine, the prototypical newer AED, is often used for psychiatric and neurological conditions other than epilepsy." | 3.78 | Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study. ( Hartung, DM; McGregor, JC; Middleton, L; Svoboda, L, 2012) |
| "The purpose of this study was to compare age and comedication as factors contributing to pharmacokinetic variability between 4 newer AEDs (lamotrigine, levetiracetam, oxcarbazepine, and topiramate) among patients with refractory epilepsy." | 3.78 | Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. ( Baftiu, A; Johannessen Landmark, C; Johannessen, SI; Larsson, PG; Rytter, E; Tysse, I; Valsø, B, 2012) |
| "We recruited 222 patients with epilepsy who were prescribed lamotrigine in monotherapy or polytherapy." | 3.78 | Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. ( Božina, N; Božina, T; Granić, P; Hajnšek, S; Kuzman, MR; Lalić, Z; Lovrić, M; Sporiš, D, 2012) |
| "To establish a population pharmacokinetics (PPK) model for lamotrigine (LTG) in Chinese children with epilepsy in order to formulate an individualized dosage guideline." | 3.78 | Population pharmacokinetics of lamotrigine in Chinese children with epilepsy. ( Bao, WQ; He, DK; Li, L; Liu, HT; Lu, W; Qin, J; Song, XQ; Wang, L; Zhang, JM; Zhang, S, 2012) |
| "To study the effectiveness and safety of lamotrigine monotherapy for treatment of epilepsy, systemic evaluation was carried out on published comparative trials between lamotrigine and carbamazepine." | 3.78 | Effectiveness and safety assessment of lamotrigine monotherapy for treatment of epilepsy. ( Gao, F; He, H; Jiang, W; Li, XW; Liu, YF; Ma, L; Meng, XD; Wei, D, 2012) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 3.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| "Lamotrigine is a newer antiepileptic drug useful as oral adjunctive therapy in refractory epilepsy." | 3.77 | Add-on lamotrigine in pediatric epilepsy in India. ( Jain, R; Juneja, M; Mishra, D, 2011) |
| "Pre-morning-dose serum valproic acid concentrations were measured in 76 subjects with epilepsy (48 M, 28 F, age range 6-20 years, mean age 14 years) in whom lamotrigine was added while the dose of valproate and other medication remained unchanged." | 3.77 | The effect of lamotrigine on valproic acid concentrations. ( Berry, DJ; Besag, FM; Besag, FP; Martin, AC, 2011) |
| " The antiepileptic drug lamotrigine (LTG) is a UGT1A4-substrate, and its serum concentration falls by over 50% during pregnancy, leading to impaired seizure control." | 3.77 | Expression of UDP-glucuronosyltransferase 1A4 in human placenta at term. ( Reimers, A; Stuen, I; Sundby, E; Østby, L, 2011) |
| "To investigate the physiological mechanisms behind the pronounced decline of lamotrigine (LTG) serum concentrations during pregnancy." | 3.77 | Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol. ( Bråthen, G; Brodtkorb, E; Helde, G; Reimers, A, 2011) |
| "Lamotrigine (LTG) which has a widespread use in epilepsy treatment as an antiepileptic agent is metabolized by UDP-glucuronosyl transferase (UGT) enzymes." | 3.77 | The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy. ( Aker, RG; Goren, MZ; Gulcebi, MI; Onat, FY; Ozkara, C; Ozkaynakcı, A, 2011) |
| "To determine the frequency of malformations among infants born to women who had taken lamotrigine or carbamazepine as part of polytherapy during the first trimester of pregnancy." | 3.77 | Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. ( Hernandez-Diaz, S; Holmes, LB; Mittendorf, R; Shen, A; Smith, CR, 2011) |
| "A retrospective cohort study using a large health insurance plan claims database comparing patients with epilepsy who switched from brand to generic equivalent phenytoin, lamotrigine, or divalproex after 6 months (switch cohorts) to matched patients who remained on the brand (nonswitch cohorts)." | 3.77 | Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. ( Curtis, B; Erickson, SC; Harada, AS; Le, L; Ramsey, SD; Solow, BK; Stockl, KM; Zakharyan, A, 2011) |
| "Relationships between reproductive hormone levels, bone turnover marker levels, bone mineral density, and rates of bone loss were evaluated in premenopausal women with epilepsy taking enzyme-inducing antiepileptic drugs (EIAEDs: phenytoin or carbamazepine) or lamotrigine." | 3.77 | Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs. ( McMahon, DJ; Morrell, MJ; Pack, AM; Shane, E, 2011) |
| "To evaluate steroid alterations in women with epilepsy (WWE) on lamotrigine monotherapy." | 3.77 | The steroid metabolome in lamotrigine-treated women with epilepsy. ( Dušková, M; Hill, M; Kancheva, L; Kancheva, R; Kubátová, J; Marusič, P; Pařízek, A; Stárka, L; Velíková, M; Vrbíková, J; Zárubová, J, 2011) |
| "We investigated the effect of lamotrigine (LTG) add-on therapy in 50 patients with childhood-onset refractory epilepsy (25 males and 25 females): 15 with localization-related epilepsy, 33 with generalized epilepsy, and 2 with undetermined epilepsy." | 3.77 | [Lamotrigine add-on therapy for childhood-onset refractory epilepsy: comparison of the efficacy between 3 months and 6 months after initiation]. ( Endoh, F; Kobayashi, K; Ohtsuka, Y; Watanabe, K; Yoshinaga, H, 2011) |
| " The usual maintenance dosage of lamotrigine is 200 to 500 mg daily given in two divided doses." | 3.77 | The clinical efficacy of lamotrigine as an antiepileptic drug. ( Pellock, JM, 1994) |
| "We present an implementation of a method we previously reported allowing the newer antiepileptic drugs (AEDs) rufinamide (RFN) and zonisamide (ZNS) to be simultaneously determined with lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine (MHD) and felbamate (FBM) in plasma of patients with epilepsy using high performance liquid chromatography (HPLC) with UV detection." | 3.76 | Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. ( Albani, F; Baruzzi, A; Candela, C; Contin, M; Mohamed, S; Riva, R, 2010) |
| "In this study of older adults with epilepsy, lamotrigine was the most effective AED as measured by 12-month retention and seizure freedom, with levetiracetam a close second." | 3.76 | Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. ( Arif, H; Bazil, CW; Buchsbaum, R; Hirsch, LJ; Pierro, J; Resor, SR; Sims, J; Whalen, M, 2010) |
| "The aim of the study was to investigate risk factors for cardiovascular disease in patients with epilepsy using the new antiepileptic drug levetiracetam (LEV), compared with patients taking carbamazepine (CBZ) or lamotrigine (LTG)." | 3.76 | Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. ( Gjerstad, L; Luef, G; Mørkrid, L; Rauchenzauner, M; Svalheim, S; Taubøll, E, 2010) |
| " Patients with clinically stable partial or generalized epilepsy, already receiving lamotrigine or valproic acid on monotherapy, were assessed in two visits: baseline and at 6 months." | 3.76 | Quality of life and treatment satisfaction in Spanish epilepsy patients on monotherapy with lamotrigine or valproic acid. ( Barriga, J; Cobaleda, S; Codina, M; Lahuerta, J; Morales, MD; Viteri, C, 2010) |
| "To assess possible alterations in the pharmacokinetics of lamotrigine (LTG) in menopause, we reviewed the database of the drug monitoring service at the Karolinska University Hospital." | 3.76 | Are lamotrigine kinetics altered in menopause? Observations from a drug monitoring database. ( Lukic, S; Ohman, I; Tomson, T, 2010) |
| "Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter." | 3.76 | Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register. ( Eadie, MJ; Graham, JE; Hitchcock, AA; Lander, CM; O'Brien, TJ; Vajda, FJ, 2010) |
| " The influence of age and concomitant medications on the dose/concentration ratio of levetiracetam was examined in 103 children with epilepsy." | 3.76 | Age and comedications influence levetiracetam pharmacokinetics in children. ( Dahlin, MG; Ohman, I; Wide, K, 2010) |
| "To report on a patient with epilepsy who developed leukopenia and thrombocytopenia during phenobarbital/lamotrigine treatment." | 3.76 | Phenobarbital/Lamotrigine coadministration-induced blood dyscrasia in a patient with epilepsy. ( Calabrò, G; De Sarro, G; Gallelli, L; Siniscalchi, A; Tolotta, GA, 2010) |
| " Between 1999 and 2004, we enrolled pregnant women with epilepsy who were taking a single AED (carbamazepine, lamotrigine, phenytoin, or valproate)." | 3.76 | Effects of breastfeeding in children of women taking antiepileptic drugs. ( Baker, GA; Browning, N; Clayton-Smith, J; Cohen, M; Combs-Cantrell, DT; Kalayjian, LA; Kanner, A; Liporace, JD; Loring, DW; Meador, KJ; Pennell, PB; Privitera, M, 2010) |
| "Lamotrigine (LTG) has shown to confer broad-spectrum, well-tolerated control of epilepsy." | 3.75 | Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy. ( Hardison, HH; Khurana, DS; Kothare, SV; Legido, A; Marks, HG; Melvin, JJ; Piñol-Ripoll, G; Valencia, I, 2009) |
| "We evaluated the serum leptin and insulin as predictors of weight gain in children receiving long-term treatment with valproate (VPA), carbamazepine (CBZ), lamotrigine (LTG)." | 3.75 | States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain. ( Fida, NM; Hamed, EA; Hamed, SA, 2009) |
| "Our study suggests that there are clinically significant differences among gabapentin, lamotrigine, levetiracetam, tiagabine, and topiramate as treatment for focal epilepsy in everyday practice." | 3.75 | Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study. ( Auvinen, A; Fallah, M; Keränen, T; Peltola, J; Peltola, M; Raitanen, J, 2009) |
| "Variations in the plasma concentration of levetiracetam during pregnancy and postpartum were prospectively monitored in five women to investigate their potential implications in epilepsy management and child outcome." | 3.75 | Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. ( Cid, AO; Juste, AO; López-Fraile, IP; Modrego, PJ, 2009) |
| "Between 1999 and 2004, we enrolled pregnant women with epilepsy who were taking a single antiepileptic agent (carbamazepine, lamotrigine, phenytoin, or valproate) in a prospective, observational, multicenter study in the United States and the United Kingdom." | 3.75 | Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. ( Baker, GA; Browning, N; Clayton-Smith, J; Cohen, M; Combs-Cantrell, DT; Kalayjian, LA; Kanner, A; Liporace, JD; Loring, DW; Meador, KJ; Pennell, PB; Privitera, M, 2009) |
| "Previous studies have demonstrated that the pharmacokinetics of the new antiepileptic drug (AED) lamotrigine (LTG) are substantially influenced by pregnancy and are more likely to be associated with seizure deterioration in pregnancy compared to other AEDs." | 3.75 | Seizure frequency in pregnant women treated with lamotrigine monotherapy. ( Petrenaite, V; Sabers, A, 2009) |
| "Lamotrigine is frequently used to manage epilepsy during pregnancy." | 3.75 | Lamotrigine and twin pregnancy, incidental event or possible correlation? ( Azimi, AR; Karvigh, SA; Motamedi, M; Navardi, S; Sahraian, MA, 2009) |
| "Using a retrospective chart review, we identified six patients with epilepsy who reported transient emergent psychological symptoms during stable, chronic lamotrigine monotherapy." | 3.75 | End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients. ( Frey, LC; Shrestha, A; Spitz, MC; Strom, LA, 2009) |
| "To report a case of severe apnea in an infant exposed to lamotrigine through breast-feeding." | 3.75 | Severe apnea in an infant exposed to lamotrigine in breast milk. ( Aronsen, L; Nordmo, E; Småbrekke, L; Vorren, S; Wasland, K, 2009) |
| "This substudy of the Neurodevelopmental Effects of Antiepileptic Drugs investigation enrolled pregnant women with epilepsy on AED monotherapy (carbamazepine, lamotrigine, and valproate)." | 3.75 | A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy. ( Gaillard, WD; McVearry, KM; Meador, KJ; VanMeter, J, 2009) |
| "The purpose of this study was to derive a population pharmacokinetics (PPK) model of lamotrigine clearance as well as to identify and describe factors that influence it in Serbian patients with epilepsy." | 3.75 | Population pharmacokinetics of lamotrigine in patients with epilepsy. ( Jankovic, SM; Milovanovic, JR, 2009) |
| "(1) Numerous follow-up studies of pregnancies in women with epilepsy show that valproic acid is more teratogenic than other antiepileptics." | 3.75 | Valproic acid: long-term effects on children exposed in utero. ( , 2009) |
| "An association between a polymorphism of the SCN1 gene, a therapeutical target of lamotrigine, and an effective dose (a blood plasma concentration) of the drug in patients with epilepsy has been studied." | 3.75 | [Association study of the SCN1 gene polymorphism and effective dose of lamotrigine]. ( Andreev, IaA; Avakian, GN; Biktimerov, RR; Burd, SG; Chukanova, AS; Denisov, EV; Krikova, EV; Rider, FK; Val'dman, EA, 2009) |
| "We prospectively surveyed 23 pregnant women with epilepsy on lamotrigine monotherapy and reported outcome of their pregnancies, including one fetal intrauterine death, one spontaneous abortion and two preterm deliveries." | 3.75 | Prospective surveillance of Croatian pregnant women on lamotrigine monotherapy--aspects of pre-pregnancy counseling and drug monitoring. ( Bakulić, TI; Bosnjak-Pasić, M; Cvitanović-Sojat, L; Demarin, V; Fucić, A; Gjergja-Juraski, R; Mikula, I; Miskov, S, 2009) |
| "The influence of smoking on lamotrigine (LTG) serum levels in 44 patients with epilepsy treated with LTG in monotherapy was examined." | 3.74 | Smoking reduces serum levels of lamotrigine. ( Dorn, T; Krämer, G; Reinsberger, C, 2008) |
| "This study develops a population pharmacokinetic model for lamotrigine (LTG) in Spanish and German patients diagnosed with epilepsy." | 3.74 | Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. ( Buelga, DS; Domínguez-Gil, A; Elger, CE; García, MJ; Otero, MJ; Rivas, N; Santos-Borbujo, J, 2008) |
| "Data from the International Lamotrigine Pregnancy Registry were analyzed to examine the effect of maximal first-trimester maternal dose of lamotrigine monotherapy on the risk of major birth defects (MBDs)." | 3.74 | Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. ( Cunnington, M; Ferber, S; Quartey, G, 2007) |
| "We retrospectively reviewed medical records from 20 patients treated with lamotrigine (LTG) who underwent epilepsy surgery between January 1997 and February 2004." | 3.74 | Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery. ( Aktas, O; Fritz, G; Lehmann, TN; Meencke, HJ; Paul, F; Veauthier, C; Zipp, F, 2007) |
| " It identifies lamotrigine as a cost-effective alternative to carbamazepine for the treatment of focal epilepsies, but confirms valproate as the most effective drug for the treatment of generalized or unclassified epilepsy." | 3.74 | Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients. ( Chadwick, D; Marson, T, 2007) |
| "The aim of this study was to characterize outcomes in patients with epilepsy who experienced adverse reactions on switching from branded to generic lamotrigine and who were subsequently switched back to the branded formulation." | 3.74 | Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. ( Makus, KG; McCormick, J, 2007) |
| "A previous study conducted in Taiwan found a 100% association between HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome (SJS) in Han Chinese subjects, with an extremely high odds ratio compared with carbamazepine-tolerant subjects (odds ratio = 2,504)." | 3.74 | Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. ( Baum, L; Cheng, AS; Kwan, P; Lau, KM; Man, CB; Ng, MH; Yu, E, 2007) |
| "As of 1st June 2005 it is possible to market generic epilepsy drugs with the active substance lamotrigine because the patent on the original product Lamictal had expired." | 3.74 | [Does generic lamotrigine lead to larger variations in plasma concentrations?]. ( Brandslund, I; Buck, TC; Schmedes, A, 2007) |
| "One of my female patients has epilepsy and is currently receiving lamotrigine monotherapy." | 3.74 | Teratogenicity of lamotrigine. ( Koren, G; Nulman, I; Shor, S, 2007) |
| "To characterize the magnitude and course of alterations in total and free lamotrigine (LTG) clearance (Cl) during pregnancy and the postpartum period, to assess the impact of therapeutic drug monitoring (TDM) on seizure frequency, to determine the ratio to individual target LTG concentration that is associated with increased seizure risk, and to evaluate maternal postpartum toxicity." | 3.74 | Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. ( Holley, DK; Koganti, A; Newman, M; Newport, DJ; Peng, L; Pennell, PB; Ritchie, JC; Stowe, ZN, 2008) |
| "To further characterize pregnancy-induced alterations in the pharmacokinetics of lamotrigine (LTG)." | 3.74 | Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. ( Beck, O; Ohman, I; Tomson, T; Vitols, S, 2008) |
| "This report describes the laboratory and physical manifestations of lamotrigine-like toxicity in a young man with refractory epilepsy receiving lamotrigine presenting as anticonvulsant hypersensitivity syndrome (AHS) associated with an abrupt change of drug product." | 3.74 | Progressive anticonvulsant hypersensitivity syndrome associated with change of drug product. ( Sabers, A; Sabroe, TP, 2008) |
| " Patients with > or = 1 epilepsy claim and treated with branded lamotrigine (Lamictal) before generic entry were selected." | 3.74 | Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. ( Duh, MS; Latrémouille-Viau, D; Lefebvre, P; LeLorier, J; Manjunath, R; Paradis, PE; Sheehy, O, 2008) |
| " In the mouse pentylenetetrazole induced seizures model, JZP-4 was approximately twice as potent as lamotrigine in prolonging the time to clonus." | 3.74 | In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity. ( Eller, M; Foreman, MM; Hanania, T; Stables, JP; Stratton, SC; White, HS; Wilcox, KS, 2008) |
| "To establish a population pharmacokinetics (PPK) model of lamotrigine, an antiepileptic drug, in Chinese children with epilepsy to formulate an individualized dosage guideline." | 3.74 | [Population pharmacokinetics of lamotrigine in Chinese children with epilepsy]. ( Lu, W; Wang, L; Zhang, S, 2008) |
| " We previously reported biochemical evidence of increased bone turnover in premenopausal women with epilepsy on phenytoin monotherapy compared with those on carbamazepine, lamotrigine, and valproate." | 3.74 | Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. ( McMahon, DJ; Morrell, MJ; Pack, AM; Randall, A; Shane, E, 2008) |
| "The infant exposed in the first trimester of pregnancy to the anticonvulsant drug lamotrigine has an increased risk to have an isolated cleft palate or cleft lip deformity." | 3.74 | Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. ( Baldwin, EJ; Glassman, L; Habecker, E; Holmes, LB; Smith, CR; Wong, SL; Wyszynski, DF, 2008) |
| "Across a range of assumptions used, the risk of hospitalization for Stevens-Johnson syndrome or toxic epidermal necrolysis in new users is low for carbamazepine, lamotrigine, phenytoin, phenobarbital, and valproic acid." | 3.73 | Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. ( Messenheimer, J; Mockenhaupt, M; Schlingmann, J; Tennis, P, 2005) |
| "To evaluate whether the administration of lamotrigine (LTG) or valproate (VPA) changes concentrations of plasma total homocysteine (tHcy), plasma and red-cell folate and plasma Vitamin B-12, we measured these indices in a total of 20 patients with epilepsy before and after a 32-week period of monotherapy of LTG or VPA." | 3.73 | Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy. ( Gidal, BE; Hammer, A; Tamura, T; Vuong, A, 2005) |
| "During her first pregnancy, a 37-year-old woman with idiopathic generalised epilepsy that was adequately controlled with lamotrigine experienced a series of epileptic seizures following an elective caesarean section." | 3.73 | [Epileptic seizures during childbirth in a patient with idiopathic generalised epilepsy]. ( Bloem, BR; Renier, WO; Voermans, NC; Zwarts, MJ, 2005) |
| "The aim of the study was to obtain pharmacokinetic data for carbamazepine (CBZ) and its fractions not bound with proteins in bitherapy with lamotrigine (LTG), topiramate (TPM), vigabatrin (VGB) or valproic acid (VPA) in children and adolescents treated for epilepsy." | 3.73 | Pharmacokinetic interactions of carbamazepine with some antiepileptic drugs during epilepsy treatment in children and adolescents. ( Steinborn, B, 2005) |
| "Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ)." | 3.73 | Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. ( Baldy-Moulinier, M; Berramdane, M; Coubes, P; Crespel, A; Gelisse, P; Genton, P; Monicard, C, 2005) |
| "A very simple and fast method has been developed and validated for simultaneous determination of the new generation antiepileptic drugs (AEDs) lamotrigine (LTG), oxcarbazepine's (OXC) main active metabolite monohydroxycarbamazepine and felbamate in plasma of patients with epilepsy using high-performance liquid chromatography (HPLC) with spectrophotometric detection." | 3.73 | Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. ( Albani, F; Balboni, M; Baruzzi, A; Callegati, E; Candela, C; Contin, M; Riva, R, 2005) |
| "Add-on therapy of lamotrigine for patients with uncontrolled epilepsy offers improved health outcomes." | 3.73 | Cost-effectiveness of add-on lamotrigine therapy in clinical practice. ( Boendermaker, AJ; Deckers, CL; Egberts, AC; Hekster, YA; Keyser, A; Knoester, PD; Renier, WO; Severens, JL, 2005) |
| "Authors presented the data on the efficacy and tolerability of the new anticonvulsant drug topiramate (topamax) in the treatment of 110 children aged from 6 months to 16 years with pharmacoresistant types of epilepsy including 42 patients with tuberous sclerosis." | 3.73 | [The efficacy of topiramate (topamax) in the treatment of resistant epilepsy in children]. ( Belousova, ED; Dorofeeva, MIu; Ermakov, AIu, 2005) |
| "Anticonvulsant hypersensitivity syndrome (AHS) developing to lamotrigine, a non-aromatic anticonvulsant, has rarely been reported." | 3.73 | Anticonvulsant hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. ( Gogtay, NJ; Kanchan, S; Karande, S; Kshirsagar, NA, 2006) |
| "Thirty patients were enrolled: 10 on gabapentin, 10 on lamotrigine and 10 on carbamazepine monotherapy for epilepsy." | 3.73 | Measuring the effects of antiepileptic medications on balance in older people. ( Blum, D; Fife, TD; Fisher, RS, 2006) |
| "To determine whether the efficacy and tolerability of adjunctive lamotrigine differ as a function of whether persons with mental retardation and refractory epilepsy resided in institutions or the community." | 3.73 | Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation. ( Hammer, AE; McKee, JR; Sunder, TR; Vuongc, A, 2006) |
| "A four-year-old male with symptomatic generalized epilepsy presented with ataxia, eye rolling, and episodes of back arching which were of non-epileptic origin following the introduction of clobazam at 0." | 3.73 | Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. ( Aylett, SE; Berry, D; Cross, H, 2006) |
| " The mother had been treated with valproic acid (1800mg per day) and lamotrigine (100mg per day) throughout pregnancy." | 3.72 | Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality. ( Cogulu, O; Gunduz, C; Kultursay, N; Ozkinay, F; Yilmaz, D, 2003) |
| "To introduce a first approximation of the cost effectiveness of the new therapeutic agents (topiramate and lamotrigine) for epilepsy that have been assessed in clinical trials against placebo." | 3.72 | The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation. ( Gagnon, DD; McNulty, P; O'Hagan, A; van Hout, BA, 2003) |
| " In the present study, lamotrigine (LTG), one of the newer antiepileptic drugs, was evaluated for its effect on epilepsy, mood and memory in mice." | 3.72 | Effects of folic acid and lamotrigine therapy in some rodent models of epilepsy and behaviour. ( Ali, A; Pal, SN; Pillai, KK, 2003) |
| "A 10-year-old girl developed a progressive rash and high fever more than a month after the start of lamotrigine as add-on medication for therapy-resistant epilepsy." | 3.72 | [Toxic epidermal necrolysis due to lamotrigine]. ( Beerhorst, K; Renier, WO, 2003) |
| "This open-label, cross-sectional study compared (1) endocrine and lipid measures during the early follicular phase of the menstrual cycle; (2) prevalence of menstrual disorders (from patient diaries recorded over three cycles); and (3) body weight of women with epilepsy on lamotrigine monotherapy (n=119) with those on valproate monotherapy (n=103) for <5 years." | 3.72 | Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. ( Ayala, R; Dam, M; Gomez, G; Isojärvi, J; Messenheimer, J; Morrell, MJ; O'Neill, F; Taylor, AE; Tennis, P, 2003) |
| "This study aimed to assess the risks and benefits of the co-administration of lamotrigine and valproate in a pediatric population with refractory epilepsy." | 3.72 | Lamotrigine and valproate: efficacy of co-administration in a pediatric population. ( Fiore, LA; Freitas, A; Thomé-Souza, S; Valente, KD, 2003) |
| "A group of 105 women (54 of whom were, and had only ever been, taking valproate for at least a year, and 51 who had only ever taken either lamotrigine or carbamazepine, for at least a year) were compared with a group of 50 women who did not have epilepsy: any oral contraceptive taken at the time of testing was recorded and blood levels of follicle stimulating hormone (FSH), luteinising hormone (LH), testosterone and prolactin were estimated from days 2 to 6 of the menstrual cycle (day 1 being the first day of bleeding) and an MRI scan made of their pelvis." | 3.72 | A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. ( Betts, T; Dutton, N; Greenhill, L; Rolfe, T; Yarrow, H, 2003) |
| "This study was performed to clarify alterations in lamotrigine (LTG) clearance during pregnancy and childbirth." | 3.72 | The impact of pregnancy and childbirth on the metabolism of lamotrigine. ( Helmers, SL; Henry, TR; Montgomery, JQ; Newport, DJ; Pennell, PB; Stowe, ZN, 2004) |
| "Many women with epilepsy who are planning a pregnancy are treated with lamotrigine (LTG), resulting in greater fetal exposure to the drug." | 3.72 | Concerns regarding lamotrigine and breast-feeding. ( D'Abreu, A; Kao, A; Liporace, J, 2004) |
| " Hence, the standard of care for older patients with epilepsy should be reevaluated, although the vast use of phenytoin in this population suggests that change in practice patterns may be difficult." | 3.72 | Potentially inappropriate antiepileptic drugs for elderly patients with epilepsy. ( Berlowitz, D; Charbonneau, A; Cramer, J; Kazis, L; Knoefel, J; Mandell, A; Pugh, MJ, 2004) |
| " Twenty-eight patients were taking carbamazepine (CBZ); five, lamotrigine (LTG); 12, oxcarbazepine (OXC); and 25, valproate (VPA) as monotherapy for epilepsy." | 3.72 | Serum androgen levels and testicular structure during pubertal maturation in male subjects with epilepsy. ( Isojärvi, JI; Mikkonen, K; Päivänsalo, M; Pakarinen, AJ; Tapanainen, P; Vainionpää, LK, 2004) |
| "The authors describe 12 pregnancies in women with epilepsy using lamotrigine (LTG) monotherapy." | 3.72 | Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. ( Augustijn, P; de Haan, GJ; Dévilé-Notschaele, M; Edelbroek, P; Engelsman, M; Lindhout, D; Segers, J, 2004) |
| "To evaluate changes in lamotrigine (LTG) clearance before, during, and after pregnancy." | 3.71 | Lamotrigine clearance during pregnancy. ( Blesi, K; Leppik, IE; Remmel, R; Sathanandan, ST; Tran, TA, 2002) |
| "We conducted a prospective, long-term audit of lamotrigine and topiramate as add-on treatment for refractory epilepsy." | 3.71 | Long-term follow-up of topiramate and lamotrigine: a perspective on quality of life. ( Kaiser, S; Selai, CE; Trimble, MR, 2002) |
| "In 1992, the International Lamotrigine Pregnancy Registry was initiated to enroll prospectively and to monitor pregnancies exposed to lamotrigine (LTG) for the occurrence of major birth defects." | 3.71 | Preliminary results on pregnancy outcomes in women using lamotrigine. ( Eldridge, RR; Tennis, P, 2002) |
| "This postmarketing surveillance study of lamotrigine (LTG) was performed to provide complementary data to large-scale Prescription-Event Monitoring study with a retrospective case records survey in five tertiary referral epilepsy centres in the United Kingdom." | 3.71 | Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom. ( Mawer, GE; Sander, JW; Wong, IC, 2001) |
| "Evaluation of daily clinical practice in prescribing lamotrigine in refractory epilepsy patients." | 3.71 | Peri-marketing surveillance of lamotrigine in The Netherlands: doctors' and patients' viewpoints. ( Arends, LR; Gilissen, KG; Rentmeester, TW; Schlosser, A; Scholtes, FB; Trenité, DG, 2001) |
| "To determine whether long-term treatment with valproate (VPA) and/or lamotrigine (LTG) in children with epilepsy is associated with altered growth and/or bone metabolism." | 3.71 | Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. ( Atkinson, SA; Guo, CY; Ronen, GM, 2001) |
| "To determine the tolerability of lamotrigine in elderly patients with epilepsy." | 3.71 | The tolerability of lamotrigine in elderly patients with epilepsy. ( Giorgi, L; Gomez, G; Hammer, AE; O'Neill, F; Risner, M, 2001) |
| "The authors examined the ratio between the plasma and the cerebrospinal fluid (CSF) concentration of topiramate in 14 adults with epilepsy." | 3.71 | Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. ( Christensen, J; Dam, M; Højskov, CS; Poulsen, JH, 2001) |
| "An observational study of all children with intractable epilepsy at the Paediatric Institute prescribed Lamotrigine as an add-on therapy between January 1994 and November 1998 was conducted." | 3.71 | Lamotrigine as an add-on therapy in intractable paediatric epilepsy--the Kuala Lumpur Hospital experience. ( Hussain, IH; Sofiah, A; Vigneswari, G, 2001) |
| " In the last decade, pregnancy registries have been activated by collaborative groups of physicians in Europe (EURAP), North America (NAREP), Australia and India (the latter two recently merged into EURAP), to enroll a large number of exposed women to be monitored prospectively with standardized methods, and by three pharmaceutical companies marketing lamotrigine, gabapentin and vigabatrin, as part of their post-marketing surveillance." | 3.71 | Pregnancy registries in epilepsy. ( Annegers, JF; Beghi, E, 2001) |
| "The relationship between lamotrigine (LTG) serum concentration and clinical response in patients with epilepsy is still controversial." | 3.71 | Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels. ( Fröscher, W; Keller, F; Krämer, G; Vogt, H, 2002) |
| " Key search terms included lamotrigine, pharmacokinetics, and epilepsy." | 3.71 | Therapeutic drug monitoring of lamotrigine. ( Chong, E; Dupuis, LL, 2002) |
| "Lamotrigine as add-on treatment (500 mg per day) is effective in patients with refractory epilepsy, but its high cost requires a pharmacoeconomic analysis." | 3.70 | Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. ( Becagli, P; Cincotta, M; Labbate, MG; Messori, A; Trippoli, S; Zaccara, G, 1998) |
| "Lamotrigine (LTG) is a valuable addition to the medical management of epilepsy with wide spectrum of efficacy and good outcomes for quality of life." | 3.70 | Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. ( Beran, RG; Gibson, RJ, 1998) |
| "To evaluate the effect of lamotrigine (LTG) on several humoral and cellular immune functions in children with epilepsy and the change in immunological status in patients with LTG-induced rash." | 3.70 | Lamotrigine hypersensitivity in childhood epilepsy. ( Iannetti, P; Pacifici, R; Raucci, U; Zuccaro, P, 1998) |
| "To describe significant positive or negative psychotropic effects of lamotrigine (LTG) observed in epilepsy patients with mental retardation (MR)." | 3.70 | Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. ( Devinsky, O; Dhoon, A; Ettinger, AB; Kanner, A; Saracco, J; Weisbrot, DM, 1998) |
| "To review (retrospectively) the relationships between lamotrigine (LTG) dosage and plasma concentrations based on data generated in a routine therapeutic drug monitoring laboratory from a heterogeneous sample of patients with epilepsy." | 3.70 | Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service. ( Batty, AB; Black, AB; Harris, AL; Morris, RG; Sallustio, BC, 1998) |
| "To review the incidence of lamotrigine (LTG)-associated insomnia in an adult tertiary care epilepsy outpatient clinic." | 3.70 | Lamotrigine associated with insomnia. ( Sadler, M, 1999) |
| " Patients starting on the adjunctive therapies lamotrigine and topiramate were recruited from the out-patient epilepsy clinics at Queen Square." | 3.70 | Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs. ( Selai, CE; Smith, K; Trimble, MR, 1999) |
| "To compare the long-term retention of gabapentin (GBP), lamotrigine (LTG), and vigabatrin (VGB) by patients with chronic epilepsy and the reasons for treatment discontinuation." | 3.70 | The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. ( Chadwick, DW; Fenwick, PB; Mawer, GE; Sander, JW; Wong, IC, 1999) |
| " The proportions of outcomes with birth defects are as follows: in the Acyclovir (antiviral medication) Pregnancy Registry (1984-1998) (19/581), 3." | 3.70 | Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. ( Andrews, EB; Ephross, SA; Heffner, CR; Reiff-Eldridge, R; Tennis, PS; White, AD, 2000) |
| " To evaluate the effect of lamotrigine on body weight in adult patients with epilepsy, we conducted a retrospective review of data from 463 patients treated with lamotrigine in 32 clinical trials." | 3.70 | Stable weight during lamotrigine therapy: a review of 32 studies. ( Barrett, PS; Devinsky, O; Hammer, A; Vuong, A, 2000) |
| "The aim of our study was to examine the influence of long term lamotrigine (LTG) add-on therapy on higher nervous function in patients at the developmental age with epilepsy and to analyse the correlation between changes in EEG and cognitive parameters as a consequence of applying LTG in bi- or polytherapy with conventional antiepileptic drugs (AEDs)." | 3.70 | [Neuropsychological aspects of cognitive functioning in epileptic children and adolescents treated with lamotrigine]. ( Galas-Zgorzalewicz, B; Mojs, E; Steinborn, B, 2000) |
| "To describe the clinical spectrum of lamotrigine (LTG)-induced tics (an uncommon side effect) in children." | 3.70 | Lamotrigine-induced tic disorder: report of five pediatric cases. ( Cheyette, S; Murphy, P; Rho, JM; Sotero de Menezes, MA, 2000) |
| "The authors examined the interindividual correlation between saliva and serum concentrations of lamotrigine (LTG) and the relationship between LTG concentration in saliva and the free LTG concentration in serum in 40 patients with epilepsy, aged 16 to 73 years, receiving stable doses of LTG and comedication." | 3.70 | Saliva and serum concentration of lamotrigine in patients with epilepsy. ( Klitgaard, NA; Kristensen, O; Tsiropoulos, I, 2000) |
| "A 57-year-old woman was under treatment for epilepsy with lamotrigine 2 mg/kg/d since 1996." | 3.70 | Lamotrigine-induced lupus. ( Cazzola, M; Muzzupappa, S; Panni, B; Sarzi-Puttini, P; Turiel, M, 2000) |
| "We sought to determine the long-term retention rates of lamotrigine (LTG), gabapentin (GBP), and topiramate (TPM) therapy for patients at a tertiary referral clinic for chronic, refractory epilepsy." | 3.70 | Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. ( Lhatoo, SD; Polizzi, G; Sander, JW; Wong, IC, 2000) |
| "This open study reports the use of lamotrigine in 93 adults and children with drug resistant epilepsy." | 3.69 | Lamotrigine: clinical experience in 93 patients with epilepsy. ( Buchanan, N, 1995) |
| "Fifty children and adolescents with intractable epilepsy were treated with lamotrigine." | 3.69 | Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. ( Bauzienè, R; Uvebrant, P, 1994) |
| "We prospectively monitored our experience of lamotrigine as add-on therapy in 45 patients with refractory epilepsy." | 3.69 | Impact of lamotrigine on patients with refractory epilepsy: the Leicester experience. ( Martin, PJ; Millac, PA, 1994) |
| "This prospective study was designed to ascertain whether measurement of lamotrigine (LTG) concentrations in the epilepsy clinic could be used to predict the onset of complete seizure control or the emergence of adverse effects." | 3.69 | Concentration--effect and concentration--toxicity relations with lamotrigine: a prospective study. ( Brodie, MJ; Forrest, G; Kilpatrick, ES, 1996) |
| "Fifty-two children with intractable epilepsy received lamotrigine as add-on therapy on a compassionate basis." | 3.69 | [Treatment of childhood epilepsy with lamotrigine. An evaluation of efficacy in different types of epilepsy]. ( Sommer, B; Uldall, PV, 1996) |
| "The present study was conducted to determine the rate of sudden unexplained death in epilepsy (SUDEP) in a well-defined cohort of patients included in the lamotrigine (LTG) clinical development database." | 3.69 | Sudden unexplained death in epilepsy: observations from a large clinical development program. ( Annegers, JF; Brodie, MJ; Brown, S; Cierpial, MA; Earl, NL; Leestma, JE; Schraeder, P; Siscovick, D; Tennis, PS; Wannamaker, BB, 1997) |
| "This study was initiated to evaluate the long-term safety, tolerability and effect on seizure control of lamotrigine (Lamictal) in paediatric patients with epilepsy." | 3.69 | Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy. ( Alving, J; Besag, FM; Dulac, O; Mullens, EL, 1997) |
| "The effects of age, dosage, and type of comedication on plasma lamotrigine (LTG) concentrations and the relationship between plasma drug levels and clinical response were evaluated in a prospective study of 45 patients, aged 3 to 38 years, with epilepsy uncontrolled by conventional anticonvulsant therapy." | 3.69 | The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. ( Alessandrì, MG; Bartoli, A; Belmonte, A; Gatti, G; Guerrini, R; Perucca, E, 1997) |
| "This single case reports an open trial of lamotrigine in the treatment of self-injurious behavior (SIB) and epilepsy in an 18-year-old female diagnosed with generalized seizure disorder, stereotypic movement disorder, and compulsive SIB in the context of profound mental retardation." | 3.69 | Open trial lamotrigine in the treatment of self-injurious behavior in an adolescent with profound mental retardation. ( Davanzo, PA; King, BH, 1996) |
| "The effects of age and concomitant treatment on plasma lamotrigine (LTG) concentration/dose (C/D) ratios were retrospectively evaluated on 482 consecutive routine LTG determinations from 106 chronically-treated patients with epilepsy (40 children and adolescents aged younger than 16 years, and 66 adults aged 17 to 62 years)." | 3.69 | Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy. ( Avanzini, G; Battino, D; Croci, D; Estienne, M; Granata, T; Pisani, F, 1997) |
| "A retrospective survey was carried out of add-on treatment with lamotrigine (LTG) and vigabatrin (GVG) in 109 children with severe epilepsy, treated between 1987 and 1994, identified from a total population of 300 patients seen annually, in a tertiary referral outpatient clinic in Cardiff, Wales." | 3.69 | A survey of lamotrigine and vigabatrin treatment in children with severe epilepsy. ( Gordon, GS; Schapel, GJ; Wallace, SJ, 1997) |
| "To examine the safety of lamotrigine (LTG) used in general practice to treat epilepsy." | 3.69 | Safety of long-term lamotrigine in epilepsy. ( Freemantle, SN; Mackay, FJ; Mann, RD; Pearce, GL; Wilton, LV, 1997) |
| "Sound-induced seizures in genetically epilepsy-prone rats were used to compare the anticonvulsant effect of phenytoin and diazepam with compounds which decrease glutamatergic neurotransmission including excitatory amino acid antagonists acting at N-methyl-D-aspartate (NMDA) receptors: D(-)CPPene, CGP 37849 and MK 801 or at the glycine/NMDA site: ACPC (1-aminocyclopropane-dicarboxylic acid) (partial agonist) or non-NMDA receptors: NBQX (2,3-dihydroxy-6-nitro-7-sulfamoylbenzo[f]-quinoxaline." | 3.68 | Excitatory amino acid antagonists, lamotrigine and BW 1003C87 as anticonvulsants in the genetically epilepsy-prone rat. ( al-Zubaidy, ZA; Chapman, AG; Meldrum, BS; Smith, SE, 1993) |
| "We report the effects of the addition of lamotrigine, a novel antiepileptic drug, to the therapy of 125 patients with severe refractory epilepsy." | 3.68 | The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. ( Hart, YM; Patsalos, PN; Sander, JW; Shorvon, SD; Trevisol-Bittencourt, PC, 1990) |
| "The classification of seizure types and epilepsies should be examined before selecting the ASMs for each patient with epilepsy." | 3.01 | [Medical Treatment of Epilepsy]. ( Jin, K, 2023) |
| "More than thirty antiseizure medications (ASMs) are available for treating epilepsy." | 2.82 | Therapeutic Basis of Generic Substitution of Antiseizure Medications. ( Elmer, S; Reddy, DS, 2022) |
| "Carbamazepine and phenytoin were the drugs most strongly associated with decreases in T4 and T3 levels while topiramate had the greatest elevating effect on TSH." | 2.82 | Side effects of long-term oral anti-seizure drugs on thyroid hormones in patients with epilepsy: a systematic review and network meta-analysis. ( Cai, M; Guo, X; Han, Y; Lin, W; Yang, J; Zhong, R, 2022) |
| "The phenytoin treatment causes cerebellar defect and anemia." | 2.82 | The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches. ( Agrawal, M; Dhurandhar, Y; Panda, SP, 2022) |
| "Lamotrigine is an antiepileptic drug that can be used to control many types of seizures as a single-agent or an add-on therapy in patients over 2 years of age." | 2.82 | Lamotrigine induced priapism in children: case analysis and literature review. ( Cao, SS; Cao, XY; Ge, J; Guan, Y; Mu, F; Qiao, Y; Tang, M; Wang, JW, 2022) |
| "The LTG population pharmacokinetic model developed in this study may be a reliable method for individualising the LTG dosing regimen in paediatric and young adult patients on combination therapy during therapeutic drug monitoring." | 2.79 | Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach. ( Brzaković, B; Kovačević, SV; Martinović, Ž; Miljković, B; Pokrajac, M; Prostran, M; Vučićević, K, 2014) |
| "The aim of this analysis was to describe the pharmacokinetics of oral lamotrigine (LTG) in Indian epileptic patients using a population pharmacokinetic (PPK) modeling approach to confirm that the PK is similar to that of the Caucasian population, and to evaluate and confirm the impact of covariates predictive of inter-individual variability using a simulation platform." | 2.78 | Population pharmacokinetics of lamotrigine in Indian epileptic patients. ( Arumugam, K; Bathala, L; Johnson, MG; Mallaysamy, S; Rajakannan, T; Ramakrishna, D; Rao, PG; van Hasselt, JG, 2013) |
| "Lamotrigine (LTG) is an antiepileptic drug (AED) that was approved in Japan in 2008." | 2.77 | Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients. ( Inoue, Y; Kagawa, Y; Matsuda, K; Takahashi, Y; Yamamoto, Y, 2012) |
| "Carbamazepine is a widely used anticonvulsive agent." | 2.76 | Effects of carbamazepine and metabolites on IL-2, IL-5, IL-6, IL-10 and IFN-γ secretion in epileptic patients: the influence of co-medication. ( Breton, H; Demoly, P; Gelisse, P; Hillaire-Buys, D; Mathieu, O; Picot, MC, 2011) |
| "There was no significant pharmacokinetic interaction between ESL and lamotrigine in healthy subjects." | 2.75 | Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects. ( Almeida, L; Brunet, JS; Falcão, A; Lefebvre, M; Nunes, T; Rocha, JF; Sicard, E; Soares-da-Silva, P, 2010) |
| "Lamotrigine was preferred by the majority of subjects, congruent with objective neuropsychological and subjective behavioral measures." | 2.72 | Subjective preference for lamotrigine or topiramate in healthy volunteers: relationship to cognitive and behavioral functioning. ( Kaul-Gupta, R; Loring, DW; Meador, KJ; Ogrocki, P; Ray, PG; Schoenberg, MR; Werz, MA, 2006) |
| " The similarity of CL/F values also was reflected by the similar exposure (AUCss), Cmax, and Cmin values of TPM in the absence, and presence of LTG." | 2.71 | Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. ( Berry, DJ; Bialer, M; Brodie, MJ; Chadwick, D; Doose, DR; Oxbury, J; Schwabe, S; Wilson, EA, 2003) |
| " Patients were converted during an lamotrigine via a protocol-specified dosing algorithm or to conventional therapy via standard dosing guidelines." | 2.71 | Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. ( Hammer, AE; Kaminow, L; Schimschock, JR; Vuong, A, 2003) |
| "Lamotrigine as adjunctive treatment and monotherapy may improve side effect burden and quality of life in patients requiring a change in AED therapy." | 2.71 | Lamotrigine therapy in patients requiring a change in antiepileptic drug regimen. ( Evans, BK; Groenke, DA; Hammer, AE; Kustra, RP; Leschek-Gelman, LM; Meador, KJ; Messenheimer, JA; Nanry, KP, 2005) |
| " An important side effect associated with the long-term use of some antiepileptic drugs is change in body weight, followed by an increased risk for subsequent maturational problems in pediatric epilepsy patients." | 2.70 | Normal growth during lamotrigine monotherapy in pediatric epilepsy patients -- a prospective evaluation of 103 children and adolescents. ( Ueberall, MA, 2001) |
| "Attempts to control the seizure disorder by resection of apparently epileptogenic mesial temporal or other cortical structures have failed consistently." | 2.70 | Resection of the lesion in patients with hypothalamic hamartomas and catastrophic epilepsy. ( Andermann, F; Aronyk, K; Chandler, C; Costa Da Costa, J; Coutinho, L; Farmer, JP; Martínez, JV; Montes, J; Paglioli, E; Paglioli-Neto, E; Palmini, A; Polkey, C; Portuguez, M; Raupp, S; Rosenblatt, B; Sinclair, B, 2002) |
| " LTG was started at a dosage of 0." | 2.69 | Lamotrigine therapy in juvenile neuronal ceroid lipofuscinosis. ( Aberg, L; Kirveskari, E; Santavuori, P, 1999) |
| "Lamotrigine is an effective add-on therapy against a range of epileptic seizure types." | 2.69 | Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. ( Abbott, R; Dellaportas, CI; Findley, LJ; Gibberd, FB; Gross, M; Park, DM; Perkin, GD; Steiner, TJ, 1999) |
| " The relative bioavailability for LTG compressed tablets was 0." | 2.69 | Rectal absorption of lamotrigine compressed tablets. ( Birnbaum, AK; Burkhardt, RT; Kriel, RL; Remmel, RP, 2000) |
| "LTG, lamotrigine is a new antiepileptic agent chemically unrelated to any established drugs in use." | 2.68 | [Lamotrigine: first experience in Italy]. ( de Romanis, F; Sopranzi, N, 1995) |
| "Lamotrigine was effective in all seizure types examined, particularly for typical and atypical absence seizures." | 2.68 | Lamotrigine for the treatment of epilepsy in childhood. ( Alving, J; Besag, FM; Dulac, O; Hosking, G; Spencer, SC; Wallace, SJ, 1995) |
| " The median elimination half-life (t1/2) in patients receiving concomitant valproate (VPA) was 43." | 2.68 | Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. ( Boreus, L; Eriksson, AS; Hoppu, K; Nergårdh, A, 1996) |
| " Headache, drowsiness, faintness, and diplopia, the common adverse events (AEs), were mild to moderate in intensity and occurred in 50-75% of patients in both groups (except for diplopia, occurring only with LTG)." | 2.68 | Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study. ( Gay, P; Lai, AA; Madsen, J; Matsuo, F; Risner, ME; Rollins, DE; Tolman, KG, 1996) |
| "Lamotrigine (LTG) is a new antiepileptic drug (AED), chemically unrelated to the drugs in current use." | 2.68 | Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. ( Jürgens, U; May, TW; Rambeck, B, 1996) |
| " Both dosage regimens of lamotrigine were well tolerated." | 2.68 | A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. ( Dam, M; Reunanen, M; Yuen, AW, 1996) |
| "The major treatment-emergent AE were infection (50%, 8 of 16) and sleep disturbance (19%, 3 of 16)." | 2.68 | Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut syndrome). ( Donaldson, JA; Glauser, TA; Olberding, LS, 1997) |
| " Subjects were allocated to 1 of 2 dosing schedules according to their concomitant AEDs." | 2.67 | A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. ( Hamilton, MJ; Oxley, JR; Patsalos, PN; Sander, JW; Yuen, WC, 1990) |
| "This narrative review aimed to provide critical findings of the available literature about the role of pharmacodynamic AEDs' interactions in patients whose epilepsies were treated with polytherapy." | 2.66 | Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice. ( Brigo, F; Lattanzi, S; Verrotti, A; Zaccara, G, 2020) |
| "Epilepsy is one of the most common neurological complications in pregnancy; some women continue to use antiepileptic drugs (AEDs) to control seizures." | 2.66 | [Transfer Mechanisms of Compounds between Mother and Fetus/Infant Aimed for Optimized Medication during Pregnancy and Breastfeeding]. ( Furugen, A, 2020) |
| " Dosage was adjusted on the basis of estimated half-life." | 2.66 | Seven day administration of lamotrigine in epilepsy: placebo-controlled add-on trial. ( Beintema, DJ; Binnie, CD; Debets, RM; Meijer, JW; Meinardi, H; Peck, AW; Van Emde Boas, W; Westendorp, AM; Yuen, WC, 1987) |
| "Any type of seizure can be observed in Alzheimer's disease (AD)." | 2.58 | Treatment of epilepsy for people with Alzheimer's disease. ( Liu, J; Wang, LN; Wang, YP; Wu, LY, 2018) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Lamotrigine was preferred in patients with co-morbid depression." | 2.55 | Epilepsy treatment in adults and adolescents: Expert opinion, 2016. ( Chimato, N; Frank, RD; Karceski, SC; Shih, JJ; Vargas, E; Whitlock, JB, 2017) |
| "Epilepsy affects fetal brain development during gestation in pregnant rats, therefore anti-epileptic therapy should be continued during pregnancy." | 2.53 | Effects of phenytoin and lamotrigine treatment on serum BDNF levels in offsprings of epileptic rats. ( Doğan, Z; Kamışlı, Ö; Soysal, H, 2016) |
| "Any type of seizure can be observed in Alzheimer's disease (AD)." | 2.53 | Treatment of epilepsy for people with Alzheimer's disease. ( Liu, J; Wang, LN; Wang, YP; Wu, LY, 2016) |
| "Lamotrigine (LTG) is a second generation anti-epileptic drug (AED) with broad spectrum of activity, a favourable side-effect profile, simpler dosing than earlier drugs and efficacious in diverse epilepsy syndromes." | 2.53 | A pharmacological overview of lamotrigine for the treatment of epilepsy. ( Arjunan, K; Eswaramoorthy, M; Jakki, SL; Nanjan, MJ; Senthil, V; Shanmuganathan, S; Yasam, VR, 2016) |
| "Lamotrigine is a safe anti-epileptic drug among pregnant and lactating women." | 2.52 | Lamotrigine effects on breastfed infants. ( Asgarzadeh, L; Dalili, H; Nayeri, F; Shariat, M, 2015) |
| "Epilepsy is one of the most common neurological conditions in the elderly, and the incidence of de novo geriatric epilepsy is rising." | 2.49 | [Epilepsy in the elderly]. ( Lossius, MI; Markhus, R; Nakken, KO; Sætre, E, 2013) |
| "Seizures and intracranial hemorrhage are possible medical diseases that any obstetrician may encounter." | 2.49 | Seizures and intracranial hemorrhage. ( Alexander, JM; Wilson, KL, 2013) |
| "Lamotrigine has been demonstrated to be effective as both an antiepileptic drug and a mood stabiliser." | 2.49 | Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons? ( Dodd, S; Horgan, D; Vajda, FJ, 2013) |
| "We report a case of Takotsubo syndrome after epilepsy, and review the literature." | 2.48 | Takotsubo syndrome (TKS): a possible mechanism of sudden unexplained death in epilepsy (SUDEP). ( Dubuisson, N; Dupuis, F; Dupuis, M; Evrard, F; van Rijckevorsel, K; Van Robays, P, 2012) |
| "Lamotrigine is a sodium-channel-modulating, antiepileptic drug (AED), which was approved in the USA in 1994 for use in partial-onset seizures." | 2.48 | Lamotrigine use in pregnancy. ( Aggarwal, P; Moore, JL, 2012) |
| "Epilepsy is a neurological disorder primarily characterized by recurrent, unprovoked seizures resulting from excessive or synchronous neuronal activity in the brain." | 2.46 | Extended-release lamotrigine in the treatment of patients with epilepsy. ( Sajatovic, M; Syed, TU, 2010) |
| "Lamotrigine has been shown to be useful in the long-term prophylaxis of depressive episodes in BD." | 2.45 | Lamotrigine-associated rash: to rechallenge or not to rechallenge? ( Bhagwagar, Z; Lorberg, B; Youssef, NA, 2009) |
| " The bioavailability of LTG-XR is similar to that of LTG-IR, except in patients taking enzyme-inducing AEDs in whom the bioavailability of LTG-XR is 21% lower." | 2.45 | Once-daily lamotrigine extended release for epilepsy management. ( Rheims, S; Ryvlin, P, 2009) |
| "Lamotrigine is a relatively new AED which is licensed in many countries for use as an initial monotherapy." | 2.43 | Lamotrigine versus carbamazepine monotherapy for epilepsy. ( Gamble, CL; Marson, AG; Williamson, PR, 2006) |
| " For drugs that are eliminated renally completely unchanged (gabapentin, pregabalin and vigabatrin) or mainly unchanged (levetiracetam and topiramate), the pharmacokinetic variability is less pronounced and more predictable." | 2.43 | Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? ( Johannessen, SI; Tomson, T, 2006) |
| "Lamotrigine has good absorption, minimal plasma protein binding and linear pharmacokinetics." | 2.43 | Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. ( Biton, V, 2006) |
| "Lamotrigine is a broad-spectrum antiepileptic drug, initially approved in 1994 for the adjunctive treatment of partial seizures in adults and for the generalized seizures of Lennox-Gastaut syndrome in pediatric (>2 years old) and adult populations." | 2.43 | Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders. ( Arif, H; Hirsch, LJ; Malik, S, 2006) |
| "Lamotrigine is an anti-epileptic agent with broad efficacy." | 2.42 | Review of lamotrigine and its clinical applications in epilepsy. ( Choi, H; Morrell, MJ, 2003) |
| "The pharmacokinetic properties of a drug are the primary deter-minant of the extent and duration of drug action, and influence susceptibility to clinically important drug interactions." | 2.42 | The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? ( Johannessen, SI; Perucca, E, 2003) |
| " Future studies of formal pharmacokinetic modeling of AEDs during pregnancy and the postpartum period could provide an important step toward achieving effective drug dosing to maintain therapeutic objectives for the mother but, at the same time, to minimize fetal drug exposure." | 2.42 | Antiepileptic drug pharmacokinetics during pregnancy and lactation. ( Pennell, PB, 2003) |
| "Vigabatrin has shown promise in treating IS patients, particularly those with tuberous sclerosis." | 2.42 | Pharmacologic treatment of the catastrophic epilepsies. ( Conry, JA, 2004) |
| " However, it should be remembered that the proportion of persons with this side effect is much reduced when the correct dosage is used, and the sliding scale of dosage starts with sufficiently low doses." | 2.41 | [Characteristics and indications of lamotrigine]. ( Rufo-Campos, M, 2002) |
| "Although antiepileptic drugs (AEDs) are commonly used to control and prevent seizures, their long-term use carries a considerable risk of morbidity." | 2.41 | Antiepileptic drug therapy for adults: when to initiate and how to choose. ( Sirven, JI, 2002) |
| "Lamotrigine is a new antiepileptic drug that is effective for a broad range of seizures in adults and children." | 2.41 | Potential hepatotoxicity of lamotrigine. ( Choueiri, R; Fayad, M; Mikati, M, 2000) |
| " However, on rare occasions, they can progress to more severe cutaneous disorders, including Stevens-Johnson syndrome and toxic epidermal necrolysis." | 2.41 | Therapeutic safety monitoring: what to look for and when to look for it. ( Harden, CL, 2000) |
| "Epilepsy affects 1." | 2.41 | New antiepileptic drugs and preparations. ( Jagoda, A; Yoon, Y, 2000) |
| "Standard antiepileptic drugs (AEDs) have a number of pharmacokinetic shortcomings, and AEDs with more favorable profiles would be preferred." | 2.40 | Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs. ( Johannessen, SI, 1997) |
| "Standard antiepileptic drugs (AEDs) are associated with a wide variety of acute and chronic adverse events and with many interactions with each other and with non-AEDs that complicate patient management." | 2.40 | Overview of the safety of newer antiepileptic drugs. ( Shorvon, S; Stefan, H, 1997) |
| "Felbamate, however, has been linked with substantially increased incidence of aplastic anemia, and the other new AEDs have been studied for relatively short periods of time." | 2.40 | Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances. ( Chapman, DP; Giles, WH, 1997) |
| "Lamotrigine is a phenyltriazine derivative with anticonvulsant properties that initially was tested in adults with partial seizures." | 2.40 | Adult experience with lamotrigine. ( Messenheimer, JA; Willmore, LJ, 1997) |
| "Lamotrigine is a new antiepileptic drug that may possess unique cognitive and behavioral characteristics." | 2.40 | Behavioral and cognitive effects of lamotrigine. ( Baker, GA; Meador, KJ, 1997) |
| "Plasma concentrations of lamotrigine, an antiepileptic drug obtained in three adult controlled clinical trials conducted in the United States were pooled and analyzed using NONMEM, a population pharmacokinetic computer program, to facilitate development of dosing guidelines." | 2.40 | Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy. ( Chen, C; Cox, E; Fiedler-Kelly, J; Grasela, TH; Risner, ME; Womble, GP, 1999) |
| "Lamotrigine (LTG) is an antiepileptic drug (AED) recently released in several countries." | 2.40 | Lamotrigine-associated rash: risk/benefit considerations in adults and children. ( Besag, FM; Brodie, MJ; Dooley, JM; Duchowny, MS; Guberman, AH; Pellock, JM; Richens, A; Stern, RS; Trevathan, E, 1999) |
| " Because dosing is often modest, cost should rarely be the overriding factor in choosing a drug for a patient with newly diagnosed epilepsy in the developed world." | 2.40 | Monostars: an aid to choosing an antiepileptic drug as monotherapy. ( Brodie, MJ, 1999) |
| "To most effectively treat children with epilepsy syndromes, further research must be completed to validate the positive effects described in case reports, open-label clinical trials, and early controlled clinical trials." | 2.40 | Managing pediatric epilepsy syndromes with new antiepileptic drugs. ( Pellock, JM, 1999) |
| " For all drugs that are metabolized, half-life is shortened and clearance is increased when patients receive concomitant enzyme-inducing agents such as barbiturates, phenytoin, and carbamazepine." | 2.40 | The clinical pharmacokinetics of the new antiepileptic drugs. ( Perucca, E, 1999) |
| "Vigabatrin is a specific and irreversible inhibitor of the enzyme gamma-amino-butyric-acid (GABA) transferase." | 2.39 | [Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic]. ( Krämer, G; Vogt, H, 1995) |
| "Lamotrigine is an anticonvulsant chemically related to the antifolate compound pyrimidine." | 2.39 | Lamotrigine--a novel approach. ( Meldrum, BS, 1994) |
| "Epilepsy is one of the most common neurological disorders." | 2.39 | Newer antiepileptic drugs. Towards an improved risk-benefit ratio. ( Patsalos, PN; Sander, JW, 1994) |
| "Felbamate was licensed in 1993 for use as adjunctive therapy or monotherapy in adults with partial or tonic-clonic seizures and as adjunctive therapy for children with the Lennox-Gastaut syndrome." | 2.39 | Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin. ( Laxer, KD, 1994) |
| "Lamotrigine (LTG) is a chemically novel antiepileptic drug (AED) that blocks voltage-sensitive sodium channels, leading to inhibition of neurotransmitter release, principally glutamate." | 2.39 | Lamotrigine: a review of antiepileptic efficacy. ( Yuen, AW, 1994) |
| " By November 1992 about 5,800 patient-years' experience of adverse effects had been compiled." | 2.39 | Safety of lamotrigine. ( Richens, A, 1994) |
| " ZNS daily dosage is 400-600 mg." | 2.39 | Antiepileptic drugs in development: prospects for the near future. ( Leppik, IE, 1994) |
| "Lamotrigine is an antiepileptic agent which blocks voltage-dependent sodium channels, thereby preventing excitatory neurotransmitter release." | 2.39 | Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. ( Fitton, A; Goa, KL, 1995) |
| "Antiepileptic drugs (AEDs) in broad use today have a number of pharmacokinetic liabilities, including a propensity for clinically meaningful drug interactions." | 2.39 | Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs. ( Perucca, E, 1996) |
| " However, the pharmacokinetic properties of an AED determine its ease of use, i." | 2.39 | Important pharmacokinetic properties of antiepileptic drugs. ( Bourgeois, BF, 1995) |
| "This article surveys the pharmacokinetic parameters for the new antiepileptic drugs (AEDs): felbamate, gabapentin, lamotrigine, oxcarbazepine, tiagabine, topiramate, and vigabatrin." | 2.39 | Pharmacokinetics of new antiepileptic drugs. ( Gram, L, 1996) |
| "For many years, the medical treatment of epilepsy was based on the use of the same few drugs, which were chosen according to the seizure type in a fairly standardized manner." | 2.39 | New antiepileptic drugs. ( Bourgeois, BF, 1996) |
| "Vigabatrin is an irreversible inhibitor of GABA transaminase." | 2.39 | [Antiepileptic drugs: mechanism of action]. ( Mercadé Cerdá, JM, 1996) |
| " Specific indications and dosage schedules have been provided." | 2.39 | New antiepileptic drugs. ( Brodie, MJ; Wilson, EA, 1996) |
| "Epilepsy is a common condition with a prevalence of just 1% in a given population." | 2.39 | New drugs and vagal stimulation for treatment of epilepsy--the Israeli experience. ( Korczyn, AD; Neufeld, MY, 1996) |
| "Epilepsy is a disorder of the central nervous system in which the clinical symptoms are recurrent seizures." | 2.38 | Advances in pharmacotherapy: recent developments in the treatment of epilepsy. ( Graves, NM; Leppik, IE, 1993) |
| " In the pooled data from the four double-blind studies (n = 92), the incidence of adverse experiences with LTG and placebo did not differ significantly." | 2.38 | Human safety of lamotrigine. ( Betts, T; Goodwin, G; Withers, RM; Yuen, AW, 1991) |
| "Forty patients (39." | 1.91 | Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy. ( Barambio, S; Becerra, JL; Chíes, E; Ciurans, J; Codina, M; Fumanal, A; García-Esperón, C; Grau-López, L; Jiménez, M, 2023) |
| "Lamotrigine." | 1.91 | Formulation and characterization of lamotrigine nasal insert targeted brain for enhanced epilepsy treatment. ( Abdel-Hakeem, M; Abdelkader, G; Abdelmonem, R; El-Enin, HAA, 2023) |
| "This study was undertaken to determine the impact of dosage in new users of lamotrigine (LTG) and the concomitant intake of valproic acid (VPA) on epidermal necrolysis (EN)." | 1.91 | Effects of dosage in new users of lamotrigine inducing epidermal necrolysis: Results of the German Registry of Severe Skin Reactions. ( Diederich, S; Hemmeter, U; Mockenhaupt, M; Paulmann, M, 2023) |
| "Seizures were classified into two categories: tonic‒clonic/focal to bilateral tonic‒clonic seizures and non-tonic‒clonic seizures." | 1.91 | Changes in seizure frequency and anti-seizure medication therapy during pregnancy and one year postpregnancy. ( Du, Y; Fang, W; Gong, J; Huang, W; Wang, X; Xia, N; Xu, H; Xu, Q; Zheng, R; Zhu, Z, 2023) |
| "Comorbid diagnosis of headache predicted use of topiramate and VPA, bipolar disease predicted use of LMT and VPA, pain predicted gabapentin, and schizophrenia was associated with VPAs use." | 1.91 | Prescribing Trends of Antiseizure Drugs in Women Veterans With Epilepsy. ( Amuan, ME; Henion, A; Lopez, MR; Panahi, S; Pugh, MJ; VanCott, AC, 2023) |
| "Epilepsy is a very common neurological disease with high morbidity and mortality." | 1.91 | [Epilepsy and inequality: demographic description and analysis of the difficulty in accessing advanced resources in a population in a small health area]. ( Cánovas-Iniesta, M; Navarro-Lozano, M; Palazón-Cabanes, B; Pérez-Navarro, VM, 2023) |
| "Epilepsy is a chronic neurological disease that affects more than 50 million people worldwide." | 1.72 | Effects of Low- and High-Dose Valproic Acid and Lamotrigine on the Heart in Female Rats. ( Ateş, B; Çolakoğlu, N; Parlakpınar, H; Vardı, N; Yıldız, A, 2022) |
| "All patients with a diagnosis of IGE, focal epilepsy, or SGE, who received either LTG or LEV, were recruited at the outpatient epilepsy clinic at Shiraz University of Medical Sciences, Shiraz, Iran from 2008 until 2020." | 1.72 | Rational therapy with lamotrigine or levetiracetam: Which one to select? ( Asadi-Pooya, AA; Farazdaghi, M, 2022) |
| "Epilepsy is one of the most common neurologic unit diseases that have different prevalence in different parts of the world." | 1.72 | Evaluation of family planning methods in married women with epilepsy. ( Avan, R; Ershadi, F; Mousavi Mirzaei, SM; Roshanravan, B; Sahebnasagh, A; Tabrizi, N, 2022) |
| "Gabapentin was the most common second- and third-line ASM." | 1.72 | Antiseizure medication treatment pathways for US Medicare beneficiaries with newly treated epilepsy. ( Burke, JF; Choi, H; Terman, SW; Youngerman, BE, 2022) |
| "Cardiac arrhythmia has been suggested as a cause of death in some patients with SUDEP." | 1.72 | Rare sudden unexpected death in epilepsy SCN5A variants cause changes in channel function implicating cardiac arrhythmia as a cause of death. ( Bagnall, RD; Berkovic, SF; Reid, CA; Scheffer, IE; Semsarian, C; Soh, MS, 2022) |
| "Specific antiseizure medications (ASM) would improve the outcome in post-stroke epilepsy (PSE)." | 1.72 | Efficacy and safety of antiseizure medication in post-stroke epilepsy. ( Groppa, S; Klimpe, S; Sandner, K; Stuckrad-Barre, SV; Uphaus, T; Winter, Y, 2022) |
| "Planned pregnancy was the only independent factor significantly associated with decreased risk of adverse pregnancy outcomes (OR, 0." | 1.72 | Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: An observation study in northwest China. ( Jiang, W; Jiang, Y; Ma, L; Shi, X; Song, C; Wang, Y; Xia, L; Zhang, Y; Zhao, J, 2022) |
| "The association between autism spectrum disorders (ASD) and epilepsy has been extensively documented, and the estimated prevalence varies depending upon the selected population and the clinical characteristics." | 1.72 | Autism with Epilepsy: A Neuropsychopharmacology Update. ( Canitano, R; Palumbi, R; Scandurra, V, 2022) |
| "Lamotrigine toxicity can cause coma, seizures, and intraventricular conduction disturbances, and treatment options include good supportive care." | 1.72 | Effectiveness of multiple-dose activated charcoal in lamotrigine poisoning: a case series. ( Haga, Y; Hanazawa, T; Hatanaka, K; Kamijo, Y; Kitamoto, T; Ochiai, H; Yoshizawa, T, 2022) |
| "Lamotrigine is a broad-spectrum antiepileptic drug with high interindividual variability in serum concentrations in children." | 1.62 | Dosing Recommendations for Lamotrigine in Children: Evaluation Based on Previous and New Population Pharmacokinetic Models. ( Aboura, R; Benaboud, S; Billette de Villemeur, T; Bouazza, N; Chenevier-Gobeaux, C; Desguerre, I; Freihuber, C; Gana, I; Hirt, D; Nabbout, R; Tauzin, M; Tréluyer, JM; Zheng, Y, 2021) |
| "Epilepsy is the third most frequent neurological disorder in aged patients after stroke and dementia." | 1.62 | [Epilepsy in the aged : Challenges in diagnostics and treatment]. ( Rohracher, A; Trinka, E, 2021) |
| "Epilepsy was diagnosed in 54." | 1.62 | The molecular and phenotypic spectrum of CLCN4-related epilepsy. ( Cao, D; Fahlke, C; Guzman, RE; He, H; Peng, J; Sierra-Marquez, J; Stauber, T; Yin, F, 2021) |
| "Carbamazepine was the second most common drug followed by lamotrigine and valproic acid." | 1.62 | Post-stroke epilepsy and antiepileptic drug use in men and women. ( Linnér, L; Loikas, D; Sundström, A; von Euler, M; Wettermark, B, 2021) |
| "Carbamazepine was ineffective, and seizures were exacerbated with levetiracetam (LEV)." | 1.56 | Improvement of epilepsy with lacosamide in a patient with ring chromosome 20 syndrome. ( Goji, A; Kagami, S; Mori, T; Tayama, T; Toda, Y, 2020) |
| " Both, the type I isobolographic analysis and the test of parallelism of dose-response effects of the ASDs were used so as to properly classify interaction among three ASDs, administered in a fixed ratio combination of 1:1:1." | 1.56 | Sub-additive (antagonistic) interaction of lacosamide with lamotrigine and valproate in the maximal electroshock-induced seizure model in mice: an isobolographic analysis. ( Bojar, H; Florek-Łuszczki, M; Karwan, S; Kondrat-Wróbel, M; Plewa, Z; Zagaja, M; Łuszczki, JJ, 2020) |
| "Epilepsy is very difficult to treat and often involves the combination of two or more AEDs." | 1.56 | Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database. ( Hayashi, T; Noguchi, Y; Tachi, T; Takaoka, M; Teramachi, H, 2020) |
| "Levetiracetam has replaced sodium valproate as the most frequently prescribed ASM in pediatric patients." | 1.56 | Trends of anti-seizure medication use in pediatric patients in six cities in China from 2013 to 2018. ( Dai, H; Feng, J; Yu, L; Yu, Z, 2020) |
| "To study the risk of intellectual disability and delayed development in childhood milestones among children of women who used valproate or other AEDs during pregnancy." | 1.56 | Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones. ( Christensen, J; Daugaard, CA; Dreier, JW; Pedersen, L; Sun, Y, 2020) |
| "Epilepsy is the disease associated with seizures and convulsions." | 1.56 | In-silico computational analysis of [6-(2, 3-Dichlorophenyl)-1, 2, 4-Triazine-3, 5-Diamine] metal complexes on voltage gated sodium channel and dihydrofolate reductase enzyme. ( Anwar, F; Arshad, S; Khan, MM; Najm, S; Naureen, H; Rehman, S; Sultana, K, 2020) |
| "Valproic acid was less frequently prescribed to female patients." | 1.56 | Observational multicentre study into the use of antiepileptic drugs in Spanish neurology consultations. ( Campos Blanco, DM; Castro Vilanova, MD; López Gonzalez, FJ; Mercadé Cerdá, JM; Querol Pascual, MR; Serrano Castro, P, 2020) |
| "22) with evidence of a dose-response relationship for carbamazepine." | 1.56 | Use of antiepileptic drugs and risk of skin cancer: A nationwide case-control study. ( Kristensen, KB; Pedersen, SA; Pottegård, A; Schmidt, SAJ, 2020) |
| "Tremor was visually assessed by clinical tremor rating scales." | 1.51 | Lamotrigine Induces Tremor among Epilepsy Patients Probably via Cerebellar Pathways. ( Farkas, Z; Juhos, V; Kamondi, A; Kelemen, A; Kovács, A; Szűcs, A, 2019) |
| "Prednisolone dosage was increased to 1 mg/kg/day, and the subsequent taper was performed slowly over the course of 10 weeks." | 1.51 | Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking lamotrigine. ( Dória, MDC; Lameiras, C; Mendes Lopes, M; Ornelas, É, 2019) |
| " The aim of this study was to establish a PPK model of MHD to investigate the effects of genetic polymorphisms in UGT2B7, UGT1A9, ABCB1, and ABCB2 in adult Chinese patients with epilepsy and to develop a new dosage guideline for OXC." | 1.51 | Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis. ( Jiao, Z; Lin, RF; Lin, S; Lin, WW; Lin, XH; Wang, CL; Yu, XL; Zhang, J; Zhang, WB, 2019) |
| "However, seizures are not typical and the majority of them were seizure-free." | 1.51 | A 16q22.2-q23.1 deletion identified in a male infant with West syndrome. ( Goji, A; Imoto, I; Ito, H; Kagami, S; Kohmoto, T; Mori, K; Mori, T; Toda, Y, 2019) |
| "The aims of this study were to develop a population pharmacokinetic (PPK) model of lamotrigine (LTG) in Chinese epileptic children by using nonlinear mixed effects modeling (NONMEM) and to investigate the effects of valproic acid (VPA) and genetic polymorphisms of the major metabolizing enzymes (UGT1A4, UGT2B7) on the pharmacokinetics of LTG." | 1.48 | Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling. ( Chen, Y; Liu, L; Liu, M; Liu, S; Lu, T; Wang, H; Xu, S; Zhao, L; Zhao, M, 2018) |
| "Lamotrigine was the most frequently initiated drug in psychiatry, in both boys and girls." | 1.48 | Utilization of Antiepileptic Medicines in Swedish Children and Adolescents with Different Diagnoses. ( Karlsson Lind, L; von Euler, M; Wettermark, B; Wide, K, 2018) |
| "The dosage and frequency of lamotrigine administration for each patient must be prescribed carefully according to the disease, age, concomitant medications, and administration period." | 1.48 | A Standard Intervention Practice to Promote Appropriate Lamotrigine Therapy by Pharmacists. ( Itabe, H; Okada, N; Sasaki, T; Shimamura, H; Tanaka, K; Uchikura, T; Yamada, H, 2018) |
| "Epilepsy is a serious neurological disease affecting about 1% of people worldwide (65 million)." | 1.48 | Isobolographic additivity among lacosamide, lamotrigine and phenobarbital in a mouse tonic-clonic seizure model. ( Kondrat-Wróbel, MW; Łuszczki, JJ, 2018) |
| "Evidence for the comparative teratogenic risk of antiepileptic drugs is insufficient, particularly in relation to the dosage used." | 1.48 | Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. ( Battino, D; Bonizzoni, E; Craig, J; Lindhout, D; Perucca, E; Sabers, A; Thomas, SV; Tomson, T; Vajda, F, 2018) |
| "The objectives of this study were to investigate the effect of age on pharmacokinetic parameters of lamotrigine (LTG) and estimate parameter variability." | 1.48 | Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age. ( Birnbaum, AK; Brundage, RC; Kistner, BM; Leppik, IE; Pennell, PB; Polepally, AR; Ramsay, RE; Remmel, RP; White, JR, 2018) |
| " Therefore, this study aimed to establish a population pharmacokinetic (PPK) model of LTG in Chinese children with epilepsy and to comprehensively evaluate the effects of genetic variations in drug-metabolizing enzymes, transporters, and a transcriptional regulator on LTG pharmacokinetics." | 1.48 | A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy. ( Chen, Y; Lu, T; Wang, H; Wang, Z; Xu, S; Zhao, L; Zhao, M, 2018) |
| "LEV provides similar seizure control to that of the older AEDs, and it is more effective and better than LTG." | 1.48 | Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine. ( Escartin Siquier, A; Forcadas Berdusan, M; Martin Moro, M; Martinez Ferri, M; Peña Mayor, P; Perez López-Fraile, I, 2018) |
| "Background The impact of adverse events (AEs) of antiepileptic drugs (AEDs) have an impact on compliance and dropouts." | 1.48 | Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events? ( Bedetti, C; Calabresi, P; Caproni, S; Corbelli, I; Costa, C; Cupini, LM; Eusebi, P; Romoli, M; Sarchielli, P; Siliquini, S, 2018) |
| " This study compared adverse event (AE) reporting rates for brand vs." | 1.46 | Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). ( Alatawi, Y; Berg, RL; Cheng, N; Hansen, RA; Page, D; Peissig, PL; Plotkina, AV; Qian, J; Rahman, MM, 2017) |
| "Lamotrigine (LTG) is a popular modern antiepileptic drug (AED), however, its mechanism of action has yet to be fully understood, as it is known to modulate many members of several ion channel families." | 1.46 | Cav2.3 (R-Type) Calcium Channels are Critical for Mediating Anticonvulsive and Neuroprotective Properties of Lamotrigine In Vivo. ( Alpdogan, S; Dibué-Adjei, M; Hescheler, J; Kamp, MA; Neiss, WF; Schneider, T; Tevoufouet, EE, 2017) |
| "Lamotrigine (LTG) is a broad-spectrum antiepileptic drug that is widely used in clinic." | 1.46 | Effect of lamotrigine on epilepsy-induced cognitive impairment and hippocampal neuronal apoptosis in pentylenetetrazole-kindled animal model. ( Dong, RF; Tian, S; Wang, WP; Zhang, B; Zhang, C; Zhang, JW, 2017) |
| "The number of seizure-free patients in the last 4 weeks was overall CBZ/VPA/LTG/LEV=60%/79%/67%/67%, for generalized epilepsy was CBZ/VPA/LTG/LEV=67%/89%/65%/94%, and for localization-related epilepsy was CBZ/VPA/LTG/LEV=59%/71%/67%/57%." | 1.46 | Efficacy and tolerability of anti-epileptic drugs-an internet study. ( Baker, G; Wieshmann, UC, 2017) |
| "Lamotrigine (LTG) is an antiepileptic drug that is metabolized via glucuronidation." | 1.46 | Hormone replacement therapy with estrogens may reduce lamotrigine serum concentrations: A matched case-control study. ( Reimers, A, 2017) |
| "Valproic acid (VPA) was the most prescribed single therapy in young patients (<15years), whereas carbamazepine (CBZ) was preferred by clinicians in older patients." | 1.46 | Effectiveness and tolerability of antiepileptic drugs in 104 girls with Rett syndrome. ( Canevini, MP; La Briola, F; Nowbut, MS; Peron, A; Savini, MN; Turner, K; Vignoli, A, 2017) |
| "Levetiracetam was independently associated with anger/aggression, nervousness/agitation, upset stomach, depression, and sleep disturbance; lamotrigine with nervousness/agitation, upset stomach, and difficulty concentrating; and valproic acid with upset stomach and shaky hands." | 1.43 | Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study. ( Fidzinski, P; Gaus, V; Holtkamp, M; Kowski, AB; Losch, F; Weissinger, F, 2016) |
| " The correlation with dose may be a spurious finding related to the fact that physicians, in adjusting dosage according to clinical response, are more likely to use larger doses in patients with high clearance values." | 1.43 | An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy. ( Alexandre, V; Baldoni, AO; de Santi Ferreira, FI; Freitas-Lima, P; Martinez, EZ; Pereira, LR; Perucca, E; Queiroz, RH; Sakamoto, AC, 2016) |
| "Treatment with lamotrigine improved the patient's condition." | 1.43 | [Psychogenic non-epileptic seizures: issues of comorbidity in the diagnosis and treatment]. ( Nikolaev, EL; Rezvy, G; SÖrlie, T, 2016) |
| "Lamotrigine (LTG) is an anti-epileptic drug and mood-stabilizing agent, whose adverse effects include skin rash and dizziness." | 1.43 | Immunoglobulin A deficiency following treatment with lamotrigine. ( Hanaya, R; Kawano, Y; Maruyama, S; Okamoto, Y; Toyoshima, M, 2016) |
| "The present study aimed to establish population pharmacokinetic model for phenobarbital (PB), examining and quantifying the magnitude of PB interactions with other antiepileptic drugs concomitantly used and to demonstrate its use for individualization of PB dosing regimen in adult epileptic patients." | 1.42 | Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients. ( Golubović, B; Jovanović, M; Kovačević, SV; Martinović, Ž; Miljković, B; Prostran, M; Vučićević, K, 2015) |
| "Lamotrigine (LTG) has been recognized as one of the best newer antiepileptic drugs (AEDs) used in developed countries since 1991." | 1.40 | [Effectiveness and role of lamotrigine in the paradigm shift towards new antiepileptic drugs: a therapeutic strategy proposed after an investigation of a large number of cases at a single hospital]. ( Enoki, H; Fujimoto, A; Kobayashi, R; Ohashi, T; Okanishi, T; Tanaka, T; Uchiyama, G; Yamamoto, T; Yamazoe, T; Yokota, T, 2014) |
| "Epilepsy was induced in seven C57Bl/6 mice by injections of KA (20 mg/kg) on days 1 and 5, which produced severe acute seizures and spontaneous seizures 10 days later." | 1.40 | Cardiac phenomena during kainic-acid induced epilepsy and lamotrigine antiepileptic therapy. ( Dibué, M; Hänggi, D; Hescheler, J; Kamp, MA; Neumaier, F; Schneider, T; Steiger, HJ, 2014) |
| " We highlighted the importance of measuring LTG blood levels, and proposed a method of adjusting the optimum dosage of LTG based on the pharmacokinetic interaction." | 1.40 | [Importance of measuring blood level of lamotrigine for optimum dosing schedule]. ( Fukumura, S; Minagawa, K; Oyanagi, R; Watanabe, T, 2014) |
| "People with epilepsy have a high incidence of mood disorders that may affect their quality of life." | 1.39 | [Mood States in outpatients with lesional epilepsy at the neurosurgical clinic and improvement in mood States after lamotrigine addiction]. ( Kajita, Y; Nagai, T; Wakabayashi, T; Yoshida, K, 2013) |
| "Brain drug bioavailability is regulated by the blood-brain barrier (BBB)." | 1.39 | Expression and functional relevance of UGT1A4 in a cohort of human drug-resistant epileptic brains. ( Alexopolous, A; Ghosh, C; Hossain, M; Janigro, D; Marchi, N; Martinez-Gonzalez, J; Puvenna, V, 2013) |
| "Psychosis is more common in people with temporal lobe epilepsy than it is in the general population." | 1.39 | Electroconvulsive therapy for psychosis in a patient with epilepsy related to hypothalamic hamartoma. ( Foucher, J; Hirsch, E; Lalanne, L; Ruppert, E; Vidailhet, P; Zimmermann, MA, 2013) |
| " Age was a significant factor contributing to pharmacokinetic variability in individuals using LTG, OXC, and CBZ with increasing clearance as a function of bioavailability (Cl/F) over age 18, a maximum Cl/F at 33years (CBZ) and 36 years (LTG and OXC), and a gradual decrease of Cl/F towards older age." | 1.39 | The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. ( Lindhout, D; Sander, JW; Wegner, I; Wilhelm, AJ, 2013) |
| "Lamotrigine (LTG) is an anti epileptic medication (AEM) for which blood levels are helpful for optimal dosing." | 1.38 | Changed constitution without change in brand name--the risk of generics in epilepsy. ( Beran, RG; Cordato, DJ; Dias, M; Patel, V, 2012) |
| "Individuals treated with combined valproate-lamotrigine rarely present late adverse effects (unrelated to introduction and titration)." | 1.38 | Late adverse effects of the coadministration of valproate and lamotrigine. ( Moreira, B; Thome-Souza, S; Valente, KD, 2012) |
| "He had been on a lamotrigine treatment due to epilepsy, and after cessation of lamotrigine, his cardiac enzyme levels returned to normal." | 1.38 | Lamotrigine related myocarditis: case report. ( Bayhan, T; Karagöz, T; Sahin, M; Yıldırım, I, 2012) |
| "Lamotrigine was more effective at lower doses and in older children." | 1.38 | Lamotrigine serum concentration in children with epilepsy. ( Bar-Haim, A; Berkovitch, M; Braunstein, R; Gandelman-Marton, R; Heyman, E; Lahat, E; Lavie, R, 2012) |
| "Lamotrigine has the advantage to have an antidepressive effect and to be well tolerated in the majority of the cases." | 1.37 | Lamotrigine-trigged obstructive hypertrophic cardiomyopathy, epilepsy and metabolic myopathy. ( Finsterer, J; Höftberger, R; Stöllberger, C, 2011) |
| "Phenytoin levels were undetectable despite a high dose." | 1.37 | Reduced phenytoin levels in an epileptic patient following Roux-En-Y gastric bypass for obesity. ( Footitt, D; Mahon, D; Pournaras, DJ; Welbourn, R, 2011) |
| " Newly diagnosed 52 pediatric epileptic patients were assessed standard speech test through a Computerized Speech Lab applied before the beginning of therapy with lamotrigine and 2months after dosage had been stabilized." | 1.37 | Acoustic effects of lamotrigine in pediatric patients with epilepsy. ( Choi, YM; Eun, SH; Kim, SJ; Seol, IJ; Yun, M, 2011) |
| "Focal cortical dysplasia is associated with the development of seizures in children and is present in up to 40% of intractable childhood epilepsies." | 1.37 | Decreased hyperpolarization-activated currents in layer 5 pyramidal neurons enhances excitability in focal cortical dysplasia. ( Albertson, AJ; Hablitz, JJ; Yang, J, 2011) |
| "An epileptic seizure is reported in a 38-year-old woman, known to be an epileptic patient." | 1.37 | Epileptic seizure induced by fennel essential oil. ( Skalli, S; Soulaymani Bencheikh, R, 2011) |
| "Epilepsy was confirmed in 58 cases." | 1.37 | [Epilepsy in elderly]. ( Kotov, AS; Rudakova, IG, 2011) |
| "Lamotrigine is a phenyltriazine derivative used as antiepileptic drug with pharmacological profile similar to phenytoin." | 1.37 | [Massive lamotrigine poisoning--case report]. ( Bazylewicz, A; Kicka, M; Kłopotowski, T; Miśkiewicz, Ł; Picheta, S, 2011) |
| " All 9 patients became hyperactive and agitated over a broad range of lamotrigine dosing (0." | 1.36 | Reversible lamotrigine-induced neurobehavioral disturbances in children with epilepsy. ( Cardenas, JF; Ng, YT; Rho, JM, 2010) |
| "Antiepileptic drugs (AEDs) have been widely used in patients with epilepsy but the adverse effects in adult Chinese patients have not been investigated." | 1.36 | Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. ( Wang, X; Xi, Z; Yan, Y; Zeng, K, 2010) |
| "Lamotrigine was eluted at 1." | 1.36 | Determination of lamotrigine in human serum by high-performance liquid chromatography–tandem mass spectrometry. ( Heo, K; Kim, HS; Kim, JH; Kwon, OH; Lee, BI; Lee, W, 2010) |
| " Results of our study show the positive correlation between dosage and serum concentration of CBZ." | 1.36 | Carbamazepine and lamotrigine plasma concentrations in epileptic patients during optimising therapy. ( Bauer, S; Islami, H; Krasniqi, S; Neziri, B, 2010) |
| "Lamotrigine has been widely used, mainly due to their greater tolerability and lower rate of drug interactions with other antiepileptic drugs however the newest antiepileptic drugs have high cost to patient." | 1.36 | [Interchangeability among therapeutics equivalents of lamotrigine in the treatment of refractory epilepsy patients: risks and benefits]. ( Alexandre, V; Feletti, F; Girolineto, BM; Pereira, LR; Queiroz, RH; Sakamoto, AC, 2010) |
| " The differences in the starting dosage of LTG among the SJS/TEN, MPE, and LTG-tolerant control groups were not statistically significant." | 1.36 | Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population. ( An, DM; Hu, FY; Stefan, H; Wu, XT; Yan, B; Zhou, D, 2010) |
| "Valproic acid was the most frequently prescribed drug, followed by carbamazepine and lamotrigine." | 1.35 | Antiepileptic drug utilization in children from 1997-2005--a study from the Netherlands. ( Brouwer, OF; de Jong-van den Berg, LT; de Vries, TW; van de Vrie-Hoekstra, NW; van den Berg, PB, 2008) |
| "Efficacy of seizure control was considered satisfactory if there was a reduction in seizures>50% or total control." | 1.35 | Association of lamotrigine and valproate in refractory epilepsies of children and adolescents. ( Antoniuk, SA; Bruck, I; Grisotto, KP; Santos, LH, 2008) |
| "Lamotrigine has showed good efficacy and safety profile." | 1.35 | Use of lamotrigine in medically intractable epilepsies in children. ( Catibusic, F; Cengic, A; Uzicanin, S; Zubcevic, S, 2008) |
| "Epilepsy is a multifaceted chronic disorder which has diverse and complex effects on the well-being of the patient." | 1.35 | Quality of life in seizure-free patients with epilepsy on monotherapy. ( Andelman, F; Auriel, E; Blatt, I; Chistik, V; Gandelman-Marton, R; Gross, B; Landov, H; Margolin, N; Neufeld, MY; Parmet, Y; Theitler, J, 2009) |
| "Epilepsy was most common among those with maternal deletions and unknown subtypes, with catastrophic epilepsies present in only these two subtypes." | 1.35 | Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options. ( Braun, EK; Bruno, P; Conant, KD; Nespeca, MP; Said, RR; Thibert, RL; Thiele, EA, 2009) |
| "Lamotrigine, known to increase Ih, reversed the impact of KA on burst duration in CA1 at both time-points linking a transcriptional reduction in HCN2 function to increased burst duration." | 1.35 | Excitotoxic-mediated transcriptional decreases in HCN2 channel function increase network excitability in CA1. ( Adams, BE; Myers, D; Ng, C; O'Brien, TJ; Phillips, AM; Powell, K; Reid, CA; Williams, DA; Zheng, T, 2009) |
| "Epilepsy is often the most important clinical manifestation of the syndrome, even if its appearance is not constantly precocious." | 1.35 | Ring chromosome 20 syndrome: a link between epilepsy onset and neuropsychological impairment in three children. ( Canevini, MP; Dalla Bernardina, B; Darra, F; Fiorini, E; La Selva, L; Lazzarotto, F; Piazzini, A; Vignoli, A; Zucca, C, 2009) |
| " The manufacturer recommends half the dosage of lamotrigine monotherapy when the patient also uses valproate." | 1.35 | Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. ( Aldenkamp, AP; Bootsma, HP; Hulsman, J; Lambrechts, D; Leenen, L; Majoie, M; Savelkoul, M; Schellekens, A; Vos, AM, 2008) |
| "Lamotrigine (LTG) has recently been shown to inhibit the cardiac rapid delayed rectifier potassium ion current (Ikr)." | 1.34 | Lamotrigine in idiopathic epilepsy - increased risk of cardiac death? ( Aurlien, D; Gjerstad, L; Taubøll, E, 2007) |
| " We then assessed pharmacy utilization and AED dosage among LTG patients switching back to branded Lamictal compared with those staying on generic formulation." | 1.34 | Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. ( Andermann, F; Duh, MS; Gosselin, A; Paradis, PE, 2007) |
| "Metabolic syndrome was more frequently associated with VPA-treated patients (41." | 1.34 | Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. ( Kim, JY; Lee, HW, 2007) |
| " Because of dosage changes, lamotrigine costs decreased by $29." | 1.34 | The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine. ( Andermann, F; Crémieux, PY; Duh, MS; Manjunath, R; Paradis, PE; Weiner, J, 2007) |
| "Lamotrigine was escalated according to a target dose of 200 mg/day over 8-weeks." | 1.34 | Conversion to lamotrigine monotherapy from valproate monotherapy in older adolescent patients with epilepsy. ( Baumann, RJ; Fakhoury, TA; Hammer, AE; Kustra, RP; Messenheimer, JA; Vuong, A, 2007) |
| "Lamotrigine is an antiepileptic agent used in a wide range of seizure disorders among the elderly." | 1.33 | [Drug hypersensitivity syndrome with lamotrigine two cases in elderly]. ( Bourdel-Marchasson, I; Jeandel, PY; Rainfray, M; Traissac, T, 2005) |
| "Vascular epilepsy was the most frequent diagnosis (56% of patients), and concomitant medication was required by 75% of patients." | 1.33 | Lamotrigine and epilepsy in the elderly: observational study of low-dose monotherapy. ( Mauri Llerda, JA; Mercadé, JM; Padró, LL; Salas Puig, J; Tejero, C, 2005) |
| "Lamotrigine (LTG) was prescribed in 29 patients as add-on therapy." | 1.33 | The use of lamotrigine and other antiepileptic drugs in paediatric patients at a Malaysian hospital. ( Ab Rahman, AF; Ibrahim, MI; Ismail, HI; Seng, TB, 2005) |
| " The number or dosage of AEDs were more often increased in pregnancies with seizures (OR: 3." | 1.33 | Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. ( , 2006) |
| "Severe rash is rare when using the currently recommended titration rate." | 1.33 | Predictors of Lamotrigine-associated rash. ( Buchsbaum, R; Hager, M; Hirsch, LJ; Resor, SR; Spencer, HT; Straka, T; Weintraub, DB, 2006) |
| "Lamotrigine (LTG) was reported to have a positive profile especially regarding cognition." | 1.33 | Long-term profile of lamotrigine in 119 children with epilepsy. ( Brodbeck, V; Fietzek, U; Heinen, F; Jansen, V; Muehe, C; Weber, G, 2006) |
| "The aim of the present study was to evaluate the pharmacokinetic profile of lamotrigine (LTG) in epileptic patients submitted to video-electroencephalography (VEEG) monitoring and, in addition, to investigate the influence of concomitant antiepileptic drugs (AEDs) on the kinetics of LTG." | 1.33 | Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring. ( Almeida, AM; Baldeiras, I; Caramona, MM; Falcão, AC; Rocha, MJ; Sales, F, 2006) |
| "Epilepsy is a major comorbid condition in adolescents with mental retardation and is often characterized by multiple seizure types that are refractory to treatment." | 1.33 | Adjunctive lamotrigine for refractory epilepsy in adolescents with mental retardation. ( Hammer, AE; McKee, JR; Sunder, TR; Vuong, A, 2006) |
| "Lamotrigine is an antiepileptic drug with a low adverse-effect profile." | 1.33 | Maternal lamotrigine treatment and elevated neonatal gamma-glutamyl transpeptidase. ( Dubnov-Raz, G; Merlob, P; Shapiro, R, 2006) |
| "If lamotrigine (LTG) has to be replaced with valproate (VPA), this exchange may be complicated by adverse events that result from the complex interaction of both drugs." | 1.33 | How to replace lamotrigine with valproate. ( Steinhoff, BJ, 2006) |
| "The lamotrigine level was 14." | 1.33 | Lamotrigine as a possible cause of QRS prolongation in a patient with known seizure disorder. ( Herold, TJ, 2006) |
| " Its therapeutic efficacy was analyzed in relation to the form of epilepsy, the type of seizures, dosage of lamictal duration of therapy, and as patients' sex, age, and social activity." | 1.32 | [Experience with lamictal in the treatment of outpatients with resistant epilepsy]. ( Perunova, NIu; Shershever, AS; Sorokina, EV, 2003) |
| "We studied 14 patients with juvenile myoclonic epilepsy (JME), 19 patients with refractory localization-related epilepsy (RLE) and 20 healthy volunteers who were matched for age and sex." | 1.32 | Uptake of GABA and activity of GABA-transaminase in platelets from epileptic patients. ( Keränen, T; Peltola, J; Rainesalo, S; Saransaari, P, 2003) |
| "Clinical pharmacologists, neurologists, internists, and all health care givers must consider the efficacy, safety, and side effect profile of a given antiepileptic drug (AED) when determining which drug is best for a given patient." | 1.32 | Clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios. ( Claycamp, HG; Lathers, CM; Schraeder, PL, 2003) |
| "The incidence of birth defects in relation to specific AEDs was: valproate (16." | 1.32 | The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. ( Graham, J; Hitchcock, A; Lander, C; O'Brien, TJ; Vajda, FJ, 2003) |
| "The pharmacodynamic interaction between the antiepileptic drugs (AEDs) tiagabine (TGB) and lamotrigine (LTG) was characterized on basis of the anticonvulsant effect in the cortical stimulation model in the rat." | 1.32 | Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat. ( Danhof, M; Jonker, DM; Voskuyl, RA, 2004) |
| "Lamotrigine (LTG) was added to other antiepileptic drugs (AEDs) in a study of adjunctive therapy." | 1.32 | Improved mood states with lamotrigine in patients with epilepsy. ( Cramer, JA; Hammer, AE; Kustra, RP, 2004) |
| " The severity of the cognitive side effects of TPM may be related to dosing to a certain extent, but this relationship may be disclosed only with larger sample sizes." | 1.32 | Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication. ( Elger, CE; Helmstaedter, C; Kockelmann, E, 2004) |
| "We describe the incidence of newly treated epilepsy in primary care and patterns of antiepileptic drug prescription, numbers of patients who remain on initial therapy and health service utilisation." | 1.32 | The outcome of initiation of antiepileptic drug monotherapy in primary care: a UK database survey. ( Buchan, S; Kerr, MP; Morgan, CL, 2004) |
| "Lamotrigine (LTG) has become established as an important new drug in treating a wide spectrum of seizure types, but there are no published data on whether LTG serum concentrations change when TPM is added to treatment." | 1.31 | Lack of an effect of topiramate on lamotrigine serum concentrations. ( Berry, DJ; Besag, FM; Doose, D; Natarajan, J; Pool, F, 2002) |
| "Lamotrigine is a relatively new anticonvulsant." | 1.31 | Postmortem investigation of lamotrigine concentrations. ( Drummer, OH; King, CV; McIntyre, IM; Opeskin, K; Pricone, MG, 2000) |
| "Sipatrigine produced no increase in paired-pulse facilitation, suggesting that the modulation of a postsynaptic site was the main pharmacological effect of this agent." | 1.31 | Electrophysiology of sipatrigine: a lamotrigine derivative exhibiting neuroprotective effects. ( Bernardi, G; Calabresi, P; Centonze, D; Giacomini, P; Hainsworth, AH; Leach, MJ; Marfia, GA; Saulle, E; Spadoni, F; Stefani, A, 2000) |
| "Lamotrigine was used concurrently in four of the 11 children with behavioral or cognitive abnormalities but in only seven of the 64 children without abnormalities (P = 0." | 1.31 | Factors associated with behavioral and cognitive abnormalities in children receiving topiramate. ( Connolly, MB; Farrell, K; Gerber, PE; Hamiwka, L, 2000) |
| "Although MSM is a valuable add-on, broad-spectrum drug when used in combination with LTG, adjustment of the LTG dose may be necessary when MSM is started or stopped, to allow for the fact that MSM lowers LTG blood levels." | 1.31 | Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. ( Berry, DJ; Besag, FM; Pool, F, 2000) |
| "Mean lamotrigine dose was 272 +/- 133 mg per day." | 1.31 | Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation. ( Gidal, BE; Lott, RS; Marty, KJ; Rutecki, P; Shaw, R; Speth, J; Walker, JK, 2000) |
| "The lamotrigine was stopped immediately when the rash was identified and was subsequently re-introduced, using a special very-low-dose-escalation regime, starting with 0." | 1.31 | Successful re-introduction of lamotrigine after initial rash. ( Besag, FM; Ng, GY; Pool, F, 2000) |
| "Overall, 45% were seizure free, 44% with focal epilepsy and 36% with generalized epilepsy." | 1.31 | Lamotrigine monotherapy in children. ( Barron, TF; Hoban, TF; Hunt, SL; Price, ML, 2000) |
| "Lamotrigine extraction was performed on a reversed-phase Oasis HBL preparation column." | 1.31 | Optimized procedure for lamotrigine analysis in serum by high-performance liquid chromatography without interferences from other frequently coadministered anticonvulsants. ( Arroyo, S; Corbella, J; Rodamilans, M; Torra, M, 2000) |
| "Patients with generalized epilepsy (p = 0." | 1.31 | A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. ( Lhatoo, SD; Mawer, GE; Sander, JW; Wong, IC, 2001) |
| "Chorea is a rare side effect of anticonvulsants." | 1.31 | Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction? ( Beach, RL; D'Cruz, O; Tennison, M; Zaatreh, M, 2001) |
| "No subjects reported insomnia with treatment." | 1.31 | The effects of lamotrigine on sleep in patients with epilepsy. ( Dinner, D; Foldvary, N; Lee, J; Morris, HH; Perry, M, 2001) |
| " Side effects were mild, but frequent; only four patients discontinued LTG because of adverse effects." | 1.31 | [Lamotrigine in the adult-onset epilepsy: efficacy and long-term safety]. ( Alegre, M; Iriarte, J; Lázaro, D; Schlumberger, E; Urrestarazu, E; Viteri, C, 2002) |
| "Epilepsy is a common condition in people with learning disabilities with many patients continuing to suffer from seizures despite antiepileptic drug (AED) treatment." | 1.30 | A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. ( Bhaumik, S; Branford, D; Duggirala, C; Ismail, IA, 1997) |
| " Then, LTG was increased in steps to maximal dosage (200 mg or 400 mg per day) within seven weeks and maintained for three months while pre-existing antiepileptic drugs remained unchanged." | 1.30 | Lamotrigine as add-on therapy in adult patients with refractory epilepsy. ( Kwan, SY; Lin, YY; Su, MS; Yen, DJ; Yiu, CH, 1997) |
| "Lamotrigine was the only drug which antagonized tonic convulsions in the MES test (ED50 = 36 mumol/kg)." | 1.30 | Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. ( Dalby, NO; Nielsen, EB, 1997) |
| "Lamotrigine is a phenyltriazine anticonvulsant recently approved for clinical use." | 1.30 | High-performance liquid chromatography quantitation of plasma lamotrigine concentrations: application measuring trough concentrations in patients with epilepsy. ( Morris, RG; Sallustio, BC, 1997) |
| "05) change in the serum concentrations of either CBZ or its epoxide metabolite when LTG was added either to the group as a whole or to the nine patients who experienced adverse CNS effects." | 1.30 | Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? ( Berry, DJ; Besag, FM; Newbery, JE; Pool, F; Subel, B, 1998) |
| "Blood level monitoring helps to determine the therapeutic and toxic ranges for anticonvulsants and antidepressants." | 1.30 | Lamotrigine toxicity secondary to sertraline. ( Gerner, R; Kaufman, KR, 1998) |
| "Length of seizure disorder, seizure frequency at initiation, the number of previously used failed drugs and the total number of drugs previously used were all significantly lower in the seizure-free group." | 1.30 | The outcome of prescribing novel anticonvulsants in an outpatient setting: factors affecting response to medication. ( Kerr, MP; Thijs, RD, 1998) |
| "A case of toxic epidermal necrolysis following treatment with lamotrigine is presented." | 1.30 | [Toxic epidermal necrolysis after treatment with lamotrigine]. ( Fogh, K; Zachariae, CO, 1998) |
| " LTG was started with a dosage of 25 mg/day until a daily maintenance dosage of 200 mg/day was reached." | 1.30 | Cortical excitability in patients after loading doses of lamotrigine: a study with magnetic brain stimulation. ( Bongiovanni, LG; Fiaschi, A; Manganotti, P; Turazzini, M; Zanette, G, 1999) |
| "With lamotrigine treatment, the patient who had not had surgery had complete cessation of monthly episodes of status epilepticus and a dramatic reduction of generalized tonic-clonic seizures, and the other patient who received lamotrigine had a 50% reduction of her atonic seizures." | 1.30 | Treatment of seizures in subcortical laminar heterotopia with corpus callosotomy and lamotrigine. ( Ko, TS; Lee, JK; Vossler, DG, 1999) |
| "In 1993, 27% of patients were being treated for epilepsy and in 1995/6, 30." | 1.30 | The management of epilepsy in a hospital for people with a learning disability. ( Carvill, S; Cassidy, G; Clarke, D, 1999) |
| "Lamotrigine (LTG) has recently been approved for marketing in Australia as add-on therapy in resistant partial seizure disorders." | 1.29 | Routine use of lamotrigine, a new anti-epileptic medication, and the value of measuring its blood levels. ( Beran, RG; Sheehan, K; Tilley, MI, 1994) |
| "Seventy-one patients had partial epilepsy and 21 had primary generalized epilepsy." | 1.29 | [Lamotrigine treatment of 92 patients with intractable epilepsy]. ( Dam, M; Gram, L; Karlsborg, M, 1996) |
| "Gabapentin is a gamma-aminobutyric acid (GABA) analog which passes the blood-brain barrier." | 1.29 | [New medical treatment of epilepsy]. ( Loiseau, P, 1996) |
| "1." | 1.29 | Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children. ( Bidault, R; Cieuta, C; d'Athis, P; Dulac, O; Olive, G; Pariente-Khayat, A; Pons, G; Rey, E; Vauzelle-Kervroëdan, F, 1996) |
| " A pharmacodynamic interaction with carbamazepine necessitates a dosage reduction in some patients when LTG is introduced." | 1.29 | Lamotrigine--an update. ( Brodie, MJ, 1996) |
| " All patients received a single dose of lamotrigine in the second week to determine single-dose pharmacokinetic parameters." | 1.27 | Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. ( Hamilton, MJ; Jawad, S; Oxley, JR; Peck, AW; Richens, A; Yuen, WC, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (0.39) | 18.7374 |
| 1990's | 222 (21.70) | 18.2507 |
| 2000's | 362 (35.39) | 29.6817 |
| 2010's | 297 (29.03) | 24.3611 |
| 2020's | 138 (13.49) | 2.80 |
| Authors | Studies |
|---|---|
| Anger, T | 1 |
| Madge, DJ | 1 |
| Mulla, M | 1 |
| Riddall, D | 1 |
| Hoyt, SB | 1 |
| London, C | 1 |
| Wyvratt, MJ | 1 |
| Fisher, MH | 1 |
| Cashen, DE | 1 |
| Felix, JP | 1 |
| Garcia, ML | 1 |
| Li, X | 6 |
| Lyons, KA | 1 |
| Euan MacIntyre, D | 1 |
| Martin, WJ | 1 |
| Priest, BT | 1 |
| Smith, MM | 1 |
| Warren, VA | 1 |
| Williams, BS | 1 |
| Kaczorowski, GJ | 1 |
| Parsons, WH | 1 |
| Ragavendran, JV | 1 |
| Sriram, D | 1 |
| Kotapati, S | 1 |
| Stables, J | 1 |
| Yogeeswari, P | 1 |
| McComsey, DF | 1 |
| Smith-Swintosky, VL | 1 |
| Parker, MH | 1 |
| Brenneman, DE | 1 |
| Malatynska, E | 1 |
| White, HS | 4 |
| Klein, BD | 1 |
| Wilcox, KS | 3 |
| Milewski, ME | 1 |
| Herb, M | 1 |
| Finley, MF | 1 |
| Liu, Y | 1 |
| Lubin, ML | 1 |
| Qin, N | 1 |
| Reitz, AB | 1 |
| Maryanoff, BE | 1 |
| Lin, CH | 1 |
| Ho, CJ | 1 |
| Lu, YT | 1 |
| Tsai, MH | 1 |
| Song, N | 1 |
| Zhang, C | 2 |
| Wang, S | 2 |
| Guan, Y | 5 |
| Müffelmann, B | 1 |
| Hagemann, A | 2 |
| Knaak, N | 1 |
| Bien, CG | 2 |
| Liguori, C | 1 |
| Toledo, M | 1 |
| Kothare, S | 1 |
| Chiang, KL | 1 |
| Liang, CY | 1 |
| Hsieh, LP | 1 |
| Chien, LN | 1 |
| Faustmann, TJ | 1 |
| Corvace, F | 1 |
| Faustmann, PM | 1 |
| Ismail, FS | 1 |
| Sotero, FD | 1 |
| Silva, CS | 1 |
| Cunha, N | 1 |
| Franco, A | 1 |
| Pimentel, J | 2 |
| Aschenbrenner, DS | 1 |
| Musaeus, CS | 1 |
| Nilsson, C | 1 |
| Cooper, C | 2 |
| Kramberger, MG | 1 |
| Verdelho, A | 1 |
| Stefanova, E | 1 |
| Religa, D | 1 |
| Waldemar, G | 1 |
| Frederiksen, KS | 1 |
| Larsson, D | 2 |
| Baftiu, A | 2 |
| Johannessen Landmark, C | 3 |
| von Euler, M | 3 |
| Kumlien, E | 2 |
| Åsberg, S | 2 |
| Zelano, J | 4 |
| Marson, AG | 12 |
| Burnside, G | 1 |
| Appleton, R | 3 |
| Smith, D | 2 |
| Leach, JP | 4 |
| Sills, G | 1 |
| Tudur-Smith, C | 2 |
| Plumpton, CO | 1 |
| Hughes, DA | 1 |
| Williamson, PR | 4 |
| Baker, G | 5 |
| Balabanova, S | 1 |
| Taylor, C | 1 |
| Brown, R | 1 |
| Hindley, D | 1 |
| Howell, S | 1 |
| Maguire, M | 1 |
| Mohanraj, R | 2 |
| Smith, PE | 1 |
| Toce, MS | 1 |
| Hudgins, JD | 1 |
| Yuskaitis, CJ | 1 |
| Monuteaux, MC | 1 |
| Bourgeois, FT | 1 |
| Yıldız, A | 1 |
| Vardı, N | 1 |
| Parlakpınar, H | 1 |
| Ateş, B | 1 |
| Çolakoğlu, N | 1 |
| Niyongere, J | 1 |
| Welty, TE | 6 |
| Bell, MW | 1 |
| Consalvo, D | 1 |
| Hammond, C | 1 |
| Leung, H | 3 |
| Patsalos, PN | 6 |
| Ryan, M | 2 |
| Suansanae, T | 1 |
| Zhou, D | 4 |
| Zuellig, H | 1 |
| Parker, G | 1 |
| Jenner, A | 1 |
| He, J | 1 |
| Wu, X | 2 |
| Pennell, PB | 18 |
| Karanam, A | 3 |
| Meador, KJ | 15 |
| Gerard, E | 1 |
| Kalayjian, L | 1 |
| Penovich, P | 3 |
| Matthews, A | 1 |
| McElrath, TM | 1 |
| Birnbaum, AK | 7 |
| Heger, K | 1 |
| Skipsfjord, J | 1 |
| Kiselev, Y | 1 |
| Burns, ML | 1 |
| Aaberg, KM | 1 |
| Johannessen, SI | 5 |
| Skurtveit, S | 1 |
| Ilhan, ZE | 1 |
| Brochard, V | 1 |
| Lapaque, N | 1 |
| Auvin, S | 1 |
| Lepage, P | 1 |
| Fong, SL | 1 |
| Lim, KS | 1 |
| Hariraj, V | 1 |
| Lee, SC | 1 |
| Wo, WK | 1 |
| Ramli, A | 1 |
| Ho, JH | 1 |
| Lai, PSM | 1 |
| Ng, WL | 1 |
| Asadi-Pooya, AA | 1 |
| Farazdaghi, M | 1 |
| Elmer, S | 1 |
| Reddy, DS | 1 |
| Ershadi, F | 1 |
| Mousavi Mirzaei, SM | 1 |
| Tabrizi, N | 1 |
| Roshanravan, B | 1 |
| Sahebnasagh, A | 1 |
| Avan, R | 1 |
| Bunschoten, JW | 1 |
| Husein, N | 1 |
| Devinsky, O | 6 |
| French, JA | 10 |
| Sander, JW | 20 |
| Thijs, RD | 3 |
| Keezer, MR | 1 |
| Terman, SW | 2 |
| Youngerman, BE | 1 |
| Choi, H | 2 |
| Burke, JF | 1 |
| Hochbaum, M | 1 |
| Kienitz, R | 1 |
| Rosenow, F | 3 |
| Schulz, J | 1 |
| Habermehl, L | 1 |
| Langenbruch, L | 1 |
| Kovac, S | 2 |
| Knake, S | 2 |
| von Podewils, F | 1 |
| von Brauchitsch, S | 1 |
| Hamacher, M | 1 |
| Strzelczyk, A | 3 |
| Willems, LM | 1 |
| Watkins, LV | 1 |
| O'Dwyer, M | 1 |
| Shankar, R | 2 |
| Soh, MS | 1 |
| Bagnall, RD | 1 |
| Semsarian, C | 1 |
| Scheffer, IE | 1 |
| Berkovic, SF | 2 |
| Reid, CA | 3 |
| Kessing, LV | 1 |
| Ziersen, SC | 1 |
| Gerds, T | 1 |
| Budtz-Jørgensen, E | 1 |
| Kikuchi, D | 1 |
| Obara, T | 1 |
| Miura, R | 1 |
| Suzuki, N | 1 |
| Josaka, R | 1 |
| Tokunaga, M | 1 |
| Ouchi, R | 2 |
| Usui, K | 2 |
| Okada, K | 2 |
| Zhou, S | 1 |
| Li, R | 1 |
| Chen, Z | 5 |
| Ren, R | 1 |
| Wang, X | 8 |
| Dai, Q | 2 |
| Wen, D | 2 |
| Zhang, X | 1 |
| Tang, S | 1 |
| Zhou, L | 4 |
| Huang, M | 4 |
| Athar, F | 1 |
| Ehsan, M | 1 |
| Farooq, M | 1 |
| Lo, KB | 1 |
| Cheema, HA | 1 |
| Ahmad, S | 1 |
| Naveed, A | 1 |
| Umer, M | 1 |
| Buraniqi, E | 1 |
| Dabaja, H | 1 |
| Wirrell, EC | 1 |
| Bjørk, MH | 5 |
| Zoega, H | 5 |
| Leinonen, MK | 5 |
| Cohen, JM | 6 |
| Dreier, JW | 4 |
| Furu, K | 5 |
| Gilhus, NE | 1 |
| Gissler, M | 5 |
| Hálfdánarson, Ó | 1 |
| Igland, J | 2 |
| Sun, Y | 5 |
| Tomson, T | 23 |
| Alvestad, S | 6 |
| Christensen, J | 8 |
| Han, Y | 1 |
| Yang, J | 2 |
| Zhong, R | 1 |
| Guo, X | 1 |
| Cai, M | 2 |
| Lin, W | 2 |
| Pa, B | 1 |
| G, SS | 1 |
| Thomas, G | 1 |
| Kp, A | 1 |
| Kumar, S | 1 |
| Ivanov, S | 1 |
| Lagunin, A | 1 |
| Goel, RK | 1 |
| Chen, Y | 6 |
| Chen, J | 2 |
| Zhuang, X | 1 |
| Chen, X | 1 |
| Zeng, J | 1 |
| Wang, R | 1 |
| Miao, J | 1 |
| Winter, Y | 1 |
| Uphaus, T | 1 |
| Sandner, K | 1 |
| Klimpe, S | 1 |
| Stuckrad-Barre, SV | 1 |
| Groppa, S | 1 |
| Panda, SP | 1 |
| Dhurandhar, Y | 1 |
| Agrawal, M | 1 |
| Yang, H | 1 |
| Zhang, D | 1 |
| Mei, S | 2 |
| Zhao, Z | 2 |
| Logue, TC | 1 |
| Huang, Y | 2 |
| Benson, RJ | 1 |
| Pack, AM | 3 |
| Wright, JD | 1 |
| D'Alton, ME | 1 |
| Friedman, AM | 1 |
| Shi, X | 1 |
| Wang, Y | 3 |
| Zhang, Y | 1 |
| Song, C | 1 |
| Jiang, Y | 1 |
| Zhao, J | 1 |
| Xia, L | 2 |
| Ma, L | 4 |
| Jiang, W | 6 |
| Jiménez, M | 1 |
| Grau-López, L | 1 |
| Ciurans, J | 1 |
| García-Esperón, C | 1 |
| Fumanal, A | 1 |
| Barambio, S | 1 |
| Chíes, E | 1 |
| Codina, M | 2 |
| Becerra, JL | 1 |
| Battino, D | 7 |
| Bromley, R | 2 |
| Kochen, S | 2 |
| Thomas, SV | 3 |
| Treadwell, JR | 1 |
| Kessler, SK | 1 |
| Wu, M | 1 |
| Abend, NS | 1 |
| Massey, SL | 1 |
| Tsou, AY | 1 |
| Canitano, R | 1 |
| Palumbi, R | 1 |
| Scandurra, V | 1 |
| Bleakley, LE | 1 |
| McKenzie, CE | 1 |
| Klimpel, D | 1 |
| Schmitter, E | 1 |
| Dufaux, B | 1 |
| May, TW | 4 |
| Brandt, C | 4 |
| Ge, J | 3 |
| Cao, SS | 3 |
| Cao, XY | 3 |
| Tang, M | 3 |
| Mu, F | 3 |
| Qiao, Y | 3 |
| Wang, JW | 3 |
| Cesta, CE | 3 |
| Nørgaard, M | 3 |
| Einarsdóttir, K | 3 |
| Engeland, A | 3 |
| Karlstad, Ø | 3 |
| Klungsøyr, K | 3 |
| Odsbu, I | 3 |
| Reutfors, J | 3 |
| Selmer, RM | 3 |
| Ulrichsen, SP | 3 |
| Abdelmonem, R | 1 |
| El-Enin, HAA | 1 |
| Abdelkader, G | 1 |
| Abdel-Hakeem, M | 1 |
| Nightscales, R | 1 |
| Barnard, S | 2 |
| Laze, J | 1 |
| Tao, G | 1 |
| Auvrez, C | 1 |
| Sivathamboo, S | 1 |
| Cook, MJ | 1 |
| Kwan, P | 5 |
| Friedman, D | 2 |
| D'Souza, W | 1 |
| Perucca, P | 2 |
| O'Brien, TJ | 6 |
| Wójcik, K | 1 |
| Franciszek Kołek, M | 1 |
| Dec-Ćwiek, M | 1 |
| Słowik, A | 2 |
| Bosak, M | 2 |
| Diederich, S | 1 |
| Hemmeter, U | 1 |
| Paulmann, M | 1 |
| Mockenhaupt, M | 2 |
| Xie, Z | 1 |
| Yin, J | 1 |
| Wang, M | 4 |
| Fan, X | 1 |
| Yu, J | 2 |
| Wang, D | 1 |
| Li, Y | 1 |
| Yu, M | 1 |
| Jin, K | 2 |
| Costa, B | 1 |
| Vale, N | 1 |
| Pedersen, S | 1 |
| Kverneland, M | 1 |
| Rudi, K | 1 |
| Gervin, K | 1 |
| Landmark, CJ | 1 |
| Iversen, PO | 1 |
| Selmer, KK | 1 |
| Harby, SA | 1 |
| Khalil, NA | 1 |
| El-Sayed, NS | 1 |
| Thabet, EH | 1 |
| Saleh, SR | 1 |
| Fathelbab, MH | 1 |
| Håkansson, S | 2 |
| Wickström, R | 1 |
| Du, Y | 4 |
| Fang, W | 1 |
| Huang, W | 1 |
| Xu, Q | 2 |
| Gong, J | 2 |
| Xia, N | 3 |
| Zhu, Z | 2 |
| Zheng, R | 3 |
| Xu, H | 3 |
| Lopez, MR | 1 |
| VanCott, AC | 1 |
| Amuan, ME | 1 |
| Panahi, S | 1 |
| Henion, A | 1 |
| Pugh, MJ | 2 |
| Božina, N | 5 |
| Sporiš, IŠ | 1 |
| Domjanović, IK | 1 |
| Ganoci, L | 2 |
| Šimičević, L | 1 |
| Lovrić, M | 4 |
| Romić, ZČ | 1 |
| Gadže, ŽP | 1 |
| Trkulja, V | 2 |
| Aboukaoud, M | 1 |
| Wilf-Yarkoni, A | 1 |
| Maor, E | 1 |
| Pekoz, MT | 1 |
| Aslan-Kara, K | 1 |
| Tekin, B | 1 |
| Gurses, C | 1 |
| Yeni, SN | 1 |
| Bozdemir, H | 1 |
| Keskin-Guler, S | 1 |
| Ataklı, D | 1 |
| Gul, G | 1 |
| Eren, F | 1 |
| Sarı, H | 1 |
| Gul, ZB | 1 |
| Ceyhan-Dirican, A | 1 |
| Genc, F | 1 |
| Bicer-Gomceli, Y | 1 |
| Ozkara, C | 3 |
| Delil, S | 1 |
| Atalar, AC | 1 |
| Bebek, N | 1 |
| Baykan, B | 2 |
| Bora, İ | 2 |
| Bican-Demir, A | 1 |
| Mısırlı, CH | 1 |
| Tutkavul, K | 1 |
| Velioglu, SK | 1 |
| Ilhan-Algin, D | 1 |
| Erdinc, O | 1 |
| Saygi, S | 1 |
| Tezer-Fılık, I | 1 |
| Apaydın-Dogan, E | 1 |
| Akyol, A | 1 |
| Kamisli, O | 2 |
| Yalcın, AD | 1 |
| Cakmak, G | 1 |
| Ersoy, A | 1 |
| Ustun-Ozek, S | 1 |
| Halac, G | 1 |
| Kutlu, G | 1 |
| Tantik-Pak, A | 1 |
| Yücel, SP | 1 |
| Ziganshina, LE | 1 |
| Abakumova, T | 1 |
| Hoyle, CHV | 1 |
| Bromley, RL | 5 |
| Bullen, P | 1 |
| Campbell, E | 2 |
| Craig, J | 5 |
| Ingham, A | 1 |
| Irwin, B | 2 |
| Jackson, C | 1 |
| Kelly, T | 1 |
| Morrow, J | 3 |
| Rushton, S | 1 |
| García-Fiñana, M | 2 |
| Hughes, DM | 1 |
| Winterbottom, J | 1 |
| Wood, A | 1 |
| Yates, LM | 1 |
| Clayton-Smith, J | 7 |
| Lawal, OD | 1 |
| Hume, AL | 1 |
| Wen, X | 1 |
| Lin, J | 2 |
| Barry, JM | 1 |
| Harden, CL | 6 |
| Adab, N | 1 |
| Bluett-Duncan, M | 2 |
| Edwards, K | 1 |
| Greenhalgh, J | 1 |
| Hill, RA | 1 |
| Jackson, CF | 1 |
| Khanom, S | 1 |
| McGinty, RN | 1 |
| Tudur Smith, C | 4 |
| Pulman, J | 1 |
| Cerulli Irelli, E | 1 |
| Cocchi, E | 1 |
| Morano, A | 1 |
| Gesche, J | 1 |
| Caraballo, RH | 1 |
| Lattanzi, S | 3 |
| Strigaro, G | 1 |
| Catania, C | 1 |
| Ferlazzo, E | 1 |
| Pascarella, A | 1 |
| Casciato, S | 1 |
| Quarato, P | 1 |
| Pizzanelli, C | 1 |
| Pulitano, P | 1 |
| Giuliano, L | 1 |
| Viola, V | 1 |
| Mostacci, B | 1 |
| Fortunato, F | 1 |
| Marini, C | 1 |
| Di Gennaro, G | 1 |
| Gambardella, A | 1 |
| Labate, A | 2 |
| Operto, FF | 1 |
| Giallonardo, AT | 1 |
| Beier, CP | 1 |
| Di Bonaventura, C | 1 |
| Sánchez Fernández, I | 1 |
| Gaínza-Lein, M | 1 |
| Amengual-Gual, M | 1 |
| Barcia Aguilar, C | 1 |
| Romeu, A | 1 |
| Torres, A | 1 |
| Jonas, R | 1 |
| Douglass, LM | 1 |
| Vajda, F | 6 |
| O'Brien, T | 2 |
| Graham, J | 5 |
| Hitchcock, A | 4 |
| Lander, C | 3 |
| Eadie, M | 3 |
| Kirkpatrick, L | 1 |
| Harrison, E | 1 |
| Benoist, C | 1 |
| Boccaletti, S | 1 |
| Cattaneo, A | 1 |
| Chaplin, A | 1 |
| Antunes, L | 1 |
| Heiman, F | 1 |
| Pérez-Navarro, VM | 1 |
| Cánovas-Iniesta, M | 1 |
| Palazón-Cabanes, B | 1 |
| Navarro-Lozano, M | 1 |
| Fu, J | 1 |
| Peng, L | 3 |
| Li, J | 3 |
| Tao, T | 1 |
| Kovács, A | 1 |
| Farkas, Z | 1 |
| Kelemen, A | 1 |
| Juhos, V | 1 |
| Szűcs, A | 1 |
| Kamondi, A | 1 |
| Pich, J | 1 |
| Lameiras, C | 1 |
| Ornelas, É | 1 |
| Mendes Lopes, M | 1 |
| Dória, MDC | 1 |
| Kuczynska, J | 1 |
| Karas-Ruszczyk, K | 1 |
| Zakrzewska, A | 1 |
| Dermanowski, M | 1 |
| Sienkiewicz-Jarosz, H | 1 |
| Kurkowska-Jastrzebska, I | 1 |
| Bienkowski, P | 1 |
| Konopko, M | 1 |
| Dominiak, M | 1 |
| Mierzejewski, P | 1 |
| Kardoost, M | 1 |
| Hajizadeh-Saffar, E | 1 |
| Ghorbanian, MT | 1 |
| Ghezelayagh, Z | 1 |
| Pooshang Bagheri, K | 1 |
| Behdani, M | 1 |
| Habibi-Anbouhi, M | 1 |
| Pejanovic-Skobic, N | 1 |
| Markovic, I | 1 |
| Basic, S | 1 |
| Rauchenzauner, M | 7 |
| Deichmann, S | 1 |
| Pittschieler, S | 2 |
| Bergmann, M | 1 |
| Prieschl, M | 2 |
| Unterberger, I | 1 |
| Rösing, B | 1 |
| Seger, C | 1 |
| Moser, C | 1 |
| Wildt, L | 2 |
| Luef, G | 9 |
| Söderberg Löfdal, K | 1 |
| Verrotti, A | 2 |
| Brigo, F | 2 |
| Zaccara, G | 3 |
| Angus-Leppan, H | 1 |
| Moghim, MM | 1 |
| Cock, H | 1 |
| Kinton, L | 1 |
| Synnott Wells, M | 1 |
| Tao, S | 1 |
| Sun, J | 1 |
| Hao, F | 1 |
| Tang, W | 1 |
| Guo, D | 1 |
| Liu, X | 1 |
| Das, S | 1 |
| Jiang, X | 3 |
| Ting, TY | 2 |
| Polli, JE | 2 |
| Wolking, S | 1 |
| Moreau, C | 1 |
| Nies, AT | 1 |
| Schaeffeler, E | 1 |
| McCormack, M | 1 |
| Auce, P | 1 |
| Avbersek, A | 1 |
| Becker, F | 1 |
| Krenn, M | 1 |
| Møller, RS | 1 |
| Nikanorova, M | 1 |
| Weber, YG | 1 |
| Weckhuysen, S | 1 |
| Cavalleri, GL | 1 |
| Delanty, N | 2 |
| Depondt, C | 1 |
| Johnson, MR | 2 |
| Koeleman, BPC | 1 |
| Kunz, WS | 1 |
| Sills, GJ | 5 |
| Striano, P | 3 |
| Zara, F | 1 |
| Zimprich, F | 1 |
| Schwab, M | 1 |
| Krause, R | 1 |
| Sisodiya, SM | 1 |
| Cossette, P | 1 |
| Girard, SL | 1 |
| Lerche, H | 2 |
| Choi, SA | 1 |
| Kim, H | 1 |
| Kim, S | 1 |
| Yoo, S | 1 |
| Yi, S | 1 |
| Jeon, Y | 1 |
| Hwang, H | 2 |
| Kim, KJ | 2 |
| Tayama, T | 1 |
| Mori, T | 2 |
| Goji, A | 2 |
| Toda, Y | 2 |
| Kagami, S | 2 |
| Jeon, JY | 1 |
| Bae, JG | 1 |
| Kim, KT | 1 |
| Cho, YW | 2 |
| Ortega-Vázquez, A | 1 |
| Fricke-Galindo, I | 1 |
| Dorado, P | 2 |
| Jung-Cook, H | 2 |
| Martínez-Juárez, IE | 1 |
| Monroy-Jaramillo, N | 1 |
| Rojas-Tomé, IS | 1 |
| Peñas-Lledó, E | 2 |
| Llerena, A | 2 |
| López-López, M | 2 |
| Łuszczki, JJ | 3 |
| Kondrat-Wróbel, M | 1 |
| Zagaja, M | 1 |
| Karwan, S | 1 |
| Bojar, H | 2 |
| Plewa, Z | 2 |
| Florek-Łuszczki, M | 2 |
| Banfi, P | 1 |
| Coll, M | 1 |
| Oliva, A | 1 |
| Alcalde, M | 1 |
| Mauri, M | 1 |
| Princiotta, L | 1 |
| Campuzano, O | 1 |
| Versino, M | 1 |
| Brugada, R | 1 |
| Chávez-Castillo, CE | 1 |
| Medellín-Garibay, SE | 1 |
| Milán-Segovia, RDC | 1 |
| Rodríguez-Leyva, I | 1 |
| Romano-Moreno, S | 1 |
| King, A | 1 |
| Bachman, E | 1 |
| Macken, MP | 2 |
| Lee, J | 2 |
| Gerard, EE | 2 |
| Ramey, P | 2 |
| Osborn, M | 1 |
| Kirshner, H | 1 |
| Abou-Khalil, B | 3 |
| Juárez-Hernández, JE | 1 |
| Gutiérrez-Ceniceros, M | 1 |
| González-Ramírez, JR | 1 |
| Medeiros, M | 1 |
| Carleton, B | 1 |
| Ross, C | 1 |
| Castañeda-Hernández, G | 1 |
| Wężyk, K | 1 |
| Noguchi, Y | 1 |
| Takaoka, M | 1 |
| Hayashi, T | 1 |
| Tachi, T | 1 |
| Teramachi, H | 1 |
| Rajendran, P | 1 |
| Yu, L | 2 |
| Feng, J | 2 |
| Yu, Z | 2 |
| Dai, H | 1 |
| Yamada, K | 2 |
| Nibuya, M | 1 |
| Takahashi, A | 1 |
| Shito, Y | 1 |
| Watanabe, Y | 1 |
| Saeki, H | 1 |
| Suzuki, E | 2 |
| Furugen, A | 1 |
| Wiggs, KK | 1 |
| Rickert, ME | 1 |
| Sujan, AC | 1 |
| Quinn, PD | 1 |
| Larsson, H | 1 |
| Lichtenstein, P | 1 |
| Oberg, AS | 1 |
| D'Onofrio, BM | 1 |
| Zhao, T | 1 |
| Yu, LH | 1 |
| Wang, TT | 1 |
| Sun, L | 1 |
| Li, HJ | 1 |
| Daugaard, CA | 2 |
| Pedersen, L | 1 |
| Guo, Y | 5 |
| Lin, Z | 1 |
| Li, KY | 1 |
| Huang, LC | 1 |
| Chang, YP | 1 |
| Yang, YH | 1 |
| Tauzin, M | 1 |
| Tréluyer, JM | 1 |
| Nabbout, R | 1 |
| Billette de Villemeur, T | 1 |
| Desguerre, I | 1 |
| Aboura, R | 1 |
| Gana, I | 1 |
| Zheng, Y | 1 |
| Benaboud, S | 1 |
| Bouazza, N | 1 |
| Chenevier-Gobeaux, C | 1 |
| Freihuber, C | 1 |
| Hirt, D | 1 |
| Łukawski, K | 1 |
| Czuczwar, SJ | 4 |
| Markoula, S | 1 |
| Siarava, E | 1 |
| Kostoulas, C | 1 |
| Zikopoulos, A | 1 |
| Georgiou, I | 1 |
| Gidal, BE | 11 |
| Duan, J | 1 |
| Privitera, MD | 3 |
| Berg, MJ | 2 |
| Krebill, R | 4 |
| Szaflarski, J | 1 |
| Diaz, FJ | 4 |
| Kaplan, YC | 1 |
| Demir, O | 1 |
| Najm, S | 1 |
| Naureen, H | 1 |
| Sultana, K | 1 |
| Anwar, F | 1 |
| Rehman, S | 1 |
| Arshad, S | 1 |
| Khan, MM | 1 |
| Müller, RM | 1 |
| Herziger, B | 1 |
| Jeschke, S | 1 |
| Neininger, MP | 1 |
| Bertsche, T | 1 |
| Bertsche, A | 1 |
| S, S | 1 |
| Kumar, L | 1 |
| Verma, R | 1 |
| Perucca, E | 15 |
| Bergfeldt, L | 1 |
| Baulac, M | 2 |
| Auerbach, DS | 1 |
| Keezer, M | 1 |
| Vossler, DG | 4 |
| Griepp, DW | 1 |
| Kim, DJ | 1 |
| Ganz, M | 1 |
| Dolphin, EJ | 1 |
| Sotudeh, N | 1 |
| Burekhovich, SA | 1 |
| Naziri, Q | 1 |
| Kakumoto, M | 1 |
| Shimokawa, K | 1 |
| Ueshima, S | 1 |
| Hira, D | 1 |
| Okano, T | 1 |
| Wang, ML | 2 |
| Tao, YY | 1 |
| Sun, XY | 1 |
| Wang, ZY | 1 |
| Cao, YF | 1 |
| Zhao, L | 6 |
| Rohracher, A | 1 |
| Trinka, E | 2 |
| He, H | 2 |
| Guzman, RE | 1 |
| Cao, D | 1 |
| Sierra-Marquez, J | 1 |
| Yin, F | 1 |
| Fahlke, C | 1 |
| Peng, J | 1 |
| Stauber, T | 1 |
| Ferry, J | 1 |
| Reyderman, L | 1 |
| Piña-Garza, JE | 1 |
| Liu, J | 3 |
| Wang, LN | 3 |
| Mahamud, Z | 1 |
| Burman, J | 1 |
| Loikas, D | 1 |
| Linnér, L | 1 |
| Sundström, A | 1 |
| Wettermark, B | 2 |
| Jang, Y | 1 |
| Moon, J | 2 |
| Kim, N | 1 |
| Kim, TJ | 2 |
| Jun, JS | 1 |
| Shin, YW | 1 |
| Chang, H | 1 |
| Kang, HR | 2 |
| Lee, ST | 2 |
| Jung, KH | 2 |
| Park, KI | 1 |
| Jung, KY | 2 |
| Chu, K | 2 |
| Lee, SK | 3 |
| Załuska-Ogryzek, K | 1 |
| Marzęda, P | 1 |
| Wróblewska-Łuczka, P | 1 |
| Zolkowska, D | 1 |
| van Opijnen, MP | 1 |
| van der Meer, PB | 1 |
| Dirven, L | 1 |
| Fiocco, M | 1 |
| Kouwenhoven, MCM | 1 |
| van den Bent, MJ | 1 |
| Taphoorn, MJB | 1 |
| Koekkoek, JAF | 1 |
| Smith, PEM | 1 |
| Khosrowshahi, EM | 1 |
| Jouyban, A | 1 |
| Farajzadeh, MA | 1 |
| Tuzen, M | 1 |
| Afshar Mogaddam, MR | 1 |
| Nemati, M | 1 |
| Wang, HX | 1 |
| Zhao, MM | 1 |
| Ma, YY | 1 |
| Zhao, LM | 1 |
| Toffa, DH | 1 |
| Nguyen, DK | 1 |
| Hatanaka, K | 1 |
| Kamijo, Y | 1 |
| Kitamoto, T | 1 |
| Hanazawa, T | 1 |
| Yoshizawa, T | 1 |
| Ochiai, H | 1 |
| Haga, Y | 1 |
| Liang, D | 1 |
| Gardella, E | 1 |
| Kragholm, K | 1 |
| Polcwiartek, C | 1 |
| Sessa, M | 1 |
| Sidhu, HS | 2 |
| Srinivas, R | 1 |
| Sadhotra, A | 2 |
| Zuberi, NA | 1 |
| Baig, M | 1 |
| Bano, S | 1 |
| Batool, Z | 1 |
| Haider, S | 1 |
| Perveen, T | 1 |
| Pariente, G | 1 |
| Leibson, T | 1 |
| Shulman, T | 1 |
| Adams-Webber, T | 1 |
| Barzilay, E | 1 |
| Nulman, I | 2 |
| Bolin, K | 1 |
| Berggren, F | 1 |
| Berling, P | 1 |
| Morberg, S | 1 |
| Gauffin, H | 1 |
| Landtblom, AM | 1 |
| Rahman, MM | 1 |
| Alatawi, Y | 1 |
| Cheng, N | 1 |
| Qian, J | 1 |
| Plotkina, AV | 1 |
| Peissig, PL | 1 |
| Berg, RL | 1 |
| Page, D | 1 |
| Hansen, RA | 1 |
| Jacob, L | 1 |
| Hamer, HM | 3 |
| Kostev, K | 2 |
| Berg, M | 2 |
| Szaflarski, JP | 2 |
| Dworetzky, BA | 4 |
| Pollard, JR | 2 |
| Elder, EJ | 2 |
| Switzer, RD | 1 |
| Krauss, GL | 1 |
| Nevitt, SJ | 2 |
| Sudell, M | 2 |
| Weston, J | 2 |
| D'Anto, J | 1 |
| Wnuk, W | 1 |
| Rossetti, AO | 1 |
| Decosterd, LA | 1 |
| Buclin, T | 1 |
| Novy, J | 1 |
| Veroniki, AA | 1 |
| Rios, P | 1 |
| Cogo, E | 1 |
| Straus, SE | 1 |
| Finkelstein, Y | 1 |
| Kealey, R | 1 |
| Reynen, E | 1 |
| Soobiah, C | 1 |
| Thavorn, K | 1 |
| Hutton, B | 1 |
| Hemmelgarn, BR | 1 |
| Yazdi, F | 1 |
| D'Souza, J | 1 |
| MacDonald, H | 1 |
| Tricco, AC | 1 |
| Abdel-Wahab, AF | 1 |
| Afify, MA | 1 |
| Mahfouz, AM | 1 |
| Shahzad, N | 1 |
| Bamagous, GA | 1 |
| Al Ghamdi, SS | 1 |
| Cohen-Israel, M | 1 |
| Berger, I | 3 |
| Martonovich, EY | 1 |
| Klinger, G | 1 |
| Stahl, B | 1 |
| Linder, N | 1 |
| Wiedemann, K | 1 |
| Stüber, T | 1 |
| Rehn, M | 1 |
| Frieauff, E | 1 |
| Srinivasa, R | 1 |
| Yang, C | 1 |
| Liu, H | 1 |
| Li, H | 3 |
| Zhong, G | 1 |
| Qin, J | 3 |
| Ni, G | 2 |
| Dibué-Adjei, M | 1 |
| Kamp, MA | 2 |
| Alpdogan, S | 1 |
| Tevoufouet, EE | 1 |
| Neiss, WF | 1 |
| Hescheler, J | 2 |
| Schneider, T | 2 |
| Rosati, A | 1 |
| Ilvento, L | 1 |
| Lucenteforte, E | 1 |
| Pugi, A | 1 |
| Crescioli, G | 1 |
| McGreevy, KS | 1 |
| Virgili, G | 1 |
| Mugelli, A | 1 |
| De Masi, S | 1 |
| Guerrini, R | 2 |
| Hernandez-Diaz, S | 2 |
| Huybrechts, KF | 1 |
| Desai, RJ | 1 |
| Mogun, H | 1 |
| Bateman, BT | 1 |
| Patorno, E | 1 |
| Bedussi, F | 1 |
| Relli, V | 1 |
| Faraoni, L | 1 |
| Eleftheriou, G | 1 |
| Giampreti, A | 1 |
| Gallo, M | 1 |
| Lorenzi, F | 1 |
| Sangiovanni, A | 1 |
| Chiara, F | 1 |
| Maccioni, R | 1 |
| Pilloni, PP | 1 |
| Falchi, G | 1 |
| Scanu, M | 1 |
| Butera, R | 1 |
| Bacis, G | 1 |
| Lee, BI | 4 |
| No, SK | 1 |
| Yi, SD | 1 |
| Lee, HW | 3 |
| Kim, OJ | 1 |
| Kim, SH | 2 |
| Kim, MK | 1 |
| Kim, SE | 2 |
| Kim, YS | 1 |
| Kim, JM | 1 |
| Lee, SJ | 2 |
| Shin, DJ | 1 |
| Park, SP | 2 |
| Kim, YI | 2 |
| Heo, K | 4 |
| Cho, YJ | 2 |
| Kim, YN | 1 |
| Xu, S | 2 |
| Liu, L | 2 |
| Liu, M | 1 |
| Lu, T | 2 |
| Wang, H | 3 |
| Liu, S | 1 |
| Zhao, M | 2 |
| Petrenaite, V | 4 |
| Öhman, I | 8 |
| Ekström, L | 1 |
| Sæbye, D | 1 |
| Hansen, TF | 1 |
| Sabers, A | 12 |
| Reimers, A | 6 |
| Karlsson Lind, L | 1 |
| Wide, K | 3 |
| Čajić, I | 2 |
| Petelin Gadže, Ž | 1 |
| Klarica Domjanović, I | 2 |
| Mercadé Cerdá, JM | 2 |
| López Gonzalez, FJ | 1 |
| Serrano Castro, P | 1 |
| Castro Vilanova, MD | 1 |
| Campos Blanco, DM | 1 |
| Querol Pascual, MR | 1 |
| Iriki, H | 1 |
| Ouchi, T | 1 |
| Ito, H | 2 |
| Sawada, M | 1 |
| Mukai, M | 1 |
| Nomura, H | 1 |
| Baba, Y | 1 |
| Adachi, T | 1 |
| Funakoshi, T | 1 |
| Amagai, M | 1 |
| Takahashi, H | 1 |
| Shimamura, H | 1 |
| Yamada, H | 1 |
| Okada, N | 1 |
| Uchikura, T | 1 |
| Tanaka, K | 1 |
| Sasaki, T | 1 |
| Itabe, H | 1 |
| Kondrat-Wróbel, MW | 1 |
| Bonizzoni, E | 3 |
| Lindhout, D | 8 |
| Thangaratinam, S | 2 |
| Marlin, N | 1 |
| Newton, S | 1 |
| Weckesser, A | 1 |
| Bagary, M | 2 |
| Greenhill, L | 3 |
| Rikunenko, R | 1 |
| D'Amico, M | 1 |
| Rogozińska, E | 1 |
| Kelso, A | 1 |
| Hard, K | 1 |
| Coleman, J | 1 |
| Moss, N | 1 |
| Roberts, T | 1 |
| Middleton, L | 2 |
| Dodds, J | 1 |
| Pullen, A | 1 |
| Eldridge, S | 1 |
| Pirie, A | 1 |
| Denny, E | 1 |
| McCorry, D | 3 |
| Khan, KS | 2 |
| Petelin-Gadže, Ž | 1 |
| Ogbebor, O | 1 |
| Agrawal, A | 1 |
| Yegneswaran, B | 1 |
| Galappatthy, P | 1 |
| Liyanage, CK | 1 |
| Lucas, MN | 1 |
| Jayasekara, DTLM | 1 |
| Abhayaratna, SA | 1 |
| Weeraratne, C | 1 |
| De Abrew, K | 1 |
| Gunaratne, PS | 1 |
| Gamage, R | 1 |
| Wijeyaratne, CN | 1 |
| El-Haggar, SM | 1 |
| Mostafa, TM | 1 |
| Allah, HMS | 1 |
| Akef, GH | 1 |
| Polepally, AR | 2 |
| Brundage, RC | 2 |
| Remmel, RP | 4 |
| Leppik, IE | 8 |
| White, JR | 2 |
| Ramsay, RE | 5 |
| Kistner, BM | 1 |
| Allien, S | 1 |
| Lau, C | 1 |
| Callisto, SP | 1 |
| Wang, Z | 1 |
| Mintzer, S | 1 |
| Kraemer, G | 1 |
| Chervoneva, I | 1 |
| Werhahn, KJ | 1 |
| Praveen, A | 1 |
| Aqil, M | 2 |
| Imam, SS | 1 |
| Ahad, A | 1 |
| Moolakkadath, T | 1 |
| Ahmad, FJ | 1 |
| Walker, DI | 1 |
| Perry-Walker, K | 1 |
| Finnell, RH | 1 |
| Pennell, KD | 1 |
| Tran, V | 1 |
| May, RC | 1 |
| McElrath, TF | 1 |
| Jones, DP | 1 |
| Wu, LY | 2 |
| Wang, YP | 2 |
| Shen, J | 1 |
| Ding, S | 1 |
| Ye, M | 1 |
| Wang, L | 4 |
| Chen, H | 1 |
| Han, X | 1 |
| Huang, J | 1 |
| Lv, J | 1 |
| Wang, J | 2 |
| Nie, X | 1 |
| Zan, X | 1 |
| Cohen, MJ | 3 |
| May, R | 1 |
| Loblein, H | 1 |
| Conrad, T | 1 |
| Baker, GA | 7 |
| Kalayjian, LA | 5 |
| Kanner, A | 5 |
| Liporace, JD | 4 |
| Privitera, M | 5 |
| Loring, DW | 7 |
| Tashiro, Y | 1 |
| Azukizawa, H | 1 |
| Asada, H | 1 |
| Niihara, H | 1 |
| Morita, E | 1 |
| Yamauchi, T | 1 |
| Mizukawa, Y | 1 |
| Kusakabe, Y | 1 |
| Numazawa, S | 1 |
| Izumi, M | 1 |
| Sueki, H | 1 |
| Watanabe, H | 1 |
| Koristkova, B | 1 |
| Grundmann, M | 3 |
| Brozmanova, H | 3 |
| Kacirova, I | 3 |
| Richards, N | 1 |
| Reith, D | 1 |
| Stitely, M | 1 |
| Smith, A | 1 |
| Laghari, AA | 1 |
| Ahmed, SI | 1 |
| Qadeer, N | 1 |
| Shamim, MS | 1 |
| Lin, WW | 1 |
| Wang, CL | 1 |
| Jiao, Z | 2 |
| Yu, XL | 1 |
| Zhang, J | 3 |
| Zhang, WB | 1 |
| Lin, RF | 1 |
| Lin, S | 1 |
| Lin, XH | 1 |
| Ding, Y | 1 |
| Tan, X | 1 |
| Zhang, S | 3 |
| El Otmani, H | 1 |
| Amzil, R | 1 |
| Rafai, MA | 1 |
| El Moutawakil, B | 1 |
| Yu, EQ | 1 |
| Wang, CY | 1 |
| Ding, JJ | 1 |
| Zhang, XH | 1 |
| Kristensen, KB | 1 |
| Pedersen, SA | 1 |
| Schmidt, SAJ | 1 |
| Pottegård, A | 1 |
| Huber-Mollema, Y | 1 |
| Oort, FJ | 1 |
| Rodenburg, R | 1 |
| Mbizvo, GK | 1 |
| Derry, C | 1 |
| Davenport, R | 1 |
| Sharobeam, A | 1 |
| Mamun, A | 1 |
| Kwok, A | 1 |
| Zandiehvakili, M | 1 |
| Beran, RG | 6 |
| Park, KM | 1 |
| Mori, K | 1 |
| Kohmoto, T | 1 |
| Imoto, I | 1 |
| Kajita, Y | 1 |
| Yoshida, K | 1 |
| Nagai, T | 1 |
| Wakabayashi, T | 1 |
| Nakken, KO | 2 |
| Sætre, E | 1 |
| Markhus, R | 1 |
| Lossius, MI | 1 |
| Wilson, KL | 1 |
| Alexander, JM | 1 |
| Płonka-Półtorak, E | 1 |
| Zagrodzki, P | 1 |
| Nicol, F | 1 |
| Kryczyk, J | 1 |
| Bartoń, H | 1 |
| Westermarck, T | 1 |
| Kaipainen, P | 1 |
| Ounjaijean, S | 1 |
| Kaski, M | 1 |
| Atroshi, F | 1 |
| Thome-Souza, S | 3 |
| Valente, KD | 3 |
| Orendi, K | 1 |
| Uhrig, S | 1 |
| Mach, M | 1 |
| Tschepper, P | 1 |
| Speicher, MR | 1 |
| Srivastava, AK | 2 |
| Alex, AB | 1 |
| Russo, E | 1 |
| Chimirri, S | 1 |
| Aiello, R | 1 |
| De Fazio, S | 1 |
| Leo, A | 1 |
| Rispoli, V | 1 |
| Marra, R | 1 |
| De Fazio, P | 1 |
| Citraro, R | 1 |
| De Sarro, G | 2 |
| Deng, Y | 2 |
| Jiang, L | 1 |
| Ma, C | 2 |
| Xi, Z | 2 |
| He, N | 2 |
| Ghosh, C | 1 |
| Hossain, M | 1 |
| Puvenna, V | 1 |
| Martinez-Gonzalez, J | 1 |
| Alexopolous, A | 1 |
| Janigro, D | 1 |
| Marchi, N | 1 |
| Ruppert, E | 1 |
| Lalanne, L | 1 |
| Foucher, J | 1 |
| Zimmermann, MA | 1 |
| Hirsch, E | 1 |
| Vidailhet, P | 1 |
| Wegner, I | 3 |
| Wilhelm, AJ | 2 |
| Welty, T | 1 |
| Alloway, R | 1 |
| Ogawa, K | 1 |
| Iyoda, K | 1 |
| Pirie, DA | 1 |
| Al Wattar, BH | 1 |
| Pirie, AM | 1 |
| Houston, V | 1 |
| Siddiqua, A | 1 |
| Doug, M | 1 |
| Brzaković, B | 1 |
| Vučićević, K | 2 |
| Kovačević, SV | 2 |
| Miljković, B | 2 |
| Prostran, M | 2 |
| Martinović, Ž | 2 |
| Pokrajac, M | 1 |
| Lee, HS | 1 |
| Wang, SY | 1 |
| Salter, DM | 1 |
| Wang, CC | 1 |
| Chen, SJ | 1 |
| Fan, HC | 1 |
| Yamamoto, T | 2 |
| Yamazoe, T | 1 |
| Fujimoto, A | 1 |
| Kobayashi, R | 1 |
| Yokota, T | 1 |
| Okanishi, T | 1 |
| Uchiyama, G | 1 |
| Ohashi, T | 1 |
| Tanaka, T | 1 |
| Enoki, H | 1 |
| Roscia, S | 1 |
| Haberlandt, E | 2 |
| Baumann, M | 1 |
| Rostasy, K | 1 |
| Agostinelli, S | 1 |
| Pizzolorusso, A | 1 |
| Kennedy, F | 1 |
| Russell, A | 1 |
| Smithson, WH | 1 |
| Parsons, L | 1 |
| Morrison, PJ | 1 |
| Liggan, B | 1 |
| Hunt, SJ | 1 |
| Conway, JM | 1 |
| Rarick, JO | 2 |
| Lambrechts, DA | 1 |
| Dibué, M | 1 |
| Neumaier, F | 1 |
| Steiger, HJ | 1 |
| Hänggi, D | 1 |
| Singh, E | 1 |
| Pillai, KK | 2 |
| Mehndiratta, M | 1 |
| Chang, Y | 1 |
| Yang, LY | 1 |
| Zhang, MC | 1 |
| Liu, SY | 1 |
| Yu, K | 1 |
| Huo, J | 1 |
| Zhu, Y | 1 |
| Wechsler, RT | 1 |
| Leroy, R | 1 |
| Van Cott, A | 1 |
| Hammer, AE | 20 |
| Vuong, A | 15 |
| Huffman, R | 1 |
| VanLandingham, K | 1 |
| Messenheimer, JA | 10 |
| Löscher, W | 3 |
| Ito, S | 2 |
| Oguni, H | 1 |
| Ohtsuka, Y | 2 |
| Bonnett, LJ | 1 |
| Donegan, S | 1 |
| Lessing, C | 1 |
| Ashton, T | 1 |
| Davis, P | 1 |
| Vajda, FJ | 5 |
| Lander, CM | 2 |
| Eadie, MJ | 3 |
| Alam, T | 1 |
| Pandit, J | 1 |
| Vohora, D | 1 |
| Ali, A | 2 |
| Sultana, Y | 1 |
| Kim, HJ | 1 |
| Kim, TE | 1 |
| Joo, EY | 1 |
| Seo, DW | 1 |
| Lee, SY | 1 |
| Hong, SB | 1 |
| Shazadi, K | 1 |
| Petrovski, S | 1 |
| Roten, A | 1 |
| Miller, H | 1 |
| Huggins, RM | 1 |
| Brodie, MJ | 24 |
| Pirmohamed, M | 1 |
| Jovanović, M | 1 |
| Golubović, B | 1 |
| Minagawa, K | 1 |
| Watanabe, T | 1 |
| Oyanagi, R | 1 |
| Fukumura, S | 1 |
| Naik, GS | 1 |
| Kodagali, R | 1 |
| Mathew, BS | 1 |
| Thomas, M | 1 |
| Prabha, R | 1 |
| Mathew, V | 1 |
| Fleming, DH | 1 |
| Briggs, M | 1 |
| Cheyne, CP | 1 |
| Gummery, A | 1 |
| Kneen, R | 1 |
| Mawer, G | 1 |
| Shallcross, R | 1 |
| Klein, P | 1 |
| Lindstrøm, P | 1 |
| Andersen, H | 1 |
| Wang, WP | 2 |
| Ni, YF | 1 |
| Wei, YN | 1 |
| Li, XF | 1 |
| Cheng, QS | 1 |
| Lu, Q | 1 |
| Pintaudi, M | 1 |
| Calevo, MG | 1 |
| Vignoli, A | 3 |
| Baglietto, MG | 1 |
| Hayek, Y | 1 |
| Traverso, M | 1 |
| Giacomini, T | 1 |
| Giordano, L | 1 |
| Renieri, A | 1 |
| Russo, S | 1 |
| Canevini, M | 1 |
| Veneselli, E | 1 |
| Yamamoto, Y | 3 |
| Takahashi, Y | 3 |
| Imai, K | 2 |
| Ikeda, H | 1 |
| Takahashi, M | 1 |
| Nakai, M | 1 |
| Inoue, Y | 4 |
| Kagawa, Y | 2 |
| Zhou, Y | 2 |
| Fang, Z | 1 |
| Zhou, J | 1 |
| Wang, Q | 3 |
| Liang, M | 2 |
| Dong, Y | 2 |
| Yun, W | 2 |
| Qiu, F | 3 |
| Okumura, A | 2 |
| Arai, E | 1 |
| Kitamura, Y | 1 |
| Abe, S | 2 |
| Ikeno, M | 1 |
| Fujimaki, T | 1 |
| Shimizu, T | 1 |
| Gavzan, H | 1 |
| Sayyah, M | 1 |
| Sardari, S | 1 |
| Babapour, V | 1 |
| Anderson, M | 1 |
| Egunsola, O | 1 |
| Cherrill, J | 1 |
| Millward, C | 1 |
| Fakis, A | 1 |
| Choonara, I | 1 |
| Wang, C | 1 |
| Hong, Z | 2 |
| Mody, SK | 1 |
| Haunschild, C | 1 |
| Farala, JP | 1 |
| Honerkamp-Smith, G | 1 |
| Hur, V | 1 |
| Kansal, L | 1 |
| Lionberger, R | 1 |
| Wong, J | 1 |
| Jones, JW | 1 |
| Kane, MA | 1 |
| Krumholz, A | 1 |
| Temple, R | 1 |
| Xie, W | 1 |
| Jang, HW | 1 |
| Kim, SW | 1 |
| Jang, IJ | 2 |
| Lee, MG | 1 |
| Kim, WJ | 1 |
| Lee, JH | 1 |
| Park, HK | 1 |
| Sunwoo, JS | 1 |
| Byun, JI | 1 |
| Lim, JA | 1 |
| Shin, JW | 1 |
| Jeon, D | 1 |
| Kim, DW | 1 |
| Yu, KS | 1 |
| Park, HW | 1 |
| Ma, Y | 1 |
| Linder, C | 1 |
| Andersson, M | 1 |
| Beck, O | 2 |
| Pohanka, A | 1 |
| Kubagawa, T | 1 |
| Furusho, J | 1 |
| Isozaki, Y | 1 |
| Janszky, J | 2 |
| Jackson, J | 1 |
| McCollum, B | 1 |
| O'Neill, A | 1 |
| de Leon, J | 1 |
| Dalili, H | 1 |
| Nayeri, F | 1 |
| Shariat, M | 1 |
| Asgarzadeh, L | 1 |
| Asadollahi, M | 1 |
| Ramezani, M | 2 |
| Karimialavijeh, E | 1 |
| Tavakolian, M | 1 |
| Shirzadi, M | 2 |
| Thorstensen, K | 1 |
| Helde, G | 3 |
| Moen, T | 1 |
| Brodtkorb, E | 4 |
| Soysal, H | 1 |
| Doğan, Z | 1 |
| Kowski, AB | 1 |
| Weissinger, F | 1 |
| Gaus, V | 1 |
| Fidzinski, P | 1 |
| Losch, F | 1 |
| Holtkamp, M | 1 |
| Meng, H | 1 |
| Inoue, K | 1 |
| Takahashi, T | 1 |
| Umemura, A | 1 |
| Hirai, K | 1 |
| Tsuji, D | 1 |
| Itoh, K | 1 |
| Ghandourah, H | 1 |
| Bhandal, S | 1 |
| Brundler, MA | 1 |
| Noseworthy, M | 1 |
| Abou-Khalil, BW | 2 |
| Warshavsky, A | 1 |
| Eilam, A | 1 |
| Gilad, R | 2 |
| Contin, M | 6 |
| Alberghini, L | 1 |
| Candela, C | 3 |
| Benini, G | 1 |
| Riva, R | 6 |
| Osborn, MR | 1 |
| Lowen, KM | 1 |
| Reed, RC | 2 |
| Takeuchi, T | 1 |
| Natsume, J | 1 |
| Kidokoro, H | 1 |
| Ishihara, N | 1 |
| Yamamoto, H | 1 |
| Azuma, Y | 1 |
| Ito, Y | 1 |
| Kurahashi, N | 1 |
| Tsuji, T | 1 |
| Suzuki, M | 1 |
| Itomi, K | 1 |
| Kurahashi, H | 1 |
| Maruyama, K | 1 |
| Negoro, T | 1 |
| Watanabe, K | 2 |
| Kojima, S | 1 |
| Vanya, M | 1 |
| Devosa, I | 1 |
| Szok, D | 1 |
| Bártfai, G | 1 |
| Dolk, H | 2 |
| Loane, M | 2 |
| Morris, J | 2 |
| Garne, E | 1 |
| Addor, MC | 1 |
| Arriola, L | 1 |
| Bakker, M | 1 |
| Barisic, I | 1 |
| Doray, B | 1 |
| Gatt, M | 1 |
| Kallen, K | 1 |
| Khoshnood, B | 1 |
| Klungsoyr, K | 1 |
| Lahesmaa-Korpinen, AM | 1 |
| Latos-Bielenska, A | 1 |
| Mejnartowicz, JP | 1 |
| Nelen, V | 1 |
| Neville, A | 1 |
| O'Mahony, M | 1 |
| Pierini, A | 1 |
| Rißmann, A | 1 |
| Tucker, D | 1 |
| Wellesley, D | 1 |
| Wiesel, A | 1 |
| de Jong-van den Berg, LT | 4 |
| Voldby, RG | 1 |
| Bajalan, S | 1 |
| Milosheska, D | 1 |
| Lorber, B | 1 |
| Vovk, T | 1 |
| Kastelic, M | 1 |
| Dolžan, V | 1 |
| Grabnar, I | 1 |
| Baldoni, AO | 1 |
| Freitas-Lima, P | 1 |
| de Santi Ferreira, FI | 1 |
| Martinez, EZ | 1 |
| Queiroz, RH | 3 |
| Sakamoto, AC | 2 |
| Alexandre, V | 3 |
| Pereira, LR | 2 |
| Byers, HM | 1 |
| Beatty, CW | 1 |
| Hahn, SH | 1 |
| Gospe, SM | 1 |
| Nikolaev, EL | 1 |
| SÖrlie, T | 1 |
| Rezvy, G | 1 |
| Sarangi, SC | 1 |
| Tripathi, M | 1 |
| Kakkar, AK | 1 |
| Gupta, YK | 1 |
| Maruyama, S | 1 |
| Okamoto, Y | 1 |
| Toyoshima, M | 1 |
| Hanaya, R | 1 |
| Kawano, Y | 1 |
| Liu, YT | 1 |
| Zhang, LL | 1 |
| Huang, L | 1 |
| Zeng, LN | 1 |
| Martinez Ferri, M | 1 |
| Peña Mayor, P | 1 |
| Perez López-Fraile, I | 1 |
| Escartin Siquier, A | 1 |
| Martin Moro, M | 1 |
| Forcadas Berdusan, M | 1 |
| Barros, LS | 1 |
| Carrão, DB | 1 |
| de Oliveira, AR | 1 |
| de Gaitani, CM | 1 |
| Lai, EC | 1 |
| Hsieh, CY | 1 |
| Su, CC | 1 |
| Yang, YK | 1 |
| Huang, CW | 2 |
| Lin, SJ | 1 |
| Setoguchi, S | 1 |
| Shen, CH | 1 |
| Zhang, YX | 1 |
| Lu, RY | 1 |
| Jin, B | 1 |
| Liu, ZR | 1 |
| Tang, YL | 1 |
| Ding, MP | 1 |
| Zhang, B | 1 |
| Zhang, JW | 1 |
| Dong, RF | 1 |
| Tian, S | 1 |
| Wieshmann, UC | 2 |
| Du, Z | 1 |
| Jiao, Y | 1 |
| Shi, L | 1 |
| Yasam, VR | 1 |
| Jakki, SL | 1 |
| Senthil, V | 1 |
| Eswaramoorthy, M | 1 |
| Shanmuganathan, S | 1 |
| Arjunan, K | 1 |
| Nanjan, MJ | 1 |
| Espinera, AR | 1 |
| Gavvala, J | 1 |
| Bellinski, I | 1 |
| Kennedy, J | 1 |
| Narechania, A | 1 |
| Templer, J | 1 |
| VanHaerents, S | 1 |
| Schuele, SU | 1 |
| Romoli, M | 1 |
| Costa, C | 3 |
| Siliquini, S | 1 |
| Corbelli, I | 1 |
| Eusebi, P | 1 |
| Bedetti, C | 1 |
| Caproni, S | 1 |
| Cupini, LM | 1 |
| Calabresi, P | 4 |
| Sarchielli, P | 1 |
| Savini, MN | 1 |
| Nowbut, MS | 1 |
| Peron, A | 1 |
| Turner, K | 1 |
| La Briola, F | 1 |
| Canevini, MP | 2 |
| Sjursen, W | 1 |
| Fong, JK | 1 |
| Chan, EL | 1 |
| Chan, I | 1 |
| Chang, RS | 1 |
| Fong, GC | 1 |
| Fung, EL | 1 |
| Lui, CH | 1 |
| Fung, BB | 1 |
| Poon, TL | 1 |
| Siu, D | 1 |
| Wong, HT | 1 |
| Yeung, E | 1 |
| Yung, AW | 1 |
| Zhu, CX | 1 |
| Shih, JJ | 1 |
| Whitlock, JB | 1 |
| Chimato, N | 1 |
| Vargas, E | 1 |
| Karceski, SC | 1 |
| Frank, RD | 1 |
| Yu, P | 1 |
| Liao, W | 1 |
| Wang, T | 1 |
| Wu, Y | 1 |
| Lang, S | 1 |
| Song, Y | 2 |
| Zhao, H | 1 |
| Fuglsang, A | 1 |
| Holte, Ø | 1 |
| Madsen, S | 1 |
| Reinsberger, C | 1 |
| Dorn, T | 1 |
| Krämer, G | 4 |
| Valencia, I | 2 |
| Piñol-Ripoll, G | 1 |
| Khurana, DS | 1 |
| Hardison, HH | 1 |
| Kothare, SV | 1 |
| Melvin, JJ | 1 |
| Marks, HG | 1 |
| Legido, A | 3 |
| Hamed, SA | 1 |
| Fida, NM | 1 |
| Hamed, EA | 1 |
| Nielsen, KA | 3 |
| Dahl, M | 4 |
| Tømmerup, E | 2 |
| Hansen, Bá | 1 |
| Erdal, J | 1 |
| Wolf, P | 4 |
| Peltola, J | 2 |
| Peltola, M | 1 |
| Auvinen, A | 1 |
| Raitanen, J | 1 |
| Fallah, M | 1 |
| Keränen, T | 2 |
| van de Vrie-Hoekstra, NW | 1 |
| de Vries, TW | 1 |
| van den Berg, PB | 1 |
| Brouwer, OF | 1 |
| Rivas, N | 1 |
| Buelga, DS | 1 |
| Elger, CE | 2 |
| Santos-Borbujo, J | 1 |
| Otero, MJ | 1 |
| Domínguez-Gil, A | 1 |
| García, MJ | 1 |
| Jentink, J | 2 |
| Ermakov, AIu | 2 |
| Boldyreva, SR | 1 |
| Litvinovich, EF | 1 |
| Aurlien, D | 5 |
| Leren, TP | 1 |
| Taubøll, E | 11 |
| Gjerstad, L | 11 |
| Morrell, MJ | 6 |
| Hayes, FJ | 1 |
| Sluss, PM | 1 |
| Adams, JM | 1 |
| Bhatt, M | 1 |
| Warnock, CR | 1 |
| Isojärvi, J | 6 |
| Carpay, JA | 1 |
| Aalbers, K | 1 |
| Graveland, GA | 1 |
| Engelsman, M | 2 |
| Grisotto, KP | 1 |
| Bruck, I | 1 |
| Antoniuk, SA | 1 |
| Santos, LH | 1 |
| Zubcevic, S | 1 |
| Cengic, A | 1 |
| Catibusic, F | 1 |
| Uzicanin, S | 1 |
| Kolamunnage-Dona, R | 1 |
| Philipson, P | 1 |
| Lorberg, B | 1 |
| Youssef, NA | 1 |
| Bhagwagar, Z | 1 |
| Auriel, E | 1 |
| Landov, H | 1 |
| Blatt, I | 1 |
| Theitler, J | 1 |
| Gandelman-Marton, R | 2 |
| Chistik, V | 1 |
| Margolin, N | 1 |
| Gross, B | 1 |
| Parmet, Y | 1 |
| Andelman, F | 1 |
| Neufeld, MY | 2 |
| Fakhoury, TA | 5 |
| Miller, JM | 2 |
| Sethi, NK | 1 |
| Bootsma, HP | 3 |
| Ricker, L | 1 |
| Hekster, YA | 6 |
| Hulsman, J | 3 |
| Lambrechts, D | 3 |
| Majoie, M | 3 |
| Schellekens, A | 3 |
| de Krom, M | 1 |
| Aldenkamp, AP | 4 |
| Tsenov, G | 1 |
| Redkozubova, O | 1 |
| Kubová, H | 1 |
| Mares, P | 1 |
| Huber, B | 1 |
| Hilgemann, C | 1 |
| Rouvel-Tallec, A | 1 |
| Rheims, S | 1 |
| Ryvlin, P | 1 |
| Fotopoulou, C | 1 |
| Kretz, R | 1 |
| Bauer, S | 3 |
| Schefold, JC | 1 |
| Schmitz, B | 2 |
| Dudenhausen, JW | 1 |
| Henrich, W | 1 |
| Herzog, AG | 3 |
| Blum, AS | 1 |
| Farina, EL | 2 |
| Maestri, XE | 1 |
| Newman, J | 1 |
| Garcia, E | 1 |
| Krishnamurthy, KB | 1 |
| Hoch, DB | 1 |
| Replansky, S | 1 |
| Fowler, KM | 1 |
| Smithson, SD | 1 |
| Bromfield, EB | 2 |
| Ackers, R | 1 |
| Besag, FM | 11 |
| Wade, A | 1 |
| Murray, ML | 2 |
| Wong, IC | 8 |
| Sadzot, B | 1 |
| Moonen, G | 1 |
| López-Fraile, IP | 1 |
| Cid, AO | 1 |
| Juste, AO | 1 |
| Modrego, PJ | 1 |
| Taillia, H | 1 |
| Alla, P | 1 |
| Fournier, B | 1 |
| Bounolleau, P | 1 |
| Ouologem, M | 1 |
| Ricard, D | 1 |
| Sallansonnet-Froment, M | 1 |
| de Greslan, T | 1 |
| Renard, JL | 1 |
| Browning, N | 3 |
| Combs-Cantrell, DT | 3 |
| Cohen, M | 2 |
| Saetre, E | 3 |
| Abdelnoor, M | 2 |
| Amlie, JP | 2 |
| Tossebro, M | 1 |
| Anfinsen, OG | 1 |
| Kalinin, VV | 1 |
| Yip, FP | 1 |
| Hui, AC | 1 |
| Ng, PW | 1 |
| Hui, KF | 1 |
| Chan, IH | 1 |
| Chan, MH | 1 |
| Lam, CW | 1 |
| Pellock, JM | 11 |
| Thibert, RL | 1 |
| Conant, KD | 1 |
| Braun, EK | 1 |
| Bruno, P | 1 |
| Said, RR | 1 |
| Nespeca, MP | 1 |
| Thiele, EA | 1 |
| Boylan, LS | 1 |
| Cardenas, JF | 1 |
| Rho, JM | 2 |
| Ng, YT | 1 |
| Adams, BE | 1 |
| Myers, D | 1 |
| Ng, C | 1 |
| Powell, K | 1 |
| Phillips, AM | 1 |
| Zheng, T | 1 |
| Williams, DA | 1 |
| Li, BM | 1 |
| Zhang, DQ | 1 |
| Stöllberger, C | 1 |
| Höftberger, R | 1 |
| Finsterer, J | 1 |
| Darra, F | 1 |
| La Selva, L | 1 |
| Fiorini, E | 1 |
| Piazzini, A | 1 |
| Lazzarotto, F | 1 |
| Zucca, C | 1 |
| Dalla Bernardina, B | 1 |
| Motamedi, M | 1 |
| Karvigh, SA | 1 |
| Sahraian, MA | 1 |
| Azimi, AR | 1 |
| Navardi, S | 1 |
| Mukhin, KIu | 1 |
| Mironov, MB | 1 |
| Pylaeva, OA | 1 |
| Petrukhin, AS | 1 |
| Frey, LC | 1 |
| Strom, LA | 1 |
| Shrestha, A | 1 |
| Spitz, MC | 1 |
| Faught, E | 1 |
| Griesmacher, A | 1 |
| Tatarczyk, T | 1 |
| Strasak, A | 1 |
| Zimmerhackl, LB | 1 |
| Falkensammer, G | 1 |
| Högler, W | 1 |
| Svalheim, S | 5 |
| Lossius, A | 1 |
| Sandvand, F | 1 |
| Bertelsen, M | 1 |
| Mørkrid, L | 2 |
| Coskun, M | 1 |
| Bozkurt, H | 1 |
| Zoroglu, S | 1 |
| Belcastro, V | 1 |
| Gorgone, G | 1 |
| Ciampa, C | 1 |
| Caccamo, D | 1 |
| Pisani, LR | 1 |
| Oteri, G | 2 |
| Marciani, MG | 2 |
| Aguglia, U | 1 |
| Striano, S | 1 |
| Ientile, R | 1 |
| Pisani, F | 5 |
| Hsia, Y | 1 |
| Neubert, A | 1 |
| Sturkenboom, MC | 1 |
| Verhamme, KM | 1 |
| Sen, F | 1 |
| Giaquinto, C | 1 |
| Ceci, A | 1 |
| Berwaerts, K | 1 |
| Sienaert, P | 1 |
| De Fruyt, J | 1 |
| Nordmo, E | 1 |
| Aronsen, L | 1 |
| Wasland, K | 1 |
| Småbrekke, L | 1 |
| Vorren, S | 1 |
| Edelbroek, PM | 1 |
| Bulk, S | 1 |
| McVearry, KM | 1 |
| Gaillard, WD | 1 |
| VanMeter, J | 1 |
| Verdian, L | 1 |
| Yi, Y | 1 |
| El-Enany, NM | 1 |
| El-Sherbiny, DT | 1 |
| Abdelal, AA | 1 |
| Belal, FF | 1 |
| Milovanovic, JR | 1 |
| Jankovic, SM | 1 |
| Mohamed, S | 1 |
| Albani, F | 5 |
| Baruzzi, A | 5 |
| Krikova, EV | 1 |
| Val'dman, EA | 1 |
| Avakian, GN | 1 |
| Andreev, IaA | 1 |
| Denisov, EV | 1 |
| Rider, FK | 1 |
| Biktimerov, RR | 1 |
| Chukanova, AS | 1 |
| Burd, SG | 1 |
| Almeida, L | 1 |
| Nunes, T | 1 |
| Sicard, E | 1 |
| Rocha, JF | 1 |
| Falcão, A | 1 |
| Brunet, JS | 1 |
| Lefebvre, M | 1 |
| Soares-da-Silva, P | 1 |
| Miskov, S | 1 |
| Gjergja-Juraski, R | 1 |
| Cvitanović-Sojat, L | 1 |
| Bakulić, TI | 1 |
| Fucić, A | 1 |
| Bosnjak-Pasić, M | 1 |
| Mikula, I | 1 |
| Demarin, V | 1 |
| Azar, NJ | 1 |
| Lagrange, AH | 1 |
| Zeng, K | 1 |
| Yan, Y | 1 |
| Mazurkiewicz-Bełdzińska, M | 1 |
| Szmuda, M | 1 |
| Matheisel, A | 1 |
| Pournaras, DJ | 1 |
| Footitt, D | 1 |
| Mahon, D | 1 |
| Welbourn, R | 1 |
| Cumbo, E | 1 |
| Ligori, LD | 1 |
| Cavanna, AE | 1 |
| Ali, F | 1 |
| Rickards, HE | 1 |
| Frey, O | 1 |
| Arif, H | 2 |
| Buchsbaum, R | 4 |
| Pierro, J | 1 |
| Whalen, M | 1 |
| Sims, J | 1 |
| Resor, SR | 4 |
| Bazil, CW | 3 |
| Hirsch, LJ | 6 |
| Lee, W | 1 |
| Kim, JH | 1 |
| Kim, HS | 1 |
| Kwon, OH | 1 |
| Arzy, S | 1 |
| Allali, G | 1 |
| Brunet, D | 1 |
| Michel, CM | 1 |
| Kaplan, PW | 1 |
| Seeck, M | 1 |
| Segal, I | 1 |
| Shmueli, D | 1 |
| Saada, A | 1 |
| Jain, R | 1 |
| Mishra, D | 1 |
| Juneja, M | 1 |
| Syed, TU | 1 |
| Sajatovic, M | 2 |
| Deligiannidis, KM | 1 |
| Krasniqi, S | 1 |
| Neziri, B | 1 |
| Islami, H | 1 |
| Viteri, C | 2 |
| Cobaleda, S | 1 |
| Lahuerta, J | 1 |
| Barriga, J | 1 |
| Morales, MD | 1 |
| Lukic, S | 1 |
| Yuen, AW | 8 |
| Bell, GS | 1 |
| Peacock, JL | 1 |
| Koepp, MM | 1 |
| Graham, JE | 1 |
| Hitchcock, AA | 1 |
| Yun, M | 1 |
| Choi, YM | 1 |
| Eun, SH | 1 |
| Seol, IJ | 1 |
| Kim, SJ | 1 |
| Dahlin, MG | 1 |
| Girolineto, BM | 1 |
| Feletti, F | 1 |
| An, DM | 1 |
| Wu, XT | 1 |
| Hu, FY | 1 |
| Yan, B | 1 |
| Stefan, H | 3 |
| Madadi, P | 1 |
| Siniscalchi, A | 1 |
| Gallelli, L | 1 |
| Calabrò, G | 1 |
| Tolotta, GA | 1 |
| Mallayasamy, SR | 1 |
| Arumugamn, K | 1 |
| Jain, T | 1 |
| Rajakannan, T | 2 |
| Bhat, K | 1 |
| Gurumadhavrao, P | 1 |
| Devarakonda, R | 1 |
| Martin, AC | 1 |
| Berry, DJ | 5 |
| Besag, FP | 1 |
| Iniesta, I | 1 |
| Machado, RA | 1 |
| Espinosa, AG | 1 |
| Melendrez, D | 1 |
| González, YR | 1 |
| García, VF | 1 |
| Rodríguez, YQ | 1 |
| Østby, L | 1 |
| Stuen, I | 1 |
| Sundby, E | 1 |
| Garcia-Arieta, A | 1 |
| Blazquez-Perez, A | 1 |
| Bråthen, G | 1 |
| Mills, JK | 1 |
| Lewis, TG | 1 |
| Mughal, K | 1 |
| Ali, I | 2 |
| Ugur, A | 1 |
| Whitehouse, WP | 1 |
| Cummings, C | 1 |
| Stewart, M | 1 |
| Stevenson, M | 1 |
| Nelson, J | 1 |
| Mathieu, O | 1 |
| Picot, MC | 1 |
| Gelisse, P | 3 |
| Breton, H | 1 |
| Demoly, P | 1 |
| Hillaire-Buys, D | 1 |
| Graovac, M | 1 |
| Ružić, K | 1 |
| Rebić, J | 1 |
| Dadić-Hero, E | 1 |
| Kaštelan, A | 1 |
| Frančišković, T | 1 |
| Thompson, CH | 1 |
| Kahlig, KM | 1 |
| George, AL | 1 |
| Forcelli, PA | 1 |
| Gale, K | 1 |
| Kondratyev, A | 1 |
| López, M | 1 |
| Monroy, N | 1 |
| Alonso, ME | 1 |
| Machín, E | 1 |
| Gulcebi, MI | 1 |
| Ozkaynakcı, A | 1 |
| Goren, MZ | 1 |
| Aker, RG | 1 |
| Onat, FY | 1 |
| Yoshino, A | 1 |
| Bittner, S | 1 |
| Höhn, K | 1 |
| Göbel, K | 1 |
| Kleinschnitz, C | 1 |
| Wiendl, H | 1 |
| Meuth, SG | 1 |
| Holmes, LB | 2 |
| Mittendorf, R | 1 |
| Shen, A | 1 |
| Smith, CR | 2 |
| Erickson, SC | 1 |
| Le, L | 1 |
| Ramsey, SD | 1 |
| Solow, BK | 1 |
| Zakharyan, A | 1 |
| Stockl, KM | 1 |
| Harada, AS | 1 |
| Curtis, B | 1 |
| McMahon, DJ | 2 |
| Shane, E | 2 |
| Bachmann, T | 1 |
| Bertheussen, KH | 1 |
| Machado, VH | 1 |
| Palmini, A | 2 |
| Bastos, FA | 1 |
| Rotert, R | 1 |
| Sitges, M | 1 |
| Sanchez-Tafolla, BM | 1 |
| Chiu, LM | 1 |
| Aldana, BI | 1 |
| Guarneros, A | 1 |
| Hill, M | 1 |
| Vrbíková, J | 1 |
| Zárubová, J | 1 |
| Kancheva, R | 1 |
| Velíková, M | 1 |
| Kancheva, L | 1 |
| Kubátová, J | 1 |
| Dušková, M | 1 |
| Marusič, P | 1 |
| Pařízek, A | 1 |
| Stárka, L | 1 |
| Albertson, AJ | 1 |
| Hablitz, JJ | 1 |
| Ravindran, V | 1 |
| Skalli, S | 1 |
| Soulaymani Bencheikh, R | 1 |
| Akamatsu, N | 1 |
| Kotov, AS | 1 |
| Rudakova, IG | 1 |
| Tan, GM | 1 |
| Dupuis, M | 1 |
| van Rijckevorsel, K | 1 |
| Evrard, F | 1 |
| Dubuisson, N | 1 |
| Dupuis, F | 1 |
| Van Robays, P | 1 |
| Kicka, M | 1 |
| Kłopotowski, T | 1 |
| Picheta, S | 1 |
| Bazylewicz, A | 1 |
| Miśkiewicz, Ł | 1 |
| Patel, V | 1 |
| Cordato, DJ | 1 |
| Dias, M | 1 |
| Larsen, JP | 1 |
| Turan, AB | 1 |
| Seferoglu, M | 1 |
| Taskapilioglu, O | 1 |
| Poolos, NP | 1 |
| Warner, LN | 1 |
| Humphreys, SZ | 1 |
| Williams, S | 1 |
| Kobayashi, K | 1 |
| Endoh, F | 1 |
| Yoshinaga, H | 1 |
| Sugiura, C | 1 |
| Matsumura, W | 1 |
| Togawa, M | 1 |
| Maegaki, Y | 1 |
| Ohno, K | 1 |
| Yamashita, Y | 1 |
| Ohya, T | 1 |
| Nagamitsu, S | 1 |
| Kusukawa, J | 1 |
| Hirose, S | 1 |
| Matsuishi, T | 1 |
| Wootton, CI | 1 |
| Patel, AN | 1 |
| Williams, HC | 1 |
| Nakasato, N | 1 |
| Iwasaki, M | 1 |
| Tominaga, T | 1 |
| Chow, JC | 1 |
| Fang, CW | 1 |
| Wu, YJ | 1 |
| Tsai, JJ | 1 |
| Simms, KM | 1 |
| Kortepeter, C | 1 |
| Avigan, M | 1 |
| Calka, O | 1 |
| Karadag, AS | 1 |
| Bilgili, SG | 1 |
| Bulut, G | 1 |
| Altun, F | 1 |
| Burakgazi, AZ | 1 |
| Matsuda, K | 1 |
| Boersma, C | 1 |
| Postma, MJ | 1 |
| Dodel, R | 1 |
| Balzer-Geldsetzer, M | 1 |
| Reese, JP | 1 |
| Schöffski, O | 1 |
| Graf, W | 1 |
| Schwab, S | 1 |
| Oertel, WH | 2 |
| Brzaković, BB | 1 |
| Vezmar Kovačević, SD | 1 |
| Vučićević, KM | 1 |
| Miljković, BR | 1 |
| Martinović, ZJ | 1 |
| Pokrajac, MV | 1 |
| Prostran, MŠ | 1 |
| Moore, JL | 1 |
| Aggarwal, P | 1 |
| Schade-Brittinger, C | 1 |
| Burchardi, N | 1 |
| Klein, KM | 1 |
| Weber, Y | 1 |
| Evers, S | 1 |
| Hallmeyer-Elgner, S | 1 |
| Winkler, G | 1 |
| Springub, J | 1 |
| Niedhammer, M | 1 |
| Roth, E | 1 |
| Eisensehr, I | 1 |
| Berrouschot, J | 1 |
| Arnold, S | 1 |
| Schröder, M | 1 |
| Beige, A | 1 |
| Haag, A | 1 |
| Reif, PS | 1 |
| Migliore, M | 1 |
| Migliore, R | 1 |
| Mallaysamy, S | 1 |
| Johnson, MG | 1 |
| Rao, PG | 1 |
| Bathala, L | 1 |
| Arumugam, K | 1 |
| van Hasselt, JG | 1 |
| Ramakrishna, D | 1 |
| Moseley, BD | 1 |
| Shin, C | 1 |
| Sofi, FA | 1 |
| Koul, PA | 1 |
| Mufti, SA | 1 |
| Dhobi, GN | 1 |
| Moreira, B | 1 |
| Hartung, DM | 1 |
| Svoboda, L | 1 |
| McGregor, JC | 1 |
| Daud, NA | 1 |
| Ab-Rahman, A | 1 |
| Tysse, I | 1 |
| Valsø, B | 1 |
| Larsson, PG | 2 |
| Rytter, E | 1 |
| Vega, J | 1 |
| Mauri, G | 1 |
| Pascual, J | 1 |
| Kang, HC | 1 |
| Hu, Q | 1 |
| Liu, XY | 1 |
| Xu, F | 1 |
| Liu, ZG | 1 |
| Zeng, Z | 1 |
| Zhu, SQ | 1 |
| Bayhan, T | 1 |
| Sahin, M | 1 |
| Yıldırım, I | 1 |
| Karagöz, T | 1 |
| Hajnšek, S | 1 |
| Kuzman, MR | 1 |
| Sporiš, D | 1 |
| Lalić, Z | 1 |
| Božina, T | 1 |
| Granić, P | 1 |
| Bester, N | 1 |
| Hammer, A | 4 |
| Irizarry, M | 1 |
| Ishihara, L | 1 |
| Krishen, A | 1 |
| Spaulding, T | 1 |
| Wamil, A | 1 |
| Leadbetter, R | 1 |
| Dodd, S | 1 |
| Horgan, D | 1 |
| He, DK | 1 |
| Lu, W | 2 |
| Li, L | 1 |
| Zhang, JM | 1 |
| Bao, WQ | 1 |
| Song, XQ | 1 |
| Liu, HT | 1 |
| Li, XW | 1 |
| Liu, YF | 1 |
| Gao, F | 1 |
| Wei, D | 1 |
| Meng, XD | 1 |
| Vlasov, PN | 1 |
| Dranko, DV | 1 |
| Agranovich, OV | 1 |
| Heyman, E | 1 |
| Lavie, R | 1 |
| Lahat, E | 2 |
| Braunstein, R | 1 |
| Bar-Haim, A | 1 |
| Berkovitch, M | 1 |
| Mushtaq, U | 1 |
| Mochol, M | 1 |
| Frøland, SS | 1 |
| Terada, K | 1 |
| Wang, W | 1 |
| Adachi, M | 1 |
| Kawasaki, Y | 1 |
| Maschio, M | 1 |
| Dinapoli, L | 1 |
| Sperati, F | 1 |
| Pace, A | 1 |
| Fabi, A | 1 |
| Vidiri, A | 1 |
| Pompili, A | 1 |
| Carapella, CM | 1 |
| Steinhoff, BJ | 2 |
| Maren Staack, A | 1 |
| Wisniewski, I | 1 |
| Helmstaedter, C | 2 |
| Witt, JA | 1 |
| Potschka, H | 2 |
| Fedrowitz, M | 2 |
| Tran, TA | 1 |
| Blesi, K | 1 |
| Sathanandan, ST | 1 |
| Remmel, R | 1 |
| Spadoni, F | 3 |
| Hainsworth, AH | 2 |
| Mercuri, NB | 1 |
| Caputi, L | 1 |
| Martella, G | 2 |
| Lavaroni, F | 1 |
| Bernardi, G | 4 |
| Stefani, A | 3 |
| Kaiser, S | 1 |
| Selai, CE | 4 |
| Trimble, MR | 5 |
| Pool, F | 4 |
| Natarajan, J | 1 |
| Doose, D | 1 |
| Chadwick, DW | 8 |
| Anhut, H | 1 |
| Otte, A | 1 |
| Messmer, SL | 1 |
| Maton, S | 1 |
| Sauermann, W | 1 |
| Murray, G | 1 |
| Garofalo, EA | 1 |
| Smyth, MD | 1 |
| Barbaro, NM | 1 |
| Baraban, SC | 1 |
| Mataringa, MI | 1 |
| Rambeck, B | 2 |
| Tennis, P | 3 |
| Eldridge, RR | 1 |
| Rufo-Campos, M | 1 |
| Borowicz, KK | 1 |
| Sirven, JI | 1 |
| Ozkinay, F | 1 |
| Cogulu, O | 1 |
| Gunduz, C | 1 |
| Yilmaz, D | 1 |
| Kultursay, N | 1 |
| Giordano, S | 1 |
| Bergin, AM | 1 |
| Connolly, M | 1 |
| Perunova, NIu | 1 |
| Sorokina, EV | 1 |
| Shershever, AS | 1 |
| van Hout, BA | 1 |
| Gagnon, DD | 1 |
| McNulty, P | 1 |
| O'Hagan, A | 1 |
| Koch, HJ | 1 |
| Szecsey, A | 1 |
| Vogel, M | 1 |
| Maksutova, EL | 1 |
| Zheleznova, EV | 1 |
| Sokolova, LV | 1 |
| Lardizabal, DV | 1 |
| Morris, HH | 3 |
| Hovinga, CA | 1 |
| Del Mar Carreño, M | 1 |
| Biton, V | 5 |
| Levisohn, P | 1 |
| Hoyler, S | 1 |
| Rainesalo, S | 1 |
| Saransaari, P | 1 |
| Clennett, S | 1 |
| Hosking, G | 2 |
| Pal, SN | 1 |
| Lathers, CM | 1 |
| Schraeder, PL | 1 |
| Claycamp, HG | 1 |
| Yerby, MS | 1 |
| Beerhorst, K | 1 |
| Renier, WO | 6 |
| Doose, DR | 1 |
| Wilson, EA | 3 |
| Chadwick, D | 5 |
| Oxbury, J | 1 |
| Schwabe, S | 1 |
| Bialer, M | 1 |
| Taylor, AE | 1 |
| Dam, M | 5 |
| Ayala, R | 1 |
| Gomez, G | 2 |
| O'Neill, F | 2 |
| Messenheimer, J | 4 |
| Green, B | 1 |
| Freitas, A | 1 |
| Fiore, LA | 1 |
| Btaiche, IF | 1 |
| Woster, PS | 1 |
| Luszczki, JJ | 2 |
| Czuczwar, M | 1 |
| Kis, J | 1 |
| Krysa, J | 1 |
| Pasztelan, I | 1 |
| Swiader, M | 1 |
| McKee, JR | 3 |
| Sunder, TR | 4 |
| FineSmith, R | 1 |
| Varner, JA | 1 |
| Barrett, PS | 3 |
| Akman, CI | 1 |
| Holmes, GL | 1 |
| Betts, T | 4 |
| Yarrow, H | 1 |
| Dutton, N | 1 |
| Rolfe, T | 1 |
| Sorokova, EV | 1 |
| Agafonova, MK | 1 |
| A-Rogvi-Hansen, B | 1 |
| Boas, J | 1 |
| Sidenius, P | 2 |
| Laue Friis, M | 1 |
| Alving, J | 3 |
| Ankerhus, J | 1 |
| Mouritzen Dam, A | 1 |
| Grim, SA | 1 |
| Miles, MV | 1 |
| Tang, PH | 1 |
| Strawsburg, RH | 1 |
| deGrauw, TJ | 1 |
| Baumann, RJ | 2 |
| Kaminow, L | 1 |
| Schimschock, JR | 1 |
| Nicolson, A | 1 |
| Appleton, RE | 4 |
| Smith, DF | 3 |
| Newport, DJ | 2 |
| Stowe, ZN | 2 |
| Helmers, SL | 1 |
| Montgomery, JQ | 1 |
| Henry, TR | 1 |
| Liporace, J | 1 |
| Kao, A | 1 |
| D'Abreu, A | 1 |
| Cramer, J | 1 |
| Knoefel, J | 1 |
| Charbonneau, A | 1 |
| Mandell, A | 1 |
| Kazis, L | 1 |
| Berlowitz, D | 1 |
| Wu, SP | 1 |
| Shyu, MK | 1 |
| Liou, HH | 2 |
| Gau, CS | 1 |
| Lin, CJ | 1 |
| Knoester, PD | 5 |
| Belitser, SV | 2 |
| Deckers, CL | 4 |
| Keyser, A | 4 |
| Egberts, AC | 4 |
| Jonker, DM | 1 |
| Voskuyl, RA | 1 |
| Danhof, M | 1 |
| Kanner, AM | 2 |
| Bautista, J | 1 |
| Browne, T | 1 |
| Theodore, WH | 1 |
| Bazil, C | 1 |
| Stern, J | 1 |
| Schachter, SC | 1 |
| Bergen, D | 1 |
| Hirtz, D | 1 |
| Montouris, GD | 1 |
| Nespeca, M | 1 |
| Gidal, B | 1 |
| Marks, WJ | 1 |
| Turk, WR | 1 |
| Fischer, JH | 1 |
| Bourgeois, B | 1 |
| Wilner, A | 1 |
| Faught, RE | 1 |
| Sachdeo, RC | 1 |
| Beydoun, A | 1 |
| Glauser, TA | 3 |
| Nissinen, J | 1 |
| Large, CH | 1 |
| Stratton, SC | 2 |
| Pitkänen, A | 1 |
| Pisani, A | 1 |
| Bonsi, P | 1 |
| De Persis, C | 1 |
| Mikkonen, K | 1 |
| Tapanainen, P | 1 |
| Pakarinen, AJ | 2 |
| Päivänsalo, M | 1 |
| Isojärvi, JI | 3 |
| Vainionpää, LK | 1 |
| Conry, JA | 1 |
| de Haan, GJ | 1 |
| Edelbroek, P | 1 |
| Segers, J | 1 |
| Dévilé-Notschaele, M | 1 |
| Augustijn, P | 1 |
| Vazquez, B | 2 |
| Cramer, JA | 2 |
| Kustra, RP | 7 |
| Kockelmann, E | 1 |
| Weintraub, D | 2 |
| Spencer, HT | 2 |
| Hager, M | 2 |
| Straka, T | 2 |
| Adams, DJ | 1 |
| Morgan, CL | 1 |
| Buchan, S | 1 |
| Kerr, MP | 2 |
| Solinas, C | 2 |
| Cook, M | 1 |
| Cunnington, MC | 1 |
| Karlov, VA | 1 |
| Morozov, GV | 1 |
| Semenova, NV | 1 |
| Slastenko, OA | 1 |
| Mishchenko, AL | 1 |
| Pressler, RM | 1 |
| Robinson, RO | 1 |
| Wilson, GA | 1 |
| Binnie, CD | 2 |
| Sale, ME | 1 |
| Natarajan, S | 1 |
| Blum, D | 3 |
| Pucci, V | 1 |
| Bugamelli, F | 1 |
| Baccini, C | 1 |
| Raggi, MA | 1 |
| Franceschi, L | 1 |
| Furlanut, M | 1 |
| Gaily, E | 2 |
| Levy, RH | 1 |
| Ragueneau-Majlessi, I | 1 |
| Shah, J | 1 |
| Pan, WJ | 1 |
| Martens-Lobenhoffer, J | 1 |
| Bode-Böger, SM | 1 |
| Schlingmann, J | 1 |
| Patrizi, A | 1 |
| Savoia, F | 1 |
| Negosanti, F | 1 |
| Posar, A | 1 |
| Santucci, M | 1 |
| Neri, I | 1 |
| Jeandel, PY | 1 |
| Traissac, T | 1 |
| Rainfray, M | 1 |
| Bourdel-Marchasson, I | 1 |
| Evans, BK | 2 |
| Leschek-Gelman, LM | 1 |
| Groenke, DA | 1 |
| Nanry, KP | 1 |
| Mauri Llerda, JA | 1 |
| Tejero, C | 1 |
| Mercadé, JM | 1 |
| Padró, LL | 1 |
| Salas Puig, J | 1 |
| Tamura, T | 1 |
| Rowan, AJ | 1 |
| Collins, JF | 1 |
| Pryor, F | 1 |
| Boardman, KD | 1 |
| Uthman, BM | 1 |
| Spitz, M | 1 |
| Frederick, T | 1 |
| Towne, A | 1 |
| Carter, GS | 1 |
| Marks, W | 1 |
| Felicetta, J | 1 |
| Tomyanovich, ML | 1 |
| Selai, C | 1 |
| Bannister, D | 1 |
| Trimble, M | 1 |
| Price, MJ | 1 |
| Remak, E | 1 |
| Vahle, VJ | 1 |
| Ray, PG | 2 |
| Werz, MA | 2 |
| Fessler, AJ | 1 |
| Ogrocki, P | 2 |
| Schoenberg, MR | 2 |
| Voermans, NC | 1 |
| Zwarts, MJ | 1 |
| Bloem, BR | 1 |
| Berry, D | 2 |
| Millington, C | 1 |
| Hansen-Schwartz, J | 1 |
| Chappell, B | 1 |
| Crawford, P | 2 |
| Steinborn, B | 2 |
| Crespel, A | 2 |
| Genton, P | 1 |
| Berramdane, M | 1 |
| Coubes, P | 1 |
| Monicard, C | 1 |
| Baldy-Moulinier, M | 3 |
| Clemens, B | 2 |
| Balboni, M | 1 |
| Callegati, E | 1 |
| Drislane, FW | 1 |
| Schomer, DL | 1 |
| Frye, CA | 1 |
| Kostov, H | 1 |
| Willmore, LJ | 2 |
| Boendermaker, AJ | 1 |
| Severens, JL | 1 |
| Dorofeeva, MIu | 1 |
| Belousova, ED | 1 |
| Ab Rahman, AF | 1 |
| Ibrahim, MI | 1 |
| Ismail, HI | 1 |
| Seng, TB | 1 |
| Coppola, G | 2 |
| Epifanio, G | 1 |
| Auricchio, G | 1 |
| Federico, RR | 1 |
| Resicato, G | 1 |
| Pascotto, A | 2 |
| Kaul-Gupta, R | 1 |
| Moret-Hartman, M | 1 |
| van der Wilt, GJ | 1 |
| Gil-Nagel, A | 1 |
| López-Muñoz, F | 1 |
| Serratosa, JM | 1 |
| Moncada, I | 1 |
| García-García, P | 1 |
| Alamo, C | 1 |
| Gamble, CL | 1 |
| Weintraub, DB | 1 |
| Karande, S | 1 |
| Gogtay, NJ | 1 |
| Kanchan, S | 1 |
| Kshirsagar, NA | 1 |
| Fife, TD | 1 |
| Fisher, RS | 1 |
| Kryscio, RJ | 1 |
| Vuongc, A | 1 |
| Brodbeck, V | 1 |
| Jansen, V | 1 |
| Fietzek, U | 1 |
| Muehe, C | 1 |
| Weber, G | 1 |
| Heinen, F | 1 |
| Paraskevas, GP | 1 |
| Triantafyllou, NI | 1 |
| Kapaki, E | 1 |
| Limpitaki, G | 1 |
| Petropoulou, O | 1 |
| Vassilopoulos, D | 1 |
| Ménes, A | 1 |
| Piros, P | 1 |
| Bessenyei, M | 1 |
| Altmann, A | 1 |
| Jerney, J | 1 |
| Kollár, K | 1 |
| Rosdy, B | 1 |
| Rózsavölgyi, M | 1 |
| Steinecker, K | 1 |
| Hollódy, K | 1 |
| Aylett, SE | 1 |
| Cross, H | 2 |
| Bóné, B | 1 |
| Almeida, AM | 2 |
| Falcão, AC | 2 |
| Sales, F | 1 |
| Baldeiras, I | 1 |
| Rocha, MJ | 1 |
| Caramona, MM | 2 |
| Gilbert, DL | 1 |
| Buncher, CR | 1 |
| Meador, K | 1 |
| Fakhoury, T | 1 |
| Shneker, B | 1 |
| Chung, S | 1 |
| Mills, K | 1 |
| Dubnov-Raz, G | 1 |
| Shapiro, R | 1 |
| Merlob, P | 1 |
| Nikolov, BG | 1 |
| Koppel, BS | 1 |
| Christos, PJ | 1 |
| Fowler, K | 1 |
| Labar, DR | 1 |
| Hauser, WA | 1 |
| Ambrosetto, G | 1 |
| Avoni, P | 3 |
| Bisulli, F | 1 |
| Tinuper, P | 1 |
| Feuerstein, TJ | 1 |
| Malone, SA | 1 |
| Addison, RS | 1 |
| Wright, AW | 1 |
| Dickinson, RG | 1 |
| Ettinger, AB | 2 |
| Kemp, S | 1 |
| Feely, M | 1 |
| Hay, A | 1 |
| Wild, H | 1 |
| Malik, S | 1 |
| Barry, JJ | 1 |
| Mitchell Miller, J | 1 |
| Bigham, S | 1 |
| McGuigan, C | 1 |
| MacDonald, BK | 1 |
| Allain, H | 1 |
| Schück, S | 1 |
| Nachit-Ouinekh, F | 1 |
| Plouin, P | 1 |
| Brunon, AM | 1 |
| Boulliat, J | 1 |
| Mercier, F | 1 |
| Slama, A | 1 |
| El Hasnaoui, A | 1 |
| Lee, JW | 1 |
| Choi, KG | 1 |
| Chung, HW | 1 |
| Matsuura, M | 1 |
| Ramsay, E | 1 |
| Nanry, K | 1 |
| Thompson, T | 1 |
| Herold, TJ | 1 |
| Prpic, I | 1 |
| Boban, M | 1 |
| Vlasic-Cicvaric, I | 1 |
| Korotaj, Z | 1 |
| Andermann, F | 3 |
| Duh, MS | 4 |
| Gosselin, A | 1 |
| Paradis, PE | 4 |
| Atterman, J | 1 |
| Cunnington, M | 1 |
| Ferber, S | 1 |
| Quartey, G | 1 |
| Kocak, S | 1 |
| Girisgin, SA | 1 |
| Gul, M | 1 |
| Cander, B | 1 |
| Kaya, H | 1 |
| Kaya, E | 1 |
| Paul, F | 1 |
| Veauthier, C | 1 |
| Fritz, G | 1 |
| Lehmann, TN | 1 |
| Aktas, O | 1 |
| Zipp, F | 1 |
| Meencke, HJ | 1 |
| Marson, T | 2 |
| Makus, KG | 1 |
| McCormick, J | 1 |
| Lydersen, S | 1 |
| Fueratsch, N | 1 |
| Boehme, V | 1 |
| Kramme, C | 1 |
| Pieridou, M | 1 |
| Villagran, A | 1 |
| Woermann, F | 1 |
| Pohlmann-Eden, B | 1 |
| Man, CB | 1 |
| Baum, L | 1 |
| Yu, E | 1 |
| Lau, KM | 1 |
| Cheng, AS | 1 |
| Ng, MH | 1 |
| Hussain, N | 1 |
| Gosalakkal, JA | 1 |
| Buck, TC | 1 |
| Schmedes, A | 1 |
| Brandslund, I | 1 |
| Stephen, LJ | 4 |
| Butler, E | 1 |
| Parker, P | 1 |
| Hitiris, N | 1 |
| Leach, VM | 1 |
| Kim, JY | 1 |
| Otoul, C | 1 |
| De Smedt, H | 1 |
| Stockis, A | 1 |
| Panayiotopoulos, CP | 3 |
| Ferrie, C | 1 |
| Lascelles, K | 1 |
| Livingston, J | 1 |
| Mewasingh, L | 1 |
| Shawcross, D | 1 |
| Knighton, S | 1 |
| Bernal, W | 1 |
| Sizer, E | 1 |
| Auzinger, G | 1 |
| Daana, M | 1 |
| Nevo, Y | 1 |
| Tenenbaum, A | 1 |
| Taustein, I | 1 |
| Weiner, J | 2 |
| Manjunath, R | 3 |
| Crémieux, PY | 1 |
| Tompson, DJ | 1 |
| Oliver-Willwong, R | 1 |
| Job, S | 1 |
| Zhu, L | 1 |
| Lemme, F | 1 |
| Shor, S | 1 |
| Koren, G | 1 |
| Gümüş, H | 1 |
| Kumandaş, S | 1 |
| Per, H | 1 |
| Karakükçü, M | 1 |
| Doughty, J | 1 |
| Eaton, B | 1 |
| Gamble, C | 1 |
| Jacoby, A | 1 |
| Shackley, P | 1 |
| Vanoli, A | 1 |
| Sheth, RD | 1 |
| Hermann, BP | 1 |
| Prabhu, LV | 1 |
| Nasar, MA | 1 |
| Rai, R | 1 |
| Madhyastha, S | 1 |
| Singh, G | 1 |
| VanLandingham, KE | 1 |
| Dixon, RM | 1 |
| Bauer, J | 1 |
| Buchmüller, L | 1 |
| Reuber, M | 1 |
| Burr, W | 1 |
| Rajna, P | 1 |
| Weisler, RH | 1 |
| Calabrese, JR | 1 |
| Bowden, CL | 1 |
| Ascher, JA | 1 |
| DeVeaugh-Geiss, J | 1 |
| Evoniuk, G | 1 |
| Ruiz Ginés, MA | 1 |
| García García, S | 1 |
| Ruiz Ginés, JA | 1 |
| Tze Kiong, E | 1 |
| Fernández Rodríguez, E | 1 |
| Macleod, S | 1 |
| Ritchie, JC | 1 |
| Koganti, A | 1 |
| Holley, DK | 1 |
| Newman, M | 1 |
| Vitols, S | 2 |
| Vos, AM | 1 |
| Leenen, L | 2 |
| Savelkoul, M | 1 |
| Mills, KC | 1 |
| Drazkowski, JF | 1 |
| Caldwell, PT | 1 |
| Blum, DE | 1 |
| Søndergaard Khinchi, M | 1 |
| Sabroe, TP | 1 |
| Lee, CY | 1 |
| Fu, WM | 1 |
| Chen, CC | 1 |
| Su, MJ | 1 |
| LeLorier, J | 2 |
| Latrémouille-Viau, D | 1 |
| Lefebvre, P | 2 |
| Sheehy, O | 2 |
| Delima, SI | 1 |
| Walsh, LE | 1 |
| Golomb, MR | 1 |
| Ferrie, CD | 1 |
| Grünewald, RA | 1 |
| Livingston, JH | 1 |
| Foreman, MM | 1 |
| Hanania, T | 1 |
| Stables, JP | 1 |
| Eller, M | 1 |
| Sadeh, M | 1 |
| Rapoport, A | 1 |
| Dabby, R | 1 |
| Lampl, Y | 1 |
| Randall, A | 1 |
| Baldwin, EJ | 1 |
| Habecker, E | 1 |
| Glassman, L | 1 |
| Wong, SL | 1 |
| Wyszynski, DF | 1 |
| Kim, W | 1 |
| Kim, JS | 1 |
| An, JY | 1 |
| Chung, SR | 1 |
| Lee, KS | 1 |
| Despland, PA | 2 |
| Macdonald, RL | 2 |
| Kelly, KM | 2 |
| Buchanan, N | 4 |
| Sheehan, K | 1 |
| Tilley, MI | 1 |
| Kilpatrick, C | 1 |
| O'Donoghue, MF | 1 |
| Kupecz, D | 1 |
| Goa, KL | 2 |
| Ross, SR | 1 |
| Chrisp, P | 1 |
| Leary, PM | 1 |
| Allie, S | 1 |
| Richens, A | 6 |
| Schmidt, D | 1 |
| Eeg-Olofsson, O | 1 |
| Reynolds, EH | 1 |
| Haedicke, C | 1 |
| Angrick, B | 1 |
| Hauswaldt, C | 1 |
| Pinto, F | 1 |
| Garnett, WR | 2 |
| Uvebrant, P | 1 |
| Bauzienè, R | 1 |
| O'Neill, BA | 1 |
| Bloom, DS | 1 |
| Tavernor, SJ | 1 |
| Newton, R | 1 |
| Brown, SW | 1 |
| de Romanis, F | 2 |
| Sopranzi, N | 2 |
| Herranz, JL | 2 |
| Arteaga, R | 1 |
| Armijo, JA | 1 |
| Luciano, D | 1 |
| Cocito, L | 1 |
| Maffini, M | 1 |
| Loeb, C | 1 |
| Mattson, RH | 2 |
| Vogt, H | 2 |
| Meldrum, BS | 5 |
| Wallace, SJ | 3 |
| Laxer, KD | 1 |
| Martin, PJ | 1 |
| Millac, PA | 1 |
| Foletti, G | 1 |
| Volanschi, D | 1 |
| Parks, BR | 1 |
| Dostrow, VG | 1 |
| Noble, SL | 1 |
| Smith, SE | 1 |
| al-Zubaidy, ZA | 1 |
| Chapman, AG | 1 |
| Byers, VL | 1 |
| Buti, D | 1 |
| Croci, D | 2 |
| Estienne, M | 2 |
| Fazio, A | 2 |
| Granata, T | 2 |
| Rota, M | 1 |
| Avanzini, G | 2 |
| Uldall, P | 2 |
| Hansen, FJ | 1 |
| Tonnby, B | 2 |
| Graves, NM | 1 |
| Skolnick, AA | 1 |
| Manack, L | 1 |
| Slater, JD | 1 |
| Shields, WD | 1 |
| Davis, G | 1 |
| Dewey, M | 1 |
| Heinzl, S | 1 |
| Dulac, O | 4 |
| Spencer, SC | 1 |
| Lee, EK | 1 |
| Fitton, A | 1 |
| Dooley, J | 1 |
| Camfield, P | 1 |
| Gordon, K | 1 |
| Camfield, C | 1 |
| Wirrell, Z | 1 |
| Smith, E | 1 |
| George, S | 1 |
| Wood, AJ | 1 |
| Braithwaite, RA | 1 |
| Kilpatrick, ES | 1 |
| Forrest, G | 1 |
| Karlsborg, M | 1 |
| Gram, L | 2 |
| Uldall, PV | 2 |
| Sommer, B | 1 |
| Mai, J | 1 |
| Iivanainen, M | 1 |
| Loiseau, P | 1 |
| Vauzelle-Kervroëdan, F | 1 |
| Rey, E | 1 |
| Cieuta, C | 1 |
| Pariente-Khayat, A | 1 |
| Pons, G | 1 |
| d'Athis, P | 1 |
| Bidault, R | 1 |
| Olive, G | 1 |
| Eriksson, AS | 1 |
| Hoppu, K | 1 |
| Nergårdh, A | 1 |
| Boreus, L | 1 |
| McDonnell, GV | 1 |
| Morrow, JI | 1 |
| Gillham, R | 2 |
| Thompson, P | 1 |
| Birbeck, K | 1 |
| McGuire, A | 1 |
| Tomlinson, L | 1 |
| Eckersley, L | 1 |
| Silveira, C | 1 |
| Brown, S | 3 |
| Bourgeois, BF | 3 |
| Matsuo, F | 2 |
| Gay, P | 1 |
| Madsen, J | 1 |
| Tolman, KG | 1 |
| Rollins, DE | 1 |
| Risner, ME | 2 |
| Lai, AA | 1 |
| Wadelius, M | 1 |
| Karlsson, T | 1 |
| Wadelius, C | 1 |
| Rane, A | 1 |
| Morton, LD | 2 |
| Jürgens, U | 1 |
| Jackson, D | 1 |
| Duthie, T | 1 |
| Kadir, ZA | 2 |
| Walker, MC | 1 |
| Li, LM | 1 |
| Kadir, Z | 1 |
| Schapel, G | 1 |
| Sullivan, JR | 1 |
| Watson, A | 1 |
| Reunanen, M | 1 |
| Grippo, J | 1 |
| Leestma, JE | 1 |
| Annegers, JF | 2 |
| Schraeder, P | 1 |
| Siscovick, D | 1 |
| Wannamaker, BB | 1 |
| Tennis, PS | 2 |
| Cierpial, MA | 1 |
| Earl, NL | 1 |
| Donaldson, JA | 1 |
| Olberding, LS | 1 |
| Mullens, EL | 3 |
| Shorvon, S | 1 |
| Dreifuss, FE | 1 |
| Bannister, SM | 1 |
| Korczyn, AD | 1 |
| Bhaumik, S | 1 |
| Branford, D | 1 |
| Duggirala, C | 1 |
| Ismail, IA | 1 |
| Hussein, Z | 1 |
| Posner, J | 1 |
| Chapman, DP | 1 |
| Giles, WH | 1 |
| Bartoli, A | 1 |
| Belmonte, A | 1 |
| Alessandrì, MG | 1 |
| Gatti, G | 1 |
| Davanzo, PA | 1 |
| King, BH | 1 |
| Wyler, AR | 1 |
| Yen, DJ | 1 |
| Yiu, CH | 1 |
| Kwan, SY | 1 |
| Lin, YY | 1 |
| Su, MS | 1 |
| Dalby, NO | 1 |
| Nielsen, EB | 1 |
| Barron, TF | 2 |
| Hunt, SL | 2 |
| Rutecki, P | 2 |
| Shaw, R | 3 |
| Maly, MM | 1 |
| Collins, DM | 1 |
| Pitterle, ME | 1 |
| Grunze, H | 1 |
| Walden, J | 1 |
| Motte, J | 1 |
| Trevathan, E | 3 |
| Arvidsson, JF | 1 |
| Barrera, MN | 1 |
| Manasco, P | 2 |
| Sallustio, BC | 2 |
| Morris, RG | 3 |
| Coulter, DA | 1 |
| Kaminska, A | 1 |
| Phillips, I | 1 |
| Martin, KF | 1 |
| Thompson, KS | 1 |
| Heal, DJ | 1 |
| Scheen, AJ | 1 |
| Pedley, TA | 1 |
| Schapel, GJ | 1 |
| Gordon, GS | 1 |
| Fearnside, M | 1 |
| Rättyä, J | 1 |
| Myllylä, VV | 1 |
| Knip, M | 1 |
| Koivunen, R | 1 |
| Tekay, A | 1 |
| Tapanainen, JS | 2 |
| Messori, A | 1 |
| Trippoli, S | 1 |
| Becagli, P | 1 |
| Cincotta, M | 1 |
| Labbate, MG | 1 |
| Stenbom, Y | 1 |
| Hagberg, B | 1 |
| Buoni, S | 1 |
| Grosso, S | 1 |
| Fois, A | 1 |
| Newbery, JE | 1 |
| Subel, B | 1 |
| Gibson, RJ | 1 |
| Hutton, JL | 1 |
| Mackay, FJ | 1 |
| Wilton, LV | 1 |
| Pearce, GL | 1 |
| Freemantle, SN | 1 |
| Mann, RD | 1 |
| Iannetti, P | 1 |
| Raucci, U | 1 |
| Zuccaro, P | 1 |
| Pacifici, R | 1 |
| De Sarro, GB | 1 |
| Berlinghieri, MC | 1 |
| Elia, M | 1 |
| Musumeci, SA | 1 |
| David, E | 1 |
| Dominijanni, A | 1 |
| Gulletta, E | 1 |
| Shakespeare, A | 1 |
| Simeon, G | 1 |
| Kaufman, KR | 1 |
| Gerner, R | 1 |
| Weisbrot, DM | 1 |
| Saracco, J | 1 |
| Dhoon, A | 1 |
| Bélanger, S | 1 |
| Coulombe, G | 1 |
| Carmant, L | 1 |
| Ferrier, IN | 1 |
| Markowitz, MA | 1 |
| Mauskopf, JA | 1 |
| Halpern, MT | 1 |
| Schlienger, RG | 2 |
| Knowles, SR | 1 |
| Shear, NH | 2 |
| Shapiro, LE | 1 |
| Kloster, R | 1 |
| Børresen, HC | 1 |
| Hoff-Olsen, P | 1 |
| Zachariae, CO | 1 |
| Fogh, K | 1 |
| Maj, R | 1 |
| Fariello, RG | 1 |
| Ukmar, G | 1 |
| Varasi, M | 1 |
| Pevarello, P | 1 |
| McArthur, RA | 1 |
| Salvati, P | 1 |
| Mahmood, I | 1 |
| Tammara, VK | 1 |
| Baweja, RK | 1 |
| Black, AB | 2 |
| Harris, AL | 1 |
| Batty, AB | 1 |
| Wilner, AN | 1 |
| Meyer, FP | 1 |
| Banditt, P | 1 |
| Schubert, A | 1 |
| Schöche, J | 1 |
| Manganotti, P | 1 |
| Bongiovanni, LG | 1 |
| Zanette, G | 1 |
| Turazzini, M | 1 |
| Fiaschi, A | 1 |
| Sadler, M | 1 |
| Smith, K | 1 |
| Grasela, TH | 1 |
| Fiedler-Kelly, J | 1 |
| Cox, E | 1 |
| Womble, GP | 1 |
| Chen, C | 2 |
| De León, OA | 1 |
| Furmaga, KM | 1 |
| Casale, EJ | 1 |
| Duncan, B | 1 |
| Culverhouse, EH | 1 |
| Gilman, J | 2 |
| Lee, JK | 1 |
| Ko, TS | 1 |
| Carvill, S | 1 |
| Clarke, D | 1 |
| Cassidy, G | 1 |
| Aberg, L | 1 |
| Kirveskari, E | 2 |
| Santavuori, P | 2 |
| Fisher, R | 1 |
| Ben-Menachem, E | 1 |
| French, J | 1 |
| Steiner, TJ | 1 |
| Dellaportas, CI | 1 |
| Findley, LJ | 1 |
| Gross, M | 1 |
| Gibberd, FB | 1 |
| Perkin, GD | 1 |
| Park, DM | 1 |
| Abbott, R | 1 |
| Guberman, AH | 2 |
| Dooley, JM | 1 |
| Duchowny, MS | 1 |
| Stern, RS | 1 |
| Gücüyener, K | 1 |
| Türktaş, I | 1 |
| Serdaroglu, A | 1 |
| Ezgü, FS | 1 |
| Heaney, DC | 1 |
| Elston, DM | 1 |
| Dunn, N | 1 |
| Wilton, L | 1 |
| Shakir, S | 1 |
| Overstall, PW | 1 |
| Giorgi, L | 2 |
| Fenwick, PB | 1 |
| Mawer, GE | 4 |
| Dimova, PS | 1 |
| Korinthenberg, R | 1 |
| Pricone, MG | 1 |
| King, CV | 1 |
| Drummer, OH | 1 |
| Opeskin, K | 1 |
| McIntyre, IM | 1 |
| Reiff-Eldridge, R | 1 |
| Heffner, CR | 1 |
| Ephross, SA | 1 |
| White, AD | 1 |
| Andrews, EB | 1 |
| Datta, PK | 1 |
| Crawford, PM | 1 |
| Fayad, M | 1 |
| Choueiri, R | 1 |
| Mikati, M | 1 |
| Meyer, MA | 1 |
| Marfia, GA | 1 |
| Centonze, D | 1 |
| Saulle, E | 1 |
| Leach, MJ | 1 |
| Giacomini, P | 1 |
| Placidi, F | 1 |
| Diomedi, M | 1 |
| Scalise, A | 1 |
| Romigi, A | 1 |
| Gigli, GL | 1 |
| Jović, NJ | 1 |
| Mirković, D | 1 |
| Majkić-Singh, N | 1 |
| Milovanović, DD | 1 |
| Gerber, PE | 1 |
| Hamiwka, L | 1 |
| Connolly, MB | 1 |
| Farrell, K | 1 |
| Léthel, V | 1 |
| Chabrol, B | 1 |
| Livet, MO | 1 |
| Mancini, J | 1 |
| Toczko, A | 1 |
| Mojs, E | 2 |
| Galas-Zgorzalewicz, B | 1 |
| Maciejek, Z | 1 |
| Niezgodzińska-Maciejek, A | 1 |
| Walker, JK | 1 |
| Lott, RS | 1 |
| Speth, J | 1 |
| Marty, KJ | 1 |
| Ng, GY | 1 |
| Kriel, RL | 1 |
| Burkhardt, RT | 1 |
| Sotero de Menezes, MA | 1 |
| Murphy, P | 1 |
| Cheyette, S | 1 |
| Nagarajan, L | 1 |
| Casas-Fernández, C | 1 |
| Frey, M | 1 |
| Kane, K | 1 |
| Bryant-Comstock, L | 1 |
| Anderson, GD | 2 |
| Rutecki, PR | 1 |
| Lanning, A | 1 |
| Hoban, TF | 1 |
| Price, ML | 1 |
| Tsiropoulos, I | 1 |
| Kristensen, O | 1 |
| Klitgaard, NA | 1 |
| Torra, M | 1 |
| Rodamilans, M | 1 |
| Arroyo, S | 1 |
| Corbella, J | 1 |
| Jozwiak, S | 1 |
| Terczynski, A | 1 |
| Sarzi-Puttini, P | 1 |
| Panni, B | 1 |
| Cazzola, M | 1 |
| Muzzupappa, S | 1 |
| Turiel, M | 1 |
| Aberg, LE | 1 |
| Bäckman, M | 1 |
| Pulik, M | 1 |
| Lionnet, F | 1 |
| Genet, P | 1 |
| Foletti, GB | 1 |
| Lhatoo, SD | 2 |
| Polizzi, G | 1 |
| Lam, E | 1 |
| Westley, IS | 1 |
| Singhi, PD | 1 |
| Yoon, Y | 1 |
| Jagoda, A | 1 |
| Fernández-Galán, M | 1 |
| Martín-Núñez, G | 1 |
| Castellanos, F | 1 |
| Miura, H | 1 |
| Mirza, W | 1 |
| Montouris, G | 1 |
| Aliev, NA | 1 |
| Kluger, G | 1 |
| Berz, K | 1 |
| Holthausen, H | 1 |
| Trenité, DG | 1 |
| Rentmeester, TW | 1 |
| Scholtes, FB | 1 |
| Gilissen, KG | 1 |
| Arends, LR | 1 |
| Schlosser, A | 1 |
| Bonanni, E | 1 |
| Galli, R | 1 |
| Gori, S | 1 |
| Pasquali, L | 1 |
| Maestri, M | 1 |
| Iudice, A | 1 |
| Murri, L | 1 |
| Villetti, G | 1 |
| Bregola, G | 1 |
| Bassani, F | 1 |
| Bergamaschi, M | 1 |
| Rondelli, I | 1 |
| Pietra, C | 1 |
| Simonato, M | 1 |
| Castel-Branco, MM | 1 |
| Macedo, TA | 1 |
| Lopez, FG | 1 |
| Ueberall, MA | 1 |
| Kerr, M | 1 |
| Arzimanoglou, A | 1 |
| Kulak, I | 1 |
| Bidaut-Mazel, C | 1 |
| Guye, M | 1 |
| Bartolomei, F | 1 |
| Gastaut, JL | 1 |
| Chauvel, P | 1 |
| Dravet, C | 1 |
| Goldberg, JF | 1 |
| Burdick, KE | 1 |
| Franz, DN | 1 |
| Tudor, C | 1 |
| Leonard, J | 1 |
| Egelhoff, JC | 1 |
| Byars, A | 1 |
| Valerius, K | 1 |
| Sethuraman, G | 1 |
| Gromov, SA | 1 |
| Shapiro, D | 1 |
| Dominiczak, M | 1 |
| Guo, CY | 1 |
| Ronen, GM | 1 |
| Atkinson, SA | 1 |
| Risner, M | 2 |
| Højskov, CS | 1 |
| Poulsen, JH | 1 |
| Buchholt, JM | 1 |
| Hansen, EL | 1 |
| Liguori, R | 1 |
| Vigneswari, G | 1 |
| Sofiah, A | 1 |
| Hussain, IH | 1 |
| Zaatreh, M | 1 |
| Tennison, M | 1 |
| D'Cruz, O | 1 |
| Beach, RL | 1 |
| Beghi, E | 1 |
| Foldvary, N | 1 |
| Perry, M | 1 |
| Dinner, D | 1 |
| Arends, J | 1 |
| Diepman, L | 1 |
| de Vocht, J | 1 |
| Kissani, N | 1 |
| Jafari, H | 1 |
| de Juan Martín, F | 1 |
| Bouthelier Moreno, M | 1 |
| Marín Bravo, MC | 1 |
| Melendo Gimeno, J | 1 |
| Alegre, M | 1 |
| Iriarte, J | 1 |
| Schlumberger, E | 1 |
| Urrestarazu, E | 1 |
| Lázaro, D | 1 |
| Fröscher, W | 1 |
| Keller, F | 1 |
| Chmielewska, B | 1 |
| Kamiński, ML | 1 |
| Kawka, Z | 1 |
| Hurley, SC | 1 |
| Chong, E | 1 |
| Dupuis, LL | 1 |
| Chandler, C | 1 |
| Costa Da Costa, J | 1 |
| Paglioli-Neto, E | 1 |
| Polkey, C | 1 |
| Rosenblatt, B | 1 |
| Montes, J | 1 |
| Martínez, JV | 1 |
| Farmer, JP | 1 |
| Sinclair, B | 1 |
| Aronyk, K | 1 |
| Paglioli, E | 1 |
| Coutinho, L | 1 |
| Raupp, S | 1 |
| Portuguez, M | 1 |
| Duchowny, M | 1 |
| Womble, G | 1 |
| Zona, C | 1 |
| Tancredi, V | 1 |
| Longone, P | 1 |
| D'Arcangelo, G | 1 |
| D'Antuono, M | 1 |
| Manfredi, M | 1 |
| Avoli, M | 1 |
| Gibbs, J | 1 |
| Rosenbloom, L | 1 |
| Yuen, WC | 5 |
| Russo, M | 1 |
| Trio, R | 1 |
| Artesi, C | 1 |
| Di Perri, R | 1 |
| Trnavska, Z | 1 |
| Krejcova, H | 1 |
| Salcmanova, Z | 1 |
| Elis, J | 1 |
| Banks, GK | 1 |
| Goodwin, G | 1 |
| Withers, RM | 1 |
| O'Donohoe, NV | 1 |
| Oxley, JR | 2 |
| Hamilton, MJ | 2 |
| Trevisol-Bittencourt, PC | 1 |
| Hart, YM | 1 |
| Shorvon, SD | 1 |
| Porter, RJ | 1 |
| Beintema, DJ | 1 |
| Debets, RM | 1 |
| Van Emde Boas, W | 1 |
| Meijer, JW | 1 |
| Meinardi, H | 1 |
| Peck, AW | 2 |
| Westendorp, AM | 1 |
| Jawad, S | 2 |
| Oxley, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Physiological-based Pharmacokinetics Approach to Determine the Extent of Drug Exposure of Antiseizure Medications During Pregnancy and Breastfeeding[NCT05450978] | 60 participants (Anticipated) | Observational [Patient Registry] | 2022-07-20 | Recruiting | |||
| The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822] | 550 participants (Anticipated) | Observational | 2022-02-18 | Recruiting | |||
| An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a Proof of Concept Study[NCT03489044] | Phase 2 | 30 participants (Anticipated) | Interventional | 2018-10-28 | Active, not recruiting | ||
| Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability[NCT02002819] | Phase 2 | 34 participants (Actual) | Interventional | 2014-10-16 | Completed | ||
| Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)[NCT01733394] | Phase 4 | 54 participants (Actual) | Interventional | 2012-12-12 | Completed | ||
| Improvement and Clinical Application of a New Minimally Invasive Closed Thoracic Drainage System[NCT04143360] | 100 participants (Anticipated) | Interventional | 2020-04-30 | Not yet recruiting | |||
| An Educational Intervention to Increase Knowledge of Drug-drug Interactions Between Antiepileptics and Hormonal Contraception Among Reproductive-aged Women With Epilepsy.[NCT02485756] | 42 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| Characterization of Epilepsy Patients At-risk for Adverse Outcomes Related to Switching Antiepileptic Drug Products: BEEP 2b Study[NCT02707965] | Phase 1 | 21 participants (Actual) | Interventional | 2017-06-08 | Completed | ||
| Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design (EQUIGEN Chronic-Dose Study)[NCT01713777] | Phase 4 | 35 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| A Retrospective Study to Evaluate Retention Rate of Topiramate With That of Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment[NCT02098941] | 2,500 participants (Anticipated) | Observational | 2014-03-31 | Recruiting | |||
| A Pilot Study of Prophylactic Management of Lamotrigine for Bipolar Disorder in Pregnant Women[NCT03774641] | 20 participants (Anticipated) | Observational | 2018-12-03 | Recruiting | |||
| Levetiracetam, Carbamazepine and Lamotrigine and Hormonal Side Effects in Adult Males and Females.[NCT00460070] | 240 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| EEG Objectification in Neuropsychiatry[NCT01476228] | 100 participants (Anticipated) | Interventional | 2011-11-30 | Not yet recruiting | |||
| Phase 1 Study for Measuring the Effect of Antiepileptic Drugs on Mitochondrial Activity[NCT01218321] | 60 participants (Actual) | Observational | 2011-01-31 | Completed | |||
| A Clinical Pharmacokinetics Comparing Brand and Generic Topiramate in Epilepsy Patients : A Open-label,Randomised, Three-period Crossover Study[NCT02113787] | 24 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| A Multicenter, Double-Blind, Randomized Conversion to Monotherapy Comparison of Two Doses of Lamotrigine for the Treatment of Partial Seizures[NCT00355082] | Phase 3 | 226 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Lamotrigine Versus Levetiracetam in the Initial Monotherapy of Epilepsy: An Open, Prospective, Multicenter, Randomized Phase III Study[NCT00242606] | Phase 3 | 409 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Neurodevelopmental Effects of Antiepileptic Drugs II: the NEAD Study[NCT00021866] | 331 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epileps[NCT00438451] | Phase 4 | 361 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Lamotrigine Pregnancy Registry (LAM05)[NCT01064297] | 3,416 participants (Actual) | Observational | 2001-11-30 | Completed | |||
| Study of Maternal Pharmacokinetic and Placental Transfer of Levetiracetam[NCT04117425] | 50 participants (Anticipated) | Interventional | 2022-04-20 | Recruiting | |||
| Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
| A Multicenter, Open-Label Conversion of Valproate Monotherapy to Lamotrigine Monotherapy in Patients With Epilepsy[NCT00043914] | Phase 4 | 72 participants | Interventional | 2002-01-14 | Completed | ||
| Does Memantine Improve Verbal Memory Task Performance in Subjects With Localization-related Epilepsy and Memory Dysfunction? A Randomized, Double-Blind, Placebo-Controlled Trial[NCT01054599] | 29 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| Cognitive Effects of Treatment of Interictal Discharges[NCT00916149] | 31 participants (Actual) | Interventional | 2007-01-31 | Completed | |||
| A Randomized, Pilot Study to Evaluate the Tolerability of OnabotulinumtoxinA Plus Topiramate vs. OnabotulinumtoxinA Plus Placebo and Long Term Effect of Treatment on Cognitive Efficiency and Continuation of Care[NCT01700387] | Phase 4 | 20 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Clinical Cohort Study of Association Between Steady State Phenytoin Treatment and Better Clinical Parameters of Glaucoma[NCT00739154] | 200 participants (Anticipated) | Observational | 2008-11-30 | Not yet recruiting | |||
| A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs[NCT02429596] | Phase 4 | 200 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| Evaluation of Bioequivalence of Lamotrigine Tablets in Epileptic Patients[NCT01995825] | Phase 4 | 35 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients[NCT02404168] | Phase 4 | 4 participants (Actual) | Interventional | 2015-07-07 | Completed | ||
| A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency[NCT01379469] | Phase 2 | 20 participants (Actual) | Interventional | 2012-01-31 | Terminated | ||
| An Open-label, Double Conversion Study to Characterize the Pharmacokinetics of Lamotrigine When Switching Patients With Epilepsy on LAMICTAL Immediate-release to Extended-release Formulation and Vice Versa[NCT00264615] | Phase 3 | 45 participants | Interventional | 2005-10-31 | Completed | ||
| Efficacy, Tolerability and Adherence of the Modified Atkins Diet on Drug-resistant Epilepsy in Adults Patients[NCT03183076] | 14 participants (Actual) | Interventional | 2015-09-01 | Completed | |||
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| Home-based Transcranial Direct Current Stimulation in Fibromyalgia Patients. Phase II, Randomized, Double-blind, Single-center Clinical Trial[NCT02652988] | 20 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| The Sumatriptan and Naratriptan Pregnancy Registry[NCT01059604] | 868 participants (Actual) | Observational [Patient Registry] | 2001-12-31 | Completed | |||
| An Open Prospective Randomised Long-Term Effectiveness Study, Comparing Best Medical Practice With or Without Adjunctive VNS Therapy in Patients 16 Years and Older With Pharmaco-resistant Partial Epilepsy[NCT00522418] | Phase 4 | 122 participants (Actual) | Interventional | 2006-02-28 | Terminated (stopped due to Insufficient enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | -1.0 |
| Placebo (Epileptiform Activity) | 1.5 |
Blood samples intended for Quest Diagnostics LEV and prolactin serum levels (one 6 mL tube) will be processed in the following manner, as outlined in the Quest Diagnostics lab manual. The whole blood will be allowed to clot for 60 minutes and centrifuged at 2200 - 2500 revolutions per minute (RPM) for at least 15 minutes. The resulting serum will be split into 2 cryovials which will be stored at -20°C and immediately shipped for external assessment of LEV and prolactin levels. Prolactin will be assessed via immunoassay. The concentration of LEV in serum will be measured using validated liquid chromatography/tandem mass spectrometry (LC/MS-MS) methods. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | ng/mL (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.2 |
Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) - The ADAS-cog rating instrument (Rosen et al. 1984) will be used to evaluate the global cognitive functioning. The ADAS-cog is a 70-point scale that includes an assessment of verbal memory, language, orientation, reasoning, and praxis.The score is derived from adding point values from each of its subsections. The higher your score on the ADAS-cog, the better you do. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.2 |
| Placebo | 0.8 |
Alzheimer's Disease Cooperative Study Activities of Daily Living Scale (ADCS-ADL) - The ADCS-ADL rating instrument (Galasko et al. 1997) will be used to evaluate functional capacity. The ADCS-ADL is a caregiver rated questionnaire. Scores on the 24-item ADCS-ADL range from 0 to 78. A higher score indicates less severity while a lower score indicates greater severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.4 |
| Placebo | 0.3 |
ADCS-Clinical Global Impression of Change (ADCS-CGIC) - The ADCS-CGIC is a seven-point scale that gives a global rating of change from baseline (Schneider et al. 1997). The baseline and follow up assessments are based on interviews with the subject and the informant. The ADCS-CGIC is a clinician-rated measure of: global severity at baseline scored from 1 (normal, not at all ill) to 7 (among the most extremely ill patients); and global change at follow-up scored from 1 (marked improvement) to 7 (marked worsening), where 4 indicates no change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 4.0 |
| Placebo | 4.0 |
Neuropsychiatric Inventory (NPI) - The NPI (Cummings et al. 1994) will be used to evaluate the severity of behavioral symptoms. The severity scale has scores ranging from 1 to 3 points (1=mild; 2=moderate; and 3=severe) and the scale for assessing caregiver distress has scores ranging from 0 to 5 points (0=no distress; 1=minimal distress; 2=mild distress; 3=moderate distress; 4=severe distress; and 5=extreme distress). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.8 |
| Placebo | 0.2 |
A 20-minute computer-based virtual navigation test will be used to assess how well a subject can navigate a virtual community to reach a goal destination. The subjects will then be measured on their ability to accurately navigate the virtual community after a period of a few hours. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | correct turns (Mean) |
|---|---|
| No Epileptiform Activity | -6.0 |
| Epileptic Activity | 17.4 |
"Epileptiform activity will be measured using a 1-hr resting magnetoencephalogram/electroencephalogram (M/EEG). M/EEG can detect abnormal epileptiform findings called spikes. The M/EEG will be read by an epileptologist with specialized training to assess whether there are any spikes. If spikes are observed during the M/EEG they will be counted to determine their frequency (e.g., 5 spikes per 1 hour recording). The frequency of spikes will then be compared to baseline values from before beginning the study treatment, using statistical tests to determine if the frequency changed with treatment." (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | Epileptiform events (Mean) |
|---|---|
| Levetiracetam | -0.1 |
| Placebo | -0.2 |
Changes in executive function were measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: antisaccade , set shifting , flanker task, dot counting, spatial 1-back, category fluency, and letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory. For this study, scores with SEs greater than 0.55 were classified as unreliable and excluded from analysis. Composite scores from 2 participants were excluded on this basis.The EXAMINER ranges for the participants in the study were -2.59 to 1.33. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | -0.06 |
| Placebo | -0.14 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 1.5 |
| Placebo | -1.4 |
Clinical Dementia Rating Sum of Boxes (CDR-SOB) - The CDR will be used as a global measure of dementia severity (Morris 1993). The CDR consists of questions addressed to the caregiver/informant. The lowest score one can receive is a 0 and the highest is a 3. Score is measured by getting the mean of the individual scores in each category. Lower scores equate to less dementia severity. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.1 |
| Placebo | 0.1 |
Changes in executive function will be measured using the NIH EXAMINER, a 1-hour computer-based battery of various executive function tasks. The subject's performance after the study treatment will be compared with results from a baseline assessment done before the study treatment, using statistical tests to assess whether there was any significant change. The Examiner assessment consists of the following scales: NIH EXAMINER - antisaccade , NIH EXAMINER - set shifting , NIH EXAMINER - flanker task, NIH EXAMINER - dot counting, NIH EXAMINER - spatial 1-back, NIH EXAMINER - category fluency, and NIH EXAMINER - letter fluency. Scores for this task have an indefinite range. Higher scores however do indicate better performance. Scores for this scale were generated using item response theory (Kramer et al. J Int Neuropsychol Soc. 2014;20(1):11-19. doi:10.1017/S1355617713001094). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| No Epileptiform Activity | -0.01 |
| Epileptiform Activity | 0.22 |
The One Day Fluctuation Assessment Scale will be used to quantitate fluctuations of dementia symptoms (Walker et al. 2000). The One Day Fluctuation Assessment Scale has a score range of 0-21 points,with higher scores indicatingmore fluctuations. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.3 |
| Placebo | -0.4 |
Two standardized methods will be used to quantitate fluctuations of dementia symptoms: The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale (Walker et al. 2000). : The Clinician Assessment of Fluctuation (score range,0-12 points, with higher scores indicating more fluctuations),26 the One Day Fluctuation Assessment Scale (score range,0-21 points, with higher scores indicatingmore fluctuations). (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam | 0.9 |
| Placebo | 0.1 |
Stroop Test - The Stroop Test (Stroop 1935) will be used to assess executive functions including selective attention, cognitive flexibility and processing speed. Subtasks include Stroop color naming and Stroop interference naming, and each subtask is restricted to 1 minute. The minimum score is 0 and the maximum score is 126. The higher the score the better a participant does. The mean below represents the average change in score between the timepoints for all participants. (NCT02002819)
Timeframe: Difference between weeks 0-4 (Baseline) and weeks 8-12 (Treatment)
| Intervention | score on a scale (Mean) |
|---|---|
| Levetiracetam (Epileptiform Activity) | 4.7 |
| Placebo (Epileptiform Activity) | -2.6 |
summed for each anti-epileptic drug from when taking brand and generic. (NCT02707965)
Timeframe: Through the approximately 2 week period when the treatment is given.
| Intervention | events (Number) |
|---|---|
| Topiramate | 29 |
| Lamotrigine ER | 9 |
| Levetiracetam IR | 17 |
| Levetiracetam ER | 4 |
| Carbamazepine ER Capsule | 15 |
| Zonisamide | 6 |
| Carbamazepine ER Tablet | 10 |
| Valproic Acid | 10 |
Average AUC (area under the drug plasma curve. (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.
| Intervention | micro/mL/hr (Mean) | |
|---|---|---|
| Test Product | Reference Product | |
| Carbamazepine ER Capsule | 114.96 | 106.45 |
| Carbamazepine ER Tablet | 104.6 | 115.16 |
| Lamotrigine ER Tablet | 62.76666667 | 67.19333333 |
| Levetiracetam ER Tablet | 260.3 | 262.305 |
| Levetiracetam IR Tablet | 419.97 | 445.2 |
| Topiramate Tablet | 92.884 | 94.456 |
| Zonisamide Capsule | 233.16 | 226.14 |
Average maximum drug plasma concentration; (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.
| Intervention | microg/mL (Mean) | |
|---|---|---|
| Test Product | Reference Product | |
| Carbamazepine ER Capsule | 10.95 | 9.91 |
| Carbamazepine ER Tablet | 10.00 | 10.6 |
| Lamotrigine ER Tablet | 6.24 | 6.903333333 |
| Levetiracetam ER Tablet | 31.05 | 28.04 |
| Levetiracetam IR Tablet | 71.02333333 | 69.29333333 |
| Topiramate Tablet | 9.874 | 9.646 |
| Zonisamide Capsule | 12.29 | 11.68 |
Average minimum drug plasma concentration (Cmin); (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.
| Intervention | microg/mL (Mean) | |
|---|---|---|
| Test Product | Reference Product | |
| Carbamazepine ER Capsule | 8.56 | 7.66 |
| Carbamazepine ER Tablet | 7.37 | 7.97 |
| Lamotrigine ER Tablet | 4.053333333 | 4.21 |
| Levetiracetam ER Tablet | 12.605 | 14.395 |
| Levetiracetam IR Tablet | 15.45333333 | 17.45666667 |
| Topiramate Tablet | 6.326 | 6.53 |
| Zonisamide Capsule | 8.46 | 8.34 |
Number of seizures reported in all groups (NCT02707965)
Timeframe: Through the approximately 2 week period when the treatment is given.
| Intervention | Number of Seizures (Number) | |
|---|---|---|
| Reference Product | Test (Generic) | |
| Carbamazepine ER Capsule | 3 | 1 |
| Carbamazepine ER Tablet | 0 | 0 |
| Lamotrigine ER Tablet Group | 44 | 25 |
| Lamotrigine IR Tablet Group | 0 | 0 |
| Levetiracetam ER Tablet Group | 42 | 72 |
| Levetiracetam IR Tablet Group | 16 | 5 |
| Topiramate Tablet Group | 9 | 5 |
| Valproic Acid ER Tablet Group | 12 | 0 |
| Zonisamide Capsule Group | 0 | 0 |
The number of participants who had no seizures during the treatment period was calculated. The last 12 weeks of treatment were either Weeks 11-22 or 12-23 depending on which background AED was being withdrawn (NCT00355082)
Timeframe: The last 12 weeks of treatment of the Treatment phase (Monotherapy phase - approximately Week 11 through Week 23)
| Intervention | participants (Number) |
|---|---|
| Lamotrigine Extended-release (LTG XR), 300 mg | 22 |
| LTG XR, 250 mg | 8 |
Change from baseline was calculated as the average seizure frequency at the end of the Continuation Phase minus the average seizure frequency at Baseline. The number of seizures during the Continuation phase divided by the number of weeks was compared to the number of seizures at Baseline. A positive number indicates a reduction in seizure frequency. (NCT00355082)
Timeframe: Baseline and start of Continuation phase through Week 24 or end of participation in the Continuation phase
| Intervention | percent change in seizures (Median) |
|---|---|
| Lamotrigine Extended-release (LTG XR), 300 mg | 72.2 |
| Baseline Failures | 68.8 |
Change from Baseline was measured as the number of seizures at Visits 3 through 9 minus the number of seizures at Baseline. The number of partial seizures during treatment divided by the number of weeks of treatment was compared to the weekly seizure frequency during Baseline. A positive number equals a reduction in seizure frequency. (NCT00355082)
Timeframe: Baseline and Study Visit 3 through Visit 9 of the Treatment phase (Treatment Week 0 through Week 23)
| Intervention | percent change in seizures (Median) |
|---|---|
| Lamotrigine Extended-release (LTG XR), 300 mg | 54.8 |
| LTG XR, 250 mg | 52.2 |
The percentage of participants meeting Escape Criteria was calculated as the number of participants who met an Escape Criterion divided by the number who had reached Visit 5 minus major protocol violators. Escape Criteria are: (1) doubling of average monthly seizure frequency; (2) doubling of the highest consecutive 2-day seizure total; (3) occurrence of a new, more severe seizure type; or (4) worsening of generalized tonic-clonic seizures. (NCT00355082)
Timeframe: Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)
| Intervention | percentage of participants (Number) |
|---|---|
| Lamotrigine Extended-release (LTG XR), 300 mg | 4 |
| LTG XR, 250 mg | 6 |
The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who had reached Visit 5 minus major protocol violators. The Control group was composed of data from other similar studies and is not part of this study. (NCT00355082)
Timeframe: From Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)
| Intervention | percentage of participants (Number) |
|---|---|
| LTG XR, 250 mg | 16 |
The percentage of participants prematurely discontinuing the study was calculated as the number of participants who discontinued the study divided by the number who reached Visit 5 minus major protocol violators. The Control group is composed of data from other similar studies and is not part of this study. (NCT00355082)
Timeframe: From Study Visit 5 through Visit 9 of the Treatment Phase (approximately Week 7 through Week 23)
| Intervention | percentage of participants (Number) |
|---|---|
| Lamotrigine Extended-release (LTG XR), 300 mg | 12 |
Time (days) until the participant discontinued the study (NCT00355082)
Timeframe: From Study Visit 5 through Visit 9 of the Treatment phase (approximately Week 7 through Week 23)
| Intervention | Days (Mean) |
|---|---|
| Lamotrigine Extended-release (LTG XR), 300 mg | 147.3 |
| LTG XR, 250 mg | 133.2 |
Change in seizure frequency was calculated as the average seizure frequency during the Continuation Phase minus the seizure frequency at Baseline. (NCT00355082)
Timeframe: Baseline and entire Continuation phase (24 Weeks)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| At least a 25% reduction in seizures | At least a 50% reduction in seizures | At least a 75% reduction in seizures | 100% reduction in seizures | At least a 50% increase in seizures | |
| Baseline Failures | 7 | 6 | 3 | 2 | 3 |
| Lamotrigine Extended-release (LTG XR), 300 mg | 169 | 137 | 85 | 38 | 6 |
(NCT00438451)
Timeframe: 58 weeks
| Intervention | proportion of participants (Mean) |
|---|---|
| Levetiracetam | 0.61 |
| Carbamazepine | 0.46 |
| Lamotrigine | 0.56 |
Percentage of patients experiencing no seizures until week 58 (Visit 6) and did not discontinue the study until week 58. (NCT00438451)
Timeframe: week 58
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 43 |
| Carbamazepine | 33 |
| Lamotrigine | 38 |
Percentage of patients experiencing no seizures until week 30 (Visit 4) and did not discontinue the study until week 30. (NCT00438451)
Timeframe: Week 30
| Intervention | percentage of participants (Number) |
|---|---|
| Levetiracetam | 48 |
| Carbamazepine | 39 |
| Lamotrigine | 49 |
(NCT00438451)
Timeframe: 52 weeks
| Intervention | proportion of seizure-free days (Number) |
|---|---|
| Levetiracetam | 0.99 |
| Carbamazepine | 0.99 |
| Lamotrigine | 0.99 |
EPITrack-Score shows the performance of attention and executive functions. Higher values indicate a better performance. The results of EPITrack Score ranges between 7 and 45. (NCT00438451)
Timeframe: week 58
| Intervention | units on a scale (Mean) |
|---|---|
| Levetiracetam | 26.0 |
| Carbamazepine | 26.0 |
| Lamotrigine | 25.4 |
"Seizure frequency was assessed by investigators in the CRF at the Visits V3, V4, V5 and V6.~The absolute seizure frequency during the maintenance phase was defined as the sum of those entries." (NCT00438451)
Timeframe: over 52 weeks
| Intervention | number of seizures (Number) |
|---|---|
| Levetiracetam | 168 |
| Carbamazepine | 131 |
| Lamotrigine | 130 |
(NCT00438451)
Timeframe: over the whole duration of 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | NA |
| Lamotrigine | NA |
number of days between randomization and premature discontinuation of the study (NCT00438451)
Timeframe: 58 weeks
| Intervention | days (Median) |
|---|---|
| Levetiracetam | NA |
| Carbamazepine | 265 |
| Lamotrigine | NA |
"The PNS is a 15-item scale. Each item can be scored from 1 to 9. There are a total score (includes all items, range:15 to 135) and two subscores: The cognitive toxicity subscore (10 items: Energy Level, Memory, Interest, Concentration, Forgetfulness, Sleepliness, Moodiness, Alertness, Attention Span, Motivation, range:10 to 90) and the somatomoto subscore (5 items: Vision, Walking, Coordination, Tremor, Speech, range:5-45). The score is calculated by taking the mean of all non-missing values times the number of items.~Lower values indicate better quality of life." (NCT00438451)
Timeframe: at week 58
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Cognitive toxicity subscore | Somatomotor subscore | Total Score | |
| Carbamazepine | 27.3 | 11.4 | 38.7 |
| Lamotrigine | 23.7 | 10.8 | 34.5 |
| Levetiracetam | 22.2 | 10.5 | 32.7 |
The QOLIE-31 is a 31 item score that measures the quality of life in epilepsy (each item with a range of 0 to 100). There are 7 sub-scores seizure worry (items 11,21,22,23,25), overall quality of life (items 1,14), emotional well-being (items 3,4,5,7,9), energy/fatigue (items 2,6,8,10), cognitive functioning (items 12,15,16,17,18,26), medication effects (items 24,29,30) and social functioning (13,19,20,27,28). These scores were combined to a total score by Total score = seizure worry*0.08 + overall quality of life*0.14 + emotional well-being*0.15 + energy/fatigue*0.12 + cognitive functioning*0.27 + medication effects*0.03 + social functioning*0.21 For all scores, higher values indicate better quality of life. Each score has a possible range from 0 to 100. (NCT00438451)
Timeframe: 58 weeks, final visit
| Intervention | units on a scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Seizure worry | Overall quality of life | Emotional well-being | Energy/fatigue | Cognitive functioning | Medication effects | Social functioning | Total Score | Health Scale | |
| Carbamazepine | 75.4 | 65.0 | 69.8 | 54.5 | 68.9 | 70.6 | 76.3 | 68.9 | 65.7 |
| Lamotrigine | 75.0 | 67.1 | 67.4 | 59.8 | 68.0 | 72.6 | 76.7 | 69.1 | 67.5 |
| Levetiracetam | 85.1 | 67.2 | 72.0 | 60.8 | 75.1 | 77.6 | 81.1 | 73.9 | 69.5 |
"Evaluation of current testing at V6:~≥29 score points: Inconspicuous; 26 to 28 score points: Borderline;~≤25 score points: Impaired" (NCT00438451)
Timeframe: 58 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| Without pathological findings | Borderline | Impaired | |
| Carbamazepine | 34 | 17 | 33 |
| Lamotrigine | 31 | 15 | 39 |
| Levetiracetam | 38 | 10 | 36 |
"Evaluation of Changes~Changes in the EpiTrack® Score were categorized as follows:~≥5 score points: Improved;~-3 to 4 score points: Unchanged;~≤-4 score points: Worsened" (NCT00438451)
Timeframe: week 58
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Carbamazepine | 16 | 56 | 8 |
| Lamotrigine | 15 | 53 | 13 |
| Levetiracetam | 15 | 61 | 6 |
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy with valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 14 |
| First Exposure During Second Trimester | 1 |
| First Exposure During Third Trimester | 0 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 1 |
The number of infants with major congenital malformations were counted and are presented by earliest trimester of exposure to lamotrigine polytherapy without valproate. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 12 |
| First Exposure During Second Trimester | 0 |
| First Exposure During Third Trimester | 1 |
| All Trimesters | 13 |
Among lamotrigine monotherapy exposures: live births, fetal deaths, induced abortions with birth defects, and live births without defects. Due to the likelihood of inconsistent identification of birth defects among spontaneous losses, fetal deaths, and induced abortions without reported birth defects, these offspring were not included in analyses. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) |
|---|---|
| First Exposure During First Trimester | 35 |
| First Exposure During Second Trimester | 4 |
| First Exposure During Third Trimester | 1 |
| Unspecified Trimester of Exposure | 0 |
| All Trimesters | 40 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine monotherapy. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of major congenital malformations are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 31 | 1 | 3 | 1523 | 10 | 33 | 98 |
| First Exposure During Second Trimester | 4 | 0 | 0 | 91 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 17 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
The number of live births, fetal deaths, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy with valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 14 | 0 | 2 | 134 | 1 | 4 | 6 |
| First Exposure During Second Trimester | 1 | 0 | 0 | 6 | 1 | 0 | 0 |
| First Exposure During Third Trimester | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Unspecified Trimester of Exposure | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The number of live births, fetal deaths with pregnancy loss occurring >=20 weeks gestation, induced abortions, and spontaneous pregnancy losses were recorded according to the time at which women were first exposed to lamotrigine polytherapy without valproate. Due to inconsistent identification of major congenital malformations (MCMs) among spontaneous losses, no comment is made concerning the presence or absence of MCMs. Although birth defects may not have been reported, they cannot be ruled out. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported following assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Live Birth (Birth Defects Reported) | Fetal Death (Birth Defects Reported) | Induced Abortion (Birth Defects Reported) | Live Birth (No Birth Defects Reported) | Fetal Death (No Birth Defects Reported) | Induced Abortion (No Birth Defects Reported) | Spontaneous Pregnancy Loss | |
| First Exposure During First Trimester | 11 | 0 | 1 | 418 | 3 | 19 | 22 |
| First Exposure During Second Trimester | 0 | 0 | 0 | 25 | 0 | 0 | 0 |
| First Exposure During Third Trimester | 1 | 0 | 0 | 2 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy with valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hydrocephalus/spina bifida | Meningomyelocele | Microcephaly | Orofacial clefts | Cardiac septal defects | Transposition of great vessels | Ventricular hypoplasia | Pulmonary stenosis | Pyloric stenosis | Gastroschisis | Club foot | Polydactyly | |
| Doses Lower Than Prescribed | 1 | 1 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Prescribed Doses | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The number of infants with the reported MCM following first trimester exposure to lamotrigine polytherapy without valproate were counted. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Neural tube defect | Cardiac septal defect/murmur | Coarctation of aorta | Tetralogy of Fallot | Esophageal defects | Hypospadias | Hydroencephalopathy | Omphalocele | Extra digit | Skin tags on ear | |
| Doses Higher Than Prescribed | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 1 |
| Doses Lower Than Prescribed | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Prescribed Doses | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
The number of infants with the reported MCM following first trimester lamotrigine monotherapy exposure were counted. Registry personnel contacted the enrolling physician to obtain information on the pregnancy outcome, lamotrigine dosing and duration of exposure, and use of concomitant antiepileptic drugs during pregnancy. (NCT01064297)
Timeframe: Although reports and diagnoses of MCMs are accepted up to six years after the birth, the majority of malformations are reported after assessments made in the delivery room or shortly after birth
| Intervention | infants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anencephaly | Orofacial clefts | Hypoplastic left heart/left ventricle hypoplasia | Transposition of great vessels | Ventricular septal defects | Minor heart defect, unspecified | Pulmonary stenosis | Hydronephrosis | Renal defect (absent, polysystic, fluid on kidney) | Cortical dysplasis | Hypospadias | Pyloric stenosis | Diaphragmatic hernia | Congenital atresia of anus | Hip dislocation | Club feet | Polydactyly | Epidermolysis bullosa | Light spot across entire abdomen | |
| Dose Higher Than Prescribed | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Doses Lower Than Prescribed | 2 | 2 | 1 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 |
| Prescribed Doses | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 1 |
| Unknown Maximal Dose in Exposed Trimester | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
| Intervention | number of drinks per treatment period (Mean) |
|---|---|
| All Subjects (n = 46) Placebo | 41.2 |
| All Subjects (n = 46) Levetiracetam | 45.4 |
SRT-CLTR (range 0-72; higher scores indicate better memory), and 7-24 Spatial Memory Test (range 0-35; scores are summed across the 5 learning trials, with higher scores indicating better memory) scores will be assessed across the first (baseline) and third (post-open label memantine) testing sessions. These measures are considered to be scores on a scale, rather than standard units. The hypothesis was that subjects randomized to memantine would demonstrate sustained improvement from baseline, while the placebo group would demonstrate improvements after taking open label memantine (compared to baseline). (NCT01054599)
Timeframe: 26 weeks
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| SRT CLTR Baseline | SRT CLTR Post-Open Label | 7-24 Total Learning Baseline | 7-24 Total Learning Post-Open Label | |
| Memantine | 32.67 | 40.33 | 30.33 | 31.67 |
| Sugar Pill | 22.71 | 40.29 | 28.14 | 32.43 |
Change scores from pre- to post-treatment/placebo were calculated for the primary outcome measures, the Selective Reminding Test Continuous Long-Term Retrieval (range 0-72; higher scores indicate better memory) and 7-24 Spatial Recall Test Total Learning (range 0-35; total correct across 5 learning trials are summed, with higher scores indicating better memory) scores. These measures are scores on a scale, rather than representing standard units. (NCT01054599)
Timeframe: 13 weeks
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| 7-24 Spatial Recall Tests Learning Change Score | SRT Continuous Long-Term Retrieval Change Score | |
| Memantine | 1.00 | 4.38 |
| Sugar Pill | 1.78 | 8.11 |
This descriptive analysis examined the change in interictal discharge rates pre to post-treatment with levetiracetam in subjects with epilepsy and with no treatment in healthy controls. (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | IEDs/hour (Mean) |
|---|---|
| No Treatment | -28.8 |
| Levetiracetam | .54 |
Change in Adverse Events Profile score (scores range from 19-76; higher scores indicate greater side effects) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | -1.27 |
| Levetiracetam | 1 |
Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall score (the score ranges from 0-6, reflecting the number of shapes recalled after a 25 minute delay) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | .36 |
| Levetiracetam | .33 |
Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Learning score (the score ranges from 0-6, reflecting the number of shapes recalled on the initial learning trial) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | .45 |
| Levetiracetam | .33 |
Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Total Learning score (the score is summed across 3 learning trials, score range 0-18, reflecting the total number of shapes recalled) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | 1.09 |
| Levetiracetam | .17 |
Change in Choice Accuracy Score (indicate if red or blue stimulus; accuracy 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | .02 |
| Levetiracetam | .1 |
Change in Choice Reaction Time Score, with reaction time measured in seconds (indicate if red or blue stimulus; lower reaction time suggests better performance) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | 34.96 |
| Levetiracetam | .45 |
Change in Continuous Performance Test Score - Accuracy (CPT; score ranges from 0-100% correct) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | -0.01 |
| Levetiracetam | .01 |
Change in Continuous Performance Test Score - Reaction Time, measured in seconds (CPT RT; less time reflects better performance) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | 1.04 |
| Levetiracetam | -11.33 |
Change in California Verbal Learning Test (CVLT) Long Delay Recall score (the score ranges from 0-16, reflecting the number of words recalled) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | 1.55 |
| Levetiracetam | 2.67 |
Change in California Verbal Learning Test (CVLT) Short Delay Recall Score (the score ranges from 0-16, reflecting the number of words recalled) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | 1.27 |
| Levetiracetam | -0.4 |
Change in California Verbal Learning Test (CVLT) Total Learning Score (the total learning score is summed across 5 learning trials, range 0-80). Higher scores indicate better memory. Scores on the CVLT reflect the number of words recalled. (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | 8.09 |
| Levetiracetam | 5.5 |
Change in California Verbal Learning Test (CVLT) Trial 1 learning score (range 0-16; higher score indicates better memory) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | 2.45 |
| Levetiracetam | 2.5 |
Change in Design Fluency score (Score range: lowest score = 0; there is no upper limit. A higher score reflects more designs generated, hence better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | 2.8 |
| Levetiracetam | .83 |
Change in Digit Span score (score ranges from 0-30; higher scores indicate better performance). Scores indicate the number of digit sequences correctly recalled, forwards and backwards. (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | .73 |
| Levetiracetam | -.33 |
Change in Digit Symbol Score (The score is the number of items completed. A higher score reflects better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | 3.2 |
| Levetiracetam | 1.5 |
Change in Facial Recognition Accuracy Score (accuracy ranges from 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | .01 |
| Levetiracetam | .03 |
Change in Facial Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -66.76 |
| Levetiracetam | .61 |
Change in Grooved Pegboard Score (The score is the time for completion. A lower score reflects better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -4.73 |
| Levetiracetam | -4.36 |
Change in Letter-Number Sequencing score (LNS; score ranges from 0-21; higher scores indicate better performance). The score reflects the number of items that the subject can correctly recall and place in proper alphabetical and numerical sequence. (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | .18 |
| Levetiracetam | -0.5 |
Change in Neurological Disorders Depression Inventory for Epilepsy (NDDIE) score (scores range from 0-24; higher scores indicate greater depressive symptoms) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | 0.18 |
| Levetiracetam | 1.5 |
Change in Non-verbal Working Memory Accuracy Score (accuracy ranges from 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | -.01 |
| Levetiracetam | 0 |
Change in Non-verbal Working Memory Reaction Time Score (indicates processing speed, with reaction time measured in seconds) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -31.99 |
| Levetiracetam | -25.54 |
Change in Quality of Life Inventory in Epilepsy-89 score (QOLIE; score ranges from 0-100; higher scores reflect better quality of life) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| Levetiracetam | 19.6 |
Change in Spatial Span score (score ranges from 0-32; higher scores indicate better performance). Scores indicate the number of spatial sequences correctly recalled, forwards and backwards. (NCT00916149)
Timeframe: 1 and 11 Weeks
| Intervention | number recalled (Mean) |
|---|---|
| No Treatment | .36 |
| Levetiracetam | -1.67 |
Change in Stroop score (The score is the time for completion in seconds; less time reflects better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | .98 |
| Levetiracetam | -7.3 |
Change in Trails Test score (The score is the time for completion in seconds. A lower score reflects better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -9.51 |
| Levetiracetam | 11.29 |
Change in Verbal Fluency score (Score range: lowest score = 0, with no upper limit, reflecting total number of words generated. Higher scores indicate better performance.) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | scores on a scale (Mean) |
|---|---|
| No Treatment | -1.55 |
| Levetiracetam | -.83 |
Change in Verbal Recognition Accuracy Score (accuracy ranges from 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | .02 |
| Levetiracetam | .14 |
Change in Verbal Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | 2.98 |
| Levetiracetam | -6.1 |
Change in Verbal Working Memory Accuracy Score (range 0-100%) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | percentage of correct responses (Mean) |
|---|---|
| No Treatment | 0 |
| Levetiracetam | -.02 |
Change in Verbal Working Memory Reaction Time Score, with reaction time measured in seconds (indicates processing speed) (NCT00916149)
Timeframe: 1 and 11 weeks
| Intervention | seconds (Mean) |
|---|---|
| No Treatment | -54.76 |
| Levetiracetam | -9.36 |
(NCT01700387)
Timeframe: 13 Months (Visit 1 to Visit 6)
| Intervention | Adverse Events (Mean) |
|---|---|
| OnabotulinumtoxinA + Topiramate | 8.60 |
| OnabotulinumtoxinA + Placebo | 4.60 |
The Headache Impact Test (HIT-6) is a tool used to measure the impact headaches have on an individual's ability to function on the job, at school, at home and in social situations. The HIT-6 score range is from 36 to 78 with higher scores indicating greater impact (worse outcome). (NCT01700387)
Timeframe: Collected on Visit 2 (Day 29), 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Visit 2 | Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 66.50 | 59.9 | 60.44 | 58.71 | 54.17 |
| OnabotulinumtoxinA + Topiramate | 66.40 | 61.89 | 54.5 | 52.83 | 52.57 |
The Mental Efficiency Workload Test (MEWT) is a cognitive functioning scale with four sub-scales (Simple Reaction Time, Running Memory Continuous Performance Task, Matching to Sample, and Mathematical Processing). Each sub-scale has a minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. MEWT sub-scale score percent change from baseline will be reported. Positive change scores represent better cognitive functioning compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 21.74 | 8.59 | 12.72 | 24.75 |
| OnabotulinumtoxinA + Topiramate | 19.06 | 15.04 | 18.49 | 40.86 |
The Mental Efficiency Workload Test (MEWT) is a cognitive functioning scale with four sub-scales (Simple Reaction Time, Running Memory Continuous Performance Task, Matching to Sample, and Mathematical Processing). Each sub-scale has a minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. MEWT sub-scale score percent change from baseline will be reported. Positive change scores represent better cognitive functioning compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 17.74 | 16.43 | 28.61 | 29.44 |
| OnabotulinumtoxinA + Topiramate | -11.23 | -22.90 | -23.81 | 1.52 |
The Mental Efficiency Workload Test (MEWT) is a cognitive functioning scale with four sub-scales (Simple Reaction Time, Running Memory Continuous Performance Task, Matching to Sample, and Mathematical Processing). Each sub-scale has a minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. MEWT sub-scale score percent change from baseline will be reported. Positive change scores represent better cognitive functioning compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 1.13 | 4.39 | 18.81 | 2.2 |
| OnabotulinumtoxinA + Topiramate | -15.66 | -1.20 | -3.96 | -6.99 |
The Mental Efficiency Workload Test (MEWT) is a cognitive functioning scale with four sub-scales (Simple Reaction Time, Running Memory Continuous Performance Task, Matching to Sample, and Mathematical Processing). Each sub-scale has a minimum and maximum values of 1 to 10, 1 indicates the poorest level and 10 indicates the best level of cognitive functioning. MEWT sub-scale score percent change from baseline will be reported. Positive change scores represent better cognitive functioning compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 14.22 | 4.76 | -4.17 | 2.31 |
| OnabotulinumtoxinA + Topiramate | -8.90 | -3.20 | -3.87 | -3.16 |
Number of Headache Days reported in 30-day Baseline Period and Treatment Period Months 1-12 (NCT01700387)
Timeframe: Baseline and Months 1-12
| Intervention | Headache days (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Month 1 | Month 2 | Month 3 | Month 4 | Month 5 | Month 6 | Month 7 | Month 8 | Month 9 | Month 10 | Month 11 | Month 12 | |
| OnabotulinumtoxinA + Placebo | 23.77 | 21.67 | 17.54 | 18.37 | 14.39 | 13.47 | 16.58 | 12.54 | 11.5 | 9.96 | 8.02 | 8.51 | 8.06 |
| OnabotulinumtoxinA + Topiramate | 22.95 | 18.41 | 16.50 | 16.83 | 15.74 | 11.34 | 15.18 | 12.64 | 12.36 | 12.02 | 6.93 | 8.36 | 7.51 |
Score on Physician Global Impression of Change at Visits 3-6 (Day 113 and 365). Likert scale ranging from 1-7, where 1 = extremely worse and 7 = extremely better. (NCT01700387)
Timeframe: Collected on Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 5.30 | 5.89 | 5.83 | 5.83 |
| OnabotulinumtoxinA + Topiramate | 5.25 | 5.40 | 6.67 | 6.83 |
Count of subject attrition following randomization and reason for attrition (Consent withdrawn, Withdrawn due to adverse event, Lost to follow up) (NCT01700387)
Timeframe: Collected on Visit 2 (Day 29) through Visit 6 (Day 365)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Consent Withdrawn | Withdrawn Due to Adverse Event | Lost to Follow Up | |
| OnabotulinumtoxinA + Placebo | 2 | 1 | 1 |
| OnabotulinumtoxinA + Topiramate | 1 | 1 | 2 |
Subject estimation of compliance with daily study drug during the study period. Compliance ranges from 0% to 100% with higher percentages indicating greater compliance with study drug. (NCT01700387)
Timeframe: Collected on Visit 2 (Day 29), 3 (Day 113), Visit 4 (Day 197), and Visit 5 (281)
| Intervention | percentage of compliance (Mean) | |||
|---|---|---|---|---|
| Visit 2 | Visit 3 | Visit 4 | Visit 5 | |
| OnabotulinumtoxinA + Placebo | 99.73 | 99.73 | 97.65 | 99.63 |
| OnabotulinumtoxinA + Topiramate | 100 | 99.84 | 99.55 | 98.69 |
Score on Subject Global Impression of Change at Visits 3-6 (Day 113 and 365). Likert scale ranging from 1-7, where 1 = extremely worse and 7 = extremely better. (NCT01700387)
Timeframe: Collected on Visit 3 (Day 113), Visit 4 (Day 197), Visit 5 (281), and Visit 6 (Day 365)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | 5.30 | 5.77 | 6.17 | 6.00 |
| OnabotulinumtoxinA + Topiramate | 5.38 | 6.33 | 6.66 | 7.00 |
The Controlled Oral Word Association Test (COWAT) is a measure of verbal fluency. Raw COWAT scores have a lower bound of 0 with no upper bound. Higher scores indicate better verbal fluency. COWAT score percent change from baseline will be reported. Positive change scores represent better verbal fluency compared to baseline. (NCT01700387)
Timeframe: Baseline, Visit 3 (Day 113) through Visit 6 (Day 365)
| Intervention | percentage of change from baseline score (Mean) | |||
|---|---|---|---|---|
| Visit 3 | Visit 4 | Visit 5 | Visit 6 | |
| OnabotulinumtoxinA + Placebo | -3.50 | -8.93 | 1.48 | -4.99 |
| OnabotulinumtoxinA + Topiramate | -17.06 | -17.93 | -12.63 | -5.05 |
The Migraine-Specific Quality of Life Questionnaire (MSQ) is a scale that measures the impact of migraine across three aspects: role function-restrictive (RR), role function-preventive (RP), and emotional function (EF). Possible scores on each sub-scale range from a 0 to 100 scale such that higher scores indicate better quality of life. (NCT01700387)
Timeframe: Baseline, Months: 3, 6, 9 and 12
| Intervention | score on a scale (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Role Function-Restrictive - Baseline | Role Function-Restrictive - Month 3 | Role Function-Restrictive - Month 6 | Role Function-Restrictive - Month 9 | Role Function-Restrictive - Month 12 | Role Function-Preventive - Baseline | Role Function-Preventive - Month 3 | Role Function-Preventive - Month 6 | Role Function-Preventive - Month 9 | Role Function-Preventive - Month 12 | Emotional Function - Baseline | Emotional Function - Month 3 | Emotional Function - Month 6 | Emotional Function - Month 9 | Emotional Function - Month 12 | |
| OnabotulinumtoxinA + Placebo | 29.71 | 56.29 | 59.37 | 60.41 | 72.38 | 46.50 | 65.00 | 72.22 | 72.86 | 80.83 | 22.67 | 56.67 | 56.30 | 70.48 | 78.89 |
| OnabotulinumtoxinA + Topiramate | 32.14 | 56.51 | 77.14 | 79.52 | 81.90 | 56.50 | 72.78 | 90.00 | 88.33 | 96.67 | 39.33 | 57.78 | 88.89 | 92.22 | 95.56 |
pharmacokinetic exposure (ng*hr/ml) (NCT01995825)
Timeframe: 0-12hr
| Intervention | ng*hr/ml (Mean) |
|---|---|
| Brand Lamotrigine | 101346 |
| Generic Lamotrigine | 101393 |
highest concentration over the time duration 0-12hr (ng/ml) (NCT01995825)
Timeframe: 0-12hr
| Intervention | ng/ml (Mean) |
|---|---|
| Brand Lamotrigine | 10670 |
| Generic Lamotrigine | 10697 |
pharmacokinetic exposure (ng*hr/ml). Pharmacokinetic (PK) blood levels will be drawn at the schedule times: immediately prior to lamotrigine administration, then after drug administration at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hr. (NCT02404168)
Timeframe: 0-12hr
| Intervention | ng*hr/ml (Mean) |
|---|---|
| Active Comparator: Lamotrigine Brand | 79640 |
| Experimental: Lamotrigine Generic | 81653 |
pharmacokinetic rate (ng/ml). Pharmacokinetic (PK) blood levels will be drawn at the schedule times: immediately prior to lamotrigine administration, then after drug administration at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, and 12.0 hr. (NCT02404168)
Timeframe: 0-12hr
| Intervention | ng/ml (Mean) |
|---|---|
| Active Comparator: Lamotrigine Brand | 8836 |
| Experimental: Lamotrigine Generic | 9024 |
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Mean change from baseline AEP Score at 12 months
| Intervention | Units on a scale (Mean) |
|---|---|
| VNS Therapy | -6.0 |
| Best Medical Practice | -3.2 |
The Center for Epidemiologic Studies Depression Scale (CES-D) includes 20 items comprising six scales reflecting major dimensions of depression: depressed mood, feelings of guilt and worthlessness, feelings of helplessness and hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance. Possible range of scores is 0 to 60, higher scores indicate more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline CES-D Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -2.2 |
| Best Medical Practice | 0.5 |
The Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) is a 6-item questionnaire validated to screen for depression in people with epilepsy. Scores range from 6 to 24, with higher scores indicating more depressive symptoms. (NCT00522418)
Timeframe: Mean change from baseline NDDI-E Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -1.0 |
| Best Medical Practice | -0.2 |
Change from baseline in number of AED medications by visit (NCT00522418)
Timeframe: Change from baseline in number of AEDs at 12 months
| Intervention | Number of AEDs Taken (Median) |
|---|---|
| VNS Therapy | 0 |
| Best Medical Practice | 0 |
The Clinical Global Impression scale (CGI-I) is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention Scores range from 1-7: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. (NCT00522418)
Timeframe: Mean change from baseline CGI-I Score at 12 months
| Intervention | Units on a Scale (Mean) |
|---|---|
| VNS Therapy | -0.8 |
| Best Medical Practice | -0.3 |
Percent change in total seizuires per week from baseline at 12 months (NCT00522418)
Timeframe: Mean percent change from baseline in seizure frequency at 12 months
| Intervention | Percent Change (Mean) |
|---|---|
| VNS Therapy | -19.1 |
| Best Medical Practice | -1.0 |
QOLIE-89 contains 17 multi-item measures of overall quality of life, emotional well-being, role limitations due to emotional problems, social support, social isolation, energy/fatigue, worry about seizure, medication effects, health discouragement, work/driving/social function, attention/concentration, language, memory, physical function, pain, role limitations due to physical problems, and health perceptions. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. (NCT00522418)
Timeframe: Mean change from baseline QOLIE-89 Overall Score at 12 months
| Intervention | units on a scale (Mean) |
|---|---|
| VNS Therapy | 5.5 |
| Best Medical Practice | 1.2 |
Response Rate is defined as the percent of participants who are responders. A Responder is defined as participants with a reduction of at least 50% or 75% in seizure frequency from baseline to the seizure count evaluation period. (NCT00522418)
Timeframe: Number of Responders at 12 Months
| Intervention | participants (Number) |
|---|---|
| VNS Therapy | 10 |
| Best Medical Practice | 7 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | units on a scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score < 40 | 3.3 | 0.5 |
QOLIE-89 contains 17 multi-item measures of overall quality of life. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life. Adverse Events Profile (AEP) is a 19-item scale used as a systematic measure of adverse effects from antiepileptic drugs (AEDs). Scores range from 19-76; higher scores indicate high prevelance and severity of adverse events. (NCT00522418)
Timeframe: Change from baseline up to 12 months
| Intervention | Units on a Scale (Least Squares Mean) | |
|---|---|---|
| VNS Therapy | Best Medical Practice | |
| Baseline Adverse Event Profile Score >= 40 | 3.3 | 0.7 |
207 reviews available for lamotrigine and Aura
| Article | Year |
|---|---|
Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
Topics: Amyotrophic Lateral Sclerosis; Analgesics; Anticonvulsants; Epilepsy; Humans; Ion Channel Gating; Mo | 2001 |
Effects of anti-seizure medications on sleep architecture and daytime sleepiness in patients with epilepsy: A literature review.
Topics: Anticonvulsants; Disorders of Excessive Somnolence; Epilepsy; Humans; Lamotrigine; Sleep | 2021 |
Pharmacological Medical Treatment of Epilepsy in Patients with Dementia: A Systematic Review.
Topics: Aged; Alzheimer Disease; Anticonvulsants; Epilepsy; Humans; Lamotrigine; Levetiracetam; Randomized C | 2021 |
The efficacy of lamotrigine after failure of the first administration of valproate in treating epilepsy: a systematic review and meta-analysis.
Topics: Epilepsy; Humans; Lamotrigine; Quality of Life; Triazines; Valproic Acid | 2022 |
Therapeutic Basis of Generic Substitution of Antiseizure Medications.
Topics: Anticonvulsants; Drug Substitution; Drugs, Generic; Epilepsy; Humans; Lamotrigine; Pharmaceutical Pr | 2022 |
Sudden Death and Cardiac Arrythmia With Lamotrigine: A Rapid Systematic Review.
Topics: Anticonvulsants; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Epilepsy; Humans; Lamotrigine; Risk F | 2022 |
A review of the pharmacotherapeutic considerations for managing epilepsy in people with autism.
Topics: Anticonvulsants; Autistic Disorder; Epilepsy; Humans; Lamotrigine; Syndrome | 2022 |
Adverse fetal and neonatal outcomes following in-utero exposure to oxcarbazepine: A systematic review and meta-analysis.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Observational Studies as Topic; Oxcarbazepin | 2022 |
Impact of Antiseizure Medications on Appetite and Weight in Children.
Topics: Anticonvulsants; Appetite; Child; Epilepsy; Humans; Lamotrigine; Weight Gain | 2022 |
Side effects of long-term oral anti-seizure drugs on thyroid hormones in patients with epilepsy: a systematic review and network meta-analysis.
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Humans; Lamotrigine; Levetiracetam; Network Meta-Analysis; | 2022 |
Dosage Optimization of Lamotrigine in Pregnancy: A Pharmacometric Approach Using Modeling and Simulation.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; Triazine | 2022 |
The interplay of epilepsy with impaired mitophagy and autophagy linked dementia (MAD): A review of therapeutic approaches.
Topics: Anticonvulsants; Carbamazepine; Dementia; Epilepsy; Felbamate; Gabapentin; Humans; Inflammasomes; La | 2022 |
Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force
Topics: Breast Feeding; Cannabidiol; Carbamazepine; Child; Clobazam; Clonazepam; Epilepsy; Ethosuximide; Eve | 2022 |
Pharmacologic and Dietary Treatments for Epilepsies in Children Aged 1-36 Months: A Systematic Review.
Topics: Anticonvulsants; Child; Diet, Ketogenic; Epilepsy; Humans; Infant; Infant, Newborn; Lamotrigine; Lev | 2023 |
Lamotrigine induced priapism in children: case analysis and literature review.
Topics: Adult; Anticonvulsants; Child; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; La | 2022 |
Lamotrigine induced priapism in children: case analysis and literature review.
Topics: Adult; Anticonvulsants; Child; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; La | 2022 |
Lamotrigine induced priapism in children: case analysis and literature review.
Topics: Adult; Anticonvulsants; Child; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; La | 2022 |
Lamotrigine induced priapism in children: case analysis and literature review.
Topics: Adult; Anticonvulsants; Child; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; La | 2022 |
Lamotrigine induced priapism in children: case analysis and literature review.
Topics: Adult; Anticonvulsants; Child; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; La | 2022 |
Lamotrigine induced priapism in children: case analysis and literature review.
Topics: Adult; Anticonvulsants; Child; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; La | 2022 |
Lamotrigine induced priapism in children: case analysis and literature review.
Topics: Adult; Anticonvulsants; Child; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; La | 2022 |
Lamotrigine induced priapism in children: case analysis and literature review.
Topics: Adult; Anticonvulsants; Child; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; La | 2022 |
Lamotrigine induced priapism in children: case analysis and literature review.
Topics: Adult; Anticonvulsants; Child; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; La | 2022 |
[Medical Treatment of Epilepsy].
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Seizures; Valproic Acid | 2023 |
Understanding Lamotrigine's Role in the CNS and Possible Future Evolution.
Topics: Anticonvulsants; Central Nervous System; Depressive Disorder, Major; Epilepsy; Glutamic Acid; Humans | 2023 |
Gabapentin monotherapy for epilepsy: A review.
Topics: Anticonvulsants; Carbamazepine; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Gabapentin; | 2023 |
Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.
Topics: Child; Cohort Studies; Epilepsy; Female; Humans; Lamotrigine; Male; Phenytoin; Pregnancy; Prenatal E | 2023 |
Effects of Second-Generation Antiepileptic Drugs Compared to First-Generation Antiepileptic Drugs on Bone Metabolism in Patients with Epilepsy: A Meta-Analysis.
Topics: Anticonvulsants; Bone and Bones; Carbamazepine; Clinical Trials as Topic; Epilepsy; Humans; Lamotrig | 2019 |
Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice.
Topics: Animals; Anticonvulsants; Drug Evaluation, Preclinical; Drug Interactions; Drug Therapy, Combination | 2020 |
[Transfer Mechanisms of Compounds between Mother and Fetus/Infant Aimed for Optimized Medication during Pregnancy and Breastfeeding].
Topics: Anticonvulsants; Benzodiazepines; Biological Transport; Breast Feeding; Cell Line; Epilepsy; Female; | 2020 |
The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy.
Topics: Adult; Affect; Anticonvulsants; Carbamazepine; Cognition; Epilepsy; Humans; Lacosamide; Lamotrigine; | 2020 |
Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications.
Topics: Anticonvulsants; Breast Feeding; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam | 2021 |
Lamotrigine-A Review of Analytical Methods Developed for Pharmaceutical Formulations and Biological Matrices.
Topics: Anticonvulsants; Drug Compounding; Epilepsy; Glutamates; Humans; Lamotrigine; Pharmaceutical Prepara | 2022 |
The effects of antiepileptic drugs on bone health: A systematic review.
Topics: Anticonvulsants; Bone Density; Carbamazepine; Epilepsy; Humans; Lamotrigine | 2021 |
Use of extended-release and immediate-release anti-seizure medications with a long half-life to improve adherence in epilepsy: A guide for clinicians.
Topics: Anticonvulsants; Delayed-Action Preparations; Epilepsy; Half-Life; Humans; Lamotrigine; Topiramate | 2021 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2021 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2021 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2021 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2021 |
Which treatment strategy in patients with epilepsy with focal seizures uncontrolled by the first anti-seizure medication?
Topics: Animals; Anticonvulsants; Epilepsy; Humans; Lamotrigine; Levetiracetam; Seizures | 2021 |
Initial Management of Seizure in Adults.
Topics: Adolescent; Adult; Anticonvulsants; Diagnosis, Differential; Electroencephalography; Epilepsy; Ethan | 2021 |
Neurodevelopment Following Exposure to Antiseizure Medications in Utero: A Review.
Topics: Anticonvulsants; Child; Epilepsy; Female; Humans; Lamotrigine; Oxcarbazepine; Pregnancy; Pregnancy C | 2021 |
Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Infant, Newbo | 2017 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis.
Topics: Anticonvulsants; Autistic Disorder; Bayes Theorem; Breast Feeding; Carbamazepine; Child; Epilepsy; F | 2017 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Comparative efficacy of antiepileptic drugs in children and adolescents: A network meta-analysis.
Topics: Adolescent; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anticonvulsants; Carbamazepine; Ch | 2018 |
Extended-release drug formulations for the treatment of epilepsy.
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Delayed-Action Preparations; Dr | 2018 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2018 |
Choice of therapeutic anti-seizure medication in patients with brain tumour.
Topics: Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilepsy; Gabapentin; Glioma; Humans; L | 2019 |
Clinical opinion: Earlier employment of polytherapy in sequential pharmacotherapy of epilepsy.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Drug Therapy, Combination; Epilepsy; Humans; Lamotrigine; | 2019 |
[Epilepsy in the elderly].
Topics: Age Factors; Aged; Aging; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Humans; Isoxa | 2013 |
Seizures and intracranial hemorrhage.
Topics: Anticonvulsants; Carbamazepine; Congenital Abnormalities; Eclampsia; Epilepsy; Female; Folic Acid; H | 2013 |
Complete and pure trisomy 18p due to a complex chromosomal rearrangement in a male adult with mild intellectual disability.
Topics: Adult; Chromosomes, Human, Pair 18; Electroencephalography; Epilepsy; Face; Humans; Intellectual Dis | 2013 |
Effects of monitoring strategies on seizures in pregnant women on lamotrigine: a meta-analysis.
Topics: Anticonvulsants; Drug Monitoring; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Compli | 2014 |
HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies.
Topics: Anticonvulsants; Case-Control Studies; Epilepsy; Genetic Predisposition to Disease; HLA-B15 Antigen; | 2015 |
[Treatment of pediatric epilepsy].
Topics: Adolescent; Amines; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecarboxylic A | 2014 |
[New antiepileptic drugs: characteristics and clinical applications].
Topics: Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Dioxolanes; Drug App | 2014 |
Lamotrigine effects on breastfed infants.
Topics: Adult; Anticonvulsants; Breast Feeding; Epilepsy; Female; Humans; Infant; Infant, Newborn; Lactation | 2015 |
Effects of phenytoin and lamotrigine treatment on serum BDNF levels in offsprings of epileptic rats.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Disease Models, Animal; Electroencephal | 2016 |
Antiepileptic Drugs.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; O | 2016 |
[Preconceptional and perinatal challenges of pregnancy in women with epilepsy].
Topics: Adult; Amines; Anticonvulsants; Benzodiazepines; Carbamazepine; Cyclohexanecarboxylic Acids; Epileps | 2016 |
[Lamotrigine monotherapy in children with epilepsy: a systematic review].
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Randomized Controlled Trials as Topic; Triazines | 2016 |
Treatment of epilepsy for people with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cognition; Depression; Epilepsy; Female | 2016 |
A pharmacological overview of lamotrigine for the treatment of epilepsy.
Topics: Anticonvulsants; Clinical Trials as Topic; Epilepsy; Humans; Lamotrigine; Molecular Structure; Triaz | 2016 |
An update of the Hong Kong Epilepsy Guideline: consensus statement on the use of antiepileptic drugs in Hong Kong.
Topics: Acetamides; Anticonvulsants; Carbamazepine; Consensus; Drugs, Generic; Epilepsy; Hong Kong; Humans; | 2017 |
Epilepsy treatment in adults and adolescents: Expert opinion, 2016.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Depression; Double-Blind Method; Dru | 2017 |
[The comparative study of effectiveness of lamotrigine and other antiepileptic drugs in criptogenic and symptomatic focal epilepsy].
Topics: Anticonvulsants; Epilepsies, Partial; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Lamotrigi | 2007 |
Lamotrigine-associated rash: to rechallenge or not to rechallenge?
Topics: Anticonvulsants; Bipolar Disorder; Databases, Bibliographic; Dose-Response Relationship, Drug; Drug | 2009 |
Epileptic disorders in pregnancy: an overview.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Epilepsy; Female; Folic Acid; Hemorrhag | 2008 |
Once-daily lamotrigine extended release for epilepsy management.
Topics: Anticonvulsants; Biological Availability; Clinical Trials as Topic; Delayed-Action Preparations; Epi | 2009 |
[Role of monotherapy with new antiepileptic drugs in the treatment of childhood epilepsy].
Topics: Anticonvulsants; Carbamazepine; Child; Drug Administration Schedule; Epilepsy; Fructose; Humans; Iso | 2009 |
[Mental disorders in epilepsy and their correction with lamotrigine].
Topics: Anticonvulsants; Epilepsy; Excitatory Amino Acid Antagonists; Humans; Lamotrigine; Mental Disorders; | 2008 |
New pharmacotherapies for pediatric seizures.
Topics: Adolescent; Amines; Animals; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecar | 2004 |
Managing antiepileptic drugs during pregnancy and lactation.
Topics: Anticonvulsants; Breast Feeding; Carbamazepine; Epilepsy; Female; Humans; Infant; Lactation; Lamotri | 2009 |
Rational polytherapy.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Inter | 2009 |
[Teratogenic effects of lamotrigine in women with bipolar disorder].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Epilepsy; Fema | 2009 |
Behavioral and cognitive effects of anti-epileptic drugs.
Topics: Amines; Anticonvulsants; Antidepressive Agents; Behavior; Cognition; Cognition Disorders; Cyclohexan | 2010 |
Extended-release lamotrigine in the treatment of patients with epilepsy.
Topics: Anticonvulsants; Delayed-Action Preparations; Epilepsy; Humans; Lamotrigine; Treatment Outcome; Tria | 2010 |
Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium.
Topics: Anticonvulsants; Antimanic Agents; Depressive Disorder; Drug Monitoring; Epilepsy; Female; Humans; L | 2010 |
Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.
Topics: Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; E | 2011 |
[Rational combinations of antiepileptic drugs for refractory epilepsy].
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamazepine; Cl | 2011 |
[Pregabalin and gabapentin in multiple sclerosis: clinical experiences and therapeutic implications].
Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Antineoplastic Agents; Carbamazepine; Cohor | 2011 |
Takotsubo syndrome (TKS): a possible mechanism of sudden unexplained death in epilepsy (SUDEP).
Topics: Adrenergic beta-1 Receptor Antagonists; Anticonvulsants; Aspirin; Bisoprolol; Death, Sudden; Epileps | 2012 |
[Recent advances in epilepsy management].
Topics: Adult; Anticonvulsants; Corpus Callosum; Electroencephalography; Epilepsy; Female; Fructose; Humans; | 2012 |
Lamotrigine use in pregnancy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Maternal-Fetal Exchange; Pregnancy; Triazine | 2012 |
Patient-reported side effects of lamotrigine during routine clinic visits.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Lo | 2012 |
Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons?
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Antipsychotic Agents; Epilepsy; Female; Humans; Lamotr | 2013 |
[Lamotrigine in treatment of women with epilepsy].
Topics: Abnormalities, Drug-Induced; Age Factors; Anticonvulsants; Breast Feeding; Contraceptive Agents, Fem | 2011 |
[Characteristics and indications of lamotrigine].
Topics: Adult; Animals; Anticonvulsants; Child; Clinical Trials as Topic; Drug Eruptions; Drug Interactions; | 2002 |
Antiepileptic drug therapy for adults: when to initiate and how to choose.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Felb | 2002 |
Review of lamotrigine and its clinical applications in epilepsy.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Child; Dose-Response Relationship, Drug; Epil | 2003 |
New antiepileptic drug therapies.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Ep | 2002 |
[Lamictal in epilepsy treatment in women].
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Middle Aged; Triazines | 2003 |
Lamotrigine in mood disorders.
Topics: Analgesics; Animals; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Clinical Trials as To | 2003 |
Gabapentin and lamotrigine: novel antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Epilepsy; | 1995 |
The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come?
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac | 2003 |
Antiepileptic drug pharmacokinetics during pregnancy and lactation.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Fetal Diseases; Fetal Hypoxia | 2003 |
[Lamotrigine in women with epilepsy. Review of present data].
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Contraceptives, Oral; Dose-Response Relationship, Drug | 2003 |
Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epileps
Topics: Acetates; Acute Disease; Adolescent; Adult; Amines; Anticonvulsants; Carbamazepine; Child; Controlle | 2004 |
Pharmacologic treatment of the catastrophic epilepsies.
Topics: Anticonvulsants; Child, Preschool; Epilepsies, Myoclonic; Epilepsy; Fructose; Humans; Infant; Isoxaz | 2004 |
Monotherapy in epilepsy: role of the newer antiepileptic drugs.
Topics: Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Epilepsy; Humans; Lamotrigine; Oxcarbazepi | 2004 |
Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Eruptions; Drug Interactions; Drug Therapy, | 2004 |
[Therapy of epilepsy: current strategy and tactics].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Age Factors; Anticonvulsants; Carbamazepine; Child; | 2004 |
Antiepileptic drugs and neuroprotection: current status and future roles.
Topics: Animals; Anticonvulsants; Brain; Epilepsy; Fructose; Humans; Isoxazoles; Lamotrigine; Levetiracetam; | 2005 |
The case for lamotrigine monitoring in pregnancy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Monitoring, Physiologic; Pregnancy; Triazine | 2006 |
Lamotrigine versus carbamazepine monotherapy for epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsies, Partial; Epilepsy; Epilepsy, Generalized; | 2006 |
[Epilepsy and male sexual dysfunction: etiology, diagnosis and therapy].
Topics: Androgens; Anticonvulsants; Bromocriptine; Carbamazepine; Cognition; Enzyme Induction; Epilepsy; Gon | 2006 |
Novel anticonvulsant drugs.
Topics: Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Fructose; Ga | 2007 |
2005 AES annual course: evidence used to treat women with epilepsy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Breast Feeding; Drug Monitoring; Drug Therapy, Combina | 2006 |
Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interactions; Drug Monitor | 2006 |
Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Exanthema; Humans; Intestinal Absorptio | 2006 |
Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders.
Topics: Anticonvulsants; Antimanic Agents; Dose-Response Relationship, Drug; Epilepsy; Humans; Lamotrigine; | 2006 |
[Newer antiepileptic drugs].
Topics: Amines; Animals; Anti-Anxiety Agents; Anticonvulsants; Calcium Channel Blockers; Carbamazepine; Cycl | 2007 |
Lamotrigine therapy in elderly patients with epilepsy, bipolar disorder or dementia.
Topics: Aged; Aged, 80 and over; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2007 |
Development of psychosis in patients with epilepsy treated with lamotrigine: report of six cases and review of the literature.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Hallucinations; Humans; Lamotrigine; Male; Middle Aged; Pa | 2007 |
Lamotrigine in pregnancy: safety profile and the risk of malformations.
Topics: Abnormalities, Drug-Induced; Animals; Anticonvulsants; Epilepsy; Female; Folic Acid Deficiency; Huma | 2007 |
[Effects of antiepileptic drugs on mood of people with epilepsy].
Topics: Affect; Anticonvulsants; Antidepressive Agents; Carbamazepine; Depressive Disorder; Epilepsy; Fructo | 2007 |
Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence.
Topics: Adult; Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Clinical Trials as | 2008 |
The new antiepileptic drugs.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Dioxolanes; Epilepsies, | 2007 |
[Current viewpoints in the treatment of epilepsies: role of new antiepileptics?].
Topics: 4-Aminobutyrate Transaminase; Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxyli | 1995 |
Mechanisms of action of currently prescribed and newly developed antiepileptic drugs.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Drugs, Investigational; Epi | 1994 |
Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy.
Topics: Animals; Anticonvulsants; Dosage Forms; Drug Evaluation; Drug Interactions; Drug Tolerance; Epilepsy | 1993 |
The new anticonvulsant drugs. Implications for avoidance of adverse effects.
Topics: Abnormalities, Drug-Induced; Anemia, Aplastic; Anticonvulsants; Chemical and Drug Induced Liver Inju | 1994 |
[New antiepileptic medications].
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; | 1995 |
Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam | 1995 |
New antiepileptic drugs--an explosion of activity.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Approval; Drug Interactions; Dr | 1995 |
[New antiepileptic drugs: vagabatrin, lamotrigine and felbamate].
Topics: Anticonvulsants; Epilepsy; Felbamate; gamma-Aminobutyric Acid; Humans; Lamotrigine; Phenylcarbamates | 1994 |
New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine, and vigabatrin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Approval; Epileps | 1994 |
[Vigabatrin and lamotrigin: experiences with 2 new anticonvulsants in the Swiss epilepsy clinic].
Topics: 4-Aminobutyrate Transaminase; Adult; Anticonvulsants; Child; Drug Therapy, Combination; Epilepsies, | 1995 |
Lamotrigine--a novel approach.
Topics: Anticonvulsants; Brain; Child; Drug Therapy, Combination; Electroencephalography; Epilepsy; Glutamic | 1994 |
Lamotrigine--a clinical overview.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, | 1994 |
Lamotrigine--managing the challenging patient.
Topics: Adolescent; Anticonvulsants; Child; Child Behavior; Child, Preschool; Dose-Response Relationship, Dr | 1994 |
Newer antiepileptic drugs. Towards an improved risk-benefit ratio.
Topics: Acetamides; Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dioxolane | 1994 |
New anti-epileptic drugs in the 1990s.
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Clobazam | 1994 |
The role of glutamate in epilepsy and other CNS disorders.
Topics: Animals; Central Nervous System Diseases; Epilepsy; Glutamic Acid; Humans; Lamotrigine; Mice; N-Meth | 1994 |
The clinical efficacy of lamotrigine as an antiepileptic drug.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Eruptions; Epilepsy; Humans; Lamotrigi | 1994 |
Guidelines for treating epilepsy in the age of felbamate, vigabatrin, lamotrigine, and gabapentin.
Topics: Acetates; Adult; Amines; Animals; Anticonvulsants; Child; Clinical Protocols; Controlled Clinical Tr | 1994 |
Lamotrigine: a review of antiepileptic efficacy.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Double-Blind Method; Epilepsy; Humans; Lamo | 1994 |
Safety of lamotrigine.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Eruptions; Epilepsy; Female; Humans; L | 1994 |
Lamotrigine versus other antiepileptic drugs: a star rating system is born.
Topics: Adolescent; Adult; Anticonvulsants; Attitude of Health Personnel; Clinical Trials as Topic; Drug Adm | 1994 |
Drug therapy for epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Decision Trees; Epilepsy; Felbamate; | 1994 |
Antiepileptic drugs in development: prospects for the near future.
Topics: Acetates; Adult; Amines; Aminocaproates; Animals; Anticonvulsants; Clinical Trials as Topic; Cyclohe | 1994 |
Advances in pharmacotherapy: recent developments in the treatment of epilepsy.
Topics: Acetates; Amines; Aminocaproates; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Aci | 1993 |
Antiepileptic drugs in clinical development.
Topics: Acetates; Amines; Aminocaproates; Anticonvulsants; Brain; Clinical Trials as Topic; Cyclohexanecarbo | 1993 |
Investigational antiepileptic drugs for the treatment of childhood seizure disorders: a review of efficacy and safety.
Topics: Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Child; Clinical Trials as | 1994 |
Advances in the pharmacotherapy of epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Gabapentin; gam | 1993 |
Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy.
Topics: Adult; Aged; Anticonvulsants; Child; Child, Preschool; Epilepsy; Humans; Lamotrigine; Triazines | 1995 |
Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Carbamazepine; Clinical Trials as Topic; | 1996 |
Utilization of new antiepileptic drugs in children.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Anticonvulsants; Carbamazepine; Child; Child, Pres | 1996 |
[Advances in the diagnostic and treatment of infantile epilepsy].
Topics: Acetates; Amines; Anticonvulsants; Brain; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Elec | 1996 |
[Current anti-epilepsy drugs].
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Therapy, Combina | 1995 |
Antiepileptic drug mechanisms of action.
Topics: Acetates; Action Potentials; Amines; Animals; Anticonvulsants; Barbiturates; Benzodiazepines; Calciu | 1995 |
Lamotrigine.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Disease Models, Animal; Drug Administration Sche | 1995 |
Important pharmacokinetic properties of antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Biopharmaceutics; Carbamazepine; Cyclohe | 1995 |
Diagnosis and treatment of epilepsy in children and adolescents.
Topics: Acetates; Adolescent; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids; | 1996 |
New antiepileptic drugs: a systematic review of their efficacy and tolerability.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Child; Cross-Over Studies; Cyclohexaneca | 1996 |
Pharmacokinetics of new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Carbamazepine; Cyclohexanecarboxylic Aci | 1996 |
Update on the mechanism of action of antiepileptic drugs.
Topics: 4-Aminobutyrate Transaminase; Acetamides; Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecar | 1996 |
Clinical administration of new antiepileptic drugs: an overview of safety and efficacy.
Topics: Acetates; Amines; Anticonvulsants; Confidence Intervals; Cyclohexanecarboxylic Acids; Drug Interacti | 1996 |
Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management.
Topics: Adult; Anticonvulsants; Cyclosporins; Epilepsy; Female; Humans; Immunosuppressive Agents; Injections | 1996 |
[Advantages and disadvantages of new antiepileptic drugs].
Topics: Acetates; Adrenocorticotropic Hormone; Amines; Anticonvulsants; Brain; Cyclohexanecarboxylic Acids; | 1996 |
[Treatment of the epilepsy: new drugs].
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbamaz | 1996 |
The new antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Acetates; Adolescent; Adult; Amines; Anticonvulsants; Child; Child, Pre | 1996 |
New antiepileptic drugs.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; F | 1996 |
[Antiepileptic drugs: mechanism of action].
Topics: Anticonvulsants; Barbiturates; Carbamazepine; Epilepsy; GABA Antagonists; gamma-Aminobutyric Acid; H | 1996 |
New antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; | 1996 |
Pharmacokinetics and interaction profile of topiramate: review and comparison with other newer antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Interactions; Drug Monitoring; | 1997 |
Overview of the safety of newer antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Inter | 1997 |
Lamotrigine in childhood epilepsies.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Lamotrigine; Triazines | 1997 |
New drugs and vagal stimulation for treatment of epilepsy--the Israeli experience.
Topics: Adult; Antidepressive Agents; Epilepsy; Female; gamma-Aminobutyric Acid; Humans; Lamotrigine; Male; | 1996 |
Pharmacologic and dietary therapies in epilepsy: conventional treatments and recent advances.
Topics: Acetates; Amines; Anticonvulsants; Benzodiazepines; Carbamazepine; Cyclohexanecarboxylic Acids; Epil | 1997 |
Recent advancements in epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap | 1997 |
A review of the newer antiepileptic drugs and the ketogenic diet.
Topics: Acetates; Age Factors; Amines; Anticonvulsants; Child; Child, Preschool; Cyclohexanecarboxylic Acids | 1997 |
Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in?
Topics: Anticonvulsants; Brain; Calcium Channels; Epilepsy; Humans; Lamotrigine; Receptors, GABA; Sodium Cha | 1997 |
Lamotrigine: pharmacokinetics.
Topics: Absorption; Adult; Age Factors; Aged; Animals; Anticonvulsants; Child; Child, Preschool; Drug Intera | 1997 |
Adult experience with lamotrigine.
Topics: Adult; Anticonvulsants; Drug Interactions; Epilepsy; Humans; Lamotrigine; Treatment Outcome; Triazin | 1997 |
Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes.
Topics: Anticonvulsants; Child; Diagnosis, Differential; Epilepsy; Epilepsy, Generalized; Humans; Lamotrigin | 1997 |
Meeting the challenge of epilepsy in persons with multiple handicaps.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Comorbidity; Developmental Disabilities | 1997 |
Behavioral and cognitive effects of lamotrigine.
Topics: Adult; Anticonvulsants; Child; Cognition Disorders; Epilepsy; Female; Humans; Intellectual Disabilit | 1997 |
Overview of lamotrigine and the new antiepileptic drugs: the challenge.
Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Interactions; Epilepsy; | 1997 |
Advances in the medical treatment of epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Diazepam; Drug Approv | 1998 |
The new antiepileptic drugs: a systematic review of their efficacy and tolerability.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug | 1997 |
Voltage-activated calcium channels: targets of antiepileptic drug therapy?
Topics: Animals; Anticonvulsants; Calcium Channels; Carbamazepine; Drug Design; Epilepsy; Felbamate; Humans; | 1997 |
Role of new and established antiepileptic drugs.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Drug Interactions; Epilepsies, Partial; Epilepsy | 1998 |
New antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Approval; Epilep | 1998 |
Lamotrigine and gabapentin. Alternative in the treatment of bipolar disorder.
Topics: Acetates; Amines; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Clinic | 1998 |
Lamotrigine-associated anticonvulsant hypersensitivity syndrome.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Drug Hypersensitivity; Epilepsy; | 1998 |
Lamotrigine-induced severe cutaneous adverse reactions.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combin | 1998 |
New medication options for patients with epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap | 1998 |
Lamotrigine in the treatment of epilepsy in people with intellectual disability.
Topics: Anticonvulsants; Epilepsy; Humans; Intellectual Disability; Lamotrigine; Treatment Outcome; Triazine | 1998 |
Population pharmacokinetics of lamotrigine adjunctive therapy in adults with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Clinical Trials, Phase II as Topic; Clinical Tria | 1999 |
New antiepileptic drugs: comparison of key clinical trials.
Topics: Acetates; Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyclohexanecarboxylic Acids; | 1999 |
Lamotrigine-associated rash: risk/benefit considerations in adults and children.
Topics: Adult; Age Factors; Anticonvulsants; Child; Drug Eruptions; Epilepsy; Humans; Incidence; Lamotrigine | 1999 |
Monostars: an aid to choosing an antiepileptic drug as monotherapy.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Administration S | 1999 |
Use of new antiepileptic drugs in the treatment of childhood epilepsy.
Topics: Acetates; Adult; Age Factors; Amines; Anticonvulsants; Child; Clinical Trials as Topic; Cyclohexanec | 1999 |
Lamotrigine.
Topics: Adolescent; Adult; Animals; Anticonvulsants; Child; Clinical Trials as Topic; Diplopia; Dizziness; D | 1999 |
Managing pediatric epilepsy syndromes with new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose | 1999 |
The clinical pharmacokinetics of the new antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Biological Availability; Cyclohexanecarboxylic Acids; Dose-Respon | 1999 |
Potential hepatotoxicity of lamotrigine.
Topics: Anticonvulsants; Child, Preschool; Encephalitis; Epilepsy; Humans; Lamotrigine; Liver Failure, Acute | 2000 |
New antiepileptic drugs.
Topics: Acetates; Amines; Animals; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Interac | 2000 |
[Current data on lamotrigine].
Topics: Adult; Aged; Anticonvulsants; Child; Child, Preschool; Epilepsy; Humans; Infant; Infant, Newborn; La | 2000 |
Idiosyncratic reactions: new methods of identifying high-risk patients.
Topics: Anticonvulsants; Biomarkers; Drug Monitoring; Epilepsy; Epoxide Hydrolases; Felbamate; Free Radical | 2000 |
Therapeutic safety monitoring: what to look for and when to look for it.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Monitoring; Epil | 2000 |
Newer antiepileptic drugs and non surgical approaches in epilepsy.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Immunoglobulins; Lamotrigine; Triazines; Vigabatrin | 2000 |
New antiepileptic drugs and preparations.
Topics: Acetates; Administration, Rectal; Age Factors; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; | 2000 |
Cognitive side effects of anticonvulsants.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Carbamazepine; Cognition Disorders; Cyclohexane | 2001 |
The role of new antiepileptic drugs.
Topics: Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epilepsies, Partial; Epilepsy; Epi | 2001 |
The management of refractory idiopathic epilepsies.
Topics: Adolescent; Anticonvulsants; Child; Clinical Protocols; Drug Administration Schedule; Drug Therapy, | 2001 |
Efficacy and safety of lamotrigine in pediatric patients.
Topics: Anticonvulsants; Child; Clinical Trials as Topic; Epilepsy; Humans; Lamotrigine; Syndrome; Treatment | 2002 |
Lamotrigine update and its use in mood disorders.
Topics: Acetates; Aggression; Amines; Antidepressive Agents; Bipolar Disorder; Cyclohexanecarboxylic Acids; | 2002 |
Children versus adults: pharmacokinetic and adverse-effect differences.
Topics: Adolescent; Age Factors; Anticonvulsants; Chemical and Drug Induced Liver Injury; Child; Child, Pres | 2002 |
Clinical use of lamotrigine.
Topics: Animals; Anticonvulsants; Epilepsy; Humans; Lamotrigine; Triazines | 1992 |
Lamotrigine.
Topics: Anticonvulsants; Drug Interactions; Epilepsy; Humans; Lamotrigine; Triazines | 1992 |
Excitatory amino acid transmitters in epilepsy.
Topics: Anticonvulsants; Aspartic Acid; Epilepsy; Epilepsy, Temporal Lobe; Glutamates; Glutamic Acid; Humans | 1991 |
Lamotrigine.
Topics: Animals; Anticonvulsants; Brain; Drugs, Investigational; Electroencephalography; Epilepsy; Evoked Po | 1991 |
Overview of the clinical efficacy of lamotrigine.
Topics: Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; Epilepsy; Humans; Lamotrigine; Meta- | 1991 |
Human safety of lamotrigine.
Topics: Anticonvulsants; Clinical Trials as Topic; Double-Blind Method; Electroencephalography; Epilepsy; Hu | 1991 |
138 trials available for lamotrigine and Aura
| Article | Year |
|---|---|
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Topics: Child, Preschool; Cost-Benefit Analysis; Epilepsies, Partial; Epilepsy; Female; Humans; Lamotrigine; | 2021 |
Value of Group Intervention on Prognosis of Quality of Life in Epileptic Patients Treated With Sodium Valproate and Lamotrigine.
Topics: Epilepsy; Humans; Lamotrigine; Prognosis; Quality of Life; Valproic Acid | 2023 |
Evaluate the effects of long-term valproic acid treatment on metabolic profiles in newly diagnosed or untreated female epileptic patients: A prospective study.
Topics: Adiponectin; Adolescent; Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Cholesterol; Choles | 2017 |
Bioequivalence Between Generic and Branded Lamotrigine in People With Epilepsy: The EQUIGEN Randomized Clinical Trial.
Topics: Adult; Anticonvulsants; Area Under Curve; Drugs, Generic; Epilepsy; Female; Humans; Lamotrigine; Mal | 2017 |
Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either Valproate or Lamotrigine monotherapy: A prospective study.
Topics: Adolescent; Adult; Anticonvulsants; Endocrine System; Epilepsy; Female; Follow-Up Studies; Hormones; | 2018 |
Unblinded, randomized multicenter trial comparing lamotrigine and valproate combination with controlled-release carbamazepine monotherapy as initial drug regimen in untreated epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Drug Therapy, Combination; Epile | 2018 |
AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies.
Topics: Anticonvulsants; Carbamazepine; Double-Blind Method; Drug Monitoring; Epilepsy; Female; Humans; Lamo | 2018 |
Impact of carbamazepine, lamotrigine, and levetiracetam on vascular risk markers and lipid-lowering agents in the elderly.
Topics: Aged; Aged, 80 and over; Anticonvulsants; C-Reactive Protein; Carbamazepine; Cholesterol, LDL; Doubl | 2018 |
A comparison of extracellular excitatory amino acids release inhibition of acute lamotrigine and topiramate treatment in the hippocampus of PTZ-kindled epileptic rats.
Topics: Animals; Anticonvulsants; Epilepsy; Excitatory Amino Acid Agents; Excitatory Amino Acid Antagonists; | 2013 |
Pharmacokinetics of lamotrigine in paediatric and young adult epileptic patients--nonlinear mixed effects modelling approach.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Interactions; Drug | 2014 |
Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China.
Topics: Adult; Anticonvulsants; Asian People; China; Epilepsy; Female; Genotype; Glucuronosyltransferase; Hu | 2014 |
Lamotrigine extended-release as adjunctive therapy with optional conversion to monotherapy in older adults with epilepsy.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Delayed-Action Preparations; Drug Therapy, Combination; Ep | 2014 |
Treatment outcome after failure of a first antiepileptic drug.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Fructose; Humans; Lamotrigine; Male; Middle Ag | 2014 |
Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anticonvulsants; Biologi | 2015 |
An educational intervention on drug interactions and contraceptive options for epilepsy patients: a pilot randomized controlled trial.
Topics: Adult; Anticonvulsants; Contraceptives, Oral, Hormonal; Drug Interactions; Epilepsy; Female; Health | 2016 |
Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.
Topics: Adolescent; Anticonvulsants; Asian People; Child; Child, Preschool; Drug Therapy, Combination; Epile | 2015 |
Factors that influence the pharmacokinetics of lamotrigine in Japanese patients with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Asian People; Child; Child, Preschool; Epilepsy; Female; G | 2016 |
Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
Topics: Adult; Anticonvulsants; Cross-Over Studies; Double-Blind Method; Drug Substitution; Drugs, Generic; | 2016 |
Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B; Epil | 2016 |
Association of UGT2B7 and UGT1A4 Polymorphisms with Serum Concentration of Antiepileptic Drugs in Children.
Topics: Adolescent; Anticonvulsants; Asian People; Base Sequence; Child; Child, Preschool; Epilepsy; Female; | 2016 |
Diurnal lamotrigine plasma level fluctuations: clinical significance and indication of shorter half-life with chronic administration.
Topics: Adult; Anticonvulsants; Circadian Rhythm; Drug Administration Schedule; Drug Compounding; Drug Inter | 2008 |
Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine.
Topics: Adolescent; Adult; Anovulation; Epilepsy; Female; Humans; Hyperandrogenism; Internationality; Lamotr | 2008 |
Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study.
Topics: Affect; Age of Onset; Aged; Aged, 80 and over; Anticonvulsants; Data Interpretation, Statistical; De | 2008 |
The impact of side effects on long-term retention in three new antiepileptic drugs.
Topics: Anticonvulsants; Drug Utilization; Epilepsy; Fructose; Humans; Lamotrigine; Levetiracetam; Longitudi | 2009 |
Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Fetal Blood; Humans; Inf | 2009 |
Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Cardiovascular System; Cohort Studies; Doub | 2009 |
Effects of valproate or lamotrigine monotherapy on the reproductive endocrine and insulin-related metabolic profile in Chinese adults with epilepsy: a prospective randomized study.
Topics: Adolescent; Adult; Anticonvulsants; China; Cross-Sectional Studies; Dose-Response Relationship, Drug | 2009 |
Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Epilepsy; F | 2009 |
Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Area Under Curve; Dibenzazepines; Drug Int | 2010 |
Antiepileptic drugs and quality of life in the elderly: results from a randomized double-blind trial of carbamazepine and lamotrigine in patients with onset of epilepsy in old age.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Cognition; Double-Blind Method; Epilepsy; F | 2010 |
Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Anticonvulsants; Case-Control Stud | 2010 |
Effects of carbamazepine and metabolites on IL-2, IL-5, IL-6, IL-10 and IFN-γ secretion in epileptic patients: the influence of co-medication.
Topics: Acridines; Adult; Aged; Anticonvulsants; Carbamazepine; Dibenzazepines; Drug Therapy, Combination; E | 2011 |
Long-term control of epileptic drop attacks with the combination of valproate, lamotrigine, and a benzodiazepine: a 'proof of concept,' open label study.
Topics: Adolescent; Adult; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Drug Therapy, Combinat | 2011 |
Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Asian People; Drug Combinations; Epilepsy; Female; Humans; | 2012 |
Analysis of three lamotrigine extended-release clinical trials: comparison of pragmatic ITT and LOCF methodologies.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Delayed-Action Preparations; Dose-Response Relationship, D | 2012 |
Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Area Under Curve; Body Weight; Carbamazepine; Child | 2012 |
The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Early Diagnosis; Epilepsy; Female; Humans; Lamotrigine; L | 2012 |
Population pharmacokinetics of lamotrigine in Indian epileptic patients.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Epilepsy; Female; Humans; Lamotrigine; Male; Middle | 2013 |
[Efficacy and safety of the combined therapy of valproic acid and lamotrigine for epileptics].
Topics: Child; Child, Preschool; Drug Therapy, Combination; Epilepsies, Partial; Epilepsy; Epilepsy, Absence | 2012 |
Reduced immunoglobulin levels in epilepsy patients treated with levetiracetam, lamotrigine, or carbamazepine.
Topics: Adolescent; Adult; Anticonvulsants; Body Mass Index; Carbamazepine; Double-Blind Method; Epilepsy; F | 2013 |
Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.
Topics: Adult; Anticonvulsants; Child; Child Development; Child, Preschool; Cognition; Epilepsy; Female; Hum | 2013 |
Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Asthenia; Clinical Protocols; Cyclohexan | 2002 |
Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units.
Topics: Administration, Oral; Adult; Anticonvulsants; Biological Availability; Dose-Response Relationship, D | 2003 |
Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Body Mass Index; Child; Double-Blind Metho | 2003 |
Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients.
Topics: Adult; Analysis of Variance; Anticonvulsants; Area Under Curve; Dose-Response Relationship, Drug; Dr | 2003 |
Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation.
Topics: Adolescent; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Humans; Intellectua | 2003 |
The effect of lamotrigine on the EEGs of children and adolescents with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Brain; Child; Child, Preschool; Electroencephalography; Epilepsy | 2003 |
Correlation of lamotrigine concentrations between serum and saliva.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Chromatography, High Pressure Liquid; D | 2003 |
Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Evaluation | 2003 |
Efficacy and tolerability of conversion to monotherapy with lamotrigine compared with valproate and carbamazepine in patients with epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Chi-Square Distribution; Drug Interactions; Drug Tolerance; E | 2004 |
Treatment of interictal epileptiform discharges can improve behavior in children with behavioral problems and epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child Behavior Disorders; Cross-Over Studies; Double-Blind Metho | 2005 |
A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy.
Topics: Adolescent; Adult; Aged; Algorithms; Anticonvulsants; Confidence Intervals; Demography; Dose-Respons | 2005 |
Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy.
Topics: Adult; Area Under Curve; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; E | 2005 |
Pharmacological outcomes in newly diagnosed epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Therapy, C | 2005 |
Lamotrigine therapy in patients requiring a change in antiepileptic drug regimen.
Topics: Adolescent; Adult; Affect; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Dru | 2005 |
New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.
Topics: Aged; Aging; Amines; Anticonvulsants; Carbamazepine; Cerebral Infarction; Cyclohexanecarboxylic Acid | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers.
Topics: Adult; Anticonvulsants; Brain; Cognition Disorders; Cross-Over Studies; Dose-Response Relationship, | 2005 |
Effectiveness of lamotrigine in clinical practice: results of a retrospective population-based study.
Topics: Adult; Anticonvulsants; Drug Interactions; Epilepsy; Female; Humans; Lamotrigine; Logistic Models; M | 2005 |
Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC.
Topics: Anticonvulsants; Calibration; Carbamazepine; Chromatography, High Pressure Liquid; Dose-Response Rel | 2005 |
Effect of antiepileptic drug comedication on lamotrigine clearance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Antidepressive Agents; Body Weight; Chi | 2005 |
Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy.
Topics: Adolescent; Adult; Age Factors; Aging; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Down | 2005 |
Plasma free carnitine in epilepsy children, adolescents and young adults treated with old and new antiepileptic drugs with or without ketogenic diet.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Carnitine; Child; Child, Preschool; Dietary Fats; | 2006 |
Subjective preference for lamotrigine or topiramate in healthy volunteers: relationship to cognitive and behavioral functioning.
Topics: Adult; Anticonvulsants; Attention; Behavior; Cognition; Cross-Over Studies; Double-Blind Method; Epi | 2006 |
Effect of lamotrigine on sexual function in patients with epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Male; Middle Aged; Prospective Studie | 2006 |
Add-on lamotrigine treatment and plasma glutamate levels in epilepsy: relation to treatment response.
Topics: Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Glutamic Acid; Humans; Lamotrig | 2006 |
Quantitative EEG effects of carbamazepine, oxcarbazepine, valproate, lamotrigine, and possible clinical relevance of the findings.
Topics: Adolescent; Adult; Alpha Rhythm; Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epil | 2006 |
Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Cognition; Double-Blind Method; Epilepsy; Female; Fructose | 2006 |
Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Ther | 2006 |
Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Contraceptives, Oral, Hormonal; Drug Administration Schedule; Dr | 2006 |
Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives.
Topics: Anticonvulsants; Contraceptives, Oral; Drug Combinations; Epilepsy; Female; Humans; Kinetics; Lamotr | 2006 |
Effect of lamotrigine on depressive symptoms in adult patients with epilepsy.
Topics: Adult; Affect; Analysis of Variance; Anticonvulsants; Depression; Double-Blind Method; Epilepsy; Fem | 2007 |
Lamotrigine in patients with epilepsy and comorbid depressive symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Depression; Drug Evaluation; Epilepsy; | 2007 |
Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial.
Topics: Adult; Anticonvulsants; Contraceptives, Oral, Combined; Cross-Over Studies; Double-Blind Method; Dru | 2007 |
Sodium valproate versus lamotrigine: a randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy.
Topics: Adolescent; Adult; Aged; Androgens; Androstenedione; Anticonvulsants; Body Mass Index; Body Weight; | 2007 |
An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Cross-Cultural Comparison; Del | 2007 |
Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Interactions; Drug Therapy | 2007 |
Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Area Under Curve; | 2008 |
A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructo | 2007 |
Relative influences of adjunctive topiramate and adjunctive lamotrigine on scanning and the effective field of view.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Cognition; Data Interpretation, Statist | 2008 |
Lamotrigine therapeutic thresholds.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Denmark; Disease-Free Survival; D | 2008 |
Comparative daily profiles with different preparations of lamotrigine: a pilot investigation.
Topics: Adult; Anticonvulsants; Drug Administration Schedule; Epilepsy; Female; Humans; Lamotrigine; Male; M | 2008 |
Lamotrigine and catamenial epilepsy.
Topics: Adult; Anticonvulsants; Electroencephalography; Epilepsy; Female; Humans; Lamotrigine; Menstruation; | 2008 |
Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
Topics: Adult; Anticonvulsants; Cohort Studies; Drug Prescriptions; Drug Utilization; Drugs, Generic; Epilep | 2008 |
A new drug suitable for children and young people with epilepsy and intellectual impairments.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Intellectual | 1995 |
Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Double-Blind Method; Epilepsy; Female; Huma | 1995 |
[Lamotrigine: first experience in Italy].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Epilepsy; Female | 1995 |
Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Follow-Up Studies; | 1994 |
Measuring antiepileptic therapies: the patient vs the physician viewpoint.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Lamotri | 1994 |
The clinical efficacy of lamotrigine as an antiepileptic drug.
Topics: Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Eruptions; Epilepsy; Humans; Lamotrigi | 1994 |
Seizure severity and the quality of life.
Topics: Anticonvulsants; Attitude to Health; Confidence Intervals; Drug Administration Schedule; Epilepsy; H | 1993 |
Lamotrigine for the treatment of epilepsy in childhood.
Topics: Adolescent; Anticonvulsants; Body Weight; Child; Child, Preschool; Consumer Product Safety; Dose-Res | 1995 |
Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy.
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cl | 1996 |
Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments.
Topics: Adolescent; Adult; Affect; Aging; Anticonvulsants; Behavior; Carbamazepine; Cognition Disorders; Dou | 1996 |
Lamotrigine high-dose tolerability and safety in patients with epilepsy: a double-blind, placebo-controlled, eleven-week study.
Topics: Adolescent; Adult; Anticonvulsants; Diplopia; Dose-Response Relationship, Drug; Double-Blind Method; | 1996 |
Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication.
Topics: Adult; Age Factors; Anticonvulsants; Body Weight; Carbamazepine; Dose-Response Relationship, Drug; D | 1996 |
A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Male | 1996 |
Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut syndrome).
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Databases, Factual; Drug A | 1997 |
The concentration-effect relationship with lamotrigine (LTG)
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Ep | 1997 |
Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Drug Synergism; Epilepsy | 1997 |
Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Body Weight; Contraceptives, Oral, Hormonal; Databases, Fa | 1997 |
Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Developmental Disabilities; Drug Resist | 1997 |
Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Double-Blind Method; Epilepsy; Female; | 1997 |
Lamotrigine in Rett syndrome: treatment experience from a pilot study.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Incidence; La | 1998 |
Lamotrigine treatment in childhood drug resistant epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Cognition; Electroencephalography; Epil | 1998 |
Economic analysis of epilepsy treatment: a cost minimization analysis comparing carbamazepine and lamotrigine in the UK.
Topics: Anticonvulsants; Carbamazepine; Cost Control; Decision Support Techniques; Drug Costs; Epilepsies, P | 1998 |
Adjunctive therapy in epilepsy with new antiepileptic drugs: is it of any value?
Topics: Acetates; Amines; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Clobazam; Cyclohexanecarbox | 1998 |
Does percent reduction in seizure frequency correlate with plasma concentration of anticonvulsant drugs? Experience with four anticonvulsant drugs.
Topics: Anticonvulsants; Double-Blind Method; Epilepsy; Flunarizine; Fructose; Humans; Lamotrigine; Linear M | 1998 |
Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs.
Topics: Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Lamotrigine; Male; Triazines | 1999 |
Lamotrigine therapy in juvenile neuronal ceroid lipofuscinosis.
Topics: Adolescent; Adult; Anticonvulsants; Child; Comorbidity; Drug Therapy, Combination; Epilepsy; Female; | 1999 |
Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Double-Blind Method; Drug Administration Schedule; Epileps | 1999 |
Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Double-Bl | 1999 |
Effect of anticonvulsants on nocturnal sleep in epilepsy.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Circadian Rhythm; Cyclohexanecarboxylic Aci | 2000 |
Plasma and urinary serotonin and 5-HIAA in children treated with lamotrigine for intractable epilepsy.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Therapy, Combination; Epil | 1999 |
[Lamotrigine therapy in children. Retrospective study of 32 children].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Cognition; Epilepsy; Female; Humans; Lamotrigi | 2000 |
Rectal absorption of lamotrigine compressed tablets.
Topics: Administration, Oral; Administration, Rectal; Anticonvulsants; Area Under Curve; Biological Availabi | 2000 |
Adding valproate to lamotrigine: a study of their pharmacokinetic interaction.
Topics: Adolescent; Adult; Aged; Child; Dose-Response Relationship, Drug; Drug Costs; Drug Interactions; Dru | 2000 |
Topiramate in refractory epilepsy: a prospective observational study.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Anticonvulsants; Carbamazepine; Drug Administration Schedu | 2000 |
A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure.
Topics: Animals; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Double-Blind Method; Epilepsy; Hea | 2000 |
Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy.
Topics: Adolescent; Adult; Algorithms; Anticonvulsants; Child; Chromatography, Gas; Chromatography, High Pre | 2000 |
Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Calcium Channel Blockers; Carbamazepine; Child; Drug Administrat | 2000 |
Epilepsy and antiepileptic drug therapy in juvenile neuronal ceroid lipofuscinosis.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Child; Child, Preschool; Clonazepam; Comorbidity; | 2000 |
Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage?
Topics: Adult; Anticonvulsants; Area Under Curve; Dose-Response Relationship, Drug; Drug Synergism; Drug The | 2000 |
Developmental and therapeutic pharmacology of antiepileptic drugs.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Admini | 2000 |
Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Body Weight; Child; Epilepsy; Female; Humans; Lamotrigine; | 2001 |
Normal growth during lamotrigine monotherapy in pediatric epilepsy patients -- a prospective evaluation of 103 children and adolescents.
Topics: Adolescent; Anticonvulsants; Body Height; Body Mass Index; Body Weight; Child; Child, Preschool; Epi | 2001 |
A randomized open-label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Administrati | 2001 |
[Optimal use of lamotrigine in clinical practice: results of an open multicenter trial in refractory epilepsy].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Lamot | 2001 |
Lamotrigine therapy of epilepsy in tuberous sclerosis.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationshi | 2001 |
Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers.
Topics: Adult; Affect; Anticonvulsants; Cognition; Double-Blind Method; Epilepsy; Humans; Lamotrigine; Male; | 2002 |
Long-term monotherapy with lamotrigine in newly diagnosed epilepsy in adults.
Topics: Adolescent; Adult; Anticonvulsants; Drug Administration Schedule; Epilepsy; Female; Humans; Lamotrig | 2001 |
Resection of the lesion in patients with hypothalamic hamartomas and catastrophic epilepsy.
Topics: Adolescent; Adult; Brain; Child; Child, Preschool; Cognition Disorders; Electroencephalography; Epil | 2002 |
Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Dose-Response Relationship, Drug; Dr | 2002 |
Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Lamotrigine; | 2002 |
An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy.
Topics: Adult; Anticonvulsants; Double-Blind Method; Epilepsy; Erythrocytes; Female; Folic Acid; Humans; Lam | 1992 |
Neuropsychological assessment in lamotrigine treated epileptic patients.
Topics: Adult; Anticonvulsants; Attention; Double-Blind Method; Epilepsy; Female; Humans; Intelligence; Lamo | 1991 |
A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy.
Topics: Adult; Anticonvulsants; Double-Blind Method; Epilepsy; Female; Humans; Lamotrigine; Male; Severity o | 1990 |
Seven day administration of lamotrigine in epilepsy: placebo-controlled add-on trial.
Topics: Adolescent; Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; | 1987 |
The effect of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy.
Topics: Adult; Anticonvulsants; Clinical Trials as Topic; Diazepam; Double-Blind Method; Electroencephalogra | 1986 |
679 other studies available for lamotrigine and Aura
| Article | Year |
|---|---|
3-Amino-1,5-benzodiazepinones: potent, state-dependent sodium channel blockers with anti-epileptic activity.
Topics: Animals; Anticonvulsants; Benzodiazepinones; Electrophysiology; Electroshock; Epilepsy; Ether-A-Go-G | 2008 |
Newer GABA derivatives for the treatment of epilepsy including febrile seizures: a bioisosteric approach.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Dru | 2008 |
Novel, broad-spectrum anticonvulsants containing a sulfamide group: pharmacological properties of (S)-N-[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2-yl)methyl]sulfamide (JNJ-26489112).
Topics: Absorption; Amides; Animals; Anticonvulsants; Dioxanes; Dogs; Drug Evaluation, Preclinical; Drug Res | 2013 |
Response to Sodium Channel blocking Antiseizure medications and coding polymorphisms of Sodium Channel genes in Taiwanese epilepsy patients.
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; NAV1.7 Voltage-Gated Sodium Channel; Retrospective S | 2021 |
Lamotrigine loaded nano-liposomes enhance brain selectivity in vivo.
Topics: A549 Cells; Animals; Anticonvulsants; Brain; Drug Delivery Systems; Epilepsy; Humans; Lamotrigine; L | 2021 |
[Women with epilepsy before and during pregnancy: a case series of outpatient counseling in a tertiary epilepsy center].
Topics: Anticonvulsants; Counseling; Epilepsy; Female; Folic Acid; Humans; Lamotrigine; Levetiracetam; Outpa | 2022 |
Analysis of trends and factors determining initial antiseizure medication choice for epilepsy in Taiwan.
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Levetiracetam; Taiwan | 2021 |
Effects of Lamotrigine and Topiramate on Glial Properties in an Astrocyte-Microglia Co-Culture Model of Inflammation.
Topics: Animals; Anticonvulsants; Astrocytes; Coculture Techniques; Connexin 43; Cytokines; Epilepsy; Inflam | 2022 |
Lamotrigine-induced Brugada syndrome: A rare adverse event.
Topics: Anticonvulsants; Brugada Syndrome; Epilepsy; Humans; Lamotrigine; Triazines | 2022 |
Lamotrigine may Increase Risk of Arrythmias.
Topics: Anticonvulsants; Arrhythmias, Cardiac; Bipolar Disorder; Epilepsy; Humans; Lamotrigine; Treatment Ou | 2021 |
Association Between Antiseizure Drug Monotherapy and Mortality for Patients With Poststroke Epilepsy.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Cardiovascular Diseases; Cohort Studies; Dr | 2022 |
National assessment of anti-epileptic drug exposures among pre-teens and adolescents, 2000-2020.
Topics: Adolescent; Anticonvulsants; Child; Cross-Sectional Studies; Epilepsy; Humans; Lamotrigine; Retrospe | 2022 |
Effects of Low- and High-Dose Valproic Acid and Lamotrigine on the Heart in Female Rats.
Topics: Animals; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Rats; Triazines; Valproic Acid | 2022 |
Barriers to generic antiseizure medication use: Results of a global survey by the International League Against Epilepsy Generic Substitution Task Force.
Topics: Anticonvulsants; Drug Substitution; Drugs, Generic; Epilepsy; Humans; Lamotrigine; Surveys and Quest | 2022 |
Quality control concerns in relation to lamotrigine and their impact.
Topics: Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Epilepsy; Humans; | 2022 |
Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lacosamide; Lamotrigine; Levetirace | 2022 |
Changes in the use of antiseizure medications in children and adolescents in Norway, 2009-2018.
Topics: Adolescent; Adult; Anticonvulsants; Child; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Val | 2022 |
Exposure to anti-seizure medications impact growth of gut bacterial species and subsequent host response.
Topics: Anticonvulsants; Child; Epilepsy; Gastrointestinal Microbiome; Humans; Lamotrigine; Topiramate | 2022 |
Incidence of Antiseizure Medication-Induced Severe Cutaneous Adverse Reactions in Malaysia.
Topics: Anticonvulsants; Drug Eruptions; Epilepsy; HLA Antigens; Humans; Incidence; Lamotrigine; Malaysia; P | 2022 |
Rational therapy with lamotrigine or levetiracetam: Which one to select?
Topics: Anticonvulsants; Epilepsies, Partial; Epilepsy; Epilepsy, Generalized; Humans; Immunoglobulin E; Lam | 2022 |
Evaluation of family planning methods in married women with epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy; Family Planning Services; Female; Humans; Lamotrigine; Levetiracet | 2022 |
Antiseizure medication treatment pathways for US Medicare beneficiaries with newly treated epilepsy.
Topics: Aged; Anticonvulsants; Epilepsy; Gabapentin; Humans; Lacosamide; Lamotrigine; Levetiracetam; Medicar | 2022 |
Trends in antiseizure medication prescription patterns among all adults, women, and older adults with epilepsy: A German longitudinal analysis from 2008 to 2020.
Topics: Aged; Anticonvulsants; Benzodiazepines; Carbamazepine; Drug Prescriptions; Epilepsy; Epilepsy, Gener | 2022 |
Rare sudden unexpected death in epilepsy SCN5A variants cause changes in channel function implicating cardiac arrhythmia as a cause of death.
Topics: Anticonvulsants; Arrhythmias, Cardiac; Cause of Death; Death, Sudden; Death, Sudden, Cardiac; Epilep | 2022 |
Response to lithium and anticonvulsants among patients with bipolar disorder with and without comorbid epilepsy - A nation-wide population-based longitudinal study.
Topics: Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Comorbidity; Epilepsy; Humans; Lamotrigine; | 2022 |
Trends in the prescription of anti-seizure medicines for pregnant women outpatients with epilepsy during 2016-2020 in Japan.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Japan; Lamotrigine; Levetiracetam; Outpatients; Pregnancy | 2022 |
LC-MS/MS quantification of levetiracetam, lamotrigine and 10-hydroxycarbazepine in TDM of epileptic patients.
Topics: Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug M | 2022 |
Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability.
Topics: Anticonvulsants; Autism Spectrum Disorder; Autistic Disorder; Carbamazepine; Child; Cohort Studies; | 2022 |
Bioinformatics guided rotenone adjuvant kindling in mice as a new animal model of drug-resistant epilepsy.
Topics: Animals; Anticonvulsants; Computational Biology; Disease Models, Animal; Epilepsy; Lamotrigine; Mice | 2022 |
Risk factors of elevated blood ammonia level in epilepsy patients treated with lamotrigine.
Topics: Ammonia; Anticonvulsants; Epilepsy; Humans; Hyperammonemia; Lamotrigine; Risk Factors; Seizures; Tri | 2022 |
Efficacy and safety of antiseizure medication in post-stroke epilepsy.
Topics: Anticonvulsants; Epilepsies, Partial; Epilepsy; Humans; Lacosamide; Lamotrigine; Levetiracetam; Seiz | 2022 |
Simultaneous determination of plasma lamotrigine, lamotrigine N2-glucuronide and lamotrigine N2-oxide by UHPLC-MS/MS in epileptic patients.
Topics: Anticonvulsants; Chromatography, High Pressure Liquid; Epilepsy; Glucuronides; Humans; Lamotrigine; | 2022 |
Use of antiepileptic drugs by trimester.
Topics: Anticonvulsants; Clonazepam; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Pregnancy; Retros | 2022 |
Effects of antiepileptic drugs polytherapy on pregnancy outcomes in women with epilepsy: An observation study in northwest China.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Male; Phenobarbital; Pregnanc | 2022 |
Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Pregnancy; Seizures; V | 2023 |
Autism with Epilepsy: A Neuropsychopharmacology Update.
Topics: Adolescent; Anticonvulsants; Autistic Disorder; Carbamazepine; Child; Epilepsy; Humans; Lamotrigine | 2022 |
Efficacy of antiseizure medication in a mouse model of HCN1 developmental and epileptic encephalopathy.
Topics: Animals; Anticonvulsants; Epilepsy; Epilepsy, Generalized; Hyperpolarization-Activated Cyclic Nucleo | 2023 |
Validation of Conversion Factors for Therapeutic Drug Monitoring of Lacosamide, Lamotrigine, and Levetiracetam in Dried Capillary Blood.
Topics: Adult; Anticonvulsants; Drug Monitoring; Epilepsy; Humans; Lacosamide; Lamotrigine; Levetiracetam | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Comparative Safety of Antiseizure Medication Monotherapy for Major Malformations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Benzodiazepines; Carbamazepine; Cohort Studies; Epilep | 2023 |
Formulation and characterization of lamotrigine nasal insert targeted brain for enhanced epilepsy treatment.
Topics: Administration, Intranasal; Animals; Anticonvulsants; Brain; Drug Carriers; Drug Delivery Systems; E | 2023 |
Risk of sudden unexpected death in epilepsy (SUDEP) with lamotrigine and other sodium channel-modulating antiseizure medications.
Topics: Anticonvulsants; Case-Control Studies; Death, Sudden; Epilepsy; Humans; Lamotrigine; Retrospective S | 2023 |
Trends in antiseizure medications utilization among women of childbearing age with epilepsy in Poland between 2015 and 2019.
Topics: Anticonvulsants; Benzodiazepines; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiraceta | 2023 |
Effects of dosage in new users of lamotrigine inducing epidermal necrolysis: Results of the German Registry of Severe Skin Reactions.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Male; Registries; Stevens-Johnson Syn | 2023 |
Decreased serum concentrations of antiseizure medications in children with drug resistant epilepsy following treatment with ketogenic diet.
Topics: Anticonvulsants; Child; Clobazam; Diet, Ketogenic; Drug Resistant Epilepsy; Epilepsy; Humans; Infant | 2023 |
Implications of BCRP modulation on PTZ-induced seizures in mice: Role of ko143 and metformin as adjuvants to lamotrigine.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily G, Member 2; Epilepsy; Lamotri | 2023 |
Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders.
Topics: Adolescent; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Carbamazepine; Child; Ch | 2023 |
Selection and Continuation of Antiseizure Medication in Children With Epilepsy in Sweden From 2007 to 2020.
Topics: Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Lamotrigine; Levetiracet | 2023 |
Changes in seizure frequency and anti-seizure medication therapy during pregnancy and one year postpregnancy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; Seizures | 2023 |
Prescribing Trends of Antiseizure Drugs in Women Veterans With Epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Gabapentin; Humans; Lamotrigine; Levetiracetam | 2023 |
Bearing variant alleles at uridine glucuronosyltransferase polymorphisms UGT2B7 -161C > T (rs7668258) or UGT1A4*3 c.142 T > G (rs2011425) has no relevant consequences for lamotrigine troughs in adults with epilepsy.
Topics: Adult; Alleles; Anticonvulsants; Bayes Theorem; Epilepsy; Genotype; Glucuronosyltransferase; Humans; | 2023 |
Investigation of cardiac arrhythmia events in patients treated with lamotrigine: FDA adverse event reporing system analysis.
Topics: Anticonvulsants; Arrhythmias, Cardiac; Bradycardia; Epilepsy; Female; Heart Arrest; Humans; Lamotrig | 2023 |
Birth outcomes in pregnant women with epilepsy: A Nationwide multicenter study from Türkiye.
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Infant; Infant, Newborn; Lamotrigine; Preg | 2023 |
Neurodevelopment of babies born to mothers with epilepsy: A prospective observational cohort study.
Topics: Anticonvulsants; Child Development; Epilepsy; Female; Humans; Infant; Lamotrigine; Levetiracetam; Mo | 2023 |
Utilization of Antiseizure Medications in Women of Childbearing Age With Epilepsy and Nonepilepsy Indications: A Retrospective Cohort Study.
Topics: Anticonvulsants; Clonazepam; Diazepam; Epilepsy; Female; Gabapentin; Humans; Lamotrigine; Lorazepam; | 2023 |
External validation of the AntiEpileptic Drug Monitoring in PREgnancy (EMPiRE) model for predicting seizures in pregnant women with epilepsy.
Topics: Anticonvulsants; Carbamazepine; Cohort Studies; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam | 2023 |
Empiric dosing strategies to predict lamotrigine concentrations during pregnancy.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; Seizures | 2023 |
Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy.
Topics: Adult; Anticonvulsants; Child; Cohort Studies; Epilepsy; Female; Humans; Immunoglobulin E; Lamotrigi | 2023 |
Evolution of antiseizure medication use and cost in the United States of America 2006-2021.
Topics: Adult; Anticonvulsants; Child; Drugs, Generic; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; | 2023 |
Changes over 24 years in a pregnancy register - Teratogenicity and epileptic seizure control.
Topics: Anticonvulsants; Australia; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complication | 2023 |
Lamotrigine and exogenous estrogen among females with epilepsy: A retrospective analysis of administrative claims data.
Topics: Anticonvulsants; Epilepsy; Estrogens; Female; Humans; Lamotrigine; Retrospective Studies | 2023 |
Characterising people with focal drug-resistant epilepsy: A retrospective cohort study.
Topics: Anticonvulsants; Drug Resistant Epilepsy; Epilepsies, Partial; Epilepsy; Female; Humans; Lamotrigine | 2023 |
[Epilepsy and inequality: demographic description and analysis of the difficulty in accessing advanced resources in a population in a small health area].
Topics: Adult; Anticonvulsants; Cross-Sectional Studies; Demography; Drug Resistant Epilepsy; Epilepsy; Huma | 2023 |
Lamotrigine Induces Tremor among Epilepsy Patients Probably via Cerebellar Pathways.
Topics: Adult; Case-Control Studies; Cerebellum; Epilepsy; Female; Humans; Lamotrigine; Logistic Models; Mal | 2019 |
Lamotrigine vs. Carbamazepine Monotherapy for Epilepsy Treatment.
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Humans; Lamotrigine; Systematic Reviews as Topic | 2019 |
Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking lamotrigine.
Topics: Anticonvulsants; Diagnosis, Differential; Drug Hypersensitivity Syndrome; Epilepsy; Glucocorticoids; | 2019 |
Comparison of plasma, saliva, and hair lamotrigine concentrations.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Chromatography, Liquid; Drug Monitoring; Epilepsy; Female; | 2019 |
Genotoxicity assessment of antiepileptic drugs (AEDs) in human embryonic stem cells.
Topics: Anticonvulsants; Carbamazepine; DNA Damage; Epilepsy; Female; Human Embryonic Stem Cells; Humans; La | 2019 |
Lack of association of SCN2A rs17183814 polymorphism with the efficacy of lamotrigine monotherapy in patients with focal epilepsy from Herzegovina area, Bosnia and Herzegovina.
Topics: Adult; Anticonvulsants; Bosnia and Herzegovina; Carbamazepine; Epilepsies, Partial; Epilepsy; Epilep | 2019 |
Bidirectional interaction between oral contraception and lamotrigine in women with epilepsy - Role of progestins.
Topics: Adolescent; Adult; Anticonvulsants; Cohort Studies; Contraceptives, Oral, Hormonal; Cross-Sectional | 2020 |
[New recommendations for antiepileptic drug therapy: the last piece in the review of epilepsy care].
Topics: Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Pregnancy; Pre | 2020 |
Valproate risk form-Surveying 215 clinicians involving 4775 encounters.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Physicians | 2020 |
Effects of Sodium Valproate Combined with Lamotrigine on Quality of Life and Serum Inflammatory Factors in Patients with Poststroke Secondary Epilepsy.
Topics: Aged; Anticonvulsants; Biomarkers; Brain; Case-Control Studies; Down-Regulation; Drug Therapy, Combi | 2020 |
Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy.
Topics: Adult; Anticonvulsants; Cohort Studies; Drug Substitution; Drug-Related Side Effects and Adverse Rea | 2020 |
Testing association of rare genetic variants with resistance to three common antiseizure medications.
Topics: Anticonvulsants; Case-Control Studies; Drug Resistance; Epilepsy; Female; Genotype; Humans; Lamotrig | 2020 |
Analysis of antiseizure drug-related adverse reactions from the electronic health record using the common data model.
Topics: Anticonvulsants; Common Data Elements; Drug-Related Side Effects and Adverse Reactions; Electronic H | 2020 |
Improvement of epilepsy with lacosamide in a patient with ring chromosome 20 syndrome.
Topics: Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsy; Humans; Lacosamide; Lamotri | 2020 |
Pregnancy and Epilepsy: a Korean Tertiary Epilepsy Center Review.
Topics: Adult; Anticonvulsants; Cesarean Section; Electroencephalography; Epilepsy; Female; Gestational Age; | 2020 |
Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Humans; India | 2020 |
Sub-additive (antagonistic) interaction of lacosamide with lamotrigine and valproate in the maximal electroshock-induced seizure model in mice: an isobolographic analysis.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Drug | 2020 |
Lamotrigine induced Brugada-pattern in a patient with genetic epilepsy associated with a novel variant in SCN9A.
Topics: Adult; Anticonvulsants; Brugada Syndrome; Epilepsy; Gene Duplication; Humans; Lamotrigine; Male; NAV | 2020 |
Dosing Recommendations Based on Population Pharmacokinetics of Lamotrigine in Mexican Adult Patients With Epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy; Humans; Lamotrigine; Triazines; Valproic Acid | 2020 |
Contraceptive vaginal ring reduces lamotrigine levels.
Topics: Adult; Anticonvulsants; Contraceptive Agents, Female; Contraceptive Devices, Female; Drug Interactio | 2020 |
Misdiagnosis of lamotrigine toxicity as posterior circulation transient ischemic attack or stroke.
Topics: Adult; Aged; Anticonvulsants; Ataxia; Diagnostic Errors; Dizziness; Dose-Response Relationship, Drug | 2020 |
Pharmacokinetic-Pharmacogenomic Model for Chinese Children Treated With Lamotrigine Also Applies for Mexican Children.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Lamotrigine; Pharmacogenetics; Pharmacogenomic Testing | 2020 |
Predictors of remission in patients with epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Male; Middle Aged; Young Adult | 2020 |
Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database.
Topics: Anticonvulsants; Carbamazepine; Clobazam; Clonazepam; Databases, Factual; Drug Therapy, Combination; | 2020 |
Lamotrigine-Induced Gingival Enlargement: An Older Problem Due to a Newer Drug - A Rare Case Report.
Topics: Anticonvulsants; Epilepsy; Gingival Hyperplasia; Gingival Hypertrophy; Gingival Overgrowth; Humans; | 2022 |
Trends of anti-seizure medication use in pediatric patients in six cities in China from 2013 to 2018.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; China; Epilepsy; Female; Humans | 2020 |
Changes in ratio of ineligible use of lamotrigine in Japan based on data from the relief system of the Pharmaceuticals and Medical Devices Agency.
Topics: Bipolar Disorder; Compensation and Redress; Drug and Narcotic Control; Drug-Related Side Effects and | 2021 |
Antiseizure medication use during pregnancy and risk of ASD and ADHD in children.
Topics: Adolescent; Adult; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2020 |
Development and validation of an innovative UPLC method to quantify lacosamide, oxcarbazepine, and lamotrigine in the serum of children with epilepsy in China.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; China; Chromatography, High Pressure Liquid; E | 2021 |
Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Clonazepam; Denmark; Developmen | 2020 |
Effects of valproate, lamotrigine, and levetiracetam monotherapy on bone health in newly diagnosed adult patients with epilepsy.
Topics: Adult; Anticonvulsants; Bone Density; Epilepsy; Humans; Lamotrigine; Levetiracetam; Triazines; Valpr | 2020 |
Dosing Recommendations for Lamotrigine in Children: Evaluation Based on Previous and New Population Pharmacokinetic Models.
Topics: Adolescent; Anticonvulsants; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; | 2021 |
Developing precision treatments for epilepsy using patient and animal models.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Humans; Lamotrigine; Phenytoin | 2021 |
An open study of valproate in subfertile men with epilepsy.
Topics: Adult; Anticonvulsants; Drug Substitution; Epilepsy; Female; Greece; Humans; Infertility, Male; Lamo | 2020 |
Coffee and cigarette smoking interactions with lamotrigine.
Topics: Anticonvulsants; Cigarette Smoking; Coffee; Drug Interactions; Epilepsy; Humans; Lamotrigine; Prospe | 2021 |
In-silico computational analysis of [6-(2, 3-Dichlorophenyl)-1, 2, 4-Triazine-3, 5-Diamine] metal complexes on voltage gated sodium channel and dihydrofolate reductase enzyme.
Topics: Anticonvulsants; Coordination Complexes; Epilepsy; Humans; Lamotrigine; Seizures; Tetrahydrofolate D | 2020 |
Knowledge of epilepsy among German pharmacists.
Topics: Anticonvulsants; Carbamazepine; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; L | 2021 |
FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force.
Topics: Advisory Committees; Anticonvulsants; Epilepsy; Heart Disease Risk Factors; Humans; Lamotrigine; Pat | 2021 |
Effects of antiepileptic drugs' administration during pregnancy on the nerve cell proliferation and axonal outgrowth of human neuroblastoma SH-SY5Y nerve cells.
Topics: Anticonvulsants; Carbamazepine; Cell Line, Tumor; Cell Proliferation; Child; Epilepsy; Female; Human | 2021 |
Estrogen profile- and pharmacogenetics-based lamotrigine dosing regimen optimization: Recommendations for pregnant women with epilepsy.
Topics: Adult; Anticonvulsants; Drug Dosage Calculations; Drug Elimination Routes; Epilepsy; Estrogens; Fema | 2021 |
[Epilepsy in the aged : Challenges in diagnostics and treatment].
Topics: Aged; Anticonvulsants; Carbamazepine; Epilepsy; Humans; Lamotrigine; Levetiracetam | 2021 |
The molecular and phenotypic spectrum of CLCN4-related epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child Behavior Disorders; Child, Preschool; Chlorid | 2021 |
Retention of antiseizure medications for epilepsy in multiple sclerosis: A retrospective observational study.
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Multiple Sclerosis; Sweden | 2021 |
Post-stroke epilepsy and antiepileptic drug use in men and women.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigin | 2021 |
A new rapid titration protocol for lamotrigine that reduces the risk of skin rash.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Epilepsy; Exanthema; Humans; Lamotrigin | 2021 |
Interactions among Lacosamide and Second-Generation Antiepileptic Drugs in the Tonic-Clonic Seizure Model in Mice.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Drug Interactions; Drug Synergism; Drug Therapy, C | 2021 |
The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide.
Topics: Anticonvulsants; Epilepsy; Glioma; Humans; Lacosamide; Lamotrigine; Retrospective Studies; Seizures; | 2021 |
pH-induced homogeneous liquid-liquid microextraction method based on new switchable deep eutectic solvent for the extraction of three antiepileptic drugs from breast milk.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Hydrogen-Ion Concentration; Lamotrigine; Liquid Phase Mic | 2021 |
Redefining the age-specific therapeutic ranges of lamotrigine for patients with epilepsy: A step towards optimizing treatment and increasing cost-effectiveness.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Cost-Benefit Analysis; Epi | 2021 |
Epilepsy and Pregnancy: An Audit of Specialized Care.
Topics: Anticonvulsants; Canada; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; | 2022 |
Effectiveness of multiple-dose activated charcoal in lamotrigine poisoning: a case series.
Topics: Adult; Anticonvulsants; Charcoal; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Middle Aged; | 2022 |
The Relationship Between Valproate and Lamotrigine/Levetiracetam Use and Prognosis in Patients With Epilepsy and Heart Failure: A Danish Register-Based Study.
Topics: Aged; Anticonvulsants; Cohort Studies; Denmark; Epilepsy; Heart Failure; Humans; Lamotrigine; Leveti | 2022 |
Assessment of atherosclerotic risk among patients with epilepsy on valproic acid, lamotrigine, and carbamazepine treatment.
Topics: Adult; Anticonvulsants; Carbamazepine; Cholesterol; Cross-Sectional Studies; Epilepsy; Female; Human | 2017 |
Patterns of antiepileptic drug prescription in Sweden: A register-based approach.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Drug Prescriptions; Epilepsy; Female; Humans; Lamotrigi | 2017 |
Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
Topics: Adverse Drug Reaction Reporting Systems; Anticonvulsants; Carbamazepine; Drugs, Generic; Epilepsy; H | 2017 |
Persistence with antiepileptic drugs in epilepsy patients treated in neurological practices in Germany.
Topics: Adult; Age Factors; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Ga | 2017 |
Potential Influence of FDA-Sponsored Studies of Antiepilepsy Drugs on Generic and Brand-name Formulation Prescribing.
Topics: Anticonvulsants; Drugs, Generic; Epilepsy; Humans; Lamotrigine; Therapeutic Equivalency | 2017 |
Lamotrigine serum levels: Ceiling effect in people with epilepsy in remission?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Diagnostic Tests, Routine; Epilepsy; Fe | 2017 |
Vitamin D enhances antiepileptic and cognitive effects of lamotrigine in pentylenetetrazole-kindled rats.
Topics: Animals; Anticonvulsants; Antioxidants; Cholecalciferol; Chronic Disease; Cognition; Disease Models, | 2017 |
Short- and long-term complications of in utero exposure to lamotrigine.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Child; Epilepsy; Female; Follow-Up Studies; Hum | 2018 |
Fetal Valproate Syndrome - Still a Problem Today!
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cesarean Section; Drug Therapy, Combination; Ep | 2017 |
A rapid and simple HPLC-MS/MS method for the simultaneous quantification of valproic acid and its five metabolites in human plasma and application to study pharmacokinetic interaction in Chinese epilepsy patients.
Topics: Adolescent; Adult; Anticonvulsants; Asian People; Chromatography, High Pressure Liquid; Drug Interac | 2018 |
Cav2.3 (R-Type) Calcium Channels are Critical for Mediating Anticonvulsive and Neuroprotective Properties of Lamotrigine In Vivo.
Topics: Acetamides; Animals; Anticonvulsants; Behavior, Animal; Calcium Channels, R-Type; Electrocorticograp | 2017 |
Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cleft Palate; Cohort Studies; Dose-Response Rel | 2018 |
Normocytic Normochromic Anaemia and Asymptomatic Neutropenia in a 40-Day-Old Infant Breastfed by an Epileptic Mother Treated With Lamotrigine: Infant's Adverse Drug Reaction.
Topics: Anemia; Anticonvulsants; Asymptomatic Diseases; Breast Feeding; Epilepsy; Follow-Up Studies; Humans; | 2018 |
Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling.
Topics: Adolescent; Anticonvulsants; Asian People; Child; Child, Preschool; Drug Therapy, Combination; Epile | 2018 |
UGT polymorphisms and lamotrigine clearance during pregnancy.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Glucuronosyltransferase; | 2018 |
Management of pregnant women with epilepsy who use lamotrigine.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy | 2018 |
Utilization of Antiepileptic Medicines in Swedish Children and Adolescents with Different Diagnoses.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Prescriptions; Drug Utilization; Epilepsy | 2018 |
Effect of antiepileptic drug comedication on lamotrigine concentrations.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Drug Inte | 2018 |
Observational multicentre study into the use of antiepileptic drugs in Spanish neurology consultations.
Topics: Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Humans; Lamotrigine; Levetirace | 2020 |
Case of lamotrigine-induced drug adverse reaction under tocilizumab treatment with clinical and virological features of drug-induced hypersensitivity syndrome.
Topics: Adult; Antibodies, Monoclonal, Humanized; Anticonvulsants; Arthritis, Rheumatoid; Biopsy; C-Reactive | 2018 |
A Standard Intervention Practice to Promote Appropriate Lamotrigine Therapy by Pharmacists.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Epilepsy; Humans; Inapp | 2018 |
Isobolographic additivity among lacosamide, lamotrigine and phenobarbital in a mouse tonic-clonic seizure model.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Epileps | 2018 |
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug | 2018 |
Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.
Topics: Adolescent; Adult; Aged; Alleles; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B; AT | 2018 |
Lesson of the month 1: To stop a fit, but swinging low.
Topics: Accidental Falls; Aged; Anticonvulsants; Drug Substitution; Epilepsy; Female; Humans; Lamotrigine; O | 2018 |
Obstetric outcomes and effects on babies born to women treated for epilepsy during pregnancy in a resource limited setting: a comparative cohort study.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anticonvulsants; Body Height; Body Weight; Carbamazepine; | 2018 |
Levetiracetam and lamotrigine effects as mono- and polytherapy on bone mineral density in epileptic patients.
Topics: Adolescent; Adult; Amino Acids; Anticonvulsants; Biomarkers; Bone Density; Bone Remodeling; Case-Con | 2018 |
Lamotrigine pharmacokinetics following oral and stable-labeled intravenous administration in young and elderly adult epilepsy patients: Effect of age.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Epilepsy; | 2018 |
Lamotrigine clearance increases by 5 weeks gestational age: Relationship to estradiol concentrations and gestational age.
Topics: Adult; Anticonvulsants; Epilepsy; Estradiol; Female; Gestational Age; Humans; Lamotrigine; Metabolic | 2018 |
A Population Pharmacokinetic-Pharmacogenetic Model of Lamotrigine in Chinese Children With Epilepsy.
Topics: Anticonvulsants; Asian People; ATP-Binding Cassette Transporters; Child; Drug Interactions; Epilepsy | 2018 |
Lamotrigine encapsulated intra-nasal nanoliposome formulation for epilepsy treatment: Formulation design, characterization and nasal toxicity study.
Topics: Administration, Intranasal; Animals; Anticonvulsants; Drug Carriers; Drug Compounding; Drug Delivery | 2019 |
Metabolome-wide association study of anti-epileptic drug treatment during pregnancy.
Topics: Adult; Anticonvulsants; Carbon; Epilepsy; Female; Fetus; Folic Acid; Humans; Lamotrigine; Levetirace | 2019 |
Retention rate of first antiepileptic drug in poststroke epilepsy: A nationwide study.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Leve | 2019 |
Adverse drug reactions associated with six commonly used antiepileptic drugs in southern China from 2003 to 2015.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Child, Preschool; China; Epileps | 2019 |
The influence of concomitant antiepileptic drugs on lamotrigine serum concentrations in Northwest Chinese Han population with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Asian People; Carbamazepine; Child; Child, Preschool; China; Dru | 2019 |
Fetal antiepileptic drug exposure and learning and memory functioning at 6 years of age: The NEAD prospective observational study.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsy; Female; Humans; Lamotrigine; Learning; Memor | 2019 |
Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms due to lamotrigine differs from that due to other drugs.
Topics: Adult; Anticonvulsants; Drug Hypersensitivity Syndrome; Epilepsy; Female; Humans; Lamotrigine; Leuko | 2019 |
Lamotrigine drug interactions in combination therapy and the influence of therapeutic drug monitoring on clinical outcomes in paediatric patients.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Czech Republic; Dose-Response R | 2019 |
A Short Communication: Lamotrigine Levels in Milk, Mothers, and Breastfed Infants During the First Postnatal Month.
Topics: Anticonvulsants; Breast Feeding; Epilepsy; Female; Humans; Infant, Newborn; Lamotrigine; Milk, Human | 2019 |
Developmental outcomes at age four following maternal antiepileptic drug use.
Topics: Adult; Anticonvulsants; Carbamazepine; Child Development; Child, Preschool; Cohort Studies; Epilepsy | 2019 |
Glomerular Filtration Rate Is a Major Predictor of Clearance of Oxcarbazepine Active Metabolite in Adult Chinese Epileptic Patients: A Population Pharmacokinetic Analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Asian People; Body Weight; Drug Monitor | 2019 |
Pharmacokinetic changes and therapeutic drug monitoring of lamotrigine during pregnancy.
Topics: Adult; Anticonvulsants; Drug Monitoring; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy | 2019 |
Complex hallucinations induced by lamotrigine.
Topics: Aged; Anticonvulsants; Epilepsy; Female; Hallucinations; Humans; Lamotrigine | 2019 |
Remedial dosing recommendations for delayed or missed doses of lamotrigine in pediatric patients with epilepsy using Monte Carlo simulations.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Administration Schedule; Epilepsy; Female | 2019 |
Use of antiepileptic drugs and risk of skin cancer: A nationwide case-control study.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Carcinoma, Basal Cell; Carcinoma, Squamous | 2020 |
Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child Behavior Disorders; Epilepsy; Female; Humans; La | 2019 |
Ictal asystole: a diagnostic and management conundrum.
Topics: Anticonvulsants; Bradycardia; Carbamazepine; Deja Vu; Epilepsy; Female; Heart Arrest; Humans; Lamotr | 2019 |
Management and attitudes toward patients with epilepsy in general practice: How far have we come in three decades?
Topics: Adult; Anticonvulsants; Attitude of Health Personnel; Australia; Carbamazepine; Clinical Competence; | 2019 |
Use of antiepileptic drugs in women of fertile age.
Topics: Adolescent; Adult; Anticonvulsants; Denmark; Epilepsy; Female; Gabapentin; Humans; Lamotrigine; Leve | 2019 |
A 16q22.2-q23.1 deletion identified in a male infant with West syndrome.
Topics: Anticonvulsants; Chromosomes, Human, Pair 16; Epilepsy; Humans; Infant; Intellectual Disability; Lam | 2019 |
[Mood States in outpatients with lesional epilepsy at the neurosurgical clinic and improvement in mood States after lamotrigine addiction].
Topics: Adult; Affect; Anticonvulsants; Epilepsy; Female; Humans; Japan; Lamotrigine; Male; Middle Aged; Out | 2013 |
Antioxidant agents and physiological responses in adult epileptic patients treated with lamotrigine.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticonvulsants; Antioxidants; Case-Control Studies; Deoxyguanos | 2013 |
Valproate and lamotrigine in pediatric patients with refractory epilepsy: after the first year.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy; Female; H | 2013 |
Depression in patients with newly diagnosed epilepsy predicts lamotrigine-induced rash: a short-term observational study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Depression; Epilepsy; Exanthema; Female; Humans; Lamotrigi | 2013 |
Rapid loss of efficacy to the antiseizure drugs lamotrigine and carbamazepine: a novel experimental model of pharmacoresistant epilepsy.
Topics: Action Potentials; Animals; Anticonvulsants; Biophysics; Carbamazepine; Disease Models, Animal; Dose | 2013 |
Lamotrigine positively affects the development of psychiatric comorbidity in epileptic animals, while psychiatric comorbidity aggravates seizures.
Topics: Animals; Anticonvulsants; Comorbidity; Disease Models, Animal; Epilepsy; Exploratory Behavior; Food | 2013 |
Expression and functional relevance of UGT1A4 in a cohort of human drug-resistant epileptic brains.
Topics: Adult; Anticonvulsants; Blood-Brain Barrier; Brain; Drug Resistance, Multiple; Endothelial Cells; Ep | 2013 |
Electroconvulsive therapy for psychosis in a patient with epilepsy related to hypothalamic hamartoma.
Topics: Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Clobazam; Delusions; Drug Resistance; Electr | 2013 |
The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study.
Topics: Adult; Aged; Aging; Anticonvulsants; Carbamazepine; Cohort Studies; Dose-Response Relationship, Drug | 2013 |
Random-effects linear modeling and sample size tables for two special crossover designs of average bioequivalence studies: the four-period, two-sequence, two-formulation and six-period, three-sequence, three-formulation designs.
Topics: Anticonvulsants; Biological Availability; Cross-Over Studies; Epilepsy; Humans; Lamotrigine; Linear | 2013 |
[The effectiveness of lamotrigine in a case of ring chromosome 14 with refractory epilepsy].
Topics: Anticonvulsants; Brain Waves; Child, Preschool; Chromosomes, Human, Pair 14; Developmental Disabilit | 2013 |
The impact of the use of antiepileptic drugs on the growth of children.
Topics: Adolescent; Anticonvulsants; Body Height; Bone Diseases, Developmental; Calcium; Carbamazepine; Cell | 2013 |
[Effectiveness and role of lamotrigine in the paradigm shift towards new antiepileptic drugs: a therapeutic strategy proposed after an investigation of a large number of cases at a single hospital].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Drug Therapy, Combination; Electroencep | 2014 |
Reproductive endocrine health in pubertal females with epilepsy on antiepileptic drugs: time to screen?
Topics: Adiposity; Adolescent; Anticonvulsants; Cohort Studies; Cross-Sectional Studies; Drug Evaluation, Pr | 2014 |
Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug | 2014 |
Safety of an intravenous formulation of lamotrigine.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; | 2014 |
Effect of oral contraceptives on lamotrigine levels depends on comedication.
Topics: Adult; Anticonvulsants; Blood Chemical Analysis; Carbamazepine; Contraceptives, Oral; Drug Interacti | 2014 |
Cardiac phenomena during kainic-acid induced epilepsy and lamotrigine antiepileptic therapy.
Topics: Animals; Anticonvulsants; Death, Sudden; Electrocardiography; Epilepsy; Kainic Acid; Lamotrigine; Mi | 2014 |
Characterization of a lamotrigine-resistant kindled model of epilepsy in mice: evaluation of drug resistance mechanisms.
Topics: Animals; Anticonvulsants; Calcium Channels; Carbamazepine; Disease Models, Animal; Drug Resistance; | 2014 |
Antiepileptic efficacy of lamotrigine in phenobarbital-resistant and -responsive epileptic rats: a pilot study.
Topics: Animals; Anticonvulsants; Electric Stimulation; Electroencephalography; Epilepsy; Female; Lamotrigin | 2014 |
The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Cost Savings; Costs and Cost Analysis; Drug Costs; | 2014 |
The teratogenicity of the newer antiepileptic drugs - an update.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Fetus; Fructose; Humans; Lamo | 2014 |
Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: in vitro characterization and in vivo efficacy in epilepsy.
Topics: Administration, Intranasal; Animals; Brain; Chemistry, Pharmaceutical; Drug Carriers; Drug Delivery | 2015 |
Effect of comedication on lamotrigine clearance in Korean epilepsy patients.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Interactions; Epilepsy; Female; Half- | 2015 |
Validation of a multigenic model to predict seizure control in newly treated epilepsy.
Topics: Adult; Algorithms; Anticonvulsants; Artificial Intelligence; Australia; Biomarkers, Pharmacological; | 2014 |
Nonlinear mixed effects modelling approach in investigating phenobarbital pharmacokinetic interactions in epileptic patients.
Topics: Adult; Anticonvulsants; Carbamazepine; Drug Interactions; Drug Therapy, Combination; Epilepsy; Femal | 2015 |
[Importance of measuring blood level of lamotrigine for optimum dosing schedule].
Topics: Adolescent; Anticonvulsants; Child, Preschool; Drug Dosage Calculations; Epilepsy; Female; Humans; L | 2014 |
Therapeutic Drug Monitoring of Levetiracetam and Lamotrigine: Is There a Need?
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Cytochrome P-450 Enzyme In | 2015 |
IQ at 6 years after in utero exposure to antiepileptic drugs: a controlled cohort study.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child Development; Epilepsy; Female; Humans; Intellige | 2015 |
Fine-tuning risk assessment with antiepileptic drug use in pregnancy.
Topics: Anticonvulsants; Carbamazepine; Child Development; Epilepsy; Female; Humans; Intelligence; Lamotrigi | 2015 |
Valproate and pregnancy: think again.
Topics: Anticonvulsants; Carbamazepine; Child Development; Epilepsy; Female; Humans; Intelligence; Lamotrigi | 2015 |
Retention rate of zonisamide in intractable epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Denmark; Drug Therapy, Combination; Epilepsy; Female; Huma | 2015 |
Bronchiolitis obliterans complicating a pneumothorax after Stevens-Johnson syndrome induced by lamotrigine.
Topics: Anticonvulsants; Bronchiolitis Obliterans; Child; Epilepsy; Female; Humans; Lamotrigine; Pneumothora | 2015 |
Antiepileptic drugs in Rett Syndrome.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Male | 2015 |
Influence of uridine diphosphate glucuronosyltransferase inducers and inhibitors on the plasma lamotrigine concentration in pediatric patients with refractory epilepsy.
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; | 2015 |
Effects of antiepileptic drug monotherapy on one-carbon metabolism and DNA methylation in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Case-Control Studies; Cross-Sectional Studies; DNA Methylation; | 2015 |
Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; China; Drug Interactions; Drug Therapy, Combin | 2015 |
Epilepsy phenotypes in siblings with Norrie disease.
Topics: Anticonvulsants; Blindness; Chromosomes, Human, X; Electroencephalography; Epilepsy; Eye Proteins; G | 2015 |
Synergistic effect of docosahexaenoic acid on anticonvulsant activity of valproic acid and lamotrigine in animal seizure models.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Docosahexaenoic Acids; Dose-Response Relationship, | 2015 |
A prospective study of adverse drug reactions to antiepileptic drugs in children.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cognition Disorders; Drug Thera | 2015 |
Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; D | 2015 |
Involvement of p38 MAPK in the Drug Resistance of Refractory Epilepsy Through the Regulation Multidrug Resistance-Associated Protein 1.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Resistance; Epilepsy; Lamotrigine; Male; Microdi | 2015 |
Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
Topics: Adult; Aged; Anticonvulsants; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Metho | 2015 |
Polymorphisms of ABCG2, ABCB1 and HNF4α are associated with Lamotrigine trough concentrations in epilepsy patients.
Topics: Adult; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter | 2015 |
GWAS identifies two susceptibility loci for lamotrigine-induced skin rash in patients with epilepsy.
Topics: Anticonvulsants; Asian People; Cohort Studies; Drug Eruptions; Epilepsy; Exanthema; Genetic Predispo | 2015 |
The HLA-A*2402/Cw*0102 haplotype is associated with lamotrigine-induced maculopapular eruption in the Korean population.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Eruptions; Epilepsy; Female; Gene Frequency; Genotype | 2015 |
A LC-MS/MS method for therapeutic drug monitoring of carbamazepine, lamotrigine and valproic acid in DBS.
Topics: Anticonvulsants; Calibration; Carbamazepine; Child; Chromatography, Liquid; Dried Blood Spot Testing | 2015 |
[Study of lamotrigine efficacy on behavior disorders affecting patients with severe mental retardation].
Topics: Adolescent; Adult; Anticonvulsants; Child; Epilepsy; Female; Humans; Intellectual Disability; Lamotr | 2015 |
Generic substitution in contravention of doctor's prescriptions.
Topics: Adult; Anticonvulsants; Drug Prescriptions; Drug Substitution; Epilepsy; Female; Humans; Lamotrigine | 2015 |
[Position Statement of Hungarian Epilepsy League: The use of valproate preparations for epilepsy in pregnancy and in women of childbearing age].
Topics: Adolescent; Adult; Anticonvulsants; Cognition; Contraception; Dose-Response Relationship, Drug; Drug | 2015 |
A Case Report That Suggested That the Patient Was Very Sensitive to Induction and Needed 1600 mg/d of Lamotrigine to Get Therapeutic Concentrations.
Topics: Adult; Anticonvulsants; Epilepsy; Humans; Lamotrigine; Male; Triazines; Young Adult | 2015 |
Can physiologic menstrual cycle change serum lamotrigine concentration?
Topics: Adult; Anticonvulsants; Cross-Sectional Studies; Epilepsy; Female; Humans; Lamotrigine; Menstrual Cy | 2015 |
Do HLA-A markers predict skin-reactions from aromatic antiepileptic drugs in a Norwegian population? A case control study.
Topics: Adult; Anticonvulsants; Carbamazepine; Case-Control Studies; Cross Reactions; Epilepsy; Female; Gene | 2015 |
Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Carbamazepine; Depression; Drug-Related Side Effects and Adve | 2016 |
Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine.
Topics: Adolescent; Age Factors; Anticonvulsants; Asian People; Child; Child, Preschool; Chromatography, Hig | 2016 |
Bronchiolitis obliterans organising pneumonia associated with anticonvulsant hypersensitivity syndrome induced by lamotrigine.
Topics: Adolescent; Anti-Bacterial Agents; Anticonvulsants; Cryptogenic Organizing Pneumonia; Drug Hypersens | 2016 |
Lamotrigine as monotherapy in clinical practice: efficacy of various dosages in epilepsy.
Topics: Adult; Drug Interactions; Epilepsy; Female; Humans; Lamotrigine; Male; Middle Aged; Retrospective St | 2016 |
Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
Topics: Adult; Anticonvulsants; Blood Chemical Analysis; Databases, Pharmaceutical; Drug Substitution; Drugs | 2016 |
Unexplained spikes in lamotrigine serum concentration: nonlinear elimination?
Topics: Adult; Aged; Anticonvulsants; Ataxia; Dizziness; Dose-Response Relationship, Drug; Drug Interactions | 2017 |
The effects of co-medications on lamotrigine clearance in Japanese children with epilepsy.
Topics: Adolescent; Anticonvulsants; Benzodiazepines; Carbamazepine; Child; Child, Preschool; Clobazam; Clon | 2016 |
Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Case-Control Studies; Cleft Lip; Cleft Palate; | 2016 |
[Atypical femoral fracture in a woman treated with lamotrigine].
Topics: Accidental Falls; Anticonvulsants; Bone Density; Epilepsy; Female; Femoral Fractures; Humans; Lamotr | 2016 |
An investigation of the influence of patient-related factors and comedications on lamotrigine clearance in patients with epilepsy.
Topics: Adult; Anticonvulsants; Body Weight; Dose-Response Relationship, Drug; Drug Interactions; Drug Thera | 2016 |
Dramatic Response After Lamotrigine in a Patient With Epileptic Encephalopathy and a De NovoCACNA1A Variant.
Topics: Anticonvulsants; Calcium Channels; Child; Epilepsy; Female; Genetic Variation; Humans; Lamotrigine; | 2016 |
[Psychogenic non-epileptic seizures: issues of comorbidity in the diagnosis and treatment].
Topics: Adult; Anticonvulsants; Bipolar Disorder; Brain; Comorbidity; Electroencephalography; Epilepsy; Huma | 2016 |
Comparison of body composition in persons with epilepsy on conventional & new antiepileptic drugs.
Topics: Adult; Anticonvulsants; Benzodiazepines; Body Composition; Body Water; Body Weight; Carbamazepine; C | 2016 |
Immunoglobulin A deficiency following treatment with lamotrigine.
Topics: Adolescent; Anticonvulsants; Common Variable Immunodeficiency; Epilepsy; Female; Humans; IgA Deficie | 2016 |
Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Longitu | 2018 |
A three phase hollow fiber liquid-phase microextraction for quantification of lamotrigine in plasma of epileptic patients by capillary electrophoresis.
Topics: Electrophoresis, Capillary; Epilepsy; Humans; Hydrogen-Ion Concentration; Lamotrigine; Limit of Dete | 2016 |
Comparative persistence of antiepileptic drugs in patients with epilepsy: A STROBE-compliant retrospective cohort study.
Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilep | 2016 |
Specific OCT1 and ABCG2 polymorphisms are associated with Lamotrigine concentrations in Chinese patients with epilepsy.
Topics: Adult; Anticonvulsants; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; Epile | 2016 |
Effect of lamotrigine on epilepsy-induced cognitive impairment and hippocampal neuronal apoptosis in pentylenetetrazole-kindled animal model.
Topics: Animals; Anticonvulsants; Apoptosis; CA1 Region, Hippocampal; Cognitive Dysfunction; Epilepsy; Femal | 2017 |
Efficacy and tolerability of anti-epileptic drugs-an internet study.
Topics: Adult; Anticonvulsants; Carbamazepine; Depression; Epilepsy; Female; Humans; Internet; Lamotrigine; | 2017 |
Hormone replacement therapy with estrogens may reduce lamotrigine serum concentrations: A matched case-control study.
Topics: Adult; Aged; Anticonvulsants; Case-Control Studies; Dose-Response Relationship, Drug; Drug Monitorin | 2017 |
Counseling by epileptologists affects contraceptive choices of women with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Choice Behavior; Cohort Studies; Contraception; Contraceptive Ag | 2016 |
Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse events?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Epilepsy; Female; Humans; Lamotr | 2018 |
Effectiveness and tolerability of antiepileptic drugs in 104 girls with Rett syndrome.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Therap | 2017 |
No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants *2(P24T) or *3(L48V) in Norwegian patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Genotype; Glucu | 2017 |
An investigation of the characteristics of outpatients with epilepsy and antiepileptic drug utilization in a multicenter cross-sectional study in China.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; China; Cross-Sectional Studies; Drug Combin | 2017 |
Comment on 'Progressive anticonvulsant hypersensitivity syndrome associated with change of drug product' by Sabroe and Sabers.
Topics: Anticonvulsants; Drugs, Generic; Epilepsy; Humans; Lamotrigine; Practice Guidelines as Topic; Safety | 2008 |
Smoking reduces serum levels of lamotrigine.
Topics: Adult; Analysis of Variance; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Male; Middle Ag | 2008 |
Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsies, Partial; E | 2009 |
States of serum leptin and insulin in children with epilepsy: risk predictors of weight gain.
Topics: Adolescent; Age Factors; Anticonvulsants; Body Mass Index; Carbamazepine; Case-Control Studies; Chil | 2009 |
Retention rates of new antiepileptic drugs in localization-related epilepsy: a single-center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Ac | 2009 |
Antiepileptic drug utilization in children from 1997-2005--a study from the Netherlands.
Topics: Anticonvulsants; Carbamazepine; Child; Databases, Factual; Drug Utilization; Epilepsy; Female; Human | 2008 |
Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy.
Topics: Adult; Anticonvulsants; Bayes Theorem; Drug Monitoring; Epilepsy; Female; Germany; Humans; Lamotrigi | 2008 |
Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?
Topics: Adolescent; Antimanic Agents; Case-Control Studies; Child; Child, Preschool; Cleft Lip; Community He | 2008 |
New SCN5A mutation in a SUDEP victim with idiopathic epilepsy.
Topics: Adolescent; Anticonvulsants; Base Sequence; Death, Sudden, Cardiac; Epilepsy; Female; Humans; Lamotr | 2009 |
Retention of new AEDs in institutionalized intellectually disabled patients with epilepsy.
Topics: Adolescent; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Drug Utilization Rev | 2009 |
What is the risk of orofacial clefts from lamotrigine exposure during pregnancy?
Topics: Anticonvulsants; Cleft Lip; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Risk; Triazines | 2008 |
Association of lamotrigine and valproate in refractory epilepsies of children and adolescents.
Topics: Adolescent; Age Distribution; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; E | 2008 |
Use of lamotrigine in medically intractable epilepsies in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Lamotrigine; Male; T | 2008 |
Joint modelling of longitudinal and competing risks data.
Topics: Carbamazepine; Computer Simulation; Epilepsy; Humans; Lamotrigine; Longitudinal Studies; Models, Sta | 2008 |
Quality of life in seizure-free patients with epilepsy on monotherapy.
Topics: Adult; Aged; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; Male; Middle Age | 2009 |
Trends and changes in the clinical use of lamotrigine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Child, Preschool; Databases, Fac | 2009 |
Effects of lamotrigine on cortically-elicited phenomena in adult rats: differences between acute application and late consequences of early postnatal administration.
Topics: Animals; Animals, Newborn; Anticonvulsants; Cerebral Cortex; Electric Stimulation; Electrodes, Impla | 2009 |
[Hallucinosis using lamotrigine].
Topics: Adult; Anticonvulsants; Epilepsy; Female; Hallucinations; Humans; Lamotrigine; Male; Middle Aged; Pa | 2009 |
[New antiepileptic drugs].
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsies, Partial; Epilepsy; | 2009 |
Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use.
Topics: Adolescent; Adult; Anticonvulsants; Body Mass Index; Contraceptives, Oral, Combined; Drug Interactio | 2009 |
Changing trends in antiepileptic drug prescribing in girls of child-bearing potential.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Carbamazepine; Child; Contraceptive Agents | 2009 |
[When a seizure occurs...].
Topics: Adult; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Epilepsy; Female; Fructose; Humans | 2009 |
Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Lamotrigine; Levetiracetam; Mat | 2009 |
[Anticonvulsant hypersensitivity syndrome and lamotrigine-associated anticonvulsant hypersensitivity syndrome].
Topics: Adult; Aged; Anticonvulsants; Bipolar Disorder; Drug Eruptions; Drug Hypersensitivity; Eosinophilia; | 2009 |
Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs.
Topics: Adult; Anticonvulsants; Carbamazepine; Child, Preschool; Cognition; Developmental Disabilities; Dose | 2009 |
Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options.
Topics: Adolescent; Adult; Angelman Syndrome; Anticonvulsants; Child; Child, Preschool; Clonazepam; Comorbid | 2009 |
Utilization of antiepileptic drugs during pregnancy: comparative patterns in 38 countries based on data from the EURAP registry.
Topics: Adult; Anticonvulsants; Child; Cross-Cultural Comparison; Drug Prescriptions; Drug Therapy, Combinat | 2009 |
Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
Topics: Anticonvulsants; Attitude of Health Personnel; Drug Industry; Drugs, Generic; Epilepsy; Health Promo | 2009 |
Seizure frequency in pregnant women treated with lamotrigine monotherapy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Cohort Studies; Dose-Response Relationship, Dru | 2009 |
Reversible lamotrigine-induced neurobehavioral disturbances in children with epilepsy.
Topics: Akathisia, Drug-Induced; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; | 2010 |
Excitotoxic-mediated transcriptional decreases in HCN2 channel function increase network excitability in CA1.
Topics: Action Potentials; Animals; Biological Clocks; Cortical Synchronization; Epilepsy; Excitatory Amino | 2009 |
[Influence of lamotrigine on multidrug resistance gene expression in the hippocampus of epileptic immature rats].
Topics: Animals; Epilepsy; Genes, MDR; Hippocampus; Lamotrigine; Male; Rats; Rats, Wistar; Triazines | 2009 |
Lamotrigine-trigged obstructive hypertrophic cardiomyopathy, epilepsy and metabolic myopathy.
Topics: Aged; Anticonvulsants; Cardiomyopathy, Hypertrophic; Epilepsy; Humans; Lamotrigine; Male; Muscular D | 2011 |
Ring chromosome 20 syndrome: a link between epilepsy onset and neuropsychological impairment in three children.
Topics: Adult; Age of Onset; Anticonvulsants; Child; Chromosomes, Human, Pair 20; Cognition Disorders; Comor | 2009 |
Lamotrigine and twin pregnancy, incidental event or possible correlation?
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Retrospective Studies; Tri | 2009 |
[Lamolep in the treatment of epilepsy].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Elect | 2008 |
End-of-dose emergent psychopathology in ambulatory patients with epilepsy on stable-dose lamotrigine monotherapy: a case series of six patients.
Topics: Adult; Affective Symptoms; Agoraphobia; Anticonvulsants; Bipolar Disorder; Depression; Epilepsy; Fem | 2009 |
Chronic antiepileptic monotherapy, bone metabolism, and body composition in non-institutionalized children.
Topics: Anthropometry; Anticonvulsants; Body Composition; Body Height; Body Mass Index; Body Weight; Carbama | 2010 |
Possible lamotrigine-induced mania in a child with autism spectrum disorder and epilepsy.
Topics: Bipolar Disorder; Child; Child Development Disorders, Pervasive; Epilepsy; Humans; Lamotrigine; Male | 2009 |
Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Enzyme Induction; Epilepsy; Female; Folic Acid; F | 2010 |
Comparison of antiepileptic drug prescribing in children in three European countries.
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Cohort Studies; Drug Prescriptions; Drug Utilizatio | 2010 |
Severe apnea in an infant exposed to lamotrigine in breast milk.
Topics: Adult; Apnea; Breast Feeding; Epilepsy; Female; Humans; Infant, Newborn; Lamotrigine; Male; Milk, Hu | 2009 |
Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives.
Topics: Adolescent; Adult; Anticonvulsants; Contraceptives, Oral; Drug Interactions; Epilepsy; Female; Human | 2009 |
A prospective study of cognitive fluency and originality in children exposed in utero to carbamazepine, lamotrigine, or valproate monotherapy.
Topics: Analysis of Variance; Anticonvulsants; Carbamazepine; Child, Preschool; Cognition; Creativity; Epile | 2009 |
Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom.
Topics: Anticonvulsants; Child; Confidence Intervals; Cost-Benefit Analysis; Drug Utilization; Epilepsy; Fol | 2010 |
Validated spectrofluorimetric method for the determination of lamotrigine in tablets and human plasma through derivatization with o-phthalaldehyde.
Topics: Blood Chemical Analysis; Child; Epilepsy; Fluorescence; Humans; Hydrogen-Ion Concentration; Lamotrig | 2010 |
Population pharmacokinetics of lamotrigine in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Epilepsy; Female; Humans; Lamotrigine; Male; Middle Aged; | 2009 |
Simultaneous HPLC-UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy.
Topics: Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Epilepsy; Felbamate; Humans; I | 2010 |
Valproic acid: long-term effects on children exposed in utero.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Cohort Studies; Contraindications; Dose | 2009 |
[Association study of the SCN1 gene polymorphism and effective dose of lamotrigine].
Topics: Adolescent; Adult; Aged; Anticonvulsants; DNA; Dose-Response Relationship, Drug; Electrophoresis; Ep | 2009 |
Prospective surveillance of Croatian pregnant women on lamotrigine monotherapy--aspects of pre-pregnancy counseling and drug monitoring.
Topics: Adult; Anticonvulsants; Drug Monitoring; Epilepsy; Female; Humans; Lamotrigine; Preconception Care; | 2009 |
Transient improvement after brief antiepileptic drug withdrawal in the epilepsy monitoring unit--possible relationship to AED tolerance.
Topics: Adult; Anticonvulsants; Carbamazepine; Drug Administration Schedule; Drug Resistance; Drug Tolerance | 2010 |
Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; China; Drug Eruptions; Epilepsy; Female; Hu | 2010 |
Long-term efficacy of valproate versus lamotrigine in treatment of idiopathic generalized epilepsies in children and adolescents.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Lamotrigine; Male; T | 2010 |
Reduced phenytoin levels in an epileptic patient following Roux-En-Y gastric bypass for obesity.
Topics: Anticonvulsants; Body Mass Index; Epilepsy; Gastric Bypass; Humans; Lamotrigine; Male; Middle Aged; | 2011 |
[Is breast feeding by the mother under lamotrigine therapy feasible? ].
Topics: Adult; Anticonvulsants; Breast Feeding; Epilepsy; Female; Humans; Infant; Infant, Newborn; Lamotrigi | 2010 |
Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy.
Topics: Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Response Rela | 2010 |
Determination of lamotrigine in human serum by high-performance liquid chromatography–tandem mass spectrometry.
Topics: Anticonvulsants; Antimanic Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Epilepsy; | 2010 |
Antiepileptic drugs modify power of high EEG frequencies and their neural generators.
Topics: Adolescent; Adult; Anticonvulsants; Brain Waves; Carbamazepine; Electroencephalography; Epilepsy; Fe | 2010 |
The effect of antiepileptic drugs on mitochondrial activity: a pilot study.
Topics: Adenosine Triphosphate; Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Electro | 2010 |
Add-on lamotrigine in pediatric epilepsy in India.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Follow-Up Studies; Humans; I | 2011 |
Carbamazepine and lamotrigine plasma concentrations in epileptic patients during optimising therapy.
Topics: Anticonvulsants; Carbamazepine; Drug Monitoring; Epilepsy; Humans; Lamotrigine; Triazines | 2010 |
Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Cardiovascular Diseases; Comorbidity; Epilepsy; F | 2010 |
Quality of life and treatment satisfaction in Spanish epilepsy patients on monotherapy with lamotrigine or valproic acid.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Male; Patient Satisfaction; Quality o | 2010 |
Serum levels of lamotrigine during delivery in mothers and their infants.
Topics: Adolescent; Adult; Cohort Studies; Delivery, Obstetric; Epilepsy; Female; Fetal Blood; Humans; Infan | 2010 |
Are lamotrigine kinetics altered in menopause? Observations from a drug monitoring database.
Topics: Anticonvulsants; Confidence Intervals; Databases, Factual; Dose-Response Relationship, Drug; Drug Mo | 2010 |
Effects of AEDs on biomarkers in people with epilepsy: CRP, HbA1c and eGFR.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Biomarkers; C-Reactive Protein; Epilepsy; Female; G | 2010 |
Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Congenital Abnormalities; Dose-Response Rel | 2010 |
Acoustic effects of lamotrigine in pediatric patients with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Female; Huma | 2011 |
Age and comedications influence levetiracetam pharmacokinetics in children.
Topics: Adolescent; Age Factors; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Interactions; | 2010 |
[Interchangeability among therapeutics equivalents of lamotrigine in the treatment of refractory epilepsy patients: risks and benefits].
Topics: Adult; Anticonvulsants; Brazil; Dosage Forms; Epilepsy; Female; Humans; Lamotrigine; Male; Middle Ag | 2010 |
Lyell syndrome and epileptic seizures after confusion between Lamictal and Lamisil.
Topics: Anticonvulsants; Antifungal Agents; Epilepsy; Humans; Lamotrigine; Medication Errors; Naphthalenes; | 2010 |
Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population.
Topics: Adolescent; Adult; Anticonvulsants; Asian People; Epilepsy; Female; Gene Frequency; Genotype; HLA-B | 2010 |
Perinatal exposure to maternal lamotrigine: clinical considerations for the mother and child.
Topics: Adult; Anticonvulsants; Breast Feeding; Epilepsy; Female; Humans; Infant, Newborn; Lactation; Lamotr | 2010 |
Phenobarbital/Lamotrigine coadministration-induced blood dyscrasia in a patient with epilepsy.
Topics: Adult; Anticonvulsants; Drug Interactions; Drug Therapy, Combination; Epilepsy; Female; Humans; Lamo | 2010 |
Effects of breastfeeding in children of women taking antiepileptic drugs.
Topics: Adult; Anticonvulsants; Breast Feeding; Carbamazepine; Child, Preschool; Cognition; Epilepsy; Female | 2010 |
A sensitive and selective HPLC method for estimation of lamotrigine in human plasma and saliva: application to plasma-saliva correlation in epileptic patients.
Topics: Anticonvulsants; Calibration; Chromatography, High Pressure Liquid; Epilepsy; Humans; Indicators and | 2010 |
The effect of lamotrigine on valproic acid concentrations.
Topics: Adolescent; Child; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Epilepsy; Female; H | 2011 |
Carbamazepine in pregnancy: Levetiracetam and lamotrigine are better options.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Contraindications; Epilepsy; Female; Hu | 2011 |
Suicidal risk and suicide attempts in people treated with antiepileptic drugs for epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Comorbidity; Depressive Disorder; Electroencephalography; | 2011 |
Expression of UDP-glucuronosyltransferase 1A4 in human placenta at term.
Topics: Anticonvulsants; Blotting, Western; Case-Control Studies; Epilepsy; Female; Gene Expression Regulati | 2011 |
[Interchangeability among therapeutics equivalents of lamotrigine].
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Therapeutic Equivalency; Treatment Outcome; Triazine | 2011 |
Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Estradiol; Female; Humans; Lamotrigine; Outpatients; P | 2011 |
Retention rate of clobazam, topiramate and lamotrigine in children with intractable epilepsies at 1 year.
Topics: Adolescent; Benzodiazepines; Child; Child, Preschool; Clobazam; Epilepsy; Exanthema; Female; Fructos | 2011 |
Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine.
Topics: Anticonvulsants; Carbamazepine; Case-Control Studies; Child, Preschool; Developmental Disabilities; | 2011 |
Weight gain induced with olanzapine in adolescent.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Cooperative Beh | 2011 |
SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs.
Topics: Alternative Splicing; Anticonvulsants; Epilepsy; Humans; Lamotrigine; NAV1.1 Voltage-Gated Sodium Ch | 2011 |
Early postnatal exposure of rats to lamotrigine, but not phenytoin, reduces seizure threshold in adulthood.
Topics: Aging; Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Female; Lamotrigine; Male; Phenyt | 2011 |
The relationship between UGT1A4 polymorphism and serum concentration of lamotrigine in patients with epilepsy.
Topics: Adult; Amino Acid Substitution; Anticonvulsants; Chromatography, High Pressure Liquid; Dose-Response | 2011 |
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epile | 2011 |
Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Canada; Carbamazepine; Cohort Studies; Drug Therapy, C | 2011 |
Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
Topics: Anticonvulsants; Drug Substitution; Drugs, Generic; Emergency Service, Hospital; Epilepsy; Female; H | 2011 |
Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs.
Topics: Adolescent; Adult; Anticonvulsants; Bone Density; Carbamazepine; Epilepsy; Estradiol; Female; Humans | 2011 |
Haematological side effects of antiepileptic drug treatment in patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Blood Platelets; Carbamazepine; Cross-Sectional Studies; Epileps | 2011 |
Vinpocetine inhibits glutamate release induced by the convulsive agent 4-aminopyridine more potently than several antiepileptic drugs.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Calcium; Carbamazepine; Drug Interactions; Epilepsy; Fruc | 2011 |
The steroid metabolome in lamotrigine-treated women with epilepsy.
Topics: 17-alpha-Hydroxypregnenolone; Adult; Androstanes; Androstanols; Anticonvulsants; Epilepsy; Female; H | 2011 |
Decreased hyperpolarization-activated currents in layer 5 pyramidal neurons enhances excitability in focal cortical dysplasia.
Topics: Action Potentials; Animals; Animals, Newborn; Anticonvulsants; Cerebral Cortex; Cyclic Nucleotide-Ga | 2011 |
Lamotrigine-induced lupus: a case report.
Topics: Adolescent; Anticonvulsants; Antirheumatic Agents; Arthralgia; Epilepsy; Female; Humans; Hydroxychlo | 2011 |
Epileptic seizure induced by fennel essential oil.
Topics: Adult; Anticonvulsants; Epilepsy; Epilepsy, Tonic-Clonic; Female; Foeniculum; Humans; Lamotrigine; O | 2011 |
[Clinical characteristics and treatment for new onset epilepsy in the elderly].
Topics: Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Diagnostic Imaging; Elect | 2010 |
[Epilepsy in elderly].
Topics: Aged; Aged, 80 and over; Aging; Anticonvulsants; Carbamazepine; Electroencephalography; Epilepsies, | 2011 |
Self-reported symptoms in patients on antiepileptic drugs in monotherapy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Male | 2011 |
[Massive lamotrigine poisoning--case report].
Topics: Adult; Anticonvulsants; Coma; Drug Overdose; Epilepsy; Female; Humans; Lamotrigine; Respiratory Insu | 2011 |
Changed constitution without change in brand name--the risk of generics in epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Australia; Child; Dose-Response Relationship, Drug; Drug S | 2012 |
Increased risk of sudden unexpected death in epilepsy in females using lamotrigine: a nested, case-control study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Case-Control Studies; Death, Sudden; Epilepsy; Female; Hum | 2012 |
Vulnerability of an epileptic case to psychosis: sodium valproate with lamotrigine, forced normalization, postictal psychosis or all?
Topics: Adult; Age of Onset; Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epil | 2012 |
Comparative efficacy of combination drug therapy in refractory epilepsy.
Topics: Anticonvulsants; Developmental Disabilities; Drug Therapy, Combination; Epilepsy; Female; Humans; La | 2012 |
[Lamotrigine add-on therapy for childhood-onset refractory epilepsy: comparison of the efficacy between 3 months and 6 months after initiation].
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination | 2011 |
[Lamotrigine-induced sleep behavior disturbance in a case with intractable epilepsy].
Topics: Adolescent; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epilepsy; | 2011 |
Parageusia in an epileptic child treated with lamotrigine.
Topics: Ageusia; Anticonvulsants; Child; Epilepsy; Excitatory Amino Acid Antagonists; Female; Humans; Lamotr | 2011 |
In a patient with toxic epidermal necrolysis, does intravenous immunoglobulin improve survival compared with supportive care?
Topics: Aged; Anticonvulsants; Biopsy; Epilepsy; Humans; Immunoglobulins, Intravenous; Immunologic Factors; | 2011 |
Lamotrigine-induced hypersensitivity syndrome in a Han Chinese patient with the HLA-B 5801 genotype.
Topics: Adult; Anticonvulsants; Asian People; Drug Eruptions; Drug Hypersensitivity; Epilepsy; Female; Genot | 2013 |
Lamotrigine and aseptic meningitis.
Topics: Adolescent; Adult; Aged; Algorithms; Animals; Anticonvulsants; Antidepressive Agents; Bipolar Disord | 2012 |
A lamotrigine induced toxic epidermal necrolysis in a child.
Topics: Anticonvulsants; Child; Drug Combinations; Epilepsy; Female; Humans; Lamotrigine; Levetiracetam; Pir | 2013 |
Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes.
Topics: Abnormalities, Drug-Induced; Adolescent; Anticonvulsants; Carbamazepine; Cost-Benefit Analysis; Epil | 2012 |
Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany--a nationwide population-based study in children and adults.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Carbamazepine; Child; Databases, Factual; Epilepsy; German | 2012 |
Know your current I(h): interaction with a shunting current explains the puzzling effects of its pharmacological or pathological modulations.
Topics: Action Potentials; Animals; CA1 Region, Hippocampal; Computer Simulation; Electrophysiological Pheno | 2012 |
Adult onset startle epilepsy.
Topics: Anticonvulsants; Electroencephalography; Epilepsy; Humans; Lamotrigine; Male; Middle Aged; Reflex, S | 2011 |
Lamotrigine-induced toxic epidermal necrolysis in a young epileptic.
Topics: Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Stevens-Johnson Syndrome; Triazines; Young A | 2011 |
Late adverse effects of the coadministration of valproate and lamotrigine.
Topics: Adolescent; Anticonvulsants; Ataxia; Child; Drug Therapy, Combination; Epilepsy; Female; Headache; H | 2012 |
Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.
Topics: Anticonvulsants; Cohort Studies; Cross-Over Studies; Drug Substitution; Drug Utilization; Drugs, Gen | 2012 |
Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Child; Chil | 2012 |
Coexistence of SUNCT and aura? A case report.
Topics: Adult; Analgesics; Epilepsy; Female; Humans; Lamotrigine; SUNCT Syndrome; Triazines | 2012 |
Lamotrigine related myocarditis: case report.
Topics: Adolescent; Anticonvulsants; Electrocardiography; Epilepsy; Humans; Lamotrigine; Magnetic Resonance | 2012 |
Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy.
Topics: Adult; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transpor | 2012 |
Sudden unexpected death in epilepsy in lamotrigine randomized-controlled trials.
Topics: Adult; Anticonvulsants; Confidence Intervals; Death, Sudden; Epilepsy; Female; Humans; Lamotrigine; | 2013 |
Population pharmacokinetics of lamotrigine in Chinese children with epilepsy.
Topics: Adolescent; Anticonvulsants; Asian People; Child; Child, Preschool; China; Chromatography, High Pres | 2012 |
Effectiveness and safety assessment of lamotrigine monotherapy for treatment of epilepsy.
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Publication Bias; Triazines | 2012 |
Lamotrigine serum concentration in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Lamotrigine; Male; R | 2012 |
Signal-averaged and standard electrocardiography in patients with newly diagnosed epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Arrhythmias, Cardiac; Carbamazepine; Electrocardiography; Epilep | 2012 |
Carbamazepine, but not valproate, displays pharmacoresistance in lamotrigine-resistant amygdala kindled rats.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Drug Resistance; Epilepsy; Kindling, Neurologic; | 2013 |
[Clinical application of newer anti-epileptic drugs].
Topics: Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructose; Gabapentin; gamma- | 2012 |
Comparison and effects of acute lamotrigine treatment on extracellular excitatory amino acids in the hippocampus of PTZ-kindled epileptic and PTZ-induced status epilepticus rats.
Topics: Animals; Aspartic Acid; Epilepsy; Excitatory Amino Acid Antagonists; Glutamic Acid; Hippocampus; Kin | 2013 |
[The effects of lamotrigine on refractory epilepsies in persons with severe motor and intellectual disabilities].
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy; Fe | 2012 |
Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Benzodiazepines; Brain Neoplasms; Carbamazepine; Clobazam; Dr | 2012 |
Seizure control with antiepileptic drug therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticonvulsants; Carbamazepine; Cross-S | 2012 |
The longer-term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting.
Topics: Acetamides; Adolescent; Adult; Anticonvulsants; Cognition; Epilepsy; Executive Function; Female; Fru | 2013 |
P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barri | 2002 |
Lamotrigine clearance during pregnancy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Pregnancy; Pregnancy Complications; P | 2002 |
Lamotrigine derivatives and riluzole inhibit INa,P in cortical neurons.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Anticonvulsants; Cerebral Cortex; Dose-Response Relatio | 2002 |
Long-term follow-up of topiramate and lamotrigine: a perspective on quality of life.
Topics: Antidepressive Agents; Electroencephalography; Epilepsy; Follow-Up Studies; Fructose; Humans; Lamotr | 2002 |
Lack of an effect of topiramate on lamotrigine serum concentrations.
Topics: Adolescent; Adult; Anticonvulsants; Child; Drug Interactions; Epilepsy; Female; Fructose; Humans; La | 2002 |
Effects of antiepileptic drugs on induced epileptiform activity in a rat model of dysplasia.
Topics: 4-Aminopyridine; Action Potentials; Animals; Animals, Newborn; Anticonvulsants; Carbamazepine; Disea | 2002 |
Does lamotrigine influence valproate concentrations?
Topics: Adolescent; Adult; Analysis of Variance; Child; Child, Preschool; Drug Interactions; Epilepsy; Femal | 2002 |
Preliminary results on pregnancy outcomes in women using lamotrigine.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Congenital Abnormalities; Drug Therapy, Combination; E | 2002 |
Polytherapy in epilepsy: the experimental evidence.
Topics: Animals; Anticonvulsants; Calcium Channel Blockers; Drug Synergism; Drug Therapy, Combination; Elect | 2002 |
Valproic acid and lamotrigine treatment during pregnancy. The risk of chromosomal abnormality.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adult; Anticonvulsants; Chromosome Aberrations | 2003 |
Comparison of lamotrigine and valproate with respect to quality of life.
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Quality of Life; Triazines; Valproic Acid | 2003 |
[Experience with lamictal in the treatment of outpatients with resistant epilepsy].
Topics: Adult; Anticonvulsants; Drug Administration Schedule; Drug Resistance; Epilepsy; Female; Humans; Lam | 2003 |
The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation.
Topics: Anticonvulsants; Bayes Theorem; Clinical Trials as Topic; Cost-Benefit Analysis; Epilepsy; Fructose; | 2003 |
Clinically relevant reduction of lamotrigine concentrations by carbamazepine.
Topics: Aged; Anticonvulsants; Carbamazepine; Drug Antagonism; Drug Therapy, Combination; Epilepsy; Humans; | 2003 |
Uptake of GABA and activity of GABA-transaminase in platelets from epileptic patients.
Topics: 4-Aminobutyrate Transaminase; Adult; Anticonvulsants; Blood Platelets; Case-Control Studies; Dose-Re | 2003 |
Management of toxic epidermal necrolysis in a 15-year-old girl.
Topics: Adolescent; Anticonvulsants; Body Surface Area; Burn Units; Critical Care; Diagnosis, Differential; | 2003 |
Effects of folic acid and lamotrigine therapy in some rodent models of epilepsy and behaviour.
Topics: Animals; Anticonvulsants; Behavior, Animal; Dose-Response Relationship, Drug; Electroshock; Epilepsy | 2003 |
Clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: comparison of efficacy and side effects using odds ratios.
Topics: Anticonvulsants; Costs and Cost Analysis; Dose-Response Relationship, Drug; Epilepsy; Fructose; Huma | 2003 |
Case reports of women with epilepsy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Epilepsy; Female; Humans; Infant, Newborn; Lamo | 2003 |
[Toxic epidermal necrolysis due to lamotrigine].
Topics: Anticonvulsants; Child; Epilepsy; Fatal Outcome; Female; Humans; Lamotrigine; Stevens-Johnson Syndro | 2003 |
Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy.
Topics: Adult; Analysis of Variance; Androgens; Confidence Intervals; Cross-Sectional Studies; Epilepsy; Fem | 2003 |
Lamotrigine and valproate: efficacy of co-administration in a pediatric population.
Topics: Adolescent; Ambulatory Care; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy; Female; F | 2003 |
Interactions of lamotrigine with topiramate and first-generation antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Drug Interactions; Electroshock; Epileps | 2003 |
A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy.
Topics: Anticonvulsants; Carbamazepine; Case-Control Studies; Epilepsy; Female; Follicle Stimulating Hormone | 2003 |
The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months.
Topics: Abortion, Induced; Anticonvulsants; Australia; Carbamazepine; Cohort Studies; Congenital Abnormaliti | 2003 |
[Use of lamictal monotherapy in epilepsy].
Topics: Adolescent; Anticonvulsants; Child; Drug Administration Schedule; Epilepsy; Female; Humans; Lamotrig | 2003 |
Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats.
Topics: Amygdala; Animals; Anticonvulsants; Biological Availability; Blood-Brain Barrier; Carbamazepine; Cer | 2003 |
Epilepsy and pregnancy: lamotrigine as main drug used.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adolescent; Adult; Anticonvulsants; Epilepsy; | 2004 |
The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Databases, Factual; Electroencephalogra | 2004 |
The impact of pregnancy and childbirth on the metabolism of lamotrigine.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Metabolic Clearance Rate; Pregnancy; | 2004 |
Concerns regarding lamotrigine and breast-feeding.
Topics: Anticonvulsants; Breast Feeding; Epilepsy; Female; Follow-Up Studies; Humans; Infant, Newborn; Lamot | 2004 |
Potentially inappropriate antiepileptic drugs for elderly patients with epilepsy.
Topics: Acetates; Aged; Amines; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Epilepsy; Female; Ga | 2004 |
Interaction between anticonvulsants and human placental carnitine transporter.
Topics: Acetates; Amines; Aminoisobutyric Acids; Anticonvulsants; Carnitine; Carrier Proteins; Culture Techn | 2004 |
Patterns of lamotrigine use in daily clinical practice during the first 5 years after introduction in the Netherlands.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Cohort Studies; Databases, Factua | 2004 |
Pharmacodynamic analysis of the anticonvulsant effects of tiagabine and lamotrigine in combination in the rat.
Topics: Animals; Anticonvulsants; Behavior, Animal; Cerebral Cortex; Disease Models, Animal; Dose-Response R | 2004 |
Effect of lamotrigine treatment on epileptogenesis: an experimental study in rat.
Topics: Animals; Drug Administration Schedule; Electric Stimulation; Epilepsy; Hippocampus; Lamotrigine; Mal | 2004 |
Intracellular calcium increase in epileptiform activity: modulation by levetiracetam and lamotrigine.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Bicuculline; Calcium; Calcium Channel Blockers; Calcium C | 2004 |
Serum androgen levels and testicular structure during pubertal maturation in male subjects with epilepsy.
Topics: Adolescent; Adult; Androgens; Androstenedione; Anticonvulsants; Carbamazepine; Child; Epilepsy; Huma | 2004 |
Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Drug Evaluation, Preclinical; Drug | 2004 |
Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study.
Topics: Adult; Anticonvulsants; Cohort Studies; Dose-Response Relationship, Drug; Epilepsy; Female; Fetal Bl | 2004 |
Improved mood states with lamotrigine in patients with epilepsy.
Topics: Adult; Affect; Anticonvulsants; Antidepressive Agents; Epilepsy; Female; Humans; Lamotrigine; Male; | 2004 |
Cognitive profile of topiramate as compared with lamotrigine in epilepsy patients on antiepileptic drug polytherapy: relationships to blood serum levels and comedication.
Topics: Adult; Anticonvulsants; Cognition; Drug Therapy, Combination; Epilepsy; Female; Fructose; Humans; La | 2004 |
Recruitment of a cohort of lamotrigine users through community pharmacists: differences between patients who gave informed consent and those who did not.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Cohort Studies; Community Pharmacy Services; | 2005 |
Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anticonvulsants; Carbamazepine; Child; Cohort Studies; Confoundi | 2004 |
The outcome of initiation of antiepileptic drug monotherapy in primary care: a UK database survey.
Topics: Aged; Anticonvulsants; Carbamazepine; Child, Preschool; Clinical Competence; Epilepsy; Family Practi | 2004 |
Australian pregnancy registry of women taking antiepileptic drugs.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Australia; Drug Therapy, Combination; Epilepsy; Female | 2004 |
The International Lamotrigine pregnancy registry update for the epilepsy foundation.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Epilepsy; Female; Foundations; Global Health; Humans; | 2004 |
[Influence of psychotropic drugs on thrombocytes aggregation in patients with epilepsy].
Topics: Adolescent; Adult; Barbiturates; Carbamazepine; Epilepsy; Humans; In Vitro Techniques; Lamotrigine; | 2004 |
Analysis of lamotrigine and its metabolites in human plasma and urine by micellar electrokinetic capillary chromatography.
Topics: Chromatography, High Pressure Liquid; Chromatography, Micellar Electrokinetic Capillary; Epilepsy; H | 2005 |
A simple method to monitor plasma concentrations of oxcarbazepine, carbamazepine, their main metabolites and lamotrigine in epileptic patients.
Topics: Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Drug Monitoring; Epilepsy; Hum | 2005 |
What can we say to women of reproductive age with epilepsy?
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; E | 2005 |
Determination of levetiracetam in human plasma with minimal sample pretreatment.
Topics: Anticonvulsants; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Epilepsy; Humans; | 2005 |
Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics.
Topics: Anticonvulsants; Carbamazepine; Causality; Epilepsy; Germany; Humans; Incidence; Inpatients; Lamotri | 2005 |
Telogen effluvium caused by magnesium valproate and lamotrigine.
Topics: Acute Disease; Adolescent; Adult; Alopecia; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; | 2005 |
[Drug hypersensitivity syndrome with lamotrigine two cases in elderly].
Topics: Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Drug Hypersensitivity; Epilepsy; Female; Huma | 2005 |
Lamotrigine and epilepsy in the elderly: observational study of low-dose monotherapy.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Humans | 2005 |
Blood homocysteine, folate and vitamin B-12 concentrations in patients with epilepsy receiving lamotrigine or sodium valproate for initial monotherapy.
Topics: Adult; Epilepsy; Female; Folic Acid; Homocysteine; Humans; Lamotrigine; Male; Middle Aged; Triazines | 2005 |
Antiepileptic drugs for the elderly: using the old to focus on the new.
Topics: Age Factors; Aged; Aged, 80 and over; Amines; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; | 2005 |
Antiepileptic drugs and the regulation of mood and quality of life (QOL): the evidence from epilepsy.
Topics: Affect; Anticonvulsants; Carbamazepine; Epilepsy; Health Status; Humans; Lamotrigine; Mood Disorders | 2005 |
Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs.
Topics: Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Fructose; Gabapentin; | 2005 |
[Epileptic seizures during childbirth in a patient with idiopathic generalised epilepsy].
Topics: Adult; Anticonvulsants; Cesarean Section; Clonazepam; Diazepam; Epilepsy; Epilepsy, Generalized; Epi | 2005 |
Individual changes in lamotrigine plasma concentrations during pregnancy.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Postpartum Period; Pregnancy; Retrosp | 2005 |
An audit of lamotrigine, levetiracetam and topiramate usage for epilepsy in a district general hospital.
Topics: Adult; Aged; Anticonvulsants; Cohort Studies; Drug Utilization; Epilepsy; Epilepsy, Generalized; Fem | 2005 |
Pharmacokinetic interactions of carbamazepine with some antiepileptic drugs during epilepsy treatment in children and adolescents.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Drug Interactions; Epilepsy; Female; Fructose; Hu | 2005 |
Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.
Topics: Adult; Anticonvulsants; Brain; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Epilepsie | 2005 |
Forced normalisation precipitated by lamotrigine.
Topics: Adolescent; Adult; Anticonvulsants; Behavioral Symptoms; Electroencephalography; Epilepsy; Female; H | 2005 |
Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy.
Topics: Anticonvulsants; Carbamazepine; Chromatography, High Pressure Liquid; Dibenzazepines; Drug Monitorin | 2005 |
Lower frequency variability in the alpha activity in EEG among patients with epilepsy.
Topics: Adult; Alpha Rhythm; Anticonvulsants; Brain; Carbamazepine; Case-Control Studies; Electroencephalogr | 2005 |
New antiepileptic drugs in practice--how do they perform in the real world?
Topics: Amines; Anticonvulsants; Controlled Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Epilepsy; | 2005 |
Cost-effectiveness of add-on lamotrigine therapy in clinical practice.
Topics: Adult; Anticonvulsants; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Therapy, Combination; E | 2005 |
[The efficacy of topiramate (topamax) in the treatment of resistant epilepsy in children].
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Resistance; Drug Therapy, | 2005 |
The use of lamotrigine and other antiepileptic drugs in paediatric patients at a Malaysian hospital.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cost-Benefit Analysis; D | 2005 |
Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epilepsy; Femal | 2006 |
Non-compliance on the part of the professional community with a national guideline: an argumentative policy analysis.
Topics: Anticonvulsants; Epilepsy; Guideline Adherence; Health Knowledge, Attitudes, Practice; Humans; Inter | 2006 |
Major congenital malformations and antiepileptic drugs: prospective observations.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combin | 2006 |
Predictors of Lamotrigine-associated rash.
Topics: Adolescent; Adult; Age Factors; Ambulatory Care; Anticonvulsants; Child; Drug Administration Schedul | 2006 |
Anticonvulsant hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro.
Topics: Anticonvulsants; Child, Preschool; Drug Hypersensitivity; Epilepsy; Humans; In Vitro Techniques; Lam | 2006 |
Measuring the effects of antiepileptic medications on balance in older people.
Topics: Aged; Amines; Anticonvulsants; Ataxia; Carbamazepine; Cyclohexanecarboxylic Acids; Dizziness; Epilep | 2006 |
Active control trials for epilepsy: avoiding bias in head-to-head trials.
Topics: Anticonvulsants; Bias; Carbamazepine; Control Groups; Dose-Response Relationship, Drug; Drug Adminis | 2006 |
Efficacy and tolerability of adjunctive lamotrigine for refractory epilepsy in institutional or community residents with mental retardation.
Topics: Activities of Daily Living; Adolescent; Adult; Anticonvulsants; Drug Tolerance; Epilepsy; Female; Hu | 2006 |
Long-term profile of lamotrigine in 119 children with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Cognition; Electroencephalography; Epil | 2006 |
Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy.
Topics: Anticonvulsants; Benzodiazepines; Child, Preschool; Clobazam; Dose-Response Relationship, Drug; Epil | 2006 |
Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring.
Topics: Adolescent; Adult; Anticonvulsants; Electroencephalography; Epilepsy; Female; Half-Life; Humans; Lam | 2006 |
Epileptiform discharges and the behavior of children with epilepsy.
Topics: Anticonvulsants; Child; Child Behavior Disorders; Electroencephalography; Epilepsy; Humans; Lamotrig | 2006 |
Adjunctive lamotrigine for refractory epilepsy in adolescents with mental retardation.
Topics: Adolescent; Adolescent Behavior; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female | 2006 |
Maternal lamotrigine treatment and elevated neonatal gamma-glutamyl transpeptidase.
Topics: Anticonvulsants; Epilepsy; Female; gamma-Glutamyltransferase; Humans; Infant, Newborn; Jaundice, Neo | 2006 |
Monitoring salivary lamotrigine concentrations.
Topics: Adolescent; Adult; Anticonvulsants; Biological Assay; Child; Child, Preschool; Drug Administration S | 2006 |
How to replace lamotrigine with valproate.
Topics: Adolescent; Adult; Anticonvulsants; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Ad | 2006 |
Psychological factors and use of antiepileptic drugs: pilot work using an objective measure of adherence.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Anxiety; Culture; Depression; Drug Monitoring; Drug Therap | 2007 |
Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat.
Topics: Adolescent; Anti-Obesity Agents; Anticonvulsants; Drug Interactions; Drug Monitoring; Epilepsy; Fema | 2006 |
Improvement in quality of life after initiation of lamotrigine therapy in patients with epilepsy in a naturalistic treatment setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Fe | 2007 |
A 6-month longitudinal study of bone mineral density with antiepileptic drug monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcitriol; | 2007 |
Lamotrigine in idiopathic epilepsy - increased risk of cardiac death?
Topics: Adolescent; Adult; Anticonvulsants; Death, Sudden, Cardiac; Epilepsy; Female; Humans; Lamotrigine; T | 2007 |
Lamotrigine as a possible cause of QRS prolongation in a patient with known seizure disorder.
Topics: Adult; Anticonvulsants; Electrocardiography; Epilepsy; Felbamate; Female; Humans; Lamotrigine; Pheny | 2006 |
Effect of lamotrigine on cognition in children with epilepsy.
Topics: Anticonvulsants; Attention; Cognition; Epilepsy; Humans; Lamotrigine; Memory; Pediatrics; Triazines | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Cohort Studies; Cost-Benefit Analysis; Drug Costs; Drug P | 2007 |
Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Congenital Abnormalities; Databases as Topic; Dose-Res | 2007 |
Stevens-Johnson syndrome due to concomitant use of lamotrigine and valproic acid.
Topics: Adult; Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Epilepsy; Female; Humans; Lamotrig | 2007 |
Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Male; Middle Aged; Postop | 2007 |
Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients.
Topics: Anticonvulsants; Carbamazepine; Cost-Benefit Analysis; Drug Costs; Drug Industry; Epilepsies, Partia | 2007 |
Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Anticonvulsants; Canada; Child; Child, P | 2007 |
Rash from antiepileptic drugs: influence by gender, age, and learning disability.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Carbamazepine; Comorbidity; Drug Eruptions; Epileps | 2007 |
Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.
Topics: Adolescent; Adult; Alleles; Anticonvulsants; Asian People; Carbamazepine; Case-Control Studies; Chil | 2007 |
Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.
Topics: Adolescent; Adult; Alleles; Anticonvulsants; Asian People; Carbamazepine; Case-Control Studies; Chil | 2007 |
Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.
Topics: Adolescent; Adult; Alleles; Anticonvulsants; Asian People; Carbamazepine; Case-Control Studies; Chil | 2007 |
Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese.
Topics: Adolescent; Adult; Alleles; Anticonvulsants; Asian People; Carbamazepine; Case-Control Studies; Chil | 2007 |
Lamotrigine rash--a potentially life-threatening complication.
Topics: Anticonvulsants; Child; Epilepsy; Exanthema; Humans; Lamotrigine; Male; Physical Examination; Triazi | 2007 |
[Does generic lamotrigine lead to larger variations in plasma concentrations?].
Topics: Anticonvulsants; Drugs, Generic; Epilepsy; Humans; Lamotrigine; Triazines | 2007 |
Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Carbamazepine; Comorbidity; Epil | 2007 |
Old versus new antiepileptic drugs: the SANAD study.
Topics: Anticonvulsants; Carbamazepine; Child; Epilepsy; Humans; Lamotrigine; Triazines | 2007 |
Old versus new antiepileptic drugs: the SANAD study.
Topics: Adult; Anticonvulsants; Carbamazepine; Dose-Response Relationship, Drug; Epilepsy; Humans; Lamotrigi | 2007 |
Old versus new antiepileptic drugs: the SANAD study.
Topics: Adult; Anticonvulsants; Carbamazepine; Epilepsy; Humans; Lamotrigine; Triazines; Valproic Acid | 2007 |
Old versus new antiepileptic drugs: the SANAD study.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Liver Failure, Acute; Triazines | 2007 |
Lamotrigine overdose in a child.
Topics: Anticonvulsants; Child, Preschool; Drug Overdose; Epilepsy; Female; Humans; Lamotrigine; Triazines | 2007 |
The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.
Topics: Adult; Anticonvulsants; Cost Savings; Drug Costs; Drug Prescriptions; Drug Utilization; Drugs, Gener | 2007 |
Assessment of tolerability in elderly patients: changing to lamotrigine therapy.
Topics: Affect; Aged; Aged, 80 and over; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Human | 2007 |
Conversion to lamotrigine monotherapy from valproate monotherapy in older adolescent patients with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; Lamo | 2007 |
Teratogenicity of lamotrigine.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cleft Palate; Drug Evaluation; Epilepsy; Female; Human | 2007 |
Hemophagocytic syndrome associated with high-dose lamotrigine.
Topics: Anticonvulsants; Child, Preschool; Epilepsy; Humans; Lamotrigine; Lymphohistiocytosis, Hemophagocyti | 2007 |
Bone mineral density with lamotrigine monotherapy for epilepsy.
Topics: Adolescent; Anticonvulsants; Bone Density; Calcium; Child; Cross-Sectional Studies; Diet; Drug Admin | 2007 |
Lamotrigine in idiopathic epilepsy - increased risk of cardiac death.
Topics: Adolescent; Adult; Anticonvulsants; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Dose-Response Rela | 2007 |
Which patients become seizure free with antiepileptic drugs? An observational study in 821 patients with epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Cohort Studies; Drug Resistance; Drug Therapy, Combination; E | 2008 |
[Symptomatic secondary hyponatraemia due to combined treatment anticonvulsant and antidepressant: risk of sudden death in epilepsy?].
Topics: Adult; Anticonvulsants; Antidepressive Agents; Carbamazepine; Cyclohexanols; Death, Sudden; Drug Int | 2007 |
Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency.
Topics: Adolescent; Adult; Anticonvulsants; Cohort Studies; Drug Monitoring; Epilepsy; Female; Humans; Lamot | 2008 |
Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epi | 2008 |
Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Drug Therapy, Co | 2008 |
Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites.
Topics: Adolescent; Adult; Anticonvulsants; Contraception; Epilepsy; Female; Glucuronides; Humans; Lamotrigi | 2008 |
Progressive anticonvulsant hypersensitivity syndrome associated with change of drug product.
Topics: Adult; Anticonvulsants; Arthralgia; Arthritis; Drugs, Generic; Epilepsy; Exanthema; Fever; Humans; L | 2008 |
Lamotrigine inhibits postsynaptic AMPA receptor and glutamate release in the dentate gyrus.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Dentate Gyrus; D | 2008 |
Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.
Topics: Adult; Anticonvulsants; Canada; Cost Savings; Drug Costs; Drug Prescriptions; Drugs, Generic; Epilep | 2008 |
New antiepileptic drugs in pediatric epilepsy.
Topics: Amines; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Cyclohexanecarboxylic Acids; Epilep | 2008 |
An insufficient effect of lamotrigine leading to fatal seizures.
Topics: Acidosis; Age Factors; Anticonvulsants; Apnea; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Dose-Re | 2008 |
Simultaneous toxicities in a child on multiple anticonvulsants.
Topics: Anticonvulsants; Bone Marrow; Bone Marrow Diseases; Chemical and Drug Induced Liver Injury; Child, P | 2008 |
Treatment of newly diagnosed epilepsies: the shortcomings of SANAD.
Topics: Anticonvulsants; Carbamazepine; Child; Epilepsy; Follow-Up Studies; Humans; Lamotrigine; Randomized | 2008 |
In vivo pharmacological effects of JZP-4, a novel anticonvulsant, in models for anticonvulsant, antimania and antidepressant activity.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Behavior, Animal; Calcium Channel | 2008 |
[Population pharmacokinetics of lamotrigine in Chinese children with epilepsy].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Infant; Lamotrigine; | 2008 |
Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy.
Topics: Adolescent; Adult; Alkaline Phosphatase; Anticonvulsants; Biomarkers; Bone Density; Bone Diseases, M | 2008 |
Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy.
Topics: Abnormalities, Drug-Induced; Anticonvulsants; Cleft Palate; Epilepsy; Female; Humans; Infant; Infant | 2008 |
Sturge-Weber syndrome, without a facial port-wine stain, with epilepsy onset in the fifth decade.
Topics: Anticonvulsants; Electroencephalography; Epilepsy; Female; Hearing Loss, Conductive; Humans; Lamotri | 2008 |
[Lamotrigin--a new anticonvulsant for epilepsy. Conference, 25 June 1993, Frankfurt].
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Triazines | 1993 |
Lamotrigine: clinical experience in 93 patients with epilepsy.
Topics: Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug | 1995 |
The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability.
Topics: Activities of Daily Living; Adolescent; Adult; Anticonvulsants; Brain Damage, Chronic; Child; Child, | 1995 |
Routine use of lamotrigine, a new anti-epileptic medication, and the value of measuring its blood levels.
Topics: Adolescent; Adult; Anticonvulsants; Child; Clinical Trials as Topic; Drug Therapy, Combination; Epil | 1994 |
The role of newer anticonvulsants in the management of epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Australia; Cyclohexanecarboxylic Acids; Epilepsy; Gabapentin; gam | 1995 |
Lamotrigine versus carbamazepine in epilepsy.
Topics: Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Drug Administration Schedule; Epilepsy; Hu | 1995 |
New drugs for the treatment of epilepsy.
Topics: Acetates; Amines; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Gabape | 1995 |
Lamotrigine versus carbamazepine in epilepsy.
Topics: Anticonvulsants; Carbamazepine; Delayed-Action Preparations; Epilepsy; Humans; Lamotrigine; Triazine | 1995 |
Lamotrigine versus carbamazepine in epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsy; Humans; Lamotrigine; Research Design; Triazi | 1995 |
Lamotrigine versus carbamazepine in epilepsy.
Topics: Adult; Anticonvulsants; beta-Thalassemia; Epilepsy; Erythropoiesis; Humans; Lamotrigine; Male; Red-C | 1995 |
Perspective on lamotrigine.
Topics: Adult; Anticonvulsants; Clinical Trials, Phase III as Topic; Epilepsies, Partial; Epilepsy; Epilepsy | 1995 |
Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits.
Topics: Adolescent; Adult; Age of Onset; Anticonvulsants; Attention; Autistic Disorder; Brain; Child; Child, | 1994 |
Rechallenge with lamotrigine after initial rash.
Topics: Adolescent; Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Administration Sch | 1995 |
Comparing antiepileptic drugs.
Topics: Anticonvulsants; Clinical Trials as Topic; Epilepsy; Humans; Lamotrigine; Triazines | 1995 |
Impact of lamotrigine on patients with refractory epilepsy: the Leicester experience.
Topics: Adolescent; Adult; Anticonvulsants; Drug Monitoring; Drug Therapy, Combination; Electroencephalograp | 1994 |
Influence of lamotrigine addition on computerized background EEG parameters in severe epileptogenic encephalopathies.
Topics: Adult; Anticonvulsants; Cerebral Cortex; Drug Therapy, Combination; Electroencephalography; Epilepsy | 1994 |
New antiepileptic drugs already registered.
Topics: Anticonvulsants; Carbamazepine; Clinical Trials as Topic; Drug Approval; Drugs, Investigational; Epi | 1994 |
Excitatory amino acid antagonists, lamotrigine and BW 1003C87 as anticonvulsants in the genetically epilepsy-prone rat.
Topics: 2-Amino-5-phosphonovalerate; Acoustic Stimulation; Amino Acids; Amino Acids, Cyclic; Analysis of Var | 1993 |
Novel antiepileptic drugs: nursing implications.
Topics: Acetates; Amines; Aminocaproates; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Approval; Drug | 1993 |
Lamotrigine in resistant childhood epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Toleran | 1993 |
Lamotrigine in Rett syndrome.
Topics: Adult; Anticonvulsants; Cerebrospinal Fluid; Child; Child, Preschool; Epilepsy; Female; Glutamates; | 1993 |
Science reporters hear wide range of recent data at 12th annual conference.
Topics: Acetates; Aged; AIDS Vaccines; American Medical Association; Amines; Animals; Anticonvulsants; beta- | 1993 |
[Campaign against epilepsy].
Topics: Aminocaproates; Animals; Anticonvulsants; Epilepsy; Felbamate; Humans; Lamotrigine; Phenylcarbamates | 1993 |
New antiepileptic medications.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Dr | 1995 |
Costing of antiepileptic drugs.
Topics: Acetates; Amines; Anticonvulsants; Argentina; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Costs | 1996 |
Lamotrigine-induced rash in children.
Topics: Adult; Anticonvulsants; Child; Child, Preschool; Epilepsy; Female; Humans; Lamotrigine; Male; Skin D | 1996 |
[Current role of novel antiepileptics in the treatment of epilepsies].
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Resistance; Epil | 1996 |
Routine therapeutic monitoring of lamotrigine in epileptic patients using a simple and rapid high performance liquid chromatographic technique.
Topics: Adolescent; Adult; Age Factors; Aged; Anticonvulsants; Child; Child, Preschool; Chromatography, High | 1995 |
Concentration--effect and concentration--toxicity relations with lamotrigine: a prospective study.
Topics: Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule; | 1996 |
[Lamotrigine treatment of 92 patients with intractable epilepsy].
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsies, Partial; Epilepsy; Epilepsy, Generalized; Fema | 1996 |
[Treatment of childhood epilepsy with lamotrigine. An evaluation of efficacy in different types of epilepsy].
Topics: Adolescent; Anticonvulsants; Child; Epilepsies, Partial; Epilepsy; Epilepsy, Generalized; Female; Hu | 1996 |
[Lamotrigine. A new possibility in the treament of epilepsy].
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Triazines | 1996 |
[New medical treatment of epilepsy].
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Costs; Epile | 1996 |
Influence of concurrent antiepileptic medication on the pharmacokinetics of lamotrigine as add-on therapy in epileptic children.
Topics: Anticonvulsants; Child, Preschool; Drug Therapy, Combination; Epilepsy; Humans; Infant; Lamotrigine; | 1996 |
An audit of the new antiepileptic drugs in clinical neurological practice.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Female; Gabapentin; | 1996 |
Lamotrigine and toxic epidermal necrolysis.
Topics: Adult; Anticonvulsants; Dermatitis, Phototoxic; Epilepsy; Female; Humans; Lamotrigine; Male; Stevens | 1996 |
If comparisons can be odious, so can assumptions.
Topics: Acetates; Amines; Anticonvulsants; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Epilepsy; Gab | 1996 |
Long-term use of lamotrigine and vigabatrin in severe refractory epilepsy: audit of outcome.
Topics: Chronic Disease; Clinical Trials as Topic; Epilepsy; Follow-Up Studies; gamma-Aminobutyric Acid; Hum | 1996 |
Lamotrigine--an update.
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Triazines | 1996 |
A survey comparing lamotrigine and vigabatrin in everyday clinical practice.
Topics: Anticonvulsants; Electroencephalography; Epilepsies, Partial; Epilepsy; Epilepsy, Generalized; Epile | 1996 |
Sudden unexplained death in epilepsy: observations from a large clinical development program.
Topics: Adolescent; Adult; Anticonvulsants; Cause of Death; Child; Clinical Trials as Topic; Cohort Studies; | 1997 |
Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adminis | 1997 |
New treatment options for epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Epilepsy; Felbamate; Fructose; Gabap | 1997 |
New antiepileptic drugs: case studies.
Topics: Acetates; Amines; Anticonvulsants; Child, Preschool; Cyclohexanecarboxylic Acids; Drug Resistance; E | 1997 |
Glaxo Wellcome epilepsy drug exhibits fatal side effects.
Topics: Adult; Anticonvulsants; Child; Death; Drug Eruptions; Drug Industry; Epilepsy; Humans; Lamotrigine; | 1997 |
A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Comorbidity; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
[Lamotrigine--a new antiepileptic drug for the treatment of epilepsy in childhood].
Topics: Anticonvulsants; Child; Epilepsy; Humans; Lamotrigine; Triazines | 1997 |
The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship | 1997 |
Open trial lamotrigine in the treatment of self-injurious behavior in an adolescent with profound mental retardation.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Epilepsy; Fear; Female; Follow-Up Studies; Humans; Intel | 1996 |
Lamotrigine as add-on therapy in adult patients with refractory epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Male; Middle Aged; Triazi | 1997 |
Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dos | 1997 |
Erroneous substitution of terbinafine for lamotrigine.
Topics: Adult; Anticonvulsants; Antifungal Agents; Drug Administration Schedule; Epilepsy; Humans; Lamotrigi | 1997 |
Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy.
Topics: Administration, Oral; Adult; Anticonvulsants; Carbamazepine; Epilepsy; Female; Humans; Lamotrigine; | 1997 |
Reduction of the frequency of occurrence of low magnesium induced field potentials in the hippocampus slice preparation of guinea pigs: a good screening tool for calcium antagonistic effects of anticonvulsant and antipsychotic drugs.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Buspirone; Calcium Channel Blockers; Carbamazepine; | 1997 |
[Lamotrigine: monotherapy in refractory epilepsy].
Topics: Adolescent; Adult; Anticonvulsants; Drug Resistance; Epilepsy; Epilepsy, Complex Partial; Female; Hu | 1997 |
[Epilepsy therapy: lamotrigine--retrospective and prospective study].
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Prospective Studies; Retrospective Studies; Triazine | 1996 |
[Lamotrigin--an effective partner in the management of epilepsy].
Topics: Adult; Age Factors; Anticonvulsants; Child; Epilepsy; Humans; Lamotrigine; Quality of Life; Triazine | 1995 |
Lamotrigine plasma concentrations in children and adults: influence of age and associated therapy.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Drug Interactions; Epileps | 1997 |
High-performance liquid chromatography quantitation of plasma lamotrigine concentrations: application measuring trough concentrations in patients with epilepsy.
Topics: Anticonvulsants; Chromatography, High Pressure Liquid; Drug Interactions; Drug Monitoring; Epilepsy; | 1997 |
Lamotrigine.
Topics: Anticonvulsants; Child; Epilepsy; Humans; Lamotrigine; Triazines | 1997 |
Weak blockade of AMPA receptor-mediated depolarisations in the rat cortical wedge by phenytoin but not lamotrigine or carbamazepine.
Topics: Animals; Anticonvulsants; Carbamazepine; Cerebral Cortex; Epilepsy; Evoked Potentials; Excitatory Am | 1997 |
[Lamotrigine (Lamictal)].
Topics: Anticonvulsants; Brain; Child; Child, Preschool; Drug Combinations; Drug Eruptions; Epilepsies, Part | 1997 |
A survey of lamotrigine and vigabatrin treatment in children with severe epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epilepsies, P | 1997 |
Lamotrigine after corpus callosotomy.
Topics: Adult; Anticonvulsants; Child; Combined Modality Therapy; Corpus Callosum; Electroencephalography; E | 1997 |
Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy.
Topics: Analysis of Variance; Anticonvulsants; Cholesterol, HDL; Epilepsy; Female; Follow-Up Studies; Humans | 1998 |
Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis.
Topics: Adjuvants, Pharmaceutic; Adult; Anticonvulsants; Cost of Illness; Cost-Benefit Analysis; Epilepsy; F | 1998 |
Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?
Topics: Anticonvulsants; Carbamazepine; Child; Diplopia; Dizziness; Dose-Response Relationship, Drug; Drug A | 1998 |
Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine.
Topics: Adolescent; Adult; Aggression; Anticonvulsants; Comorbidity; Drug Administration Schedule; Epilepsy; | 1998 |
Safety of long-term lamotrigine in epilepsy.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Anticonvulsants; Chil | 1997 |
Lamotrigine hypersensitivity in childhood epilepsy.
Topics: Antibody Formation; Anticonvulsants; Child; Drug Eruptions; Epilepsy; Humans; Immunity, Cellular; La | 1998 |
Does antiepileptic therapy affect immune response?
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; Carbama | 1998 |
Lamotrigine toxicity secondary to sertraline.
Topics: 1-Naphthylamine; Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, | 1998 |
Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation.
Topics: Adolescent; Adult; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Follow-Up Studies; | 1998 |
Role of vigabatrin and lamotrigine in treatment of childhood epileptic syndromes.
Topics: Adolescent; Adult; Age Factors; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; | 1998 |
Lamotrigine and topiramate may be a useful combination.
Topics: Adolescent; Adult; Animals; Anticonvulsants; Drug Therapy, Combination; Epilepsy; Female; Fructose; | 1998 |
Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome.
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Triazines | 1998 |
The role of lamotrigine in the treatment of epilepsy.
Topics: Anticonvulsants; Epilepsy; Humans; Lamotrigine; Triazines | 1998 |
Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy.
Topics: Ambulatory Care Facilities; Anticonvulsants; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Dru | 1998 |
The outcome of prescribing novel anticonvulsants in an outpatient setting: factors affecting response to medication.
Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Chi-Square Distribution; Cycl | 1998 |
Sudden death in two patients with epilepsy and the syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Topics: Adolescent; Adult; Anticonvulsants; Autopsy; Carbamazepine; Death, Sudden; Epilepsy; gamma-Aminobuty | 1998 |
[Toxic epidermal necrolysis after treatment with lamotrigine].
Topics: Adult; Anticonvulsants; Epilepsy; Humans; Lamotrigine; Male; Stevens-Johnson Syndrome; Triazines | 1998 |
PNU-151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat.
Topics: Alanine; Animals; Anticonvulsants; Benzylamines; Diazepam; Epilepsy; Hippocampus; Kainic Acid; Lamot | 1998 |
Lamotrigine and therapeutic drug monitoring: retrospective survey following the introduction of a routine service.
Topics: Anticonvulsants; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Epilepsy; Health Car | 1998 |
Lamotrigine concentrations in human serum, brain tissue, and tumor tissue.
Topics: Adult; Aged; Animals; Anticonvulsants; Blood-Brain Barrier; Brain; Brain Chemistry; Brain Neoplasms; | 1999 |
[Antiepileptic treatment with lamotrigine].
Topics: Anticonvulsants; Contraindications; Epilepsy; Humans; Lamotrigine; Stevens-Johnson Syndrome; Triazin | 1999 |
Cortical excitability in patients after loading doses of lamotrigine: a study with magnetic brain stimulation.
Topics: Action Potentials; Adolescent; Adult; Anticonvulsants; Cerebral Cortex; Epilepsy; Epilepsy, Complex | 1999 |
Lamotrigine associated with insomnia.
Topics: Adult; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; Incidence; Lamot | 1999 |
Adjunctive therapy in epilepsy: a cost-effectiveness comparison of two AEDs.
Topics: Adult; Anticonvulsants; Cost-Benefit Analysis; Epilepsy; Female; Follow-Up Studies; Fructose; Humans | 1999 |
Effect of lamotrigine treatment in epileptic psychosis.
Topics: Adult; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Male; Psychotic Disorders; Triazines | 1999 |
Treatment of seizures in subcortical laminar heterotopia with corpus callosotomy and lamotrigine.
Topics: Adult; Anticonvulsants; Atrophy; Brain Diseases; Cerebellum; Child; Choristoma; Corpus Callosum; Ele | 1999 |
The management of epilepsy in a hospital for people with a learning disability.
Topics: Acetates; Adult; Aged; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Uti | 1999 |
Suspected allergy to lamotrigine.
Topics: Anticonvulsants; Child; Drug Hypersensitivity; Epilepsy; Humans; Lamotrigine; Male; Serum Sickness; | 1999 |
Beneficial effect of relatively small doses of lamotrigine.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule; Epilepsy; Lamotrigi | 1999 |
Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy.
Topics: Anticonvulsants; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Epilepsy; Humans; Lamotrigine; | 1999 |
Photo Quiz.
Topics: Aged; Anticonvulsants; Drug Interactions; Epilepsy; Female; Humans; Lamotrigine; Skin; Stevens-Johns | 1999 |
Stevens-Johnson syndrome and antiepileptics.
Topics: Adult; Anticonvulsants; Child; Drug Therapy, Combination; Epilepsy; Humans; Lamotrigine; Stevens-Joh | 1999 |
The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy.
Topics: Acetates; Ambulatory Care; Amines; Anticonvulsants; Chronic Disease; Clinical Trials as Topic; Cyclo | 1999 |
Factors influencing the incidence of lamotrigine-related skin rash.
Topics: Adolescent; Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Therapy, Combinati | 1999 |
Efficacy of lamotrigine and vigabatrin in drug-resistant epilepsies of childhood.
Topics: Adolescent; Anticonvulsants; Chi-Square Distribution; Child; Child, Preschool; Drug Resistance; Elec | 1999 |
Postmortem investigation of lamotrigine concentrations.
Topics: Adult; Anticonvulsants; Aqueous Humor; Autopsy; Bile; Child, Preschool; Chromatography, High Pressur | 2000 |
Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment.
Topics: Abnormalities, Drug-Induced; Acyclovir; Anticonvulsants; Antiviral Agents; Drug Industry; Epilepsy; | 2000 |
Refractory epilepsy: treatment with new antiepileptic drugs.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Resist | 2000 |
Stable weight during lamotrigine therapy: a review of 32 studies.
Topics: Adult; Body Weight; Epilepsy; Female; Humans; Lamotrigine; Male; Triazines | 2000 |
Valproic acid dosing recommendations questioned.
Topics: Adult; Age Factors; Anticonvulsants; Drug Combinations; Drug Interactions; Epilepsy; Half-Life; Huma | 2000 |
Electrophysiology of sipatrigine: a lamotrigine derivative exhibiting neuroprotective effects.
Topics: Action Potentials; Animals; Anticonvulsants; Brain Chemistry; Calcium Channels; Corpus Striatum; Epi | 2000 |
Factors associated with behavioral and cognitive abnormalities in children receiving topiramate.
Topics: Adolescent; Anticonvulsants; Child; Child Behavior Disorders; Child, Preschool; Cognition Disorders; | 2000 |
Rash with lamotrigine: dosing guidelines.
Topics: Age Factors; Anticonvulsants; Child; Child, Preschool; Epilepsy; Exanthema; Humans; Lamotrigine; Pra | 2000 |
[Effectiveness and tolerance of adjunctive treatment of lamotrigine and conversion to monotherapy in pediatric patients with epilepsy. Preliminary studies].
Topics: Adolescent; Adult; Anticonvulsants; Child; Drug Tolerance; Electroencephalography; Epilepsy; Female; | 2000 |
[Neuropsychological aspects of cognitive functioning in epileptic children and adolescents treated with lamotrigine].
Topics: Adolescent; Anticonvulsants; Attention; Child; Cognition Disorders; Dose-Response Relationship, Drug | 2000 |
[Lamotrigine versus vigabatrin as an add-on therapy in refractory epilepsy: prospective study].
Topics: Adolescent; Adult; Anticonvulsants; Brain; Dose-Response Relationship, Drug; Electroencephalography; | 2000 |
Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction.
Topics: Adolescent; Adult; Anticonvulsants; Child; Depression, Chemical; Drug Interactions; Drug Therapy, Co | 2000 |
Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation.
Topics: Adult; Anticonvulsants; Breast Feeding; Chromatography, High Pressure Liquid; Epilepsy; Female; Feta | 2000 |
Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation.
Topics: Adolescent; Adult; Anticonvulsants; Child; Drug Administration Schedule; Epilepsy; Female; Humans; I | 2000 |
Successful re-introduction of lamotrigine after initial rash.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adminis | 2000 |
Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases.
Topics: Adolescent; Adult; Anticonvulsants; Body Weight; Electroencephalography; Epilepsy; Female; Humans; H | 2000 |
Lamotrigine-induced tic disorder: report of five pediatric cases.
Topics: Age Factors; Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Basal Ganglia; Child; C | 2000 |
Re: Sadler's article regarding lamotrigine-associated insomnia in an adult tertiary care epilepsy out-patient clinic.
Topics: Adult; Anticonvulsants; Child; Epilepsy; Female; Humans; Lamotrigine; Melatonin; Sleep Initiation an | 2000 |
Lamotrigine monotherapy in children.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Epilepsies, Partial; Epilepsy; Epilepsy | 2000 |
Saliva and serum concentration of lamotrigine in patients with epilepsy.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Chromatography, High Pressure Liquid; Drug Monitoring; Epi | 2000 |
Optimized procedure for lamotrigine analysis in serum by high-performance liquid chromatography without interferences from other frequently coadministered anticonvulsants.
Topics: Adolescent; Adult; Anticonvulsants; Chromatography, High Pressure Liquid; Drug Administration Schedu | 2000 |
Lamotrigine-induced lupus.
Topics: Antibodies, Antinuclear; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Lupus Erythematosus | 2000 |
Successful treatment of lamotrigine-induced erythroblastopenic crisis with folinic acid.
Topics: Adult; Epilepsy; Erythroblasts; Fanconi Anemia; Female; Humans; Lamotrigine; Leucovorin; Triazines | 2000 |
[Clinical utilization of new anti-epileptic agents].
Topics: Acetates; Amines; Anemia, Aplastic; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dru | 2000 |
Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy.
Topics: Acetates; Adolescent; Adult; Age of Onset; Aged; Amines; Anticonvulsants; Chronic Disease; Cyclohexa | 2000 |
[Lamotrigine-induced agranulocytosis].
Topics: Adolescent; Agranulocytosis; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; Triazines | 2000 |
[On article by Gekht AB, Avakian GN, Gusev EI "Modern standards of diagnosis and treatment of epilepsy in Europe"].
Topics: Anticonvulsants; Epilepsy; Europe; Humans; Lamotrigine; Triazines; Vigabatrin | 2000 |
Adverse event monitoring in lamotrigine patients: a pharmacoepidemiologic study in the United Kingdom.
Topics: Acetates; Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Amines; Anticonvulsants; | 2001 |
The long-term use of vigabatrin and lamotrigine in patients with severe childhood onset epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Epilepsy; Femal | 2001 |
Important changes in the treatment of epilepsy.
Topics: Adult; Anticonvulsants; Child; Child, Preschool; Drug Administration Schedule; Epilepsy; Humans; Lam | 2001 |
Peri-marketing surveillance of lamotrigine in The Netherlands: doctors' and patients' viewpoints.
Topics: Adolescent; Adult; Anticonvulsants; Child; Epilepsy; Female; Humans; Lamotrigine; Male; Middle Aged; | 2001 |
Neurophysiological evaluation of vigilance in epileptic patients on monotherapy with lamotrigine.
Topics: Adult; Analysis of Variance; Anticonvulsants; Arousal; Cohort Studies; Epilepsy; Female; Humans; Lam | 2001 |
Preclinical evaluation of CHF3381 as a novel antiepileptic agent.
Topics: Animals; Anticonvulsants; Dizocilpine Maleate; Drug Evaluation, Preclinical; Epilepsy; Excitatory Am | 2001 |
Lamotrigine analysis in blood and brain by high-performance liquid chromatography.
Topics: Animals; Anticonvulsants; Brain Chemistry; Chromatography, High Pressure Liquid; Drug Stability; Epi | 2001 |
Effects of antiepileptic drugs on cognition.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cognition; Cognition Disorders; Cyclohexanecarboxy | 2001 |
Case reports.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Anticonvulsants; Child; Diagnosis, Differential; Epileps | 2001 |
Absence epilepsy with fast rhythmic discharges during sleep: an intermediary form of generalized epilepsy?
Topics: Adult; Age of Onset; Anticonvulsants; Cerebral Cortex; Child; Child, Preschool; Diagnosis, Different | 2001 |
[Some medical-social aspects of the therapy of epilepsy with drugs of new generation: financial side].
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Female; Health Care Costs; Humans; Lamotrigine; Male; | 2001 |
Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy.
Topics: Adult; Anticonvulsants; Blood Glucose; Body Mass Index; Comorbidity; Dehydroepiandrosterone; Epileps | 2001 |
Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Bone and Bones; Bone Density; Bone Diseases, Developmental; Bone Diseas | 2001 |
The tolerability of lamotrigine in elderly patients with epilepsy.
Topics: Aged; Anticonvulsants; Clinical Trials as Topic; Databases, Factual; Drug Tolerance; Epilepsy; Femal | 2001 |
Plasma concentration of topiramate correlates with cerebrospinal fluid concentration.
Topics: Adolescent; Adult; Anticonvulsants; Blood-Brain Barrier; Brain; Carbamazepine; Drug Monitoring; Drug | 2001 |
Lamotrigine plasma levels reduced by oral contraceptives.
Topics: Adolescent; Adult; Anticonvulsants; Contraceptives, Oral, Hormonal; Drug Interactions; Epilepsy; Fem | 2001 |
Dysgeusia in epileptic patients treated with lamotrigine: report of three cases.
Topics: Aged; Anticonvulsants; Dysgeusia; Epilepsy; Female; Humans; Lamotrigine; Male; Middle Aged; Triazine | 2001 |
Lamotrigine as an add-on therapy in intractable paediatric epilepsy--the Kuala Lumpur Hospital experience.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Epilepsy; Female; H | 2001 |
Effectiveness of first antiepileptic drug.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Child; Dose-Response Relationship, Drug; Electroe | 2001 |
A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy.
Topics: Anticonvulsants; Chronic Disease; Drug Therapy, Combination; Electroencephalography; England; Epilep | 2001 |
Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction?
Topics: Anticonvulsants; Child, Preschool; Chorea; Drug Synergism; Drug Therapy, Combination; Dyskinesia, Dr | 2001 |
Pregnancy registries in epilepsy.
Topics: Abnormalities, Drug-Induced; Acetates; Amines; Anticonvulsants; Australia; Cross-Cultural Comparison | 2001 |
The effects of lamotrigine on sleep in patients with epilepsy.
Topics: Adult; Anticonvulsants; Cohort Studies; Epilepsy; Female; Humans; Lamotrigine; Male; Middle Aged; Po | 2001 |
Is there a lamotrigine withdrawal syndrome?
Topics: Adult; Anticonvulsants; Epilepsy; Humans; Lamotrigine; Male; Preoperative Care; Substance Withdrawal | 2002 |
[Toxic epidermal necrolysis treated with intravenous immunoglobulin].
Topics: Anticonvulsants; Child; Epilepsy; Female; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; L | 2002 |
[Lamotrigine in the adult-onset epilepsy: efficacy and long-term safety].
Topics: Adolescent; Adult; Anticonvulsants; Epilepsy; Humans; Lamotrigine; Retrospective Studies; Treatment | 2002 |
Prospective study on concentration-efficacy and concentration-toxicity: correlations with lamotrigine serum levels.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Humans | 2002 |
Therapeutic drug monitoring of lamotrigine.
Topics: Anticonvulsants; Biological Availability; Clinical Trials as Topic; Drug Monitoring; Epilepsy; Human | 2002 |
Neocortical potassium currents are enhanced by the antiepileptic drug lamotrigine.
Topics: 4-Aminopyridine; Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; In Vitro Techniques; La | 2002 |
What to do when the first anticonvulsant does not work.
Topics: Aminocaproates; Anticonvulsants; Carbamazepine; Epilepsy; Humans; Lamotrigine; Phenytoin; Treatment | 1992 |
Lamotrigine for intractable childhood epilepsy: a preliminary communication.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adminis | 1992 |
Lamotrigine in refractory epilepsy: a long-term open study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 1991 |
Pharmacokinetics of lamotrigine (Lamictal) in plasma and saliva.
Topics: Adult; Anticonvulsants; Blood Proteins; Chromatography, High Pressure Liquid; Drug Interactions; Enz | 1991 |
Use of antiepileptic drugs in childhood epilepsy.
Topics: Adult; Aminocaproates; Anticonvulsants; Chemical and Drug Induced Liver Injury; Child; Child, Presch | 1991 |
The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; Lamotrigine; Male; Osmo | 1990 |
Mechanisms of action of new antiepileptic drugs.
Topics: Acetamides; Acetates; Amines; Aminocaproates; Aminopyridines; Anti-Anxiety Agents; Anticonvulsants; | 1989 |
Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Dose-Response Relationship, Drug; Drug Interactions; Drug Tolera | 1987 |